Contents
- Part 1 Preliminary and interpretation
- Part 2 Controls on substances
- Appendix A General exemptions
- Appendix B Substances considered not to require control by scheduling
- Appendix C Blank
- Appendix D Additional controls on possession or supply of poisons included in Schedule 4 or 8
- Appendix E First aid instructions for poisons
- Appendix F Warning statements and general safety directions for poisons
- Appendix G Dilute preparations
- Appendix H Schedule 3 medicines permitted to be advertised
- Appendix I Blank
- Appendix J Conditions for availability and use of certain poisons included in Schedule 7
- Appendix K Human medicines required to be labelled with a sedation warning
- Appendix L Requirements for dispensing labels for medicines
- Appendix M Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist
- Index
- Schedule 1 Blank
- Schedule 2 Pharmacy medicines
- Schedule 3 Pharmacist only medicines
- Schedule 4 Prescription only medicines and prescription animal remedies
- Schedule 5 Caution
- Schedule 6 Poisons
- Schedule 7 Dangerous poisons
- Schedule 8 Controlled drugs
- Schedule 9 Prohibited substances
- Schedule 10 Substances of such danger to health as to warrant prohibition of supply and use
Contents
15,497 provisions, too many to show on one page. Open a part or section to read it with its history and connections, or search inside the text.
- Part 1 · Preliminary and interpretation
- Part 2 · Controls on substances
- Appendix A · General exemptions
- Appendix B · Substances considered not to require control by scheduling
- Appendix C · Blank
- Appendix D · Additional controls on possession or supply of poisons included in Schedule 4 or 8
- Note: See section 64.
- 1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner
- 2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist
- 3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act
- 4 Poisons available only from or on the order of a specialist physician
- 5 Poisons for which possession without authority is illegal
- 6 Poisons available for human use only from or on the prescription or order of a specialist physician
- 7 Poisons available for human use only from or on the prescription or order of a dermatologist
- 8 Poisons which must be stored in a locked container to prevent unauthorised access
- 9 Poisons available only when prescribed or authorised in certain circumstances
- Appendix E · First aid instructions for poisons
- Appendix F · Warning statements and general safety directions for poisons
- Appendix G · Dilute preparations
- Appendix H · Schedule 3 medicines permitted to be advertised
- Appendix I · Blank
- Appendix J · Conditions for availability and use of certain poisons included in Schedule 7
- Appendix K · Human medicines required to be labelled with a sedation warning
- Appendix L · Requirements for dispensing labels for medicines
- Appendix M · Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist
- Index
- A
- ABACAVIR
- Schedule 4
- ABALOPARATIDE
- Schedule 4
- ABAMECTIN
- Schedule 7 Schedule 6 Schedule 5 Appendix J, clause 1
- ABATACEPT
- Schedule 4
- ABCIXIMAB
- Schedule 4
- ABEMACICLIB
- Schedule 4
- ABIRATERONE ACETATE
- Schedule 4
- ABROCITINIB
- Schedule 4
- ABRUS PRECATORIUS cross reference: JEQUIRITY
- Schedule 10
- ABSCISIC ACID
- Schedule 5
- ACALABRUTINIB
- Schedule 4
- ACAMPROSATE CALCIUM
- Schedule 4
- ACARBOSE
- Schedule 4
- ACEBUTOLOL
- Schedule 4
- ACEPHATE
- Schedule 6
- ACEPROMAZINE
- Schedule 4
- ACEQUINOCYL
- Schedule 5
- ACETAMIPRID
- Schedule 6
- ACETANILIDE cross reference: ALKYL ACETANILIDES
- Schedule 4
- ACETARSOL
- Schedule 4
- ACETAZOLAMIDE
- Schedule 4
- ACETIC ACID
- Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- ACETIC ANHYDRIDE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- ACETOHEXAMIDE
- Schedule 4
- ACETONE cross reference: DESIGNATED SOLVENT
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- ACETORPHINE
- cross reference: CAS No. 25333-77-1
- Schedule 9
- ACETYL-ALPHA-METHYLFENTANYL
- cross reference: CAS No. 101860-00-8
- Schedule 9
- ACETYLCARBROMAL
- Schedule 4
- ACETYLCHOLINE
- Schedule 4 Appendix G, clause 1
- ACETYLCYSTEINE
- Schedule 4 Schedule 2
- ACETYLDIGITOXIN
- Schedule 4
- ACETYLDIHYDROCODEINE
- Schedule 8
- ACETYL ISOVALERYLTYLOSIN
- Schedule 4
- ACETYLMETHADOL
- Schedule 8
- ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE
- Schedule 4
- ACETYLMORPHINES
- Schedule 8
- 4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE
- Appendix B, clause 3
- ACETYLSTROPHANTHIDIN
- Schedule 4
- ACIBENZOLAR-S-METHYL
- Schedule 7 Appendix J, clause 1
- ACICLOVIR
- Schedule 4
- ACIFLUORFEN
- Schedule 6
- ACINITRAZOLE
- Schedule 6
- ACIPIMOX
- Schedule 4
- ACITRETIN
- Schedule 4 Appendix D, clause 2 Appendix F, clause 4 Appendix L, clause 2
- ACLIDINIUM BROMIDE
- Schedule 4
- ACLONIFEN
- Schedule 6
- ACOKANTHERA OUABAIO
- Schedule 4
- ACOKANTHERA SCHIMPERI
- Schedule 4
- ACONITUM spp.
- Schedule 4 Schedule 2
- ACORUS CALAMUS cross reference: CALAMUS
- Schedule 10
- ACRIFLAVINE cross reference: ACRIFLAVINIUM CHLORIDE
- ACRIFLAVINUM CHLORIDE
- Schedule 7 Schedule 5
- ACRIVASTINE
- Schedule 4
- ACROLEIN
- Schedule 7 Appendix E, clause 3 Appendix F, clause 4
- ACRYLONITRILE
- Schedule 7 Appendix J, clause 1
- ADALIMUMAB
- Schedule 4
- ADAPALENE
- Schedule 4 Schedule 3 Appendix F, clause 4 Appendix H, clause 1 Appendix L, clause 2
- ADEFOVIR
- Schedule 4
- ADENOSINE
- Schedule 4
- ADIPHENINE
- Schedule 4
- ADONIS VERNALIS
- Schedule 4
- ADRAFINIL
- Schedule 4
- ADRENALINE
- Schedule 4 Schedule 3
- Appendix H, clause 1
- ADRENOCORTICAL HORMONES
- Schedule 4
- AFAMELANOTIDE cross reference: MELANOCYTE STIMULATING HORMONE, MELANOTAN I
- Schedule 4
- AFATINIB DIMALEATE
- Schedule 4
- AFIDOPYROPEN
- Appendix B, clause 3
- AFLIBERCEPT
- Schedule 4
- AFOXOLANER
- Schedule 5
- AGALSIDASE
- Schedule 4
- AGLEPRISTONE
- Schedule 4
- AGOMELATINE
- Schedule 4
- AKLOMIDE
- Schedule 5
- ALACHLOR
- Schedule 7 Appendix J, clause 1
- ALANYLGLUTAMINE
- Schedule 4
- ALATROFLOXACIN MESILATE cross reference: ALATROFLOXACIN MESYLATE
- Schedule 4
- ALBENDAZOLE
- Schedule 6 Schedule 5 Schedule 4
- ALCLOFENAC
- Schedule 4
- ALCLOMETASONE
- Schedule 4 Schedule 3 Appendix F, clause 4
- ALCOHOL, DEHYDRATED
- Appendix B, clause 3
- ALCURONIUM
- Schedule 4
- ALDESLEUKIN
- Schedule 4
- ALDICARB
- Schedule 7
- ALDOSTERONE
- Schedule 4 Appendix G, clause 1
- ALDOXYCARB
- Schedule 7
- ALDRIN
- Schedule 6
- ALECTINIB
- Schedule 4
- ALEFACEPT
- Schedule 4 Appendix D, clause 7
- ALEMTUZUMAB
- Schedule 4
- ALENDRONIC ACID
- Schedule 4
- ALFACALCIDOL
- Schedule 4
- ALFENTANIL
- Schedule 8
- ALFUZOSIN
- Schedule 4
- ALGICIDES
- Appendix A, clause 1
- ALGLUCERASE
- Schedule 4
- ALGLUCOSIDASE
- Schedule 4
- ALIMEMAZINE cross reference: TRIMEPRAZINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- ALIROCUMAB
- Schedule 4
- ALISKIREN
- Schedule 4
- ALKALINE SALTS cross reference: LYE WATER, POTASSIUM CARBONATE. POTASSIUM PHOSPHATE, POTASSIUM SALTS, POTASSIUM SILICATE, SODIUM CARBONATE, SODIUM SALTS, SODIUM
- Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- ALKOXYAMFETAMINES cross reference: ALKOXYAMPHETAMINES
- Schedule 9
- ALKOXYLATED FATTY ALKYLAMINE POLYMER
- Schedule 6 Schedule 5
- ALKOXYPHENYLETHYLAMINES
- Schedule 9
- ALKYLAMINES WITH STIMULANT PROPERTIES cross reference: 1,3-DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 1,5-DIMETHYLHEXYLAMINE, 4-METHYLHEXANE-
- Schedule 10
- ALKYL NITRITES
- Schedule 4 Appendix E, clause 3
- ALKYLTHIOAMFETAMINES cross reference: ALKYLTHIOAMPHETAMINES
- Schedule 9
- ALLERGENS
- Schedule 4
- ALLETHRIN
- Schedule 6 Schedule 5
- ALLOPURINOL
- Schedule 4
- ALLOXYDIM
- Schedule 5
- ALLYL ALCOHOL
- Schedule 7 Appendix J, clause 1
- ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9)
- Schedule 6
- ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5)
- Schedule 6
- ALLYL ESTERS (excluding derivatives)
- Schedule 6
- ALLYLESTRENOL cross reference: ALLYLOESTRENOL
- Schedule 4
- ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8)
- Schedule 6
- ALLYL HEXANOATE (CAS No. 123-68-2)
- Schedule 6
- ALLYL ISOVALERATE (CAS No. 2835-39-4)
- Schedule 6
- ALLYL NONANOATE (CAS No. 7493-72-3)
- Schedule 6
- ALLYL OCTANOATE (CAS No. 4230-97-1)
- Schedule 6
- ALLYLOESTRENOL cross reference: ALLYLESTRENOL
- ALLYL PHENYLACETATE (CAS No. 1797-74-6)
- Schedule 6
- ALLYLPRODINE
- cross reference: CAS No. 25384-17-2
- Schedule 9
- ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9)
- Schedule 6
- ALOGLIPTIN
- Schedule 4
- ALOSETRON
- Schedule 4
- ALOXIPRIN
- Schedule 2
- ALPELISIB
- Schedule 4
- ALPHACETYLMETHADOL
- Schedule 8
- ALPHA-CHLOROHYDRIN
- Schedule 6 Appendix F, clause 4
- ALPHA-CYPERMETHRIN
- Schedule 7 Schedule 6 Schedule 5
- ALPHADOLONE
- Schedule 4
- ALPHAMEPRODINE
- cross reference: CAS No. 468-51-9
- Schedule 9
- ALPHAMETHADOL
- cross reference: CAS No. 17199-54-1
- Schedule 9
- ALPHA-METHYLFENTANYL
- cross reference: CAS No. 79704-88-4
- Schedule 9
- ALPHA-METHYLTHIOFENTANYL
- cross reference: CAS No. 103963-66-2
- Schedule 9
- ALPHAPRODINE
- Schedule 8
- ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP).
- cross reference: CAS No. 14530-33-7
- Schedule 9
- ALPHA1-PROTEINASE INHIBITOR (HUMAN)
- Schedule 4
- ALFAXALONE
- Schedule 4
- ALPRAZOLAM
- Schedule 8 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- ALPRENOLOL
- Schedule 4
- ALPROSTADIL
- Schedule 4
- ALSEROXYLON
- Schedule 4
- ALTEPLASE
- Schedule 4
- ALTRENOGEST
- Schedule 4
- ALTRETAMINE cross reference: HEXAMETHYLMELAMINE
- Schedule 4
- ALUM
- Appendix B, clause 3
- ALUMINIUM AMMONIUM SULFATE
- Appendix B, clause 3
- ALUMINIUM POTASSIUM SULFATE
- Appendix B, clause 3
- ALUMINIUM SILICATE
- Appendix B, clause 3
- ALUMINIUM tris (ETHYLPHOSPHONATE)
- Appendix B, clause 3
- AMANTADINE
- Schedule 4
- AMBENONIUM CHLORIDE
- Schedule 4
- AMBRISENTAN
- Schedule 4 Appendix D, clause 6 Appendix F, clause 4 Appendix L, clause 2
- AMBUCETAMIDE
- Schedule 4
- AMBUTONIUM BROMIDE
- Schedule 4
- AMCINONIDE
- Schedule 4
- AMETOCTRADIN
- Appendix B, clause 3
- AMETRYN
- Schedule 5
- AMICARBAZONE
- Schedule 6
- AMIDITHION
- Schedule 6
- AMIDOPROPYL BETAINES
- Schedule 6 Appendix E, clause 3
- AMIFAMPRIDINE
- Schedule 4
- AMIFOSTINE
- Schedule 4
- AMIKACIN
- Schedule 4
- AMILORIDE
- Schedule 4
- AMINACRINE cross reference: AMINOACRIDINE
- AMINES cross reference: CURING AGENTS FOR EPOXY RESINS
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- AMINOACRIDINE cross reference: AMINACRINE
- Schedule 7 Schedule 5
- AMINOCAPROIC ACID
- Schedule 4
- AMINOCARB
- Schedule 7 Schedule 6
- 2-AMINO-6-CHLORO-4-NITROPHENOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- 4-AMINO-m-CRESOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- 5-AMINO-o-CRESOL cross reference: 4-AMINO-2-HYDROXYTOLUENE
- 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID Schedule 5
- AMINOCYCLOPYRACHLOR
- Schedule 5
- 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE cross reference: DOM, STP (CAS No. 15588-95-1), DOM HYDROCHLORIDE (CAS No. 15589-00-1)
- Schedule 9
- AMINOETHOXYVINYLGLYCINE
- Schedule 6
- 2-AMINO-5-ETHYLPHENOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- AMINOGLUTETHIMIDE
- Schedule 4
- 4-AMINO-2-HYDROXYTOLUENE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- 5-AMINOLEVULINIC ACID
- Schedule 4
- 1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE
- Schedule 6
- 2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL cross reference: HC VIOLET 1
- 2-AMINO-5-METHYLPHENOL
- cross reference: CAS No. 2835-98-5
- Schedule 10 Schedule 7
- AMINOMETRADINE
- Schedule 4
- 4-AMINO-3-NITROPHENOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL cross reference: HC RED 13
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- AMINOPHENAZONE cross reference: AMIDOPYRINE (CAS No. 58-15-1), AMINOPHENAZONE HYDROCHLORIDE (CAS No. 6170-29-2)
- Schedule 10 Schedule 4
- m-AMINOPHENOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- p-AMINOPHENOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- AMINOPHYLLINE
- Schedule 4 Schedule 3
- 4-AMINOPROPIOPHENONE cross reference: PARA-AMINOPROPIOPHENONE (PAPP)
- Schedule 7 Appendix J, clause 1
- 5-(2-AMINOPROPYL)INDAN
- cross reference: CAS No. 13396-94-6
- Schedule 9
- AMINOPTERIN
- Schedule 4
- AMINOPYRALID
- Schedule 6 Schedule 5
- 4-AMINOPYRIDINE cross reference: FAMPRIDINE
- Schedule 7 Schedule 4 Appendix E, clause 3 Appendix J, clause 1
- AMINOREX
- Schedule 4
- AMINOSALICYLIC ACID
- Schedule 4
- AMIODARONE
- Schedule 4
- AMIPHENAZOLE
- Schedule 4
- AMISOMETRADINE
- Schedule 4
- AMISULBROM
- Schedule 5
- AMISULPRIDE
- Schedule 4 Appendix K, clause 1
- AMITON
- Schedule 7
- AMITRAZ
- Schedule 6
- AMITRIPTYLINE
- Schedule 4 Appendix K, clause 1
- AMITROLE
- Schedule 5
- AMLODIPINE
- Schedule 4
- AMMI VISNAGA
- Schedule 4
- AMMONIA cross reference: AMMONIUM HYDROXIDE, CHROMATES
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- AMMONIUM BROMIDE
- Schedule 4
- AMMONIUM COCOYL ISETHIONATE
- Schedule 6 Appendix E, clause 3
- AMMONIUM PERSULFATE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- AMMONIUM PHOSPHATE
- Appendix B, clause 3
- AMMONIUM THIOCYANATE
- Schedule 5 Appendix E, clause 3
- AMMONIUM THIOSULPHATE
- Appendix B, clause 3
- AMOBARBITAL
- Schedule 8 Schedule 4 Appendix K, clause 1
- AMODIAQUINE
- Schedule 4
- AMOROLFINE
- Schedule 4 Schedule 2
- AMOXAPINE
- Schedule 4
- AMOXICILLIN
- Schedule 4
- AMOXYCILLIN cross reference: AMOXICILLIN
- AMFETAMINE cross reference: AMPHETAMINE
- Schedule 8
- AMPHOMYCIN
- Schedule 4
- AMPHOTERICIN cross reference: AMPHOTERICIN B
- AMPHOTERICIN B
- Schedule 4
- AMPICILLIN
- Schedule 4
- AMPRENAVIR
- Schedule 4
- AMPROLIUM
- Appendix B, clause 3
- AMRINONE
- Schedule 4
- AMSACRINE
- Schedule 4
- AMYGDALIN cross reference: CAS No. 29883-15-6, APRICOT KERNELS
- Schedule 10
- AMYL ACETATE
- Appendix B, clause 3
- AMYL NITRITE
- Schedule 4 Schedule 3 Appendix E, clause 3
- α-AMYLASE derived from Aspergillus niger
- Appendix B, clause 3
- AMYL CINNAMALDEHYDE
- Appendix B, clause 3
- AMYLOBARBITAL cross reference: AMOBARBITAL
- AMYLOBARBITONE cross reference: AMOBARBITAL
- AMYLOCAINE
- Schedule 4
- ANABOLIC STEROIDAL AGENTS cross reference: ANDROSTERONE, STEROIDAL AGENTS
- Schedule 4 Appendix D, clause 5
- ANACAULASE-BCDB
- Schedule 4
- ANAGRELIDE
- Schedule 4
- ANAKINRA
- Schedule 4
- ANASTROZOLE
- Schedule 4
- ANCESTIM
- Schedule 4
- ANCHUSA OFFICINALIS
- Schedule 10
- ANCROD
- Schedule 4
- ANDEXANET ALFA
- Schedule 4
- ANDROGENIC STEROIDAL AGENTS cross reference: STEROIDAL AGENTS
- Schedule 4 Appendix D, clause 5
- ANDROISOXAZOLE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ANDROSTANOLONE
- Schedule 4
- ANDROSTENEDIOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ANDROSTENEDIONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ANDROSTENEDIONE ALBUMEN
- Appendix B, clause 3
- ANECORTAVE
- Schedule 4
- ANGIOTENSIN AMIDE
- Schedule 4
- ANHYDRIDES, ORGANIC ACID cross reference: CURING AGENTS FOR EPOXY RESINS
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- ANIDULAFUNGIN
- Schedule 4
- ANILERIDINE
- Schedule 8
- ANILINE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- ANIMAL BLOOD PRODUCTS
- Schedule 4
- ANIRACETAM cross reference: RACETAMS
- Schedule 4
- ANISE OIL
- Schedule 5 Appendix E, clause 3, Part 4
- o-ANISIDINE
- cross reference: CAS No. 90-04-0, o-ANISIDINE HYDROCHLORIDE (CAS No. 134-29-2)
- Schedule 10
- ANISTREPLASE
- Schedule 4
- ANTAZOLINE
- Schedule 4 Schedule 2
- ANTIBIOTIC SUBSTANCES cross reference: NISIN
- Schedule 4
- ANTIGENS
- Schedule 4
- ANTIHISTAMINES cross reference: ASTEMIZOLE, AZELASTINE, BILASTINE, CETIRIZINE, DESLORATADINE, FEXOFENADINE, LORATADINE, OLOPATADINE, TERFENADINE
- Schedule 4 Appendix F, clause 4
- ANTIMONY cross reference: ANTIMONY COMPOUNDS, ANTIMONY CHLORIDE, ANTIMONY TITANATE
- Schedule 6 Schedule 4 Appendix E, clause 3 Appendix G, clause 1
- ANTISERA cross reference: IMMUNOSERA
- Schedule 4
- AOD-9604 (CAS No. 221231-10-3)
- Schedule 4 Appendix D, clause 5
- APADAMTASE ALFA
- Schedule 4
- APALUTAMIDE
- Schedule 4
- APIXABAN
- Schedule 4
- APOCYNUM spp.
- Schedule 4
- APOMORPHINE
- Schedule 4 Appendix G, clause 1
- APRACLONIDINE
- Schedule 4
- APRAMYCIN
- Schedule 4
- APREMILAST
- Schedule 4
- APREPITANT
- Schedule 4
- APRICOT KERNELS
- cross reference: AMYGDALIN, HYDROCYANIC ACID
- APRONAL
- cross reference: ALLYLISOPROPYLACETYLUREA (CAS No. 528-92-7)
- Schedule 10
- APROTININ
- Schedule 4
- ARBUTIN (ALPHA)
- cross reference: ARBUTIN (BETA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)
- Schedule 6
- Appendix E, clause 3
- Appendix F, clause 4
- ARBUTIN (BETA)
- cross reference: ARBUTIN (ALPHA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)
- Schedule 6
- Schedule 4
- Appendix E, clause 3
- Appendix F, clause 4
- ARBUTIN (DEOXY OR OTHER DERIVATIVES)
- cross reference: ARBUTIN (ALPHA); ARBUTIN (BETA)
- Schedule 6
- Appendix E, clause 3
- Appendix F, clause 4
- ARECOLINE
- Schedule 4
- ARIPIPRAZOLE
- Schedule 4 Appendix K, clause 1
- ARISTOLOCHIA spp.
- Schedule 10
- ARISTOLOCHIC ACID(S) cross reference: ASARUM spp, BRAGANTIA (CAS No. 313-67-7)
- Schedule 10
- ARPRINOCID
- Schedule 7 Appendix J, clause 1
- ARMODAFINIL
- Schedule 4
- ARSENIC cross reference: ARSENIC TRIOXIDE, CACODYLIC ACID, TERMITE BARRIERS, COPPER-CHROME-ARSENIC, SELENIUM ARSENIDE, THIACETARSAMIDE
- Schedule 7 Schedule 6 Schedule 4 Appendix G, clause 1 Appendix J, clause 1
- ARTEMETHER
- Schedule 4
- ARTESUNATE
- Schedule 4
- ARTICAINE
- Schedule 4
- ASARUM spp
- Schedule 10
- ASCIMINIB
- Schedule 4
- ASENAPINE
- Schedule 4 Appendix K, clause 1
- ASFOTASE ALFA
- Schedule 4
- ASPARAGINASE
- cross reference: CRISANTASPASE
- Schedule 4
- ASPARTIC ACID
- Appendix B, clause 3
- ASPIRIN cross reference: CAFFEINE, PARACETAMOL, SALICYLAMIDE
- Schedule 6 Schedule 5 Schedule 4 Schedule 2 Appendix F, clause 4
- ASTEMIZOLE
- Schedule 4 Appendix F, clause 4
- ASTODRIMER SODIUM
- Schedule 3
- Schedule 2
- Appendix F, clause 4
- Appendix H, clause 1
- ASULAM
- Appendix B, clause 3
- ASUNAPREVIR
- Schedule 4
- ATAMESTANE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ATAZANAVIR
- Schedule 4
- ATENOLOL
- Schedule 4
- ATEZOLIZUMAB
- Schedule 4
- ATINVICITINIB
- Schedule 4
- ATIPAMEZOLE
- Schedule 4
- ATOMOXETINE
- Schedule 4
- ATORVASTATIN
- Schedule 4
- ATOSIBAN
- Schedule 4
- ATOVAQUONE
- Schedule 4
- ATRACURIUM BESILATE cross reference: ATRACURIUM BESYLATE
- Schedule 4
- ATRAZINE
- Schedule 5
- ATROPA BELLADONNA cross reference: BELLADONNA
- Schedule 4 Schedule 2 Appendix G, clause 1
- ATROPINE
- Schedule 4 Schedule 2 Appendix G, clause 1
- ATROPINE METHONITRATE
- Schedule 4
- AURANOFIN
- Schedule 4
- AUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941)
- Appendix B
- AUROTHIOMALATE SODIUM
- Schedule 4
- AVACINCAPTAD PEGOL
- Schedule 4
- AVACOPAN
- Schedule 4
- AVATROMBOPAG
- Schedule 4
- AVELUMAB
- Schedule 4
- AVILAMYCIN
- Schedule 4
- AVIPTADIL
- Schedule 4
- AVOPARCIN
- Schedule 4
- AXITINIB
- Schedule 4
- AZACITIDINE
- Schedule 4
- AZACONAZOLE
- Schedule 6
- AZACYCLONOL
- Schedule 4
- AZADIRACHTA INDICA cross reference: DEBITTERISED NEEM SEED OIL, NEEM
- Schedule 10 Schedule 6
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- AZADIRACHTA INDICA EXTRACTS
- Schedule 5
- AZAFENIDIN
- Schedule 7
- AZAMETHIPHOS
- Schedule 6
- AZAPERONE
- Schedule 4
- AZAPROPAZONE
- Schedule 4
- AZARIBINE
- Schedule 4
- AZATADINE
- Appendix K, clause 1
- AZATADINE
- Schedule 4 Schedule 3
- AZATHIOPRINE
- Schedule 4
- AZELAIC ACID
- cross reference: NONANEDIOIC ACID Schedule 5 Schedule 4 Schedule 2 Appendix E, clause 3
- Appendix F, clause 4
- AZELASTINE
- Schedule 4 Schedule 2
- AZIMSULFURON
- Appendix B, clause 3
- AZINPHOS-ETHYL
- Schedule 7
- AZINPHOS-METHYL
- Schedule 7
- AZITHROMYCIN
- Schedule 4
- AZLOCILLIN
- Schedule 4
- AZOBENZENE
- Schedule 6
- AZOCYCLOTIN
- Schedule 7 Appendix F, clause 4 Appendix J, clause 1
- AZO DYES (derivatives by diazotisation)
- Schedule 7 Appendix E, clause 3 Appendix F, clause 4
- AZOXYSTROBIN
- Schedule 5
- AZTREONAM
- Schedule 4
- B
- BACAMPICILLIN
- Schedule 4
- BACILLUS AMYLOLIQUEFACIENS cross reference: BACILLUS SUBTILIS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, BACILLUS
- Appendix B, clause 3
- BACILLUS PARALICHENIFORMIS
- Appendix B, clause 3
- BACILLUS SPHAERICUS, STRAIN 2362
- Appendix B, clause 3
- BACILLUS SUBTILIS, STRAIN QST 713 cross reference: BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713
- BACILLUS THURINGIENSIS cross reference: ENDOTOXIN
- Appendix B, clause 3
- BACILLUS THURINGIENSIS DELTA ENDOTOXIN
- Schedule 5
- BACILLUS TOYOI
- Appendix B, clause 3
- BACITRACIN
- Schedule 4
- BACLOFEN
- Schedule 4 Appendix K, clause 1
- BACTERIAL CULTURE MEDIA cross reference: ANTIBIOTIC SUBSTANCES
- Appendix A, clause 1
- BACTERICIDES
- Appendix A, clause 1
- BACULOVIRUS CYDIA POMONELLA
- Appendix B, clause 3
- BALOXAVIR MARBOXIL
- Schedule 4
- BALSALAZIDE
- Schedule 4
- BAMBERMYCIN cross reference: FLAVOPHOSPHOLIPOL
- Schedule 6 Schedule 4
- BAMBUTEROL
- Schedule 4
- BAMETHAN
- Schedule 4
- BAMIPINE
- Schedule 4
- BPA GLYCIDYL DIACRYLATE
- Schedule 6
- Appendix E, clause 3
- Appendix F, clause 4
- BPA GLYCIDYL DIMETHACRYLATE
- Schedule 6
- Appendix E, clause 3
- Appendix F, clause 4BARBITURATES
- Schedule 4
- BARICITINIB
- Schedule 4
- BARIUM SALTS cross reference: BARIUM METABORATE, BARIUM SULFATE
- Schedule 6 Appendix E, clause 3
- BARIUM SILICOFLUORIDE
- Schedule 5
- BASIC BLUE 26
- Schedule 10 Schedule 6
- BASIC ORANGE 31 cross reference: 2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM, CHLORIDE (CAS No. 97404-02-9)
- Schedule 10 Schedule 6
- BASIC RED 76 (CAS No. 68391-30-0) cross reference: [7-HYDROXY-8-[(2- METHOXYPHENYL)AZO]-2-NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0)
- Schedule 7 Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- BASIL OIL cross reference: METHYL CHAVICOL
- Schedule 5 Appendix E, clause 3
- BASILIXIMAB
- Schedule 4
- BATTERIES
- Appendix A, clause 1
- BAY OIL
- Schedule 6 Appendix E, clause 3
- BAZEDOXIFENE
- Schedule 4
- BEAUVERIA BASSIANA
- Schedule 6 Schedule 5
- BECAPLERMIN
- Schedule 4
- BECLAMIDE
- Schedule 4
- BECLOMETASONE cross reference: BECLOMETHASONE
- Schedule 4 Schedule 2
- BECLOMETHASONE cross reference: BECLOMETASONE
- BELANTAMAB MAFODOTIN
- Schedule 4
- BELATACEPT
- Schedule 4
- BELIMUMAB
- Schedule 4
- BELUMOSUDIL
- Schedule 4
- Appendix L, clause 2
- BELZUTIFAN
- Schedule 4
- BEMEGRIDE
- Schedule 4
- BEMPEDOIC ACID Schedule 4
- BENACTYZINE
- Schedule 4
- BENALAXYL
- Schedule 5
- BENAZEPRIL
- Schedule 4
- BENDAMUSTINE
- Schedule 4
- BENDIOCARB cross reference: DENATONIUM BENZOATE
- Schedule 7 Schedule 6 Schedule 5
- BENDROFLUAZIDE
- Schedule 4
- BENETHAMINE PENICILLIN
- Schedule 4
- BENFLURALIN
- Appendix B, clause 3
- BENOMYL
- Schedule 7 Appendix F, clause 4
- BENORYLATE
- Schedule 4
- BENOXAPROFEN
- Schedule 4
- BENPERIDOL
- Schedule 4
- BENQUINOX
- Schedule 6
- BENRALIZUMAB
- Schedule 4
- BENSERAZIDE
- Schedule 4
- BENSULFURON-METHYL
- Appendix B, clause 3
- BENSULIDE
- Schedule 6
- BENTAZONE
- Schedule 5
- BENTONITE
- Appendix B, clause 3
- BENZALKONIUM CHLORIDE
- Schedule 6 Schedule 5 Appendix E, clause 3
- BENZATHINE PENICILLIN
- Schedule 4
- BENZENE
- cross reference: LIQUID HYDROCARBONS Schedule 7 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1
- 1,2-BENZENEDIAMINE
- cross reference: CAS No. 95-54-5, 1,2-BENZENEDIAMINE DIHYDROCHLORIDE (CAS No. 615-28-1)
- Schedule 10
- 1,3-BENZENEDIAMINE
- cross reference: CAS No. 108-45-2
- Schedule 10
- 1,2-BENZENEDIOL cross reference: CATECHOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- BENZETHIDINE
- cross reference: CAS No. 3691-78-9
- Schedule 9
- BENZHEXOL cross reference: TRIHEXYPHENIDYL
- BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES
- Schedule 7
- BENZIDINE-BASED AZO DYES
- Schedule 7
- BENZILONIUM
- Schedule 4
- BENZOCAINE
- Schedule 4 Schedule 2
- BENZODIAZEPINE DERIVATIVES
- Schedule 4 Appendix D, clause 5
- BENZOFENAP
- Schedule 5
- BENZOIC ACID
- Schedule 5
- BENZOVINDIFLUPYR
- Schedule 6
- BENZOYL PEROXIDE
- Schedule 5 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- BENZOYLINDOLES
- Schedule 9
- BENZPHETAMINE
- Schedule 4
- BENZTHIAZIDE
- Schedule 4
- BENZATROPINE cross reference: BENZITROPINE
- Schedule 4 Appendix K, clause 1
- BENZYDAMINE
- Schedule 4 Schedule 2
- 6-BENZYLADENINE
- Schedule 6
- BENZYL BENZOATE
- Appendix B, clause 3
- BENZYLMORPHINE
- Schedule 8
- BENZYLPENICILLIN
- Schedule 4
- BENZYLPIPERAZINE cross reference: BZP (CAS No. 2759-28-6), BENZYLPIPERAZINE TARTRATE (CAS No. 10510-56-2), BENZYLPIPERAZINE DIHYDROCHLORIDE (CAS No. 5321-63-1)
- Schedule 9
- BEPHENIUM SALTS
- Schedule 2
- BEPRIDIL
- Schedule 4
- BERACTANT
- Schedule 4
- BERGAMOT OIL
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- BERYLLIUM
- Schedule 6 Appendix F, clause 4
- BESIFLOXACIN
- Schedule 4
- BETACETYLMETHADOL
- cross reference: CAS No. 17199-59-6
- Schedule 9
- BETACYFLUTHRIN
- Schedule 7 Schedule 6 Schedule 5
- BETA-CYPERMETHRIN
- Schedule 6
- BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID cross reference: PHENIBUT
- BETAHISTINE
- Schedule 4
- BETA-HYDROXY-3-METHYLFENTANYL
- cross reference: CAS No. 78995-14-9
- Schedule 9
- BETA-HYDROXYFENTANYL
- cross reference: CAS No. 78995-10-5
- Schedule 9
- BETAINE HYDROCHLORIDE
- Appendix B, clause 3
- BETAMEPRODINE
- cross reference: CAS No. 468-50-8
- Schedule 9
- BETAMETHADOL
- cross reference: CAS No. 17199-55-2
- Schedule 9
- BETAMETHASONE
- Schedule 4
- 1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3
- Appendix F, clause 4
- BETAPRODINE
- cross reference: CAS No. 468-59-7
- Schedule 9
- BETAXOLOL
- Schedule 4
- BETHANECHOL CHLORIDE
- Schedule 4
- BETHANIDINE
- Schedule 4
- BEVACIZUMAB
- Schedule 4
- BEVANTOLOL
- Schedule 4
- BEXAROTENE
- Schedule 4 Appendix D, clause 2 Appendix F, clause 4 Appendix L, clause 2
- BEZAFIBRATE
- Schedule 4
- BEZITRAMIDE
- Schedule 8
- BEZLOTOXUMAB
- Schedule 4
- BHC
- Schedule 6
- BIBROCATHOL
- Schedule 4
- BICALUTAMIDE
- Schedule 4
- BICTEGRAVIR
- Schedule 4
- BICYCLOPYRONE
- Schedule 6 Schedule 5
- BIFENAZATE
- Appendix B, clause 3
- BIFENTHRIN
- Schedule 7 Schedule 6
- BIFLUORIDES cross reference: AMMONIUM BIFLUORIDE, AMMONIUM SALTS, POTASSIUM SALTS, SODIUM SALTS
- Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1
- BIFONAZOLE
- Schedule 4 Schedule 2
- BILASTINE
- Schedule 4 Schedule 3
- Schedule 2 Appendix H, clause 1
- BIMATOPROST
- Schedule 4
- BINIMETINIB
- Schedule 4
- BIOALLETHRIN
- Schedule 6 Schedule 5
- BIORESMETHRIN
- Schedule 5
- BIPERIDEN
- Schedule 4
- BISACODYL
- Schedule 2
- 1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- BISMUTH COMPOUNDS cross reference: BISMUTH CITRATE, BISMUTH FORMIC IODIDE, BISMUTH OXYCHLORIDE, BISMUTH SUBIODIDE
- Schedule 4
- BISMUTH SUBNITRATE
- Appendix B, clause 3
- BISOPROLOL
- Schedule 4
- N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE cross reference: N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE cross reference: N,N-bIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- BISPYRIBAC
- Schedule 5
- BISTRIFLURON
- Appendix B, clause 3
- BITHIONOL
- cross reference: CAS No. 97-18-7
- Schedule 10 Schedule 6 Appendix F, clause 4
- BIURET
- Appendix B, clause 3
- BIVALIRUDIN
- Schedule 4
- BIXAFEN
- Schedule 5
- BIXLOZONE
- Appendix B, clause 3
- BLAD (banda de Lupinus albus doce)
- Appendix B, clause 3
- BLEOMYCIN
- Schedule 4
- BLINATUMOMAB
- Schedule 4
- BOCEPREVIR
- Schedule 4
- BOLANDIOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- BOLASTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- BOLAZINE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- BOLDENONE cross reference: DEHYDROTESTOSTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- BOLENOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- BOLMANTALATE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- BORAGO OFFICINALIS cross reference: BORAGE
- Schedule 10
- BORIC ACID cross reference: BORAX, SODIUM BORATE, POTASSIUM BORATE, MEA-BORATE, MIPA-BORATE
- Schedule 5
- Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- BORON cross reference: BORATES, BORAX, BORIC ACID, BORON COMPOUNDS
- Schedule 4
- BORON TRIFLUORIDE
- Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1
- BORTEZOMIB
- Schedule 4
- BOSCALID
- Appendix B, clause 3
- BOSENTAN
- Schedule 4 Appendix D, clause 6 Appendix F, clause 4 Appendix L, clause 2
- BOSUTINIB
- Schedule 4
- BOTULINUM TOXINS
- Schedule 4
- BOVINE SOMATOTROPHIN
- Appendix B, clause 3
- BPC-157
- Schedule 4
- Appendix D, clause 5
- BRAGANTIA spp
- Schedule 10
- BRENTUXIMAB VEDOTIN
- Schedule 4
- BRETYLIUM TOSILATE
- Schedule 4
- BRETYLIUM TOSYLATE
- cross reference: BRETYLIUM TOSILATE
- BREXPIPRAZOLE
- Schedule 4 Appendix K, clause 1
- BRIGATINIB
- Schedule 4
- BRIMONIDINE
- Schedule 4 Schedule 2
- BRINZOLAMIDE
- Schedule 4
- BRIVARACETAM
- cross reference: RACETAMS
- Schedule 4 Appendix K, clause 1
- BRODIFACOUM
- Schedule 7 Schedule 6 Appendix J, clause 1
- BROFLANILIDE
- Schedule 6 Schedule 5
- BROMACIL
- Appendix B, clause 3
- BROMADIOLONE
- Schedule 7 Schedule 6
- Appendix J, clause 1
- BROMAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- BROMETHALIN
- Schedule 7 Schedule 6
- BROMHEXINE
- Schedule 2
- BROMIDES
- Schedule 4
- BROMINE
- Schedule 7 Appendix J, clause 1
- 1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE cross reference: BROMO-DRAGONFLY (CAS No. 502759-67-3)
- Schedule 9
- BROMOCRIPTINE
- Schedule 4
- 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE cross reference: BDMPEA (CAS No. 66142-81-2)
- Schedule 9
- BROMOFORM
- Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- BROMOPHOS
- Schedule 6
- BROMOPHOS-ETHYL
- Schedule 6
- BROMOPROPYLATE
- Appendix B, clause 3
- BROMOXYNIL
- Schedule 7
- Schedule 6
- BROMPHENIRAMINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- BROMUCONAZOLE
- Schedule 6
- Schedule 5
- BROMVALETONE
- Schedule 4
- BROTIANIDE
- Schedule 6
- BRUCINE
- Schedule 7 Appendix E, clause 3 Appendix J, clause 1
- BRUGMANSIA spp.
- Schedule 4
- BUCLIZINE
- Schedule 4 Schedule 3
- Appendix K, clause 1
- BUCLOSAMIDE
- cross reference: CAS No. 575-74-6
- Schedule 10
- BUDESONIDE
- Schedule 4 Schedule 2
- BUFEXAMAC
- Schedule 4
- BUFOTENINE
- cross reference: CAS No. 487-93-4
- Schedule 9
- BULEVIRTIDE
- Schedule 4
- BUMETANIDE
- Schedule 4
- BUNAMIDINE
- Schedule 6
- BUNIODYL SODIUM
- cross reference: CAS No. 1923-76-8, BUNIODYL BASE (CAS No. 1233-53-0)
- Schedule 10
- BUPHENINE
- Schedule 4
- BUPIRIMATE
- Appendix B, clause 3
- BUPIVACAINE
- Schedule 5 Schedule 4
- BUPRENORPHINE
- Schedule 8 Appendix K, clause 1
- BUPROFEZIN
- Schedule 5
- BUPROPION cross reference: AMFEBUTAMONE
- Schedule 4
- BUSERELIN
- Schedule 4
- BUSPIRONE
- Schedule 4
- BUSULPHAN
- Schedule 4
- BUTACAINE
- Schedule 4
- BUTACARB
- Schedule 6
- BUTAFENACIL
- Appendix B, clause 3
- BUTAMBEN cross reference: BUTYL AMINOBENZOATE
- Schedule 4
- 1,4-BUTANEDIOL
- cross reference: CAS No. 110-63-4
- Schedule 10
- BUTHIDAZOLE
- Schedule 5
- BUTOBARBITAL
- Schedule 8 Appendix K, clause 1
- BUTOBARBITONE cross reference: BUTOBARBITAL
- BUTOCONAZOLE
- Schedule 4 Schedule 3 Appendix H, clause 1
- BUTONITAZENE
- cross reference: CAS No. 95810-54-1
- Schedule 9
- BUTORPHANOL
- Schedule 8
- BUTOXYCARBOXIM
- Schedule 6 Schedule 5
- 2-BUTOXYETHANOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- BUTOXYPOLYPROPYLENE GLYCOL
- Appendix B, clause 3
- 2-BUTOXY-2'-THIOCYANODIETHYL ETHER
- Schedule 6 Appendix F, clause 4
- BUTRACONAZOLE
- Schedule 4
- BUTRALIN
- Schedule 5
- BUTROXYDIM
- Schedule 5
- n-BUTYL ALCOHOL
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- BUTYL AMINOBENZOATE cross reference BUTAMBEN
- BUTYL BENZYL PHTHALATE
- cross reference: CAS No. 85-68-7
- Schedule 10
- n-BUTYL BUTYRATE
- Appendix B, clause 3
- n-BUTYL LACTATE
- Appendix B, clause 3
- BUTYL NITRITE
- Schedule 4 Appendix E, clause 3
- BUTYLCHLORAL HYDRATE
- Schedule 4
- BUTYRIC ACID
- Schedule 6
- C
- CABAZITAXEL
- Schedule 4
- CABERGOLINE
- Schedule 4
- CABOTEGRAVIR
- Schedule 4
- CABOZANTINIB
- Schedule 4
- CACALIA spp.
- Schedule 10
- CACODYLIC ACID
- Schedule 7 Schedule 6
- CADMIUM COMPOUNDS cross reference: CADMIUM, CADMIUM ACETATE, CADMIUM CHLORIDE, CADMIUM NITRATE
- Schedule 6 Schedule 4 Appendix E, clause 3
- CADUSAFOS
- Schedule 7 Schedule 6
- CAFFEINE cross reference: PARACETAMOL, ASPIRIN, SALICYLAMIDE
- Schedule 6 Schedule 4
- CAJUPUT OIL
- Schedule 6 Appendix E, clause 3
- CALCIFEDIOL
- Schedule 4
- CALCIFEROL
- Schedule 7 Schedule 6 Appendix J, clause 1
- CALCIPOTRIOL
- Schedule 4
- CALCITONIN SALMON
- Schedule 4
- CALCITRIOL
- Schedule 4
- CALCIUM CARBIMIDE
- Schedule 4
- CALCIUM HYDROXYLAPATITE
- Schedule 4
- CALCIUM POLYSTYRENE SULPHONATE
- Schedule 4
- CALOTROPIS GIGANTEA
- Schedule 4
- CALOTROPIS PROCERA
- Schedule 4
- CALUSTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- CAMBENDAZOLE
- Schedule 6
- CAMELLIA SINENSIS EXTRACT
- cross reference: GREEN TEA EXTRACT
- Schedule 5
- Appendix F, clause 4
- CAMPHOR cross reference: ESSENTIAL OILS, LAVANDIN OIL, ROSEMARY OIL, SHUI OIL
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- CAMPHORATED OIL
- Schedule 4
- CAMPHOTAMIDE
- Schedule 4
- CANAGLIFLOZIN
- Schedule 4
- CANAKINUMAB
- Schedule 4
- CANDESARTAN CILEXETIL
- Schedule 4
- CANDICIDIN
- Schedule 4
- CANINE TICK ANTI-SERUM
- Schedule 4
- CANNABICHROMENE cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
- CANNABIDIOL cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
- Schedule 4 Schedule 3 Appendix F, clause 4
- CANNABIDIOLIC ACID cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
- CANNABIDIVAROL cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
- CANNABIGEROL cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
- CANNABINOIDS cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
- CANNABINOL cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
- CANNABIS cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL, TETRAHYDROCANNABINOLS
- Schedule 9 Schedule 8 Appendix D, clause 1 Appendix K, clause 1
- CANTHARIDIN
- Schedule 4 Appendix G, clause 1
- CAPECITABINE
- Schedule 4
- CAPIVASERTIB
- Schedule 4
- CAPMATINIB
- Schedule 4
- CAPREOMYCIN
- Schedule 4
- CAPROMORELIN
- Schedule 4
- Appendix D, clause 5
- CAPTAFOL
- Schedule 7
- CAPTAN
- Schedule 6
- CAPTODIAME
- Schedule 4
- CAPTOPRIL
- Schedule 4
- CAPURIDE
- Schedule 4
- CARAMIPHEN
- Schedule 4
- CARBACHOL
- Schedule 4
- CARBADOX
- Schedule 7 Appendix J, clause 1
- CARBAMAZEPINE
- Schedule 4
- CARBAMIDE PEROXIDE
- cross reference: CAS No. 124-43-6
- Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- CARBARYL
- Schedule 6 Schedule 5 Schedule 4
- CARBAZOCHROME
- Schedule 4
- CARBENDAZIM
- Schedule 7
- CARBENICILLIN
- Schedule 4
- CARBENOXOLONE
- Schedule 4
- CARBETAMIDE
- Schedule 6
- CARBETAPENTANE
- Schedule 2
- CARBETOCIN
- Schedule 4
- CARBIDOPA
- Schedule 4
- CARBIMAZOLE
- Schedule 4
- CARBOCISTEINE
- Schedule 2
- CARBOCROMEN
- Schedule 4
- CARBOFURAN
- Schedule 7
- CARBON DISULFIDE
- Schedule 6 Appendix E, clause 3
- CARBON TETRACHLORIDE
- Schedule 7 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1
- CARBONYL SULFIDE
- Schedule 7
- Appendix J, clause 1
- CARBOPHENOTHION
- Schedule 7
- CARBOPLATIN
- Schedule 4
- CARBOPROST
- Schedule 4
- CARBOSULFAN
- Schedule 7
- CARBOXIN
- Appendix B, clause 3
- CARBROMAL
- Schedule 4
- CARBUTAMIDE
- Schedule 4
- CARBUTEROL
- Schedule 4
- CARDARINE
- cross reference: CAS No. 317318-70-0
- Schedule 10
- CARFENTANYL
- Schedule 8
- CARFENTRAZONE-ETHYL
- Appendix B, clause 3
- CARFILZOMIB.
- Schedule 4
- CARGLUMIC ACID
- Schedule 4
- CARINDACILLIN
- Schedule 4
- CARIPRAZINE
- Schedule 4
- CARISOPRODOL
- Schedule 4
- CARMUSTINE
- Schedule 4
- CARNIDAZOLE
- Schedule 4
- CARPROFEN
- Schedule 4
- CARVEDILOL
- Schedule 4
- CASIRIVIMAB
- Schedule 4
- CASPOFUNGIN
- Schedule 4
- CASSIA OIL
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- CASTOR OIL, MONOMALEATE
- Schedule 6
- CATHINE
- Schedule 4
- CATHINONES cross reference: SYNTHETIC CATHINONES
- Schedule 9
- CATUMAXOMAB
- Schedule 4
- CEDAZURIDINE
- Schedule 4
- CEFACETRILE cross reference: CEPHACETRILE
- Schedule 4
- CEFACLOR
- Schedule 4
- CEFADROXIL
- Schedule 4
- CEFALEXIN cross reference: CEPHALEXIN
- Schedule 4
- CEFALORIDINE cross reference: CEPHALORIDINE
- Schedule 4
- CEFALOTIN cross reference: CEPHALOTHIN, CEFALOTHIN
- Schedule 4
- CEFAMANDOLE cross reference: CEPHAMANDOLE
- Schedule 4
- CEFAPIRIN cross reference: CEPHAPIRIN
- Schedule 4
- CEFAZOLIN cross reference: CEPHAZOLIN
- Schedule 4
- CEFEPIME
- Schedule 4
- CEFETAMET
- Schedule 4
- CEFIDEROCOL
- Schedule 4
- CEFIXIME
- Schedule 4
- CEFODIZIME
- Schedule 4
- CEFONICID
- Schedule 4
- CEFOPERAZONE
- Schedule 4
- CEFOTAXIME
- Schedule 4
- CEFOTETAN
- Schedule 4
- CEFOTIAM
- Schedule 4
- CEFOVECIN
- Schedule 4
- CEFOXITIN
- Schedule 4
- CEFPIROME
- Schedule 4
- CEFPODOXIME
- Schedule 4
- CEFQUINOME
- Schedule 4
- CEFSULODIN
- Schedule 4
- CEFTAROLINE FOSAMIL
- Schedule 4
- CEFTAZIDIME
- Schedule 4
- CEFTIBUTEN
- Schedule 4
- CEFTIOFUR
- Schedule 4
- CEFTRIAXONE
- Schedule 4
- CEFUROXIME
- Schedule 4
- CELECOXIB
- Schedule 4 Schedule 3 Appendix H, clause 1
- CELIPROLOL
- Schedule 4
- CELLULASE derived from Aspergillus niger
- Appendix B, clause 3
- CENEGERMIN
- Schedule 4
- CEPHAELIS ACUMINATA cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA
- Schedule 4
- CEPHAELIS IPECACUANHA cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA
- Schedule 4
- CEPHALEXIN cross reference: CEFALEXIN
- CEPHALONIUM
- Schedule 4
- CEPHALOTHIN cross reference: CEFALOTIN
- CEPHRADINE
- Schedule 4
- CERAMICS
- Appendix A, clause 1
- CERITINIB
- Schedule 4
- CERIVASTATIN
- Schedule 4
- CERLIPONASE ALFA
- Schedule 4
- CERTOLIZUMAB PEGOL
- Schedule 4
- CERULETIDE
- Schedule 4
- CETIRIZINE
- Schedule 4 Schedule 2 Appendix K, clause 1
- CETRORELIX
- Schedule 4
- CETUXIMAB
- Schedule 4
- CETYL ALCOHOL
- Appendix B, clause 3
- CHAMOMILE OIL
- Appendix B, clause 3
- CHEMISTRY SETS
- Appendix A, clause 1
- CHENODEOXYCHOLIC ACID
- Schedule 4
- CHINA CLAY
- Appendix B, clause 3
- CHLOPHEDIANOL
- Schedule 2
- CHLORAL FORMAMIDE
- Schedule 4
- CHLORAL HYDRATE
- Schedule 4 Appendix K, clause 1
- CHLORALOSE cross reference: ALPHA-CHLORALOSE
- Schedule 6 Schedule 4
- CHLORAMBUCIL
- Schedule 4
- CHLORAMPHENICOL
- Schedule 4 Schedule 3
- CHLORANDROSTENOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- CHLORANTRANILIPROLE
- Appendix B, clause 3
- CHLORAZANIL
- Schedule 4
- CHLORBUTANOL
- Schedule 3 Schedule 2
- CHLORBUTOL cross reference: CHLOROBUTANOL
- CHLORCYCLIZINE
- Schedule 4
- CHLORDANE
- Schedule 6
- CHLORDECONE
- Schedule 7 Appendix J, clause 1
- CHLORDIAZEPOXIDE
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- CHLORDIMEFORM
- Schedule 7 Appendix J, clause 1
- CHLORFENAC
- Schedule 5
- CHLORFENAPYR
- Schedule 7 Schedule 6 Schedule 5
- CHLORFENETHOL
- Schedule 6
- CHLORFENSON
- Schedule 5
- CHLORFENVINPHOS
- Schedule 7
- CHLORFLUAZURON
- Appendix B, clause 3
- CHLORFLURENOL
- Appendix B, clause 3
- CHLORHEXIDINE
- Schedule 7 Schedule 6 Schedule 5
- CHLORIDAZON
- Appendix B, clause 3
- CHLORIDE
- Appendix E, clause 3
- CHLORINATING COMPOUNDS cross reference: BLEACHES, BROMOCHLORODIMETHYLHYDANTOIN, TRICHLOROISOCYANURIC ACID, CALCIUM HYPOCHLORITE, CHLORINE, DICHLOROETHYL ETHER,
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1
- CHLORINE cross reference: CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, DICHLOROISOCYANURIC ACID
- Schedule 7 Appendix G, clause 1 Appendix J, clause 1
- CHLORMEQUAT
- Schedule 6
- CHLORMERODRIN
- Schedule 4
- CHLORMETHIAZOLE
- Schedule 4 Appendix K, clause 1
- CHLORMEZANONE
- Schedule 4
- CHLORNIDINE
- Schedule 5
- CHLOROACETAMIDE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- CHLOROCRESOL
- Schedule 5 Appendix E, clause 3
- 2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- CHLOROFORM
- Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- 4-CHLOROMETHANDIENONE
- Schedule 4 Appendix D, clause D (Anabolic and/or androgenic steroidal agents)
- CHLOROMETHIURON
- Schedule 7 Appendix J, clause 1
- 5-CHLORO-3-METHYL-4-NITROPYRAZOLE
- Schedule 7
- 2-CHLORO-5-NITRO-N-HYDROXYETHYL-p-PHENYLENEDIAMINE cross reference: PHENYLENEDIAMINES
- CHLOROPHACINONE
- Schedule 6
- 2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE
- Schedule 4
- CHLOROPICRIN
- Schedule 7 Schedule 6
- CHLOROPICRIN
- Appendix J, clause 1
- CHLOROQUINE
- Schedule 4
- CHLOROTHALONIL
- Schedule 6
- CHLOROTHIAZIDE
- Schedule 4
- 4-CHLORO-o-TOLUIDINE
- Schedule 7 Appendix J, clause 1
- CHLOROTRIANISENE
- Schedule 4
- 2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE
- Schedule 6
- CHLOROXYDIENONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- CHLOROXYLENOLS
- Appendix B, clause 3
- CHLORPHENAMINE cross reference: CHLORPHENIRAMINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- CHLORPHENIRAMINE cross reference: CHLORPHENAMINE
- CHLORPHENTERMINE
- Schedule 4
- CHLORPROMAZINE
- Schedule 4 Appendix K, clause 1
- CHLORPROPAMIDE
- Schedule 4
- CHLORPROPHAM
- Schedule 5
- CHLORPROTHIXENE
- Schedule 4
- CHLORPYRIFOS
- Schedule 6 Schedule 5
- CHLORPYRIFOS-METHYL
- Schedule 6
- CHLORQUINALDOL
- Schedule 4
- CHLORSULFURON
- Schedule 5
- CHLORTALIDONE
- Schedule 4
- CHLORTETRACYCLINE
- Schedule 5 Schedule 4
- CHLORTHAL-DIMETHYL
- Schedule 7
- CHLORTHALIDONE cross reference: CHLORTALIDONE
- CHLORTHIAMID
- Schedule 6
- CHLORTHIOPHOS
- Schedule 7
- CHLORZOXAZONE
- Schedule 4
- CHOLECALCIFEROL cross reference: COLECALCIFEROL
- Schedule 7 Appendix J, clause 1
- CHOLERA VACCINE
- Schedule 4
- CHOLESTYRAMINE cross reference: COLESTYRAMINE
- CHOLIC ACID
- Schedule 4
- CHOLINE SALICYLATE
- Schedule 2
- CHROMATES cross reference: AMMONIUM CHROMATE, BARIUM CHROMATE, CHROMIUM, COPPER-CHROME-ARSENIC, DICHROMATES, POTASSIUM CHROMATE, ZINC CHROMATE SODIUM CHROMATE,
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- CHROMIUM TRICHLORIDE HEXAHYDRATE
- Schedule 6
- CHROMIUM TRIOXIDE cross reference: CHROMIC ACID
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- CHRYSOIDINE BASE
- cross reference: CAS No. 495-54-5
- Schedule 10 Schedule 6 Appendix E, clause 3
- CHYMOPAPAIN
- Schedule 4
- CICLACILLIN
- Schedule 4
- CICLESONIDE
- Schedule 4
- CICLOPIROX
- Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1
- CICLOSPORIN
- Schedule 4
- CIDOFOVIR
- Schedule 4
- CILASTATIN
- Schedule 4
- CILAZAPRIL
- Schedule 4
- CILGAVIMAB
- Schedule 4
- CILOSTAZOL
- Schedule 4
- CIMETIDINE
- Schedule 4 Schedule 3 Appendix F, clause 4
- CIMICOXIB
- Schedule 4
- CINACALCET
- Schedule 4
- CINCHOCAINE
- Schedule 4 Schedule 2
- CINCHOPHEN
- cross reference: CAS No. 132-60-5, CINCHOPHEN HYDROCHLORIDE (CAS No. 132-58-1), CINCHOPHEN SODIUM (CAS No. 5949-18-8)
- Schedule 10
- CINEOLE cross reference: CAMPHOR OIL (white), ROSEMARY OIL
- Schedule 6 Appendix E, clause 3
- CINMETHYLIN
- Schedule 5
- CINNAMEDRINE
- Schedule 2
- CINNAMON BARK OIL
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- CINNAMON LEAF OIL
- Schedule 6 Appendix E, clause 3
- CINNARIZINE
- Schedule 4
- CINOXACIN
- Schedule 4
- CIPAGLUCOSIDASE ALFA
- Schedule 4
- CIPROFLOXACIN
- Schedule 4
- CISAPRIDE
- Schedule 4
- CISATRACURIUM BESILATE cross reference: CISATRACURIUM BESYLATE
- Schedule 4
- CIS-JASMONE cross reference: (Z)-JASMONE
- Schedule 5
- CISPLATIN
- Schedule 4
- CITALOPRAM
- Schedule 4
- CITRONELLA OIL
- Appendix B, clause 3
- CJC-1295 (CAS No. 863288-34-0)
- Schedule 4 Appendix D, clause 5
- CLADRIBINE
- Schedule 4
- CLANOBUTIN
- Schedule 4
- CLARITHROMYCIN
- Schedule 4
- CLARY SAGE OIL
- Appendix B, clause 3
- CLASCOTERONE
- Schedule 4
- CLAVULANIC ACID
- Schedule 4
- CLEMASTINE
- Schedule 4 Schedule 3 Appendix K, clause 1
- CLEMIZOLE
- Schedule 4
- CLENBUTEROL
- Schedule 4
- CLETHODIM
- Schedule 5
- CLEVIDIPINE
- Schedule 4
- CLIDINIUM BROMIDE
- Schedule 4
- CLIMBAZOLE
- Schedule 6 Schedule 5 Appendix E, clause 3
- CLINDAMYCIN
- Schedule 4
- CLIOQUINOL cross reference: OXYQUINOLINE, CHLORQUINALDOL, HALQUINOL (CAS No. 130-26-7)
- Schedule 10 Schedule 4
- CLITORIA TERNATEA EXTRACT
- Appendix B, clause 3
- CLOBAZAM
- Schedule 4
- CLOBETASOL
- Schedule 4
- CLOBETASONE
- Schedule 4 Schedule 3 Appendix F, clause 4
- Appendix H, clause 1
- CLOCORTOLONE
- Schedule 4
- CLODINAFOP-PROPARGYL
- Schedule 6
- CLODRONIC ACID cross reference: SODIUM CLODRONATE
- Schedule 4
- CLOFARABINE
- Schedule 4
- CLOFAZIMINE
- Schedule 4
- CLOFENAMIDE
- Schedule 4
- CLOFENTEZINE
- Schedule 5
- CLOFIBRATE
- Schedule 4
- CLOMAZONE
- Schedule 6
- CLOMIFENE cross reference: CLOMIPHENE
- Schedule 4 Appendix D, clause 1
- CLOMIPHENE cross reference: CLOMIFENE
- CLOMIPRAMINE
- Schedule 4 Appendix K, clause 1
- CLOMOCYCLINE
- Schedule 4
- CLONAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- CLONAZOLAM
- cross reference: CAS No. 33887-02-4
- Schedule 9
- CLONIDINE
- Schedule 4 Appendix K, clause 1
- CLONITAZENE
- cross reference: CAS No. 3861-76-5
- Schedule 9
- CLOPAMIDE
- Schedule 4
- CLOPIDOGREL
- Schedule 4
- CLOPIDOL
- Appendix B, clause 3
- CLOPROSTENOL
- Schedule 4
- CLOPYRALID
- Schedule 5
- CLOQUINTOCET
- Schedule 5
- CLORAZEPATE
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- CLOREXOLONE
- Schedule 4
- CLORPRENALINE
- Schedule 4
- CLORSULON
- Schedule 5
- CLOSANTEL
- Schedule 6
- CLOSTEBOL cross reference: 4-CHLOROTESTOSTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- CLOTHIANIDIN
- Schedule 6 Schedule 5
- CLOTRIMAZOLE
- Schedule 6 Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1
- CLOVE OIL
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- CLOXACILLIN
- Schedule 4
- CLOZAPINE
- Schedule 4 Appendix D, clause 1 Appendix K, clause 1
- COAL TAR
- Schedule 10
- COBALT cross reference: DICOBALT EDETATE
- Schedule 4
- COBALT NAPHTHENATE
- Appendix B, clause 3
- COBICISTAT
- Schedule 4
- COBIMETINIB
- Schedule 4
- COCA LEAF
- Schedule 9
- COCAINE
- Schedule 8
- N-COCO-1,3-DIAMINOPROPANE
- Schedule 6
- COCOYL GLYCINATE
- Schedule 6 Appendix E, clause 3
- COCOYL METHYL GLUCAMAIDE cross reference: 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES
- CODEINE
- Schedule 8 Schedule 4 Appendix K, clause 1
- CODEINE-N-OXIDE
- Schedule 8
- CO-DERGOCRINE
- Schedule 4
- CODOXIME
- cross reference: CAS No. 7125-76-0
- Schedule 9
- COLASPASE cross reference: ASPARAGINASE
- COLCHICINE
- Schedule 4
- COLCHICUM AUTUMNALE
- Schedule 4
- COLECALCIFEROL cross reference: CHOLECALCIFEROL
- Schedule 7 Appendix J, clause 1
- COLESTIPOL
- Schedule 4
- COLESTYRAMINE
- Schedule 4
- COLFOSCERIL PALMITATE
- Schedule 4
- COLISTIN
- Schedule 4
- COLLAGEN
- Schedule 4
- COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
- Schedule 4
- COLURACETAM cross reference: RACETAMS
- Schedule 4
- CONCENTRATE OF POPPY STRAW
- Schedule 8
- CONCIZUMAB
- Schedule 4
- CONIUM MACULATUM cross reference: CONIINE (CAS No. 3238-60-6), CONIINE R-ISOMER (CAS No. 5985-99-9), CONIINE S-ISOMER (CAS No. 458-88-8)
- Schedule 10
- CONVALLARIA KEISKI
- Schedule 4
- CONVALLARIA MAJALIS
- Schedule 4
- COPPER ACETATE
- Schedule 6 Schedule 5
- COPPER COMPOUNDS cross reference: COPPER
- Schedule 6 Schedule 5 Schedule 4 Appendix A, clause 1
- COPPER HYDROXIDE
- Schedule 6 Schedule 5
- COPPER NITRATE cross reference: COPPER CHLORIDE
- Schedule 6
- COPPER OXIDES
- Schedule 6 Schedule 5
- COPPER OXYCHLORIDE
- Schedule 6 Schedule 5
- COPPER SULFATE
- Schedule 6 Schedule 5 Appendix E, clause 3
- CORIFOLLITROPIN ALFA cross reference: FOLLICLE STIMULANT, RECOMBINANT
- Schedule 4 Appendix D, clause 1
- CORONILLA spp.
- Schedule 4
- CORTICOSTERONE
- Schedule 4
- CORTICOTROPHIN
- Schedule 4
- CORTISONE
- Schedule 4
- COTARNINE
- cross reference: CAS No. 82-54-2, COTARNINE HYDROCHLORIDE (CAS No. 36647-02-6), COTARNINE CHLORIDE (CAS No. 10018-19-6)
- Schedule 10
- CO-TRIMOXAZOLE
- Schedule 4
- COUMAPHOS
- Schedule 7 Schedule 6
- COUMARIN
- Schedule 4
- COUMATETRALYL
- Schedule 7 Schedule 6 Schedule 5 Appendix J, clause 1
- 4-CPA
- Schedule 5
- CREOSOTE cross reference: BEECHWOOD, PHENOL, WOOD
- Schedule 7 Schedule 6 Schedule 2 Appendix E, clause 3
- CRESOLS
- Appendix E, clause 3
- CRISABOROLE
- Schedule 4
- CRIZOTINIB
- Schedule 4
- CROFELEMER
- Schedule 4
- CROSPOVIDONE
- Appendix B, clause 3
- CROTALARIA spp.
- Schedule 10
- CROTON TIGLIUM cross reference: CROTON OIL
- Schedule 10 Appendix G, clause 1
- CROTOXYPHOS
- Schedule 6
- CRUFOMATE
- Schedule 6
- CRYSTAL VIOLET cross reference: METHYLROSANILINIUM CHLORIDE, GENTIAN VIOLET
- CULICINOMYCES CLAVOSPORUS
- Appendix B, clause 3
- CUPRIMYXIN
- Schedule 4
- CURARE
- Schedule 4
- 13C-UREA
- Appendix B, clause 3
- CYANAMIDE
- Schedule 6
- CYANATRYN
- Schedule 5
- CYANAZINE
- Schedule 6
- CYANIDES cross reference: FERRICYANIDES, FERROCYANIDES
- Schedule 7 Appendix E, clause 3 Appendix F, clause 4
- CYANOACRYLATE ESTERS
- Schedule 5
- CYANOACRYLIC ACID ESTERS
- Appendix E, clause 3
- 4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE cross reference: METHADONE INTERMEDIATE (CAS No. 125-79-1)
- Schedule 9
- CYANOGEN cross reference: ETHANEDINITRILE, OXALONITRILE
- Schedule 7 Appendix J, clause 1
- 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE cross reference: PETHIDINE INTERMEDIATE A
- Schedule 8
- CYANTRANILIPROLE
- Schedule 5
- CYANURIC ACID
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- CYAZOFAMID
- Schedule 5
- CYCLAMIC ACID
- Appendix B, clause 3
- CYCLANDELATE
- Schedule 4
- CYCLANILIDE
- Schedule 6
- CYCLANILIPROLE
- Appendix B
- CYCLIZINE
- Schedule 4 Schedule 3 Appendix K, clause 1
- CYCLOBARBITAL
- Schedule 8 Appendix K, clause 1
- CYCLOBARBITONE cross reference: CYCLOBARBITAL
- CYCLOBENZAPRINE
- Schedule 4
- CYCLOBUTRIFLURAM
- Appendix B, clause 3
- CYCLOFENIL
- Schedule 4 Appendix D, clause 1
- CYCLOHEXANE
- Appendix B, clause 3
- CYCLOHEXANOL ACETATE
- Appendix B, clause 3
- CYCLOHEXANONE PEROXIDE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- CYCLOHEXIMIDE
- Schedule 4
- N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM cross reference: K-HDO
- Schedule 6
- CYCLOHEXYLPHENOLS
- Schedule 9
- CYCLOPENTHIAZIDE
- Schedule 4
- CYCLOPENTOLATE
- Schedule 4
- CYCLOPHOSPHAMIDE
- Schedule 4
- CYCLOPROPANE
- Schedule 4
- CYCLOPROTHRIN
- Schedule 5
- CYCLOSERINE
- Schedule 4 Appendix J, clause 1
- CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2)
- Schedule 7 Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- CYCLOSPORIN cross reference: CICLOSPORIN
- CYCLOTHIAZIDE
- Schedule 4
- CYCLOXYDIM
- Schedule 5
- CYCRIMINE
- Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- CYFLUFENAMID
- Schedule 5
- CYFLUMETOFEN
- Schedule 5
- CYFLUTHRIN
- Schedule 6 Schedule 5
- CYHALOFOP-BUTYL
- Schedule 5
- CYHALOTHRIN
- Schedule 7
- CYHEXATIN
- Schedule 7
- CYMARIN
- Schedule 4
- CYMIAZOLE
- Schedule 5
- CYNOGLOSSUM spp.
- Schedule 10
- CYOMETRINIL
- Schedule 6
- CYPERMETHRIN cross reference: ALPHA-CYPERMETHRIN AND BETA-CYPERMETHRIN, ZETA-CYPERMETHRIN
- Schedule 6 Schedule 5
- CYPHENOTHRIN
- Schedule 6 Schedule 5
- CYPRINID HERPESVIRUS-3
- Appendix B, clause 3
- CYPROCONAZOLE
- Schedule 5
- CYPRODINIL
- Schedule 5
- CYPROHEPTADINE
- Schedule 4 Schedule 3 Appendix K, clause 1
- CYPROTERONE
- Schedule 4
- CYROMAZINE
- Appendix B, clause 3
- CYSTEAMINE cross reference: MERCAPTAMINE
- CYTARABINE
- Schedule 4
- CYTHIOATE
- Schedule 6 Schedule 5
- CYTISINE
- Schedule 4 Schedule 3 Appendix H, clause 1
- D
- 2,4-D
- Schedule 6 Schedule 5
- DABIGATRAN
- Schedule 4
- DABRAFENIB MESILATE
- Schedule 4
- DACARBAZINE
- Schedule 4
- DACLATASVIR
- Schedule 4
- DACLIZUMAB
- Schedule 4
- DACTINOMYCIN
- Schedule 4
- DALFOPRISTIN
- Schedule 4
- DALTEPARIN
- Schedule 4
- DAMINOZIDE
- Schedule 5
- DANAPAROID
- Schedule 4
- DANAZOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- DANICOPAN
- Schedule 4
- DANTHRON
- Schedule 4
- DANTROLENE
- Schedule 4
- Appendix K, clause 1
- DAPAGLIFLOZIN
- Schedule 4
- DAPOXETINE
- Schedule 4
- DAPSONE
- Schedule 4
- DAPTOMYCIN
- Schedule 4
- DARATUMUMAB
- Schedule 4
- DARBEPOETIN
- Schedule 4 Appendix D, clause 5
- DARIFENACIN
- Schedule 4
- DAROLUTAMIDE
- Schedule 4
- DARUNAVIR
- Schedule 4
- DASABUVIR
- Schedule 4
- DASATINIB
- Schedule 4
- DATOPOTAMAB DERUXTECAN
- Schedule 4
- DATURA spp.
- Schedule 4 Schedule 2
- DATURA STRAMONIUM cross reference: STRAMONIUM
- Schedule 4 Schedule 2
- DATURA TATULA cross reference: STRAMONIUM
- Schedule 4 Schedule 2
- DAUNORUBICIN
- Schedule 4
- DAZOMET
- Schedule 6
- 2,4-DB
- Schedule 5
- DEANOL cross reference: 2-(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA
- Schedule 4
- DEBRISOQUINE
- Schedule 4
- DECAMETHONIUM
- Schedule 4
- DECITABINE
- Schedule 4
- DECOQUINATE
- Schedule 5
- DEFERASIROX
- Schedule 4
- DEFERIPRONE
- Schedule 4
- DEFIBROTIDE
- Schedule 4
- DEFLAZACORT
- Schedule 4
- DEGARELIX
- Schedule 4
- DEHYDROCHLOROMETHYLTESTOSTERONE cross reference: CHLOROMESTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- DEHYDROCORTICOSTERONE
- Schedule 4
- DELAVIRDINE cross reference: DELAVIRDINE MESILATE
- DELAVIRDINE MESILATE
- Schedule 4
- DELGOCITINIB
- Schedule 4
- DELPHINIUM STAPHISAGRIA cross reference: STAPHISAGRIA
- Schedule 2
- DELTAMETHRIN
- Schedule 7 Schedule 6 Schedule 5
- DEMBREXINE
- Schedule 5 Schedule 4
- DEMECARIUM
- Schedule 4
- DEMECLOCYCLINE
- Schedule 4
- DEMETON
- Schedule 7
- DEMETON-O-METHYL
- Schedule 7
- DEMETON-S-METHYL
- Schedule 7
- DENGUE VACCINE cross reference: LIVE ATTENUATED CHIMERIC DENGUE VIRUS (SEROTYPES 1, 2, 3 and 4)
- Schedule 4
- DENOSUMAB
- Schedule 4
- DEOXYCHOLIC ACID
- Schedule 4
- DEOXYCORTONE
- Schedule 4
- 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES cross reference: COCOYL METHYL GLUCAMAIDE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- DEOXYRIBONUCLEASE
- Schedule 4
- DEPEMOKIMAB
- Schedule 4
- DERACOXIB
- Schedule 4
- DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT
- Schedule 4
- DERQUANTEL
- Schedule 6
- 2,4-DES
- Schedule 5
- DESCHLOROETIZOLAM
- cross reference: CAS No. 40054-73-7
- Schedule 9
- DESFERRIOXAMINE
- Schedule 4
- DESFLURANE
- Schedule 4
- DESIPRAMINE
- Schedule 4 Appendix K, clause 1
- DESIRUDIN
- Schedule 4
- DESLANOSIDE
- Schedule 4
- DESLORATADINE
- Schedule 4 Schedule 2
- DESLORELIN
- Schedule 4
- DESMOPRESSIN cross reference: D.D.A.V.P.
- Schedule 4
- DESOGESTREL
- Schedule 4
- DESOMORPHINE
- cross reference: CAS No. 427-00-9
- Schedule 9
- DESONIDE
- Schedule 4
- DESOXYMETHASONE
- Schedule 4
- DESVENLAFAXINE
- Schedule 4
- DETOMIDINE
- Schedule 4
- DEUCRAVACITINIB
- Schedule 4
- DEUTETRABENAZINE
- Schedule 4 Appendix K, clause 1
- DEUTIVACAFTOR
- Schedule 4
- DEXAMETHASONE
- Schedule 4
- DEXAMFETAMINE cross reference: DEXAMPHETAMINE
- Schedule 8
- DEXCHLORPHENAMINE cross reference: DEXCHLORPHENIRAMINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- DEXCHLORPHENIRAMINE cross reference: DEXCHLORPHENAMINE
- DEXFENFLURAMINE
- Schedule 4
- DEXMEDETOMIDINE
- Schedule 4
- DEXRAZOXANE
- Schedule 4
- DEXTRANS
- Appendix A
- DEXTROMETHORPHAN
- Schedule 4 Schedule 2
- DEXTROMORAMIDE cross reference: MORAMIDE
- Schedule 8 Appendix K, clause 1
- DEXTROPROPOXYPHENE
- Schedule 8 Schedule 4 Appendix D, clause 5 Appendix K, clause 1
- DEXTRORPHAN
- Schedule 4
- N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES cross reference:3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBENZAMIDE *(U-47700) (CAS No. 82657-23-
- Schedule 9
- N,N-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES Cross reference:3,4-DICHLORO-N-{[1-(DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH-7921) (CAS No. 55154-30-8)
- Schedule 9
- 4,4-DIAMINODIPHENYLMETHANE cross reference: METHYLENE DIANILINE
- Schedule 7 Appendix F, clause 4 Appendix J, clause 1
- 2,4-DIAMINO-5-METHYLPHENETOLE cross reference: PHENYLENEDIAMINES
- 2,4-DIAMINOPHENOXYETHANOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- DIAFENTHIURON
- Schedule 5
- DIALIFOS
- Schedule 7
- N,N-DIALLYLDICHLOROACETAMIDE
- Schedule 5
- DIAMPROMIDE
- cross reference: CAS No. 552-25-0
- Schedule 9
- DIAMTHAZOLE
- Schedule 4
- DIAVERIDINE
- Schedule 4
- DIAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- DIAZINON
- Schedule 6 Schedule 5
- DIAZOXIDE
- Schedule 4
- DIBENZEPIN
- Schedule 4
- DIBENZOPYRANS
- Schedule 9
- DIBOTERMIN
- Schedule 4
- 1,2-DIBROMO-3-CHLOROPROPANE
- Schedule 7 Appendix J, clause 1
- DIBROMOPROPAMIDINE
- Schedule 4 Schedule 2
- DIBUTYL PHTHALATE
- cross reference: CAS No. 84-74-2
- Schedule 10
- DICAMBA
- Schedule 6 Schedule 5
- DICLAZEPAM
- cross reference: CAS No. 2894-68-0
- Schedule 9
- DICHLOBENIL
- Schedule 6
- o-DICHLOROBENZENE
- Appendix F, clause 4
- DICHLOEOETHYL ETHER
- Appendix F, clause 4
- DICHLOFENTHION
- Schedule 6
- DICHLOFLUANID
- Schedule 6
- DICHLONE
- Schedule 5
- DICHLORALPHENAZONE
- Schedule 4
- DICHLOROBENZENE
- Schedule 6 Schedule 5 Appendix E, clause 3
- 3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBENZAMIDE (U-47700) cross reference: N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES (CAS No. 82657-23-
- Schedule 9
- DICHLOROETHYL ETHER
- Schedule 6 Appendix E, clause 3
- DICHLOROETHYLENE
- Appendix F, clause 4
- DICHLOROISOCYANURIC ACID cross reference: CHLORINE, CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, SODIUM DICHLOROISOCYANURATE
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- DICHLOROMETHANE cross reference: METHYLENE CHLORIDE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- 3,4-DICHLORO-N-{[1-DIMETHYLAMINO)CYCLOHEXYL]METHYL} BENZAMIDE cross reference: AH-7921 (CAS No. 55154-30-8)
- Schedule 9
- 4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE
- Schedule 6
- DICHLOROPHEN
- Schedule 6 Schedule 5 Schedule 4
- 2,4-DICHLORPROP
- Schedule 6
- 1,2-DICHLOROPROPANE
- Schedule 6
- 1,3-DICHLOROPROPENE
- Schedule 7 Appendix J, clause 1
- DICHLORPHENAMIDE
- Schedule 4
- DICHLORVOS
- Schedule 7 Schedule 6 Schedule 5
- DICHROMATES
- Appendix E, clause 3
- DICLAZURIL
- Appendix B, clause 3
- DICLOBUTRAZOL
- Schedule 5
- DICLOFENAC
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1
- DICLOFOP-METHYL
- Schedule 6
- DICLORAN
- Schedule 5
- DICLOXACILLIN
- Schedule 4
- DICOFOL
- Schedule 5
- DICOPHANE cross reference: DDT (CAS No. 50-29-3)
- Schedule 10
- DICROTOPHOS
- Schedule 7
- DICYCLANIL
- Schedule 6
- DICYCLOMINE
- Schedule 4
- DIDANOSINE
- Schedule 4
- DIDECYLDIMETHYLAMMONIUM SALTS
- Schedule 6
- DIELDRIN
- Schedule 6
- DIENESTROL
- Schedule 4 Appendix F, clause 4 Appendix L, clause 2
- DIENOGEST
- Schedule 4
- DIESEL
- Appendix E, clause 3
- DIETHANOLAMINE
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- DIETHAZINE
- Schedule 4
- DIETHYL CARBONATE
- Appendix B, clause 3
- DIETHYLCARBAMAZINE
- Schedule 4
- DIETHYLENE GLYCOL cross reference: DENATONIUM BENZOATE (CAS No. 111-46-6)
- Schedule 10 Schedule 6 Schedule 5
- DIETHYLENE GLYCOL MONOBUTYL ETHER
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- DIETHYLENE GLYCOL MONOMETHYL ETHER
- cross reference: CAS No. 111-77-3
- Schedule 10 Schedule 6
- DIETHYLHEXYL PHTHALATE
- cross reference: DEHP (CAS No. 117-81-7)
- Schedule 10
- DIETHYLPHTHALATE
- cross reference: CAS No. 84-66-2
- Schedule 10
- DIETHYLPROPION
- Schedule 4
- DIETHYLTHIAMBUTENE
- cross reference: CAS No. 86-14-6, DIETHYLTHIAMBUTENE HYDROCHLORIDE (CAS No. 132-19-4)
- Schedule 9
- DIETHYLTOLUAMIDE (DEET)
- Schedule 5 Appendix F, clause 4
- N,N-DIETHYLTRYPTAMINE cross reference: DET (CAS No. 61-51-8)
- Schedule 9
- DIFELIKEFALIN
- Schedule 4 Appendix K, clause 1
- DIFENACOUM
- Schedule 7 Schedule 6 Appendix J, clause 1
- DIFENOCONAZOLE
- Schedule 5
- DIFENOXIN
- Schedule 8 Schedule 4 Appendix K, clause 1
- DIFENZOQUAT
- Schedule 6
- DIFETHIALONE
- Schedule 7 Schedule 6
- DIFLORASONE
- Schedule 4
- DIFLOXACIN
- Schedule 4
- DIFLUBENZURON
- Schedule 5
- DIFLUCORTOLONE
- Schedule 4
- DIFLUFENICAN
- Appendix B, clause 3
- DIFLUNISAL
- Schedule 4
- DIGITALIS LANATA
- Schedule 4
- DIGITALIS PURPUREA
- Schedule 4
- DIGITOXIN
- Schedule 4
- DIGOXIN
- Schedule 4
- DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab)
- Schedule 4
- DIHYDRALAZINE
- Schedule 4
- DIHYDROCODEINE
- Schedule 8 Schedule 4 Schedule 3 Appendix K, clause 1
- DIHYDROERGOTOXINE
- Schedule 4
- DIHYDROLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- 2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-B]INDOL-1-ONE (SGT-151) cross reference: SGT-151, CUMYL-PEGACLONE (CAS No. 2160555-55-3)
- Schedule 9
- DIHYDROMORPHINE
- Schedule 8
- DIHYDROSTREPTOMYCIN
- Schedule 4
- DIHYDROTACHYSTEROL
- Schedule 4
- 5,6-DIHYDROXYINDOLINE
- cross reference: CAS No. 29539-03-5, 5,6-DIHYDROXYINDOLINE HYDROBROMIDE (CAS No. 138937-28-7)
- Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- DIIODOHYDROXYQUINOLINE cross reference: IODOQUINOL (CAS No. 83-73-8)
- Schedule 10 Schedule 4 Schedule 3
- DI-IODOHYDROXYQUINOLINE cross reference: DIIODOHYDROXYQUINOLINE
- DIISOBUTYL PHTHALATE
- cross reference: CAS No. 84-69-5
- Schedule 10
- DIISOPROPYLAMINE DICHLOROACETATE
- Schedule 4
- DIKEGULAC-SODIUM
- Appendix B, clause 3
- DILTIAZEM
- Schedule 4
- DIMEFOX
- Schedule 7
- DIMENHYDRINATE
- Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 Appendix K, clause 1
- DIMENOXADOL
- cross reference: CAS No. 509-78-4, DIMENOXADOL HYDROCHLORIDE (CAS No. 2424-75-1)
- Schedule 9
- DIMEPHEPTANOL
- cross reference: CAS No. 545-90-4
- Schedule 9
- DIMERCAPROL
- Schedule 4
- DIMETHANDROSTANOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- DIMETHAZINE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- DIMETHENAMID-P
- Schedule 6
- DIMETHICODIETHYLBENZALMALONATE cross reference: POLYSILICONE-15
- Schedule 5
- DIMETHICONE cross reference: DIMETICONE
- DIMETHINDENE
- Schedule 4 Appendix K, clause 1
- DIMETHIPIN
- Schedule 6
- DIMETHIRIMOL
- Schedule 5
- DIMETHOATE
- Schedule 6
- DIMETHOMORPH
- Schedule 5
- DIMETHOTHIAZINE
- Schedule 4
- DIMETHOXANATE
- Schedule 4
- 2,5-DIMETHOXYAMFETAMINE cross reference: 2,5-DIMETHOXYAMPHETAMINE, DMA (CAS No. 2801-68-5), DMA HYDROCHLORIDE (CAS No. 24973-25-9)
- Schedule 9
- 2,5-DIMETHOXY-4-BROMOAMFETAMINE cross reference: 2,5-DIMETHOXY-4-BROMOAMPHETAMINE, DOB (CAS No. 64638-07-9)
- Schedule 9
- 2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE cross reference: 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE, DOET (CAS No. 22004-32-6), DOET HYDROCHLORIDE (CAS No. 22139-65-7)
- Schedule 9
- 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE cross reference: 2C-T-2 (CAS No. 207740-24-7)
- Schedule 9
- 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE cross reference: 2C-I (CAS No. 69587-11-7)
- Schedule 9
- 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE cross reference: 2C-T-7 (CAS No. 207740-26-9)
- Schedule 9
- 2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE
- Schedule 6 Appendix F, clause 4
- DIMETHYLACETAMIDE
- Schedule 6 Schedule 5
- N,N-DIMETHYLAMFETAMINE cross reference: N,N-DIMETHYLAMPHETAMINE, DIMETAMFETAMINE (CAS No. 4075-96-1), DIMETAMFETAMINE S-ISOMER (CAS No. 17279-39-9)
- Schedule 9
- 4-DIMETHYLAMINOAZOBENZENE cross reference: MOCA, N,N-DIMETHYL-4-[PHENYLAZO]-BENZENAMINE
- Schedule 7 Appendix J, clause 1
- 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE cross reference: PSILOCINE, PSILOTSIN (CAS No. 520-53-6)
- Schedule 9
- 1,3-DIMETHYLAMYLAMINE cross reference: 4-METHYLHEXANE-2-AMINE, DMAA (CAS No. 105-41-9)
- Schedule 10
- 1,3-DIMETHYLBUTYLAMINE (DMBA) cross reference: OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 1,5-DIMETHYLHEXYLAMINE, 4-METHYLHEXANE-2-AMINE, 1,3-DIMETHYLAMYLAMINE, DMAA,
- Schedule 10
- 4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- N,N-DIMETHYLDECANAMIDE
- Schedule 6
- DIMETHYL DISULFIDE
- Schedule 6
- DIMETHYL ETHER
- Appendix B, clause 3
- 1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette) cross reference: AMBER MUSK (CAS No. 83-66-9)
- Schedule 10
- DIMETHYLFORMAMIDE cross reference: DESIGNATED SOLVENT
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- DIMETHYL FUMARATE
- Schedule 4
- 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN cross reference: DMHP (CAS No. 32904-22-6)
- Schedule 9
- 1,5-DIMETHYLHEXYLAMINE (DMHA) cross reference: 1,3-DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 4-METHYLHEXANE-2-AMINE, 1,3-DIMETHYLAMYLAMINE,
- Schedule 10
- N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) cross reference: 3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE, MDMA, MIDOMAFETAMINE (CAS No. 4254
- Schedule 9 Schedule 8 Appendix D, clause 5 Appendix D, clause 9
- 1,4-DIMETHYLNAPHTHALENE
- Schedule 5
- 3,7-DIMETHYL-2,6-OCTADIENAL cross reference: CITRAL, NERAL, GERANIAL
- Schedule 5
- 3,7-DIMETHYL-2,6-OCTADIEN-1-OL cross reference: GERANIOL, NEROL, CITROL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- N,N-DIMETHYLOCTANAMIDE
- Schedule 6
- DI(METHYLOXYETHYL) PHTHALATE
- cross reference: CAS No. 117-82-8
- Schedule 10
- 1,4-DIMETHYLPENTYLAMINE (DMPA) cross reference: 1,4-DIMETHYLAMYLAMINE (DMAA) (CAS No. 28292-43-5)
- Schedule 10
- DIMETHYLPHTHALATE
- cross reference: CAS No. 131-11-3
- Schedule 10
- DIMETHYL SULFATE
- Schedule 7 Appendix F, clause 4
- DIMETHYL SULFOXIDE cross reference: COPPER SALICYLATE, METHYL SALICYLATE
- Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- DIMETHYLTHIAMBUTENE
- cross reference: CAS No. 524-84-5
- Schedule 9
- N,N-DIMETHYLTRYPTAMINE cross reference: DMT (CAS No. 61-50-7)
- Schedule 9
- DIMETICONE cross reference: DIMETHICONE
- Appendix B, clause 3
- DIMETILAN
- Schedule 7
- DIMETRIDAZOLE
- Schedule 4
- DIMIRACETAM cross reference: RACETAMS
- Schedule 4
- DIMPROPYRIDAZ
- Schedule 6
- Schedule 5
- DINICONAZOLE
- Schedule 5
- 2,4-DINITROCHLOROBENZENE
- Schedule 4
- DINITROCRESOLS
- Schedule 7 Schedule 6 Schedule 4 Appendix E, clause 3 Appendix J, clause 1
- DINITRONAPHTHOLS
- Schedule 4
- 2,4-DINITROPHENOL cross reference: CAS No. 51-28-5 Schedule 10
- DINITROPHENOLS
- Schedule 10
- Schedule 7 Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1
- DINITROTHYMOLS
- Schedule 4
- DINOCAP
- Schedule 7 Appendix F, clause 4
- DINOPROST
- Schedule 4 Appendix D, clause 1
- DINOPROSTONE
- Schedule 4 Appendix D, clause 1
- DINOSEB
- Schedule 7 Appendix J, clause 1
- DINOTEFURAN
- Schedule 5
- DI-n-PROPYL ISOCINCHOMERONATE (previously di-N propyl isocinchomeronate)
- Schedule 5
- DIOXACARB
- Schedule 6
- DIOXANE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- DIOXAPHETYL BUTYRATE
- cross reference: CAS No. 467-86-7
- Schedule 9
- DIPERODON
- Schedule 4
- DIPHACINONE
- Schedule 6
- DIPHEMANIL
- Schedule 4
- DIPHENAMID
- Schedule 5
- DIPHENHYDRAMINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- DIPHENIDINE
- cross reference: CAS No. 28383-15-5 Schedule 9
- DIPHENIDOL
- Schedule 4
- DIPHENOXYLATE
- Schedule 8 Schedule 4 Schedule 3 Appendix F, clause 4 Appendix H, clause 1 Appendix K, clause 1
- DIPHENYLAMINE
- Appendix B, clause 3
- DIPHENYLPYRALINE
- Schedule 4 Appendix K, clause 1
- DIPHTHERIA TOXOID
- cross reference: TRIPLE ANTIGEN VACCINE
- Schedule 4
- DIPIPANONE
- Schedule 8
- DIPIVEFRIN
- Schedule 4
- DIPROPYLENE GLYCOL
- Appendix B, clause 3
- DIPYRIDAMOLE
- Schedule 4
- DIQUAT
- Schedule 7 Schedule 6
- DIRECT RED 254 cross reference: 2-NAPHTHALENESULFONIC ACID, 7-AMINO-4-HYDROXY-3-[[p-[(p-SULFOPHENYL)AZO]PHENYL]AZO]-, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)D
- Schedule 6 Schedule 5
- DIRITHROMYCIN
- Schedule 4
- DIRLOTAPIDE
- Schedule 4
- DIROXIMEL FUMARATE
- Schedule 4
- DISODIUM MANGANESE EDTA
- Appendix B, clause 3
- DISOPHENOL
- Schedule 4
- DISOPYRAMIDE
- Schedule 4
- DISPERSE YELLOW 3
- cross reference: CAS No. 2832-40-8
- Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- DISTIGMINE
- Schedule 4
- DISTILLATE
- Appendix E, clause 3
- DISULFIRAM
- Schedule 6 Schedule 4
- DISULFOTON
- Schedule 7 Schedule 6
- DISULPHAMIDE
- Schedule 4
- DITHIANON
- Schedule 6
- DITHIAZANINE
- Schedule 6 Schedule 4
- DITHIOPYR
- Schedule 5
- DITHRANOL
- Schedule 3
- DITIOCARB
- Schedule 4
- DIUREDOSAN
- Schedule 6
- DIURON
- Appendix B, clause 3
- DOBUTAMINE
- Schedule 4
- DOCETAXEL
- Schedule 4
- DOCUSATE SODIUM cross reference: DIOCTYL SODIUM SULFOSUCCINATE
- Appendix B, clause 3
- (Z,E)-7,9,11-DODECATRIENYL FORMATE Schedule 6
- N-(N-DODECYL)-2-PYRROLIDONE cross reference: DESIGNATED SOLVENT, N-(N-OCTYL)-2-PYRROLIDONE, N-METHYL-2-PYRROLIDONE
- Schedule 6 Schedule 5 Appendix E, clause 3
- DODINE
- Schedule 6
- DOFETILIDE
- Schedule 4
- DOLASETRON
- Schedule 4
- DOLUTEGRAVIR
- Schedule 4
- DOMPERIDONE
- Schedule 4
- DONEPEZIL
- Schedule 4
- DOPAMINE
- Schedule 4
- DOPEXAMINE
- Schedule 4
- DORAMECTIN
- Schedule 7 Schedule 6 Schedule 5
- DORAVIRINE
- Schedule 4
- DORIPENEM
- Schedule 4
- DORNASE
- Schedule 4
- DORZOLAMIDE
- Schedule 4
- DOSULEPIN cross reference: DOTHIEPIN.
- Schedule 4 Appendix K, clause 1
- DOTHIEPIN cross reference: DOSULEPIN
- DOXANTRAZOLE
- Schedule 4
- DOXAPRAM
- Schedule 4
- DOXAZOSIN
- Schedule 4
- DOXEPIN
- Schedule 4 Appendix K, clause 1
- DOXORUBICIN
- Schedule 4
- DOXYCYCLINE
- Schedule 4
- DOXYLAMINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- 2,2-DPA cross reference: SODIUM 2,2-DICHLOROPROPIONATE
- Appendix B, clause 3
- DROMETRIZOLE TRISILOXANE
- Appendix B, clause 3
- DRONABINOL cross reference: DELTA-9-TETRAHYDROCANNABINOL, NABIXIMOLS
- Schedule 8 Appendix D, clause 3 Appendix K, clause 1
- DRONEDARONE
- Schedule 4
- DROPERIDOL
- Schedule 4 Appendix K, clause 1
- DROSPIRENONE
- Schedule 4
- DROSTANOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- DROTEBANOL
- Schedule 8
- DROTRECOGIN
- Schedule 4
- DSMA
- Schedule 7 Schedule 6
- DUBOISIA LEICHHARDTII
- Schedule 4 Schedule 2
- DUBOISIA MYOPOROIDES
- Schedule 4 Schedule 2
- DUDDINGTONIA FLAGRANS, STRAIN IAH 1297
- Appendix B, clause 3
- DULAGLUTIDE
- Schedule 4
- DULCIN
- cross reference: CAS No. 150-69-6
- Schedule 10
- DULOXETINE
- Schedule 4 Appendix K, clause 1
- DUPILUMAB
- Schedule 4
- DURVALUMAB
- Schedule 4
- DUTASTERIDE
- Schedule 4
- DYDROGESTERONE
- Schedule 4
- E
- (E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL cross reference: UNICONAZOLE-P
- Schedule 6
- ECGONINE
- cross reference: CAS No. 481-37-8, ECGONINE HYDROCHLORIDE (CAS No. 5796-31-6), ECGONINE RACEMATE (CAS No. 876657-17-9)
- Schedule 9
- ECONAZOLE
- Schedule 6 Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1
- ECOTHIOPATE cross reference: ECOTHIOPATE IODIDE
- Schedule 4
- ECTYLUREA
- Schedule 4
- ECULIZUMAB
- Schedule 4
- EDARAVONE
- Schedule 4
- EDETIC ACID cross reference: DICOBALT EDETATE
- Schedule 4
- EDOXUDINE
- Schedule 4
- EDROPHONIUM
- Schedule 4
- EFALIZUMAB
- Schedule 4
- EFANESOCTOCOG ALFA
- Schedule 4
- EFAVIRENZ
- Schedule 4
- EFGARTIGIMOD ALFA
- Schedule 4
- EFLORNITHINE
- Schedule 4
- EFORMOTEROL cross reference: FORMOTEROL
- ELACESTRANT DIHYDROCHLORIDE
- Schedule 4
- ELAFIBRANOR
- Schedule 4
- ELBASVIR
- Schedule 4
- ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS
- Appendix A, clause 1
- ELECTRONIC COMPONENTS
- Appendix A, clause 1
- ELETRIPTAN
- Schedule 4 Schedule 3 Appendix H, clause 1
- ELEXACAFTOR
- Schedule 4
- ELINZANETANT
- Schedule 4
- ELOSULFASE ALFA
- Schedule 4
- ELOTUZUMAB
- Schedule 4
- ELRANATAMAB
- Schedule 4
- ELTENAC
- Schedule 4
- ELTROMBOPAG
- Schedule 4
- ELUXADOLINE
- Schedule 4
- ELVITEGRAVIR
- Schedule 4
- EMAMECTIN
- Schedule 7 Schedule 6 Schedule 5
- EMEPRONIUM
- Schedule 4
- EMETINE cross reference: CEPHAELIS ACUMINATA
- Schedule 4
- EMODEPSIDE
- Schedule 6 Schedule 5
- EMPAGLIFLOZIN
- Schedule 4
- EMTRICITABINE
- Schedule 4
- ENALAPRIL
- Schedule 4
- ENASIDENIB
- Schedule 4
- ENCORAFENIB
- Schedule 4
- ENDOSULFAN
- Schedule 7 Schedule 6
- ENDOTHAL
- Schedule 7 Schedule 6
- ENDRIN
- Schedule 7
- ENESTEBOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ENFLICOXIB
- Schedule 4
- ENFLURANE
- Schedule 4
- ENFORTUMAB VEDOTIN
- Schedule 4
- ENFUVIRTIDE
- Schedule 4
- ENHANCING AGENTS cross reference: MAGNETIC RESONANCE IMAGING ENHANCING AGENTS, ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING
- Appendix A, clause 1
- ENOBOSARM
- Schedule 4 Appendix D, clause 5 (SELECTIVE ANDROGEN RECEPTOR MODULATORS)
- ENOXACIN
- Schedule 4
- ENOXAPARIN
- Schedule 4
- ENOXIMONE
- Schedule 4
- ENPROSTIL
- Schedule 4
- ENROFLOXACIN
- Schedule 4
- ENTACAPONE
- Schedule 4
- ENTECAVIR
- Schedule 4
- ENTRECTINIB
- Schedule 4
- ENZALUTAMIDE
- Schedule 4 Appendix D, clause 6 Appendix F, clause 4 Appendix L, clause 2
- EPHEDRA spp.
- Schedule 4
- EPHEDRINE cross reference: EPHEDRA
- Schedule 4 Appendix D, clause 5 Appendix F, clause 4
- EPHENIDINE cross reference: CAS No. 60951-19-1, EPHENIDINE HYDROCHLORIDE (CAS No. 6272-97-5) Schedule 9
- EPICHLOROHYDRIN
- Schedule 7 Appendix F, clause 4 Appendix J, clause 1
- EPICILLIN
- Schedule 4
- EPIDERMAL GROWTH FACTOR cross reference: SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1
- Schedule 7 Appendix G, clause 1 Appendix J, clause 1
- EPINASTINE
- Schedule 4
- EPINEPHRINE cross reference: ADRENALINE
- EPIRUBICIN
- Schedule 4
- EPITIOSTANOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- EPLERENONE
- Schedule 4
- EPLONTERSEN
- cross reference: EPLONTERSEN SODIUM
- Schedule 4
- EPOETINS cross reference: METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
- Schedule 4 Appendix D, clause 5
- EPOPROSTENOL
- Schedule 4
- EPOXICONAZOLE
- Schedule 5
- EPOXY RESINS, LIQUID cross reference: RESINS
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- EPRINOMECTIN
- Schedule 7 Schedule 6 Schedule 5
- EPROSARTAN
- Schedule 4
- EPSIPRANTEL
- Appendix B, clause 3
- EPTC
- Schedule 6
- EPTIFIBATIDE
- Schedule 4
- EPYRIFENACIL
- Schedule 5
- EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN cross reference: IMMUNOGLOBULINSERGOMETRINE
- Schedule 4
- ERENUMAB
- Schedule 4
- ERGOT
- Schedule 4
- ERGOTAMINE
- Schedule 4
- ERGOTOXINE
- Schedule 4
- ERIBULIN MESILATE cross reference: ERIBULIN MESYLATE
- Schedule 4
- ERLOTINIB
- Schedule 4
- ERTAPENEM
- Schedule 4
- ERTUGLIFLOZIN
- Schedule 4
- ERYSIMUM spp.
- Schedule 4 Appendix G, clause 1
- ERYTHRITYL TETRANITRATE
- Schedule 3
- ERYTHROMYCIN
- Schedule 4
- ERYTHROPOIETIN
- Schedule 4 Appendix D, clause 5
- ERYTHROPOIETINS
- Schedule 4 Appendix D, clause 5
- ESBIOTHRIN
- Schedule 6 Schedule 5
- ESCITALOPRAM
- Schedule 4
- ESFENVALERATE
- Schedule 6 Schedule 5
- ESKETAMINE
- Schedule 8 Appendix K, clause 1
- ESLICARBAZEPINE ACETATE
- Schedule 4
- ESMOLOL
- Schedule 4
- ESOMEPRAZOLE
- Schedule 4 Schedule 2
- ESTETROL MONOHYDRATE
- Schedule 4
- ESTRADIOL
- Schedule 5 Schedule 4 Appendix G, clause 1
- ESTRAMUSTINE
- Schedule 4
- ESTRIOL
- Schedule 4
- ESTROGENS
- Schedule 4
- ESTRONE
- Schedule 4 Appendix G, clause 1
- ESTROPIPATE cross reference: PIPERAZINE ESTRONE SULFATE
- Schedule 4
- ETACONAZOLE
- Schedule 7 Appendix J, clause 1
- ETACRYNIC ACID
- Schedule 4
- ETAFEDRINE
- Schedule 2
- ETANERCEPT
- Schedule 4
- ETHACRYNIC ACID cross reference: ETACRYNIC ACID
- ETHALFLURALIN
- Schedule 7
- ETHAMBUTOL
- Schedule 4
- ETHAMETSULFURON-METHYL
- Appendix B, clause 3
- ETHAMIVAN
- Schedule 4
- 1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE cross reference: N-METHYLMETHANAMINE
- Schedule 5
- ETHANOL cross reference: ETHYL ALCOHOL
- ETHANOLAMINE cross reference: MONOETHANOLAMINE
- ETHCHLORVYNOL
- Schedule 4
- ETHEPHON
- Schedule 6
- ETHER
- Schedule 6 Schedule 5 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- ETHERIFIED STARCHES
- Appendix A
- ETHINAMATE
- Schedule 4
- ETHINYLESTRADIOL
- Schedule 4
- ETHINYLOESTRADIOL cross reference: ETHINYLESTRADIOL
- ETHIOFENCARB
- Schedule 6
- ETHION
- Schedule 7
- ETHIONAMIDE
- Schedule 4
- ETHISTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ETHOATE-METHYL
- Schedule 6
- ETHOFUMESATE
- Schedule 5
- ETHOGLUCID
- Schedule 4
- ETHOHEPTAZINE
- Schedule 4
- ETHOPABATE
- Appendix B, clause 3
- ETHOPROPAZINE
- Schedule 4
- ETHOPROPHOS cross reference: LINSEED OIL
- Schedule 7 Schedule 6
- ETHOSUXIMIDE
- Schedule 4
- ETHOTOIN
- Schedule 4
- 2-ETHOXYETHANOL
- Schedule 7 Appendix F, clause 4
- ETHOXYETHYLMERCURIC CHLORIDE
- Appendix F, clause 4
- ETHOXYQUIN
- Schedule 5
- ETHOXYSULFURON
- Schedule 5
- ETHOXZOLAMIDE
- Schedule 4
- ETHYL ACETATE
- Appendix B, clause 3
- ETHYL ALCOHOL
- Appendix B, clause 3
- ETHYL BROMIDE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- ETHYL BUTYRATE
- Appendix B, clause 3
- ETHYL CHLORIDE
- Schedule 4
- ETHYL FORMATE
- Schedule 6
- ETHYL LACTATE
- Appendix B, clause 3
- ETHYL METHACRYLATE
- Schedule 5 Appendix F, clause 4
- ETHYLAMFETAMINE cross reference: ETHYLAMPHETAMINE
- Schedule 8
- ETHYLBUTYLACETYL-
- Appendix B, clause 3
- ETHYLDIENOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ETHYLENE CHLOROHYDRIN
- Schedule 6 Appendix F, clause 4
- ETHYLENE DIBROMIDE
- Schedule 7 Appendix J, clause 1
- ETHYLENE DICHLORIDE
- Schedule 6
- ETHYLENE GLYCOL cross reference: DENATONIUM BENZOATE (CAS No. 107-21-1)
- Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3
- ETHYLENE GLYCOL MONOALKYL ETHERS
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- ETHYLENE OXIDE
- Schedule 7 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1
- ETHYLESTRENOL cross reference: ETHYLOESTRENOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ETHYLHEXANEDIOL
- cross reference: ETHOHEXADIOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- 2-ETHYLHEXANOIC ACID
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- ETHYLMERCURIC CHLORIDE
- Appendix F, clause 4
- N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE cross reference: N-ETHYL MDA (CAS No. 82801-81-8), N-ETHYL MDA HYDROCHLORIDE (CAS No. 74341-78-9)
- Schedule 9
- ETHYLMETHYLTHIAMBUTENE
- cross reference: CAS No: 441-61-2
- Schedule 9
- ETHYLMORPHINE
- Schedule 8 Schedule 4 Appendix K, clause 1
- ETHYLOESTRENOL cross reference: ETHYLESTRENOL
- ETHYNODIOL cross reference: ETYNODIOL
- ETICYCLIDINE cross reference: PCE (CAS No. 2201-15-2)
- Schedule 9
- ETIDOCAINE
- Schedule 4
- ETIDRONIC ACID cross reference: ETIDRONATE DISODIUM
- Schedule 4
- ETILEFRIN
- Schedule 4
- ETIPROSTON
- Schedule 4
- ETODESNITAZENE
- cross reference: CAS No. 14030-76-3, ETAZENE
- Schedule 9
- ETODOLAC
- Schedule 4
- ETOFENAMATE
- Schedule 4 Schedule 2
- ETOFENPROX
- Appendix B, clause 3
- ETOMIDATE
- Schedule 4
- ETONITAZENE
- cross reference: CAS No. 911-65-9
- Schedule 9
- ETONITAZEPIPNE
- cross reference: CAS No. 734496-28-7, N-PIPERIDINO ETONITAZENE
- Schedule 9
- ETONITAZEPYNE
- cross reference: CAS No. 2785346-75-8, N-PYRROLIDINO ETONITAZENE
- Schedule 9
- ETONOGESTREL
- Schedule 4
- ETOPOSIDE
- Schedule 4
- ETORICOXIB
- Schedule 4
- ETORPHINE
- cross reference: CAS No. 14521-96-1
- Schedule 9
- ETOXAZOLE
- Appendix B, clause 3
- ETOXERIDINE
- cross reference: CAS No. 469-82-9
- Schedule 9
- ETRANACOGENE DEZAPARVOVEC
- Schedule 4
- ETRASIMOD
- Schedule 4
- ETRAVIRINE
- Schedule 4
- ETRETINATE
- Schedule 4 Appendix D, clause 5 Appendix F, clause 4 Appendix L, clause 2
- ETRIDIAZOLE
- Schedule 5
- ETRIMFOS
- Schedule 6
- ETYNODIOL cross reference: ETHYNODIOL
- Schedule 4
- EUBACTERIUM sp. strain DSM11798
- Appendix B, clause 3
- EUCALYPTUS OIL
- Schedule 6 Appendix E, clause 3
- EUGENOL
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- EUPATORIUM CANNABINUM cross reference: HEMP AGRIMONY
- Schedule 10
- EVEROLIMUS
- Schedule 4
- EXEMESTANE
- Schedule 4
- EXENATIDE
- Schedule 4
- EXPLOSIVES
- Appendix A, clause 1
- EXTRACT OF LEMON EUCALYPTUS cross reference: CORYMBIA CITRIODORA, OIL OF LEMON EUCALYPTUS
- Schedule 5
- EZETIMIBE
- Schedule 4
- F
- FAMCICLOVIR
- Schedule 4 Schedule 3
- Appendix H, clause 1
- FAMOTIDINE
- Schedule 4 Schedule 2 Appendix F, clause 4
- FAMOXADONE
- Schedule 6
- FAMPHUR
- Schedule 7 Schedule 6
- FARFUGIUM JAPONICUM
- Schedule 10
- FARICIMAB
- Schedule 4 Appendix L, clause 2
- FASORACETAM cross reference: RACETAMS
- Schedule 4
- FEBANTEL
- Schedule 6
- FEBUXOSTAT
- Schedule 4
- FEDRATINIB
- Schedule 4
- FELBINAC
- Schedule 4 Schedule 2
- FELODIPINE
- Schedule 4
- FELYPRESSIN
- Schedule 4
- FENAMIPHOS
- Schedule 7 Schedule 6
- FENARIMOL
- Schedule 5
- FENAZAFLOR
- Schedule 6
- FENBENDAZOLE
- Schedule 5 Schedule 4
- FENBUCONAZOLE
- Schedule 5
- FENBUFEN
- Schedule 4
- FENBUTATIN OXIDE
- Schedule 6
- FENCAMFAMIN
- Schedule 4
- FENCHLORAZOLE-ETHYL
- Schedule 5
- FENCHLORPHOS
- Schedule 6
- FENCLOFENAC
- Schedule 4
- FENETYLLINE
- cross reference: CAS No. 3736-08-1, FENETYLLINE HYDROCHLORIDE (CAS No. 1892-80-4)
- Schedule 9
- FENFLURAMINE
- Schedule 4 Appendix K, clause 1
- FENFURAM
- Appendix B, clause 3
- FENHEXAMID
- Appendix B, clause 3
- FENITROTHION
- FENMEZODITIAZ
- Schedule 6
- FENNEL OIL
- Schedule 5 Appendix E, clause 3
- FENOFIBRATE
- Schedule 4
- FENOLDOPAM
- Schedule 4
- FENOPROFEN
- Schedule 4
- FENOPROP
- Schedule 5
- FENOTEROL
- Schedule 4
- FENOXACRIM
- Schedule 7 Schedule 6
- FENOXAPROP-ETHYL
- Schedule 5
- FENOXAPROP-p-ETHYL
- Schedule 5
- FENOXYCARB
- Appendix B, clause 3
- FENPIPRAMIDE
- Schedule 4
- FENPIPRANE
- Schedule 4
- FENPROPIDIN
- Schedule 6
- FENPROPOREX
- Schedule 4
- FENPROSTALENE
- Schedule 4
- FENPYRAZAMINE
- Schedule 5
- FENPYROXIMATE
- Schedule 6
- FENSON
- Schedule 5
- FENSULFOTHION
- Schedule 7
- FENTANYL
- Schedule 8 Appendix K, clause 1
- FENTEROL
- Appendix F, clause 4
- FENTHION
- Schedule 7 Schedule 6 Schedule 5
- FENTHION-ETHYL
- Schedule 7
- FENVALERATE
- Schedule 6
- FERRIC DERISOMALTOSE
- Schedule 4
- FEXOFENADINE
- Schedule 4 Schedule 2
- FEZOLINETANT
- Schedule 4
- FIBRINOLYSIN
- Schedule 4
- FIBROBLAST GROWTH FACTORS
- Schedule 4 Appendix D, clause 5
- FIDAXOMICIN
- Schedule 4
- FILGOTINIB
- Schedule 4
- FILGRASTIM
- Schedule 4
- FINASTERIDE
- Schedule 4
- FINERENONE
- Schedule 4
- Appendix L, clause 2
- FINGOLIMOD
- Schedule 4 Appendix L, clause 2
- FIPRONIL
- Schedule 6 Schedule 5
- FIROCOXIB
- Schedule 4
- FLAMPROP-METHYL
- Schedule 5
- FLAMPROP-M-METHYL
- Schedule 5
- FLAVOXATE
- Schedule 3
- FLAZASULFURON
- Schedule 5
- FLECAINIDE
- Schedule 4
- FLEROXACIN
- Schedule 4
- FLOCOUMAFEN
- Schedule 7 Schedule 6
- FLOCTAFENINE
- Schedule 4
- FLONICAMID
- Schedule 6
- FLORASULAM
- Schedule 5
- FLORFENICOL
- Schedule 4
- FLORPYRAUXIFEN-BENZYL
- Appendix B, clause 3
- FLORYLPICOXAMID
- Appendix B, clause 3
- FLUANISONE
- Schedule 4
- FLUAZAINDOLIZINE
- Schedule 6 Schedule 5
- FLUAZIFOP-BUTYL
- Schedule 6
- FLUAZIFOP-p-BUTYL
- Schedule 6
- FLUAZINAM
- Schedule 6
- FLUAZURON
- Schedule 5
- FLUBENDAZOLE
- Schedule 5
- FLUBENDIAMIDE
- Schedule 5
- FLUBROMAZEPAM
- cross reference: CAS No. 2647-50-9
- Schedule 9
- FLUBROMAZOLAM
- cross reference: CAS No. 612526-40-6
- Schedule 9
- FLUCHLORALIN
- Schedule 5
- FLUCLOROLONE
- Schedule 4
- FLUCLOXACILLIN
- Schedule 4
- FLUCOFURON
- Schedule 7 Schedule 6
- FLUCONAZOLE
- Schedule 4 Schedule 3 Appendix F, clause 4 Appendix H, clause 1
- FLUCYTHRINATE
- Schedule 7
- FLUCYTOSINE
- Schedule 4
- FLUDARABINE
- Schedule 4
- FLUDIOXONIL
- Schedule 5
- FLUDROCORTISONE
- Schedule 4
- FLUENSULFONE
- Schedule 6
- FLUFENAMIC ACID
- Schedule 4
- FLUFENOXURON
- Appendix B, clause 3
- FLUMAZENIL
- Schedule 4
- FLUMETASONE cross reference: FLUMETHASONE
- Schedule 4
- FLUMETHASONE cross reference: FLUMETASONE
- FLUMETHIAZIDE
- Schedule 4
- FLUMETHRIN
- Schedule 6 Schedule 5
- FLUMETSULAM
- Appendix B, clause 3
- FLUMICLORAC PENTYL
- Schedule 5
- FLUMIOXAZIN
- Schedule 7 Schedule 6
- FLUNISOLIDE
- Schedule 4
- FLUNITAZENE
- cross reference: CAS No. 2249-36-7, FLUNITAZENE HYDROCHLORIDE (CAS No. 2728-91-8) Schedule 9
- FLUNITRAZEPAM
- Schedule 8 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- FLUNIXIN MEGLUMINE
- Schedule 4
- FLUOCINOLONE
- Schedule 4
- FLUOCINONIDE
- Schedule 4
- FLUOCORTIN
- Schedule 4
- FLUOCORTOLONE
- Schedule 4
- FLUOMETURON
- Appendix B, clause 3
- FLUOPICOLIDE
- Appendix B, clause 3
- FLUOPYRAM
- Schedule 5
- FLUORESCEIN
- Schedule 4
- FLUORIDES cross reference: SILICOFLUORIDES
- Schedule 6 Schedule 5 Schedule 4 Schedule 3 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- Appendix H, clause 1
- FLUOROACETAMIDE
- Schedule 7
- FLUOROACETIC ACID
- Schedule 7 Appendix J, clause 1
- FLUOROMETHOLONE
- Schedule 4
- 4-FLUORO-N-METHYLAMFETAMINE cross reference: 4-FLUORO-N-METHYLAMPHETAMINE, 4-FLUORO-N-METHAMFETAMINE (CAS No. 351-03-1)
- Schedule 9
- 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE cross reference: AM-694 (CAS No. 335161-03-0)
- Schedule 9
- FLUOROURACIL
- Schedule 4
- FLUOXETINE
- Schedule 4
- FLUOXYMESTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- FLUPENTIXOL cross reference: FLUPENTHIXOL
- Schedule 4 Appendix K, clause 1
- FLUPHENAZINE
- Schedule 4 Appendix K, clause 1
- FLUPROPANATE cross reference: TETRAPION
- Schedule 6
- FLUPROSTENOL
- Schedule 4
- FLUPYRADIFURONE
- Schedule 6
- FLUQUINCONAZOLE
- Schedule 6
- FLURALANER cross-reference: CARBAMOYL BENZAMIDE, PHENYL ISOXAZOLINE
- Schedule 5
- Schedule 4
- FLURANDRENOLONE
- Schedule 4
- FLURAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- FLURBIPROFEN
- Schedule 4 Schedule 2
- FLUOROACETAMIDE
- Appendix J, clause 1
- FLUOXAPIPROLIN
- Appendix B, clause 3
- FLUROXENE
- Schedule 4
- FLUROXYPYR
- Appendix B, clause 3
- FLUSILAZOL
- Schedule 6
- FLUSPIRILENE
- Schedule 4
- FLUTAMIDE
- Schedule 4
- FLUTICASONE cross reference: FLUTICASONE FUROATE, FLUTICASONE PROPIONATE
- Schedule 4
- FLUTICASONE FUROATE cross reference FLUTICASONE
- FLUTICASONE PROPIONATE
- cross reference: FLUTICASONE
- Schedule 4 Schedule 2
- FLUTOLANIL
- Appendix B, clause 3
- FLUTRIAFOL
- Schedule 6
- FLUVALINATE
- Schedule 6 Schedule 5
- FLUVASTATIN
- Schedule 4
- FLUVOXAMINE
- Schedule 4
- FLUXAPYROXAD
- Schedule 5
- FOLIC ACID
- Schedule 4 Schedule 2
- FOLINIC ACID cross reference: CALCIUM FOLINATE
- Schedule 4 Schedule 2
- FOLLICLE-STIMULATING HORMONE
- Schedule 4 Appendix D, clause 1
- FOLLISTATIN
- Schedule 4 Appendix D, clause 5
- FOLLITROPIN ALFA cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
- Schedule 4 Appendix D, clause 1
- FOLLITROPIN BETA cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
- Schedule 4 Appendix D, clause 1
- FOLLITROPIN DELTA cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
- Schedule 4 Appendix D, clause 1
- FOLPET
- Schedule 6
- FOMEPIZOLE
- Schedule 4
- FOMESAFEN SODIUM
- Schedule 6
- FOMIVIRSEN
- Schedule 4
- FONDAPARINUX
- Schedule 4
- FOOD
- Appendix A, clause 1
- FORAMSULFURON
- Schedule 5
- FORCHLORFENURON
- Appendix B, clause 3
- FORMALDEHYDE cross reference: FORMALDEHYDE CONDENSATION PRODUCT, FREE FORMALDEHYDE, METACRESOLSULPHONIC ACID, METHYLENE GLYCOL (CAS No. 50-00-0)
- Schedule 10 Schedule 6 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- FORMALDEHYDE CONDENSATION PRODUCT
- Schedule 6
- FORMEBOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- FORMESTANE
- Schedule 4
- FORMETANATE
- Schedule 7
- FORMIC ACID
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- FORMOTEROL
- Schedule 4
- FORMOTHION
- Schedule 6
- FOSAMPRENAVIR
- Schedule 4
- FOSAPREPITANT
- Schedule 4
- FOSCARNET
- Schedule 4
- FOSFESTROL cross reference: DIETHYLSTILBESTROL DIPHOSPHATE
- Schedule 4
- FOSFOMYCIN
- Schedule 4
- FOSINOPRIL
- Schedule 4
- FOSNETUPITANT
- Schedule 4
- FOSPHENYTOIN
- Schedule 4
- FOSPIRATE
- Schedule 6 Schedule 5
- FOSTEMSAVIR
- Schedule 4
- FOSTHIAZATE
- Schedule 7
- FOTEMUSTINE
- Schedule 4
- FRAMYCETIN
- Schedule 4
- FRITTED GLAZING OR ENAMELLING PREPARATIONS
- Appendix A, clause 1
- FRUQUINTINIB
- Schedule 4
- FULLERS EARTH
- Appendix B, clause 3
- FULVESTRANT
- Schedule 4
- FUMAGILLIN
- Schedule 6
- FUNGAL PROTEASE derived from Aspergillus niger
- Appendix B, clause 3
- FURALAXYL
- Schedule 5
- FURALTADONE
- Schedule 4
- FURATHIOCARB
- Schedule 7 Schedule 5
- FURAZABOL
- Schedule 4
- FURAZOLIDONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- FURETHIDINE
- cross reference: CAS No. 2385-81-1
- Schedule 9
- FURFURAL cross reference: 2-FURANCARBOXALDEHYDE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- FUROSEMIDE cross reference: FRUSEMIDE
- Schedule 4
- FUSIDIC ACID
- Schedule 4
- FUTIBATINIB
- Schedule 4
- FUZAPLADIB SODIUM
- Schedule 4
- G
- GABAPENTIN
- Schedule 4 Appendix K, clause 1
- GADOQUATRANE
- Schedule 4
- GALANTAMINE
- Schedule 4
- GALANTHUS spp.
- Schedule 4
- GALCANEZUMAB
- Schedule 4
- GALLAMINE
- Schedule 4
- GALSULFASE
- Schedule 4
- GAMMA BUTYROLACTONE
- cross reference: CAS No. 96-48-0
- Schedule 10
- GAMMA HYDROXYBUTYRATE cross reference: 4-HYDROXYBUTANOIC ACID, GHB, SODIUM OXYBATE
- Schedule 9
- GAMMA-CYHALOTHRIN
- Schedule 7 Schedule 5
- GANCICLOVIR
- Schedule 4
- GANIRELIX
- Schedule 4
- GARADACIMAB
- Schedule 4
- GATIFLOXACIN
- Schedule 4
- GEFITINIB
- Schedule 4
- GELATIN – SUCCINYLATED
- Appendix A
- GELSEMIUM SEMPERVIRENS
- Schedule 2 Appendix G, clause 1
- GEMCITABINE
- Schedule 4 Appendix K, clause 1
- GEMEPROST
- Schedule 4
- GEMFIBROZIL
- Schedule 4
- GEMIFLOXACIN
- Schedule 4
- GEMTUZUMAB OZOGAMICIN
- Schedule 4
- GENTAMICIN
- Schedule 4
- GENTIAN VIOLET cross reference: METHYLROSANILINIUM CHLORIDE, CRYSTAL VIOLET
- GEPOTIDACIN cross reference: GEPOTIDACIN MESILATE Schedule 4
- GERANIUM OIL
- Appendix B, clause 3
- GESTODENE
- Schedule 4
- GESTONORONE
- Schedule 4
- GESTRINONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- GHRH INJECTABLE PLASMID
- Schedule 4
- GIBBERELLIC ACID
- Appendix B, clause 3
- GILTERITINIB
- Schedule 4
- GITALIN
- Schedule 4
- GIVOSIRAN
- Schedule 4
- GLASS cross reference: CRYSTAL WARE
- Appendix A, clause 1
- GLATIRAMER ACETATE
- Schedule 4
- GLAZED POTTERY
- Appendix A, clause 1
- GLECAPREVIR
- Schedule 4
- GLIBENCLAMIDE
- Schedule 4
- GLIBORNURIDE
- Schedule 4
- GLICLAZIDE
- Schedule 4
- GLIMEPIRIDE
- Schedule 4
- GLIPIZIDE
- Schedule 4
- GLIPTINS
- cross reference: DIPEPTIDYL PEPTIDASE-4 (DDP-4) INHIBITORS Schedule 4
- GLISOXEPIDE
- Schedule 4
- GLOFITAMAB
- Schedule 4
- GLUCAGON
- Schedule 3 Appendix G, clause 1
- Appendix H, clause 1
- α-GLUCANASE derived from Aspergillus niger
- Appendix B, clause 3
- GLUFOSINATE-AMMONIUM
- Schedule 5
- GLUTARAL
- Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- GLUTARALDEHYDE cross reference: GLUTARAL
- GLUTATHIONE
- Schedule 4
- GLUTETHIMIDE
- Schedule 4 Appendix D, clause 5 Appendix K, clause 1
- GLYCERYL THIOGLYCOLLATE
- Schedule 6
- GLYCERYL TRINITRATE
- Schedule 4 Schedule 3 Appendix G, clause 1 Appendix H, clause 1
- GLYCOLIC ACID
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- GLYCOPYRRONIUM
- Schedule 4
- GLYCOSYLATED HYDROQUINONE cross reference: HYDROQUINONE
- GLYMIDINE
- Schedule 4
- GLYOXYLIC ACID
- Schedule 6
- Appendix E, clause 3
- Appendix F, clause 4
- GLYPHOSATE
- Schedule 5
- GnRH VACCINE
- Schedule 4
- GOLIMUMAB
- Schedule 4
- GONADORELIN
- Schedule 4
- GONADOTROPHIC HORMONES
- Schedule 4
- GOSERELIN
- Schedule 4
- GRAMICIDIN
- Schedule 4
- GRANISETRON
- Schedule 4
- GRAPIPRANT
- Schedule 4
- GRAZOPREVIR
- Schedule 4
- GREPAFLOXACIN
- Schedule 4
- GRISEOFULVIN
- Schedule 4
- GROWTH HORMONE RELEASING HORMONES *(GHRHs)
- Schedule 4 Appendix D, clause 5
- GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6)
- Schedule 4 Appendix D, clause 5
- GROWTH HORMONE RELEASING PEPTIDE *(GHRPs)
- Schedule 4 Appendix D, clause 5
- GROWTH HORMONE SECRETAGOGUES *(GHSs)
- Schedule 4 Appendix D, clause 5
- GUAIFENESIN cross reference: PARACETAMOL
- Schedule 4 Schedule 2
- GUAIPHENESIN cross reference: GUAIFENESIN
- GUANABENZ
- Schedule 4
- GUANACLINE
- Schedule 4
- GUANETHIDINE
- Schedule 4
- GUANFACINE
- Schedule 4 Appendix K, clause 1
- GUANIDINE
- Schedule 6 Schedule 4 Appendix E, clause 3
- GUAZATINE
- Schedule 6
- GUSELKUMAB
- Schedule 4
- H
- HACHIMYCIN
- Schedule 4
- HAEMATIN
- Schedule 4
- HAEMOPHILUS INFLUENZAE VACCINE
- Schedule 4
- HALAUXIFEN METHYL
- Appendix B, clause 3
- HALCINONIDE
- Schedule 4
- HALOFANTRINE
- Schedule 4
- HALOFENATE
- Schedule 4
- HALOFUGINONE
- Schedule 7 Schedule 4 Appendix J, clause 1
- HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS cross reference: DIBENZODIOXINS, HALOGENATED - DIBENZOFURANS, HALOGENATED, DIOXINS
- Schedule 7 Appendix J, clause 1
- HALOPERIDOL cross reference: BUTYPHENONES
- Schedule 4 Appendix G, clause 1 Appendix K, clause 1
- HALOSULFURON-METHYL
- Schedule 5
- HALOTHANE
- Schedule 4
- HALOXON
- Schedule 6
- HALOXYFOP
- Schedule 6
- HARMALA ALKALOIDS
- Schedule 9
- HC RED 13 cross reference: 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL
- HC VIOLET 1 cross reference: 2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- HCB
- Schedule 7 Appendix J, clause 1
- HELIONAL
- Appendix B, Part 3
- HELIOTROPIUM spp.
- Schedule 10
- HEMEROCALLIS
- Schedule 4
- HEMP SEED OIL cross reference: CANNABIDIOL, CANNABIS, TETRAHYDROCANNABINOLS
- HEPARINS
- Schedule 4
- HEPATITIS A VACCINE
- Schedule 4
- HEPATITIS B VACCINE
- Schedule 4
- HEPTACHLOR
- Schedule 6
- HEROIN
- cross reference: CAS No. 561-27-3, HEROIN HYDROCHLORIDE (CAS No. 1502-95-0)
- Schedule 9
- HETACILLIN
- Schedule 4
- HEXACHLOROPHANE cross reference: HEXACHLOROPHENE
- HEXACHLOROPHENE cross reference: HCB
- Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- HEXACONAZOLE
- Schedule 5
- HEXAFLURON
- Appendix B, clause 3
- HEXAMETHONIUM
- Schedule 4
- HEXARELIN
- Schedule 4 Appendix D, clause 5
- HEXAZINONE
- Schedule 6 Schedule 5
- HEXETIDINE
- Schedule 4
- HEXLOXYETHANOL
- Appendix F, clause 4
- HEXOBENDINE
- Schedule 4
- HEXOCYCLIUM
- Schedule 4
- HEXOPRENALINE
- Schedule 4
- HEXYL ACETATE
- Appendix B, clause 3
- HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE)
- Schedule 4
- HEXYL CINNAMALDEHYDE
- Appendix B, clause 3
- 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN cross reference: PARAHEXYL (CAS No. 117-51-1)
- Schedule 9
- HEXYLOXYETHANOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- HEXYTHIAZOX
- Appendix B, clause 3
- HISTAMINE
- Schedule 4
- HMG-CoA REDUCTASE INHIBITORS cross reference: STATINS
- Schedule 4
- HOMATROPINE
- Schedule 4
- HOMOBRASSINOLIDE
- Schedule 5
- HUMAN BLOOD PRODUCTS cross reference: ALBUMIN, ANTICOAGULATION COMPLEX, C1 ESTERASE INHIBITORS, CLOTTING FACTORS, CRYOPRECIPITATE, FIBRINOGEN, PLASMA, PLATELETS
- Appendix A, clause 1
- HUMAN CHORIONIC GONADOTROPHIN
- Schedule 4
- HUMAN OSTEOGENIC PROTEIN-1 (OP-1)
- Appendix B, clause 3
- HUMAN PAPILLOMAVIRUS VACCINE
- Schedule 4
- HYALURONIC ACID
- Schedule 4
- HYALURONIC ACID AND ITS POLYMERS
- Schedule 4
- HYDRALAZINE
- Schedule 4
- HYDRAMETHYLNON
- Schedule 6 Schedule 5
- HYDRARGAPHEN
- Schedule 4
- HYDRAZINE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- HYDROCARBONS LIQUID AROMATIC cross reference: AROMATIC EXTRACT OILS,
- Schedule 7 Appendix F, clause 4
- HYDROCARBONS, LIQUID cross reference: BENZENE, DESIGNATED SOLVENT, DIESEL (DISTILLATE), DRY CLEANING FLUID, KEROSENE, LAMP OIL, LIGHT MINERAL OILS, LIQUID HYDRO
- Schedule 5 Appendix E, clause 3
- HYDROCHLORIC ACID
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- HYDROCHLOROTHIAZIDE
- Schedule 4
- HYDROCODONE
- Schedule 8 Appendix K, clause 1
- HYDROCORTISONE
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1
- HYDROCORTISONE ACETATE
- Schedule 3 Schedule 2
- HYDROCYANIC ACID cross reference: CYANIDES, APRICOT KERNELS
- Schedule 7 Schedule 4 Appendix F, clause 4 Appendix G, clause 1 Appendix J, clause 1
- HYDROFLUMETHIAZIDE
- Schedule 4
- HYDROFLUORIC ACID cross reference: HYDROGEN FLUORIDE
- Schedule 7 Schedule 6 Schedule 5
- Appendix E, clause 3
- Appendix F, clause 4 Appendix J, clause 1
- HYDROGEN PEROXIDE
- cross reference: CAS No. 7722-84-1
- Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- HYDROGEN SULFIDE
- Schedule 7
- HYDROMORPHINOL
- Schedule 8
- HYDROMORPHONE
- Schedule 8 Appendix K, clause 1
- HYDROPRENE
- Appendix B, clause 3
- HYDROQUINONE cross reference: ARBUTIN, GLYCOSYLATED HYDROQUINONE, MONOBENZONE
- Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- HYDROSILICOFLUORIC ACID cross reference: FLUOROSILICIC ACID, HEXAFLUOROSILIC ACID, HYDROFLUOSILICIC ACID, SILICOFLUORIC ACID
- Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- 4-HYDROXYBUTANOIC ACID
- cross reference: CAS No. 591-81-1, SODIUM OXYBATE (CAS No. 502-85-2)
- Schedule 9
- HYDROXYCARBAMIDE
- Schedule 4
- HYDROXYCHLOROQUINE
- Schedule 4
- 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL cross reference: CANNABICYCLOHEXANOL (CAS No. 70434-92-3), CP 47,497 C8 HOMOLOGUE, CP 47,497 (CAS N
- Schedule 9
- HYDROXYEPHEDRINE
- Schedule 4
- 4-[(2-HYDROXYETHYL)AMINO]-3-NITROPHENOL cross reference: 3-NITRO-p-HYDROXYETHYLAMINOPHENOL
- 2-HYDROXYETHYL METHACRYLATE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- [7-HYDROXY-8-[(2- METHOXYPHENYL)AZO]-2-NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0) cross reference: BASIC RED 76 (CAS No. 68391-30-0)
- HYDROXYPETHIDINE
- cross reference: CAS No. 468-56-4
- Schedule 9
- HYDROXYPHENAMATE
- Schedule 4
- HYDROXYPROGESTERONE
- Schedule 4
- HYDROXYPROPYL CELLULOSE
- Appendix B, clause 3
- 2-HYDROXYPROPYL METHACRYLATE
- Schedule 5
- 8-HYDROXYQUINOLINE cross reference: OXYQUINOLINE
- HYDROXYSTENOZOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- HYDROXYUREA cross reference: HYDROXYCARBAMIDE
- HYDROXYZINE
- Schedule 4 Appendix K, clause 1
- HYGROMYCIN
- Schedule 4
- HYOSCINE cross reference: HYOSCINE BUTYLBROMIDE
- Schedule 4 Schedule 2 Appendix G, clause 1
- HYOSCINE BUTYLBROMIDE
- Schedule 4
- Schedule 3
- Schedule 2
- Appendix H, clause 1
- HYOSCYAMINE
- Schedule 4
- Schedule 2
- Appendix G, clause 1
- HYOSCYAMUS NIGER
- Schedule 4
- Schedule 2
- Appendix G, clause 1
- HYPOTHALAMIC RELEASING FACTORS
- Schedule 4 Appendix G, clause 1
- HYPROMELLOSE
- Schedule 4
- I
- IBAFLOXACIN
- Schedule 4
- IBANDRONIC ACID
- Schedule 4
- IBOGAINE
- Schedule 4
- IBOTENIC ACID
- cross reference: MUSCIMOL
- Schedule 9
- IBRITUMOMAB
- Schedule 4
- IBRUTINIB
- Schedule 4
- IBUFENAC
- Schedule 4
- IBUPROFEN cross reference: PARACETAMOL
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1
- IBUTAMOREN cross reference: MK-677, NUTROBAL
- Schedule 4 Appendix D, clause 5
- IBUTEROL
- Schedule 4
- IBUTILIDE
- Schedule 4
- ICATIBANT
- Schedule 4
- ICODEXTRIN
- Appendix B, clause 3
- IDARUBICIN
- Schedule 4
- IDARUCIZUMAB
- Schedule 4
- IDEBENONE
- Schedule 4
- IDOXURIDINE
- Schedule 4
- IDURSULFASE
- Schedule 4
- IFOSFAMIDE
- Schedule 4
- ILOPROST
- Schedule 4
- ILUNOCITINIB
- Schedule 4
- IMATINIB
- Schedule 4
- IMAZALIL cross reference: ENILCONAZOLE
- Schedule 5
- IMAZAMOX
- Schedule 5
- IMAZAPIC
- Schedule 5
- IMAZAPYR
- Schedule 5
- IMAZETHAPYR
- Schedule 5
- IMDEVIMAB
- Schedule 4
- IMEPITOIN
- Schedule 4
- IMIDACLOPRID
- Schedule 6 Schedule 5
- IMIDAPRIL
- Schedule 4
- IMIDOCARB
- Schedule 6
- IMIGLUCERASE
- Schedule 4
- IMINOCTADINE TRIALBESILATE
- Schedule 6
- IMIPENEM
- Schedule 4
- IMIPRAMINE
- Schedule 4 Appendix K, clause 1
- IMIPROTHRIN
- Schedule 6 Schedule 5
- IMIQUIMOD
- Schedule 4
- IMLIFIDASE
- IMLUNESTRANT
- Schedule 4
- IMMUNOGLOBULINS cross reference: EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, POLYCLONAL ANTIBODIES
- Schedule 4
- IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS
- Appendix A, clause 1
- INAVOLISIB
- Schedule 4
- INCLISIRAN
- Schedule 4
- INDACATEROL
- Schedule 4
- INDANAZOLINE
- Schedule 2
- INDAPAMIDE
- Schedule 4
- INDAZIFLAM
- Schedule 6
- INDINAVIR
- Schedule 4
- INDOLE-3-ACETIC ACID
- Appendix B, clause 3
- INDOMETACIN
- Schedule 4 Schedule 2 Appendix G, clause 1
- INDOMETHACIN cross reference: INDOMETACIN
- INDOPROFEN
- Schedule 4
- INDORAMIN
- Schedule 4
- INDOXACARB
- Schedule 6 Schedule 5
- INEBILIZUMAB
- Schedule 4
- INFIGRATINIB
- Schedule 4
- INFLIXIMAB
- Schedule 4
- INFLUENZA AND CORYZA VACCINES cross reference: H5N1 INFLUENZA VIRUS HAEMAGGLUTININ
- Schedule 4
- INGENOL MEBUTATE
- Schedule 4
- INOTUZUMAB OZOGAMICIN
- Schedule 4
- INOSITOL NICOTINATE
- Schedule 3
- INPYRFLUXAM
- Schedule 6
- INSULIN DEGLUDEC
- Schedule 4
- INSULIN GLARGINE
- Schedule 4
- INSULIN-LIKE GROWTH FACTOR I
- Schedule 4
- INSULIN-LIKE GROWTH FACTORS
- Schedule 4 Appendix D, clause 5
- INSULINS
- Schedule 4
- INTERFERONS
- Schedule 4
- INTERLEUKINS
- Schedule 4
- INTRAOCULAR VISCOELASTIC PRODUCTS
- Appendix A, clause 1
- IODINE cross reference: IODOPHORS
- Schedule 6 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- IODOMETHANE
- Schedule 7 Appendix J, clause 1
- IODOPHORS cross reference: IODINE
- Schedule 6 Appendix E, clause 3
- 3-IODO-2-PROPYNYL BUTYL CARBAMATE cross reference: IODOCARB
- Schedule 6 Schedule 5
- IODOSULFURON-METHYL-SODIUM
- Schedule 5
- IODOTHIOURACIL
- Schedule 4
- IOXYNIL
- Schedule 6
- IPAMORELIN
- Schedule 4, Appendix D, clause 5
- IPCONAZOLE
- Schedule 6 Schedule 5
- IPFLUFENOQUIN
- Appendix B, Part 3
- IPILIMUMAB
- Schedule 4
- IPRATROPIUM
- Schedule 4 Schedule 2
- IPRATROPIUM BROMIDE
- Appendix F, clause 4
- IPRIFLAVONE
- Schedule 4
- IPRINDOLE
- Schedule 4
- IPRODIONE
- Appendix B, clause 3
- IPRONIAZID
- Schedule 4
- IPTACOPAN
- Schedule 4
- IRBESARTAN
- Schedule 4
- IRINOTECAN
- Schedule 4
- IRON COMPOUNDS cross reference: IRON OXIDES
- Schedule 6 Schedule 5 Schedule 4 Schedule 2
- ISAVUCONAZOLE
- Schedule 4 Appendix L, clause 2
- ISETHIONATE
- Appendix B, clause 3
- ISOAMINILE
- Schedule 4
- ISOAMYL NITRITE
- Schedule 4 Appendix E, clause 3
- ISOBUTYL NITRITE
- Schedule 4 Appendix E, clause 3
- ISOCARBOPHOS
- Schedule 7
- ISOCARBOXAZID
- Schedule 4
- ISOCONAZOLE
- Schedule 6 Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1
- ISOCYANATES
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- ISOCYCLOSERAM
- Schedule 6
- ISOETARINE
- Schedule 4
- ISOEUGENOL
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- ISOFENPHOS
- Schedule 7
- ISOFETAMID
- Appendix B, clause 3
- ISOFLURANE
- Schedule 4
- ISOMETHADONE
- cross reference: CAS No. 466-40-0
- Schedule 9
- ISOMETHEPTENE
- Schedule 4
- ISONIAZID
- Schedule 4
- ISOPHENIDINE
- cross reference: CAS No. 774118-46-6, NPDPA, ISOPHENIDINE HYDROCHLORIDE (CAS No. 6267-56-7), ISOPROPYLPHENIDINE Schedule 9
- ISOPHORONE
- Schedule 5 Appendix E, clause 3
- ISOPRENALINE
- Schedule 4 Appendix F, clause 4
- ISOPRENE ALCOHOL
- Appendix B, clause 3
- ISOPRINOSINE
- Schedule 4
- ISOPROPAMIDE
- Schedule 4 Schedule 2
- ISOPROPYL NITRITE
- cross reference: CAS No. 541-42-4
- Schedule 10
- ISOPROTURON
- Schedule 7
- ISOPYRAZAM
- Schedule 6
- ISOSORBIDE DINITRATE
- Schedule 4 Schedule 3
- ISOSORBIDE MONONITRATE
- Schedule 4
- ISOSTEARYL ALCOHOL ETHOXYLATE
- Appendix B, clause 3
- ISOTIANIL
- Schedule 6
- ISOTONITAZENE
- cross reference: CAS No. 14188-81-9
- Schedule 9
- ISOTRETINOIN
- Schedule 4 Appendix D, clause 2 Appendix F, clause 4 Appendix L, clause 2
- ISOXABEN
- Schedule 5
- ISOXAFLUTOLE
- Schedule 5
- ISOXICAM
- Schedule 4
- ISOXSUPRINE
- Schedule 4
- ISRADIPINE
- Schedule 4
- ITRACONAZOLE
- Schedule 4
- IVABRADINE
- Schedule 4
- IVACAFTOR
- Schedule 4
- IVERMECTIN
- Schedule 7 Schedule 5 Schedule 4
- IVOSIDENIB
- Schedule 4
- IXABEPILONE
- Schedule 4
- IXAZOMIB
- Schedule 4
- IXEKIZUMAB
- Schedule 4
- J
- JAPANESE ENCEPHALITIS VACCINE
- Schedule 4
- JUNIPERUS SABINE cross reference: SAVIN(E)
- Schedule 10
- K
- KAMBO cross reference: Secretion of the South American Giant Leaf Frog or Giant Monkey Frog (Phyllomedusa bicolor)
- Schedule 10
- KANAMYCIN
- Schedule 4
- KAOLIN
- Appendix B, clause 3
- KEROSENE
- Appendix E, clause 3
- KETAMINE
- Schedule 8
- KETANSERIN
- Schedule 4
- KETAZOLAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives)
- KETOBEMIDONE
- cross reference: CAS No. 469-79-4, KETOBEMIDONE HYDROCHLORIDE (CAS No. 5965-49-1)
- Schedule 9
- KETOCONAZOLE
- Schedule 4 Schedule 2
- KETOPROFEN
- Schedule 4 Schedule 3
- Appendix H, clause 1
- KETOROLAC
- Schedule 4
- KETOTIFEN
- Schedule 4 Schedule 2
- KHELLIN
- Schedule 4
- KINETIN
- Appendix B, clause 3
- KITASAMYCIN
- Schedule 5 Schedule 4
- KRATOM
- cross reference: MITRAGYNA SPECIOSA, MITRAGYNINE
- KRESOXIM-METHYL
- Appendix B, clause 3
- KUNZEA OIL
- Appendix B, clause 3
- L
- LABETALOL
- Schedule 4
- LACIDIPINE
- Schedule 4
- LACOSAMIDE
- Schedule 4
- LAMBDA-CYHALOTHRIN
- Schedule 7 Schedule 6 Schedule 5
- LAMIVUDINE
- Schedule 4
- LAMOTRIGINE
- Schedule 4 Appendix K, clause 1
- LANADELUMAB
- Schedule 4
- LANATOSIDES
- Schedule 4
- LANDIOLOL
- Schedule 4
- LANREOTIDE
- Schedule 4
- LANSOPRAZOLE
- Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1
- LANTHANUM
- Schedule 4
- LAPATINIB
- Schedule 4
- LARONIDASE
- Schedule 4
- LAROPIPRANT
- Schedule 4
- LAROTRECTINIB
- Schedule 4
- LASALOCID
- Schedule 6
- LASIODIPLODIA PSEUDOTHEOBROMAE
- Schedule 5
- LATAMOXEF
- Schedule 4
- LATANOPROST
- Schedule 4
- LAUDEXIUM
- Schedule 4
- LAURETH CARBOXYLIC ACIDS
- Schedule 6 Appendix E, clause 3
- LAURIC ACID
- Appendix B, clause 3
- LAUROMACROGOLS cross reference: LAURETH-9
- Schedule 4
- LAURYL ALCOHOL cross reference: 1-DODECANOL
- Appendix B, clause 3
- LAURYL ISOQUINOLINIUM BROMIDE
- Schedule 6 Appendix E, clause 3
- LAURYL SULFATE SALTS cross reference: SODIUM LAURYL SULPHATE, DODECYL SULFATES
- Schedule 6 Appendix E, clause 3
- LAVANDIN OIL cross reference: CAMPHOR
- Appendix B, clause 3
- LAVENDER OIL
- Appendix B, clause 3
- LAZERTINIB
- Schedule 4
- LEAD COMPOUNDS cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM
- Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 (in glazing preparations) Appendix F, clause 4
- LEAD METALLIC
- Appendix B, clause 3
- LEBRIKIZUMAB
- Schedule 4
- LECANEMAB
- Schedule 4
- LEDIPASVIR
- Schedule 4
- LEFETAMINE
- Schedule 4
- LEFLUNOMIDE
- Schedule 4 Appendix F, clause 4 Appendix L, clause 2
- LEMBOREXANT
- Schedule 4 Appendix K, clause 1
- LEMON OIL
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- LEMONGRASS OIL
- Schedule 5
- LENACAPAVIR
- Schedule 4
- LENALIDOMIDE
- Schedule 4 Appendix D, clause 4 Appendix F, clause 4 Appendix L, clause 2
- LENIOLISIB
- Schedule 4
- LENOGRASTIM
- Schedule 4
- LENVATINIB
- Schedule 4
- LEPIRUDIN
- Schedule 4
- LEPTAZOL
- Schedule 4
- LEPTOPHOS
- Schedule 7
- LEPTOSPERMUM SCOPARIUM OIL cross reference: MANUKA OIL
- Schedule 6 Appendix E, clause 3
- LERCANIDIPINE
- Schedule 4
- LESINURAD
- Schedule 4
- LETERMOVIR
- Schedule 4
- LETROZOLE
- Schedule 4
- LEUPRORELIN
- Schedule 4
- LEVALLORPHAN
- Schedule 4
- LEVAMISOLE
- Schedule 6 Schedule 5 Schedule 4
- LEVAMFETAMINE cross reference: LEVAMPHETAMINE
- Schedule 8
- LEVETIRACETAM
- cross reference: RACETAMS
- Schedule 4 Appendix K, clause 1
- LEVOBUNOLOL
- Schedule 4
- LEVOBUPIVACAINE
- Schedule 4
- LEVOCABASTINE
- Schedule 4 Schedule 2 Appendix F, clause 4 Appendix L, clause 2
- LEVOCETIRIZINE
- Schedule 4 Schedule 2 Appendix K, clause 1
- LEVODOPA
- Schedule 4
- LEVOMEPROMAZINE cross reference: METHOTRIMEPRAZINE
- Schedule 4
- LEVOMETHAMFETAMINE cross reference: LEVOMETHAMPHETAMINE
- Schedule 8
- LEVOMETHORPHAN
- cross reference: CAS No. 125-70-2
- Schedule 9
- LEVOMILNACIPRAN
- Schedule 4
- LEVOMORAMIDE
- Schedule 8
- LEVONORGESTREL
- Schedule 4 Schedule 3
- Appendix H, clause 1
- LEVOPHENACYLMORPHAN
- cross reference: CAS No. 10061-32-2
- Schedule 9
- LEVORPHANOL
- Schedule 8
- LEVOSIMENDAN
- Schedule 4
- LIDOCAINE
- Schedule 5 Schedule 4 Schedule 2
- LIDOFLAZINE
- Schedule 4
- LIFITEGRAST
- Schedule 4
- LIGNOCAINE cross reference: LIDOCAINE
- LIGULARIA DENTATA
- Schedule 10
- LIME OIL
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- LIMONENE cross reference: DIPENTENE
- Appendix B, clause 3
- LINACLOTIDE
- Schedule 4
- LINAGLIPTIN
- Schedule 4
- LINCOMYCIN
- Schedule 4
- LINDANE cross reference: BHC
- Schedule 6 Schedule 5 Schedule 4 Schedule 2
- LINEZOLID
- Schedule 4
- LINOLEIC ACID
- Appendix B, clause 3
- LINSEED FATTY ACIDS
- Appendix B, clause 3
- LINURON
- Appendix B, clause 3
- LIOTHYRONINE cross reference: TRIIODOTHYRONINE
- Schedule 4
- LIPEGFILGRASTIM
- Schedule 4
- LIQUORICE, DEGLYCYRRHISINISED
- Appendix B, clause 3
- LIRAGLUTIDE
- Schedule 4
- LISDEXAMFETAMINE
- Schedule 8
- LISINOPRIL
- Schedule 4
- LISURIDE
- Schedule 4
- LITHIUM
- Schedule 4 Schedule 2
- LITHIUM PERFLUOROOCTANE SULFONATE
- Schedule 7
- LIXISENATIDE
- Schedule 4
- LOBELIA INFLATA
- Schedule 2
- LOBELINE
- Schedule 2
- LODOXAMIDE
- Schedule 4 Schedule 2
- LOFEXIDINE
- Schedule 4
- LOGIPARIN
- Schedule 4
- LOMEFLOXACIN
- Schedule 4
- LOMUSTINE
- Schedule 4
- LONAPEGSOMATROPIN
- Schedule 4
- Appendix D, clause 5
- LONCASTUXIMAB TESIRINE
- Schedule 4
- LOPERAMIDE
- Schedule 4 Schedule 2 Appendix F, clause 4
- LOPINAVIR
- Schedule 4
- LOPRAZOLAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives)
- LORACARBEF
- Schedule 4
- LORATADINE
- Schedule 4 Schedule 2
- LORAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- LORLATINIB
- Schedule 4
- LORMETAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives)
- LOSARTAN
- Schedule 4
- LOTEPREDNOL
- Schedule 4
- LOTILANER
- Schedule 5
- LOXAPINE
- Schedule 4
- LUBRICANTS
- Appendix A, clause 1
- LUFENURON
- Schedule 5
- LUMACAFTOR
- Schedule 4
- LUMASIRAN
- Schedule 4
- LUMEFANTRINE
- Schedule 4
- LUMIRACOXIB
- Schedule 4
- LURASIDONE
- Schedule 4 Appendix K, clause 1
- LURBINECTEDIN
- Schedule 4
- LUSPATERCEPT
- Schedule 4
- LUTEINISING HORMONE
- Schedule 4 Appendix D, clause 1
- LYMECYCLINE
- Schedule 4
- LYSERGIC ACID
- cross reference: CAS No. 82-58-6
- Schedule 9
- LYSERGIDE
- cross reference: CAS No. 50-37-3
- Schedule 9
- M
- MACITENTAN
- Schedule 4 Appendix D, clause 6 Appendix L, clause 2
- MACROGOLS
- Schedule 3 Schedule 2
- MACROPHOMINA PHASEOLINA
- Schedule 5
- MADURAMICIN
- Schedule 7 Schedule 5 Appendix J, clause 1
- MAFENIDE
- Schedule 6 Schedule 4
- MAGNESIUM CHLORATE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- MAGNESIUM HYDROXIDE
- Appendix B, clause 3
- MAGNESIUM SULFATE
- Schedule 3
- MALACHITE GREEN
- Schedule 7 Schedule 5
- MALATHION cross reference: MALDISON, ORGANOPHOSPHORUS COMPOUNDS
- Schedule 6 Schedule 5 Schedule 3 Appendix E, clause 3
- MALEIC HYDRAZIDE
- Appendix B, clause 3
- MANCOZEB
- Schedule 5
- MANDESTROBIN
- Schedule 5
- MANDIPROPAMID
- Schedule 5
- MANDRAGORA OFFICINARUM
- Schedule 4
- MANGANESE DIOXIDE
- Appendix B, clause 3
- MANNITYL HEXANITRATE
- Schedule 3
- MANNOMUSTINE
- Schedule 4
- MAPROTILINE
- Schedule 4
- MARAVIROC
- Schedule 4
- MARBOFLOXACIN
- Schedule 4
- MARIBAVIR
- Schedule 4
- MARJORAM OIL
- Schedule 5 Appendix E, clause 3
- MAROPITANT
- Schedule 4
- MARSTACIMAB
- Schedule 4
- MATCHES
- Appendix A, clause 1
- MAVACAMTEN
- Schedule 4
- MAVACOXIB
- Schedule 4
- MAZIDOX
- Schedule 7
- MAZINDOL
- Schedule 4 Appendix K, clause 1
- MCPA
- Schedule 6 Schedule 5
- MCPB cross reference: (4-(4-CHLORO-2-METHYLPHENOXY)BUTANOIC ACID
- Schedule 6
- MEASLES VACCINE
- Schedule 4
- MEBANAZINE
- Schedule 4
- MEBENDAZOLE
- Schedule 6 Schedule 5 Schedule 2
- MEBEVERINE
- Schedule 4
- MEBHYDROLIN
- Schedule 4 Appendix K, clause 1
- MEBOLAZINE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- MEBUTAMATE
- Schedule 4
- MECAMYLAMINE
- Schedule 4
- MECARBAM
- Schedule 7
- MECASERMIN
- Schedule 4
- MECILLINAM
- Schedule 4
- MECLOCYCLINE
- Schedule 4
- MECLOFENAMATE
- Schedule 4
- MECLOFENAMIC ACID
- Schedule 5
- MECLOFENOXATE
- Schedule 4
- MECLONAZEPAM
- cross reference: CAS No. 58662-84-3
- Schedule 9
- MECLOQUALONE
- cross reference: CAS No. 340-57-8
- Schedule 9
- MECLOZINE cross reference: MECLIZINE
- Schedule 4 Schedule 2 Appendix K, clause 1
- MECOPROP
- Schedule 6 Schedule 5
- MECOPROP-P
- Schedule 6
- MEDAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- MEDETOMIDINE
- Schedule 4
- MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS
- Appendix A, clause 1
- MEDICAL DEVICES cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS, COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATER
- Appendix A, clause 1
- MEDIGOXIN cross reference: METHYLDIGOXIN
- Schedule 4
- MEDROXYPROGESTERONE
- Schedule 4
- MEDRYSONE
- Schedule 4
- MEFENAMIC ACID
- Schedule 4 Schedule 2 Appendix F, clause 4
- MEFENOREX
- Schedule 4
- MEFENPYR-DIETHYL
- Schedule 5
- MEFENTRIFLUCONAZOLE
- Schedule 5
- MEFLOQUINE
- Schedule 4
- MEFLUIDIDE
- Schedule 6
- MEFRUSIDE
- Schedule 4
- MEGASPHAERA ELSDENII strain 41125
- Appendix B, clause 3
- MEGESTROL
- Schedule 4
- MELAGATRAN
- Schedule 4
- MELALEUCA OIL cross reference: TEA TREE OIL
- Schedule 6 Appendix E, clause 3
- MELANOTAN II cross reference: α–MELANOCYTE STIMULATING HORMONE
- Schedule 4
- MELATONIN
- Schedule 4 Schedule 3 Appendix H, clause 1
- MELENGESTROL
- Schedule 4
- MELENGESTROL ACETATE
- Schedule 6
- MELIA AZEDARACH
- Schedule 10
- MELOXICAM
- Schedule 6
- Schedule 4
- MELPHALAN
- Schedule 4
- MEMANTINE
- Schedule 4
- MENAZON
- Schedule 6
- MENINGOCOCCAL VACCINE
- Schedule 4
- MENINGOCOCCAL GROUP B VACCINE cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086) Subfamily A Protein and Subfamily B Protein
- Schedule 4
- MENOTROPHIN
- cross reference: HUMAN MENOPAUSAL GONADOTROPHIN
- Schedule 4
- MEPACRINE
- Schedule 4
- MEPENZOLATE
- Schedule 4
- MEPHENESIN
- Schedule 4
- MEPHENTERMINE
- Schedule 4
- MEPINDOLOL
- Schedule 4
- MEPIQUAT
- Schedule 5
- MEPITIOSTANE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- MEPIVACAINE
- Schedule 4
- MEPROBAMATE
- Schedule 4 Appendix K, clause 1
- MEPTAZINOL
- Schedule 4
- MEPYRAMINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- MEQUITAZINE
- Schedule 4
- MERCAPTAMINE cross reference: CYSTEAMINE
- Schedule 6 Schedule 5 Schedule 4 Appendix K, clause 1
- MERCAPTOACETIC ACID cross reference: THIOGLYCOLIC ACID
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- 2-MERCAPTOETHANOL
- Schedule 6
- MERCAPTOMERIN
- Schedule 4
- MERCAPTOPURINE
- Schedule 4
- MERCURIC CHLORIDE cross reference: CALOMEL
- Schedule 7 Appendix E, clause 3
- MERCURIC IODIDE
- Appendix E, clause 3
- MERCURIC NITRATE
- Appendix E, clause 3
- MERCURIC OXIDE
- Schedule 6 Appendix E, clause 3
- MERCURIC POTASSIUM IODIDE
- Appendix E, clause 3
- MERCURIC THIOCYANATE
- Appendix E, clause 3 Appendix F, clause 4
- MERCUROCHROME
- Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3
- MERCUROUS CHLORIDE cross reference: CORROSIVE SUBLIMATE
- Appendix E, clause 3
- MERCURY cross reference: ETHOXYETHYLMERCURIC CHLORIDE, ETHOXYQUIN, PHENYL MERCURIC CHLORIDE
- Schedule 7 Schedule 4 Schedule 2 Appendix G, clause 1 Appendix J, clause 1
- MERCURY metallic
- Appendix E, clause 3
- MERCURY, organic compounds
- Appendix E, clause 3
- MEROPENEM
- Schedule 4
- MERSALYL
- Schedule 4
- MESABOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- MESALAZINE
- Schedule 4
- MESNA
- Schedule 4
- MESOSULFURON-METHYL
- Appendix B, clause 3
- MESOTRIONE
- Schedule 5
- MESTANOLONE cross reference: ANDROSTALONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- MESTEROLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- MESTRANOL
- Schedule 4
- METACRESOLSULPHONIC ACID
- Schedule 6 Appendix F, clause 4
- METAFLUMIZONE
- Schedule 5
- METALAXYL
- Schedule 6 Schedule 5
- METALDEHYDE
- Schedule 6 Schedule 5 Appendix E, clause 3
- METAMFETAMINE cross reference: METHAMFETAMINE, METHAMPHETAMINE, METHYLAMFETAMINE, METHYLAMPHETAMINE
- Schedule 8
- METAMITRON
- Schedule 6
- METANDIENONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- METARAMINOL
- Schedule 4
- METARHIZIUM ANISOPLIAE
- Appendix B, clause 3
- METARYLPICOXAMID
- Schedule 5
- METAZACHLOR
- Schedule 5
- METAZOCINE
- cross reference: CAS No. 3734-52-9, METAZOCINE RACEMATE CIS-FORM (CAS No. 25144-79-0)
- Schedule 9
- METCAMIFEN
- Appendix B, clause 3
- METENOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- METERGOLINE
- Schedule 4
- METFORMIN
- Schedule 4
- METHABENZTHIAZURON
- Schedule 5
- METHACHOLINE
- Schedule 4
- METHACRIFOS
- Schedule 7 Schedule 6 Appendix J, clause 1
- METHACYCLINE
- Schedule 4
- METHADONE
- Schedule 8 Appendix K, clause 1
- METHALLENESTRIL cross reference: METHALLENOESTRIL
- Schedule 4
- METHAM cross reference: METHAM SODIUM
- Schedule 6
- METHAMIDOPHOS
- Schedule 7
- METHANDRIOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- METHANOL
- cross reference: CAS No. 67-56-1
- Schedule 10
- Schedule 6
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- METHANTHELINIUM
- Schedule 4
- METHAPYRILENE
- Schedule 7
- METHAQUALONE
- cross reference: CAS No. 72-44-6, METHAQUALONE HYDROCHLORIDE (CAS No. 340-56-7)
- Schedule 9
- METHAZOLAMIDE
- Schedule 4
- METHAZOLE
- Schedule 7
- METHCATHINONE
- cross reference: CAS No. 5650-44-2, METHCATHINONE HYDROCHLORIDE (CAS No. 49656-78-2)
- Schedule 9
- METHDILAZINE
- Schedule 4 Schedule 3 Appendix K, clause 1
- METHENAMINE cross reference: 1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE, HEXAMINE, HEXAMETHYLENETETRAMINE
- Schedule 5
- Schedule 3
- Appendix H, clause 1
- METHENOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- METHICILLIN
- Schedule 4
- METHIDATHION
- Schedule 7
- METHIMAZOLE cross reference: THIAMAZOLE
- Schedule 4
- METHIOCARB
- Schedule 7 Schedule 6 Schedule 5
- METHISAZONE
- Schedule 4
- METHIOZOLIN
- Schedule 5
- METHIXENE
- Schedule 4
- METHOCARBAMOL
- Schedule 4 Appendix K, clause 1
- METHOFLUTHRIN
- Schedule 5
- METHOHEXITONE
- Schedule 4
- METHOIN
- Schedule 4
- METHOMYL cross reference: DENATONIUM BENZOATE
- Schedule 7 Schedule 6
- METHOPRENE
- Appendix B, clause 3
- METHOTREXATE
- Schedule 4
- METHOXAMINE
- Schedule 4 Schedule 2 Appendix F, clause 4
- METHOXPHENIDINE
- cross reference: CAS No. 127529-46-8, METHOXPHENIDINE HYDROCHLORIDE (CAS No. 2055777-48-3), MXP Schedule 9
- METHOXSALEN
- Schedule 4
- METHOXYCHLOR
- Schedule 5
- 2-METHOXYETHANOL
- Schedule 7 Appendix F, clause 4
- METHOXYETHYLMERCURIC ACETATE
- Schedule 7 Appendix J, clause 1
- METHOXYETHYLMERCURIC CHLORIDE
- Schedule 7 Appendix J, clause 1
- METHOXYFENOZIDE
- Appendix B, clause 3
- METHOXYFLURANE
- Schedule 4
- 5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE cross reference: 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE, MMDA (CAS No. 13674-05-0), MMDA HYDROCHLORIDE (CAS No. 60676-84
- Schedule 9
- 4-METHOXY- α –METHYLPHENYLETHYLAMINE cross reference: PMA (CAS No. 64-13-1), PMA HYDROCHLORIDE (CAS No. 3706-26-1)
- Schedule 9
- 5-METHOXY- α –METHYLTRYPTAMINE cross reference: 5-MeO-AMT (CAS No. 1137-04-8)
- Schedule 9
- 6-METHOXY-N2-METHYL-2,3-PYRIDINEDIAMINE
- Schedule 6
- 2-METHOXY-5-NITROPHENOL
- Schedule 6
- METHOXYPHENAMINE
- Schedule 2
- 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE cross reference: JWH-250 (CAS No. 864445-43-2)
- Schedule 9
- METHSUXIMIDE
- Schedule 4
- METHYCLOTHIAZIDE
- Schedule 4
- METHYL ACETATE
- Appendix B, clause 3
- METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE cross reference: SAL
- Schedule 9
- METHYL AMINOLEVULINATE
- Schedule 4
- p-METHYLAMINOPHENOL
- Schedule 6 Appendix F, clause 4
- 4-METHYLAMINOREX
- cross reference: CAS No. 3568-94-3
- Schedule 9
- METHYLANDROSTANOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- METHYLATED SPIRIT(S) cross reference: DENATONIUM BENZOATE, ETHANOL, FLUORESCEIN
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- METHYL BENZOQUATE
- Appendix B, clause 3
- METHYL BROMIDE
- Schedule 7 Appendix J, clause 1
- METHYL CHLORIDE
- Appendix F, clause 4
- METHYLCHLOROISOTHIAZOLINONE cross reference: METHYLISOTHIAZOLINONE
- Schedule 6 Appendix F, clause 4
- METHYLCLOSTEBOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL
- Schedule 7 Schedule 6
- 1-METHYLCYCLOPROPENE
- Appendix B, clause 3
- METHYLDESORPHINE
- cross reference: CAS No. 16008-36-9
- Schedule 9
- METHYLDIBROMO GLUTARONITRILE
- cross reference: CAS No. 35691-65-7
- Schedule 10 Schedule 6 Appendix F, clause 4
- METHYLDIHYDROMORPHINE
- Schedule 8
- METHYLDOPA
- Schedule 4
- 4,4'-METHYLENEBIS[2-CHLOROANILINE]
- Schedule 7 Appendix J, clause 1
- METHYLENE BISTHIOCYANATE
- Schedule 6 Appendix F, clause 4
- METHYLENE BLUE
- Schedule 7 Schedule 5 Schedule 4
- 3,4-METHYLENEDIOXYAMFETAMINE cross reference: 3,4-METHYLENEDIOXYAMPHETAMINE, MDA, TENAMFETAMINE (CAS No. 4764-17-4)
- Schedule 9
- 3,4-METHYLENEDIOXYPYROVALERONE cross reference: MDPV (CAS No. 687603-66-3)
- Schedule 9
- METHYLEPHEDRINE
- Schedule 2
- METHYLERGOMETRINE
- Schedule 4
- METHYL ETHYL KETONE cross reference: DESIGNATED SOLVENT
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- METHYL ETHYL KETONE OXIME
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- METHYL ETHYL KETONE PEROXIDE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- METHYLEUGENOL
- Schedule 6 Appendix E, clause 3, Appendix F, clause 4
- 3-METHYLFENTANYL
- cross reference: CAS No. 42045-86-3
- Schedule 9
- METHYLPHENYLPIRACETAM cross reference: RACETAMS
- Schedule 4
- METHYL p-HYDROXYBENZOATE
- Appendix B, clause 3
- METHYL ISOAMYL KETONE cross reference: DESIGNATED SOLVENT
- Schedule 5 Appendix E, clause 3
- METHYL ISOBUTYL KETONE cross reference: DESIGNATED SOLVENT, METHYLATED SPIRIT(S)
- Schedule 5 Appendix E, clause 3
- METHYL ISOTHIOCYANATE
- Schedule 6
- METHYLISOTHIAZOLINONE cross reference: METHYLCHLOROISOTHIAZOLINONE
- Schedule 6 Appendix F, clause 4
- METHYLMERCURY
- Schedule 4 Appendix G, clause 1
- METHYL METHACRYLATE
- cross reference: CAS No. 80-62-6
- Schedule 10 Schedule 6 Appendix F, clause 4
- 4-METHYLMETHCATHINONE cross reference: MEPHEDRONE (CAS No. 1189805-46-6)
- Schedule 9
- N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE cross reference: MBDB (CAS No. 135795-90-3)
- Schedule 9
- N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE cross reference: N-HYDROXY MDA (CAS No. 74698-47-8)
- Schedule 9
- 2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID cross reference: MORAMIDE INTERMEDIATE (CAS No. 3626-55-9)
- Schedule 9
- METHYLNALTREXONE
- Schedule 4
- METHYL NEODECANAMIDE
- Schedule 6
- 6-METHYLNICOTINE
- cross-reference: CAS No. 13270-56-9
- Schedule 9
- METHYLNORBORNYLPYRIDINE
- Schedule 6
- METHYLONE *(MDMC)
- cross reference: CAS No. 186028-79-5, MDMC HYDROCHLORIDE (CAS No. 186028-80-8)
- Schedule 9
- METHYLPENTYNOL
- Schedule 4
- METHYLPHENIDATE
- Schedule 8
- METHYLPHENOBARBITAL cross reference: BARBITURATE METHYLPREDNISOLONE
- Schedule 4 Appendix K, clause 1
- METHYLPHENOBARBITONE cross reference: METHYLPHENOBARBITAL, BARBITURATE METHYLPREDNISOLONE
- 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE cross reference: ACIDMPPP (CAS No. 13147-09-6), MPPP HYDROCHLORIDE (CAS No. 4968-48-3)
- Schedule 9
- 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID cross reference: PETHIDINE INTERMEDIATE C
- Schedule 8
- METHYLPREDNISOLONE
- Schedule 4
- N-METHYL-2-PYRROLIDONE
- Schedule 6
- Schedule 5 Appendix E, clause 3
- 2-METHYLRESORCINOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- METHYLROSANILINIUM CHLORIDE cross reference: CRYSTAL VIOLET (CAS No. 548-62-9), GENTIAN VIOLET, ACID VIOLET 49 (CAS No. 1694-09-3), ETHYL VIOLET (CAS No. 2390-5
- Schedule 10 Schedule 6 Schedule 4
- METHYL SALICYLATE
- Schedule 6 Schedule 5 Schedule 4
- METHYL SALICYLATE LIQUID
- Appendix E, clause 3
- METHYLTESTOSTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- 4-METHYLTHIOAMFETAMINE cross reference: 4-METHYLTHIOAMPHETAMINE (CAS No. 14116-06-4)
- Schedule 9
- 3-METHYLTHIOFENTANYL
- cross reference: CAS No. 86052-04-2
- Schedule 9
- 2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE
- Schedule 5
- METHYLTHIOURACIL
- Schedule 4
- METHYLTRIENOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- METHYPRYLONE
- Schedule 4
- METHYSERGIDE
- Schedule 4
- METIRAM
- Schedule 5
- METOBROMURON
- Schedule 5
- METOCLOPRAMIDE
- Schedule 4 Schedule 3
- METODESNITAZENE
- cross reference: CAS No. 14030-77-4, METAZENE
- Schedule 9
- METOFLUTHRIN
- Schedule 6 Schedule 5
- METOLACHLOR
- Schedule 5
- METOLAZONE
- Schedule 4
- METONITAZENE
- cross reference: CAS No. 14680-51-4
- Schedule 9
- METOPON
- cross reference: CAS No. 143-52-2
- Schedule 9
- METOPROLOL
- Schedule 4
- METOSULAM
- Schedule 6
- METRAFENONE
- Schedule 6 Schedule 5
- METRIBOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- METRIBUZIN
- Schedule 6
- METRIFONATE cross reference: TRICHLORFON
- Schedule 4
- METRONIDAZOLE cross reference: BENZOYL METRONIDAZOLE
- Schedule 4
- METSULFURONMETHYL
- Appendix B, clause 3
- METYRAPONE
- Schedule 4
- MEVINPHOS
- Schedule 7
- MEXILETINE
- Schedule 4
- MEZLOCILLIN
- Schedule 4
- MIANSERIN
- Schedule 4 Appendix K, clause 1
- MIBEFRADIL
- Schedule 4
- MIBOLERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- MICAFUNGIN
- Schedule 4
- MICONAZOLE
- Schedule 6 Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1
- MIDAZOLAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives)
- Appendix K, clause 1
- MIDODRINE
- Schedule 4
- MIDOSTAURIN
- Schedule 4
- MIFEPRISTONE
- Schedule 4
- MIGALASTAT
- Schedule 4
- MIGLITOL
- Schedule 4
- MIGLUSTAT
- Schedule 4
- MILBEMECTIN
- Schedule 6 Schedule 5
- MILNACIPRAN
- Schedule 4
- MILBEMYCIN OXIME
- Schedule 5 Schedule 4
- MILRINONE
- Schedule 4
- MINOCYCLINE
- Schedule 4
- MINOXIDIL
- Schedule 4 Schedule 2
- MIPAFOX
- Schedule 7
- MIRABEGRON
- Schedule 4
- MIREX
- Schedule 7 Appendix J, clause 1
- MIRIKIZUMAB
- Schedule 4
- MIRTAZAPINE
- Schedule 4 Appendix K, clause 1
- MIRVETUXIMAB SORAVTANSINE
- Schedule 4
- MISOPROSTOL
- Schedule 4 Appendix F, clause 4 Appendix L, clause 2
- MITOBRONITOL
- Schedule 4
- MITOMYCIN
- Schedule 4
- MITOTANE
- Schedule 4
- MITOXANTRONE
- Schedule 4
- MITRAGYNA SPECIOSA cross reference: KRATOM; MITRAGYNINE (CAS No. 4098-40-2) Schedule 9
- MITRAGYNINE cross reference: (CAS No. 4098-40-2), KRATOM; MITRAGYNA SPECIOSA
- Schedule 9
- MITRATAPIDE
- Schedule 4
- MIVACURIUM CHLORIDE
- Schedule 4
- MOBOCERTINIB
- Schedule 4
- MOCLOBEMIDE
- Schedule 4
- MODAFINIL
- Schedule 4
- MOLGRAMOSTIM
- Schedule 4
- MOLIDUSTAT
- Schedule 4 Appendix D, clause 5
- MOLINATE
- Schedule 7 Appendix J, clause 1
- MOLINDONE
- Schedule 4
- MOLNUPIRAVIR
- Schedule 4
- MOMELOTINIB
- Schedule 4
- MOMETASONE
- Schedule 4
- Schedule 3 Schedule 2
- MOMFLUOROTHRIN
- Schedule 6
- MONENSIN
- Schedule 6 Schedule 5 Schedule 4
- MONEPANTEL
- Schedule 5
- MONOBENZONE cross reference: HYDROQUINONE
- Schedule 4
- MONOCLONAL ANTIBODIES
- Schedule 4
- MONOCROTOPHOS
- Schedule 7
- MONOETHANOLAMINE
- Schedule 6 Schedule 5 Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- MONTELUKAST
- Schedule 4
- MOPERONE
- Schedule 4
- MORANTEL
- Schedule 6 Schedule 5
- MORAZONE
- Schedule 4
- MORICIZINE
- Schedule 4
- MORPHERIDINE
- cross reference: CAS No. 469-81-8
- Schedule 9
- MORPHINE
- Schedule 8 Appendix K, clause 1
- MORPHINE METHOBROMIDE
- Schedule 8
- MORPHINE-N-OXIDE
- Schedule 8
- (1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1- YLMETHANONE cross reference: JWH-200 (CAS No. 103610-04-4)
- Schedule 9
- MOTOR, HEATING or FURNACE FUELS cross reference: FUELS, FUELS, HOBBY - FUELS, TOY, KEROSENE, METHANOL, PETROL
- Appendix A, clause 1
- MOTRAZEPAM
- Schedule 4
- MOTRETINIDE
- Schedule 4
- MOXIDECTIN
- Schedule 7 Schedule 6 Schedule 5 Schedule 4
- MOXIFLOXACIN
- Schedule 4
- MOXONIDINE
- Schedule 4
- MSMA
- Schedule 7 Schedule 6
- MUMPS VACCINE
- Schedule 4
- MUPIROCIN
- Schedule 4
- MURAGLITAZAR
- Schedule 4
- MUROMONAB
- Schedule 4
- MUSCIMOL
- cross reference: CAS No. 2763-96-4, MUSCIMOL HYDROBROMIDE (CAS No. 18174-72-6)
- Schedule 9
- MUSTINE cross reference: NITROGEN MUSTARD
- Schedule 4
- MYCLOBUTANIL
- Schedule 5
- MYCOPHENOLIC ACID cross reference: MYCOPHENOLATE MOFETIL
- Schedule 4
- MYRISTIC ACID
- Appendix B, clause 3
- MYROPHINE
- cross reference: CAS No. 467-18-5
- Schedule 9
- N
- NAA cross reference: NAPTHALENEACETIC ACID
- Schedule 5
- NABILONE
- Schedule 8
- NABIXIMOLS cross reference: CANNABICHROMENE, CANNABIDIOL, CANNABIDIOLIC ACID, CANNABIDIVAROL, CANNABIGEROL, CANNABINOIDS, CANNABINOL, CANNABIS SATIVA, TETRAHYDR
- Schedule 8 Appendix D, clause 1 Appendix K, clause 1
- NABUMETONE
- Schedule 4
- NADOLOL
- Schedule 4
- NADROPARIN
- Schedule 4
- NAFARELIN
- Schedule 4
- NAFTIDROFURYL
- Schedule 4
- NALBUPHINE
- Schedule 4 Appendix K, clause 1
- NALED
- Schedule 6 Schedule 5
- NALIDIXIC ACID
- Schedule 4
- NALMEFENE
- Schedule 4
- NALORPHINE
- Schedule 4
- NALOXEGOL
- Schedule 4
- NALOXONE
- Schedule 4 Schedule 3
- Appendix H, clause 1
- NALTREXONE
- Schedule 4
- NANDROLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- NAPHAZOLINE
- Schedule 2 Appendix F, clause 4
- NAPHTHALENE
- cross reference: CAS No. 91-20-3
- Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 Appendix G, clause 1
- 1,5-NAPHTHALENEDIOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- 2,7-NAPTHALENEDIOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE cross reference: JWH-073 (CAS No. 208987-48-8)
- Schedule 9
- NAPHTHALOPHOS
- Schedule 7
- Schedule 6
- 1-NAPHTHOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- NAPHTHOYLINDOLES
- cross reference: WIN 55,212-2 (CAS 137795-17-6)
- Schedule 9
- NAPHTHOYLPYRROLES
- Schedule 9
- NAPHTHYLMETHYLINDENES
- Schedule 9
- NAPHTHYLMETHYLINDOLES
- Schedule 9
- NAPROPAMIDE
- Appendix B, clause 3
- NAPROXEN
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1
- NAPTALAM
- Schedule 5
- NAPTHYL ACETAMIDE
- Appendix B, clause 3
- NARASIN
- Schedule 6 Schedule 4
- NARATRIPTAN
- Schedule 4
- Schedule 3
- Appendix H, clause 1
- NATALIZUMAB
- Schedule 4
- NATAMYCIN cross reference: PIMARCIN
- Schedule 4
- NATEGLINIDE
- Schedule 4
- NEBACUMAB
- Schedule 4
- NEBIVOLOL
- Schedule 4
- NEBRACETAM cross reference: RACETAMS
- Schedule 4
- NEDOCROMIL
- Schedule 4
- NEFAZODONE
- Schedule 4
- NEFIRACETAM cross reference: RACETAMS
- Schedule 4
- NEFOPAM
- Schedule 4
- NELARABINE
- Schedule 4
- NELFINAVIR
- Schedule 4
- NEOMYCIN
- Schedule 4
- NEOSCYTALIDIUM NOVAEHOLLANDIAE
- Schedule 5
- NEOSTIGMIN
- Schedule 4
- NEPAFENAC
- Schedule 4
- NERATINIB
- Schedule 4
- NERIUM OLEANDER
- Schedule 4 Appendix G, clause 1
- NEROLI OIL
- Appendix B, clause 3
- NESIRITIDE
- Schedule 4
- NETILMICIN
- Schedule 4
- NETOBIMIN
- Schedule 6 Schedule 5
- NETUPITANT
- Schedule 4
- NEVIRAPINE
- Schedule 4
- NIALAMIDE
- Schedule 4
- NICARBAZIN
- Appendix B, clause 3
- NICARDIPINE
- Schedule 4
- NICERGOLINE
- Schedule 4
- NICKEL SULFATE
- Schedule 6
- NICLOSAMIDE
- Schedule 6 Schedule 5 Schedule 2
- NICOCODINE
- cross reference: CAS No. 3688-66-2, NICOCODINE HYDROCHLORIDE (CAS No. 58263-01-7)
- Schedule 9
- NICODICODINE
- cross reference: CAS No. 808-24-2
- Schedule 9
- NICOFURANOSE
- Schedule 4
- NICOMORPHINE
- cross reference: CAS No. 639-48-5, NICOMORPHINE HYDROCHLORIDE (CAS No. 12040-41-4)
- Schedule 9
- NICORANDIL
- Schedule 4
- NICOTINE
- Schedule 7 Schedule 4 Schedule 3 Appendix D, clause 5 Appendix F, clause 4 Appendix J, clause 1
- NICOTINIC ACID cross reference: NICOTINAMIDE
- Schedule 5
- Schedule 4 Schedule 3
- NICOTINYL ALCOHOL
- Schedule 3
- NICOUMALONE
- Schedule 4
- NIFEDIPINE
- Schedule 4
- NIFENAZONE
- Schedule 4
- NIFOXIPAM
- cross reference: CAS No. 74723-10-7
- Schedule 9
- NIKETHAMIDE
- Schedule 4
- NILOTINIB
- Schedule 4
- NILUTAMIDE
- Schedule 4
- NIMESULIDE
- Schedule 4
- NIMIDANE
- Schedule 7 Schedule 6
- NIMODIPINE
- Schedule 4
- NIMORAZOLE
- Schedule 4
- NINTEDANIB
- Schedule 4
- NIRAPARIB
- Schedule 4
- NIRIDAZOLE
- Schedule 4
- NIRMATRELVIR
- Schedule 4
- NIRSEVIMAB
- Schedule 4
- NISIN
- Appendix B, clause 3
- NISOLDIPINE
- Schedule 4
- NITENPYRAM
- Schedule 6
- NITISINONE
- Schedule 4
- NITRAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- NITRENDIPINE
- Schedule 4
- NITRIC ACID
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- NITRIC OXIDE
- Schedule 4
- NITROBENZENE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- NITROFEN
- Schedule 7 Appendix J, clause 1
- NITROFURANTOIN
- Schedule 4
- NITROFURAZONE
- Schedule 4
- 3-NITRO-p-HYDROXYETHYLAMINOPHENOL cross reference: 4-[(2-HYDROXYETHYL)AMINO]-3-NITROPHENOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- NITROPHENOLS
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- NITROPRUSSIDES
- Schedule 7 Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- NITROSCANATE
- Schedule 5
- 2-NITROTOLUENE
- Schedule 7
- NITROUS OXIDE
- Schedule 4
- Schedule 6
- Appendix E, clause 3
- Appendix F, clause 4
- NITROXOLINE
- Schedule 4
- NITROXYNIL
- Schedule 6
- NIVOLUMAB
- Schedule 4
- NIZATIDINE
- Schedule 4 Schedule 2 Appendix F, clause 4
- NOMEGESTROL
- Schedule 4
- NOMIFENSINE
- Schedule 4
- NONANOIC ACID
- Schedule 5
- NONOXINOL 9
- Schedule 6 Schedule 5 Appendix E, clause 3
- NORACYMETHADOL
- cross reference: CAS No. 1477-39-0, NORACYMETHADOL HYDROCHLORIDE (CAS No. 5633-25-0)
- Schedule 9
- NORADRENALINE
- Schedule 4 Appendix F, clause 4
- 19-NORANDROSTENEDIOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- 19-NORANDROSTENEDIONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- NORANDROSTENOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- NORBOLETHONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- NORBORMIDE
- Schedule 5
- NORCLOSTEBOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- NORCODEINE
- Schedule 8
- NORELGESTROMIN
- Schedule 4
- NOREPINEPHRINE cross reference: NORADRENALINE
- NORETHANDROLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- NORETHISTERONE
- Schedule 4
- NORFLOXACIN
- Schedule 4
- NORFLURAZON
- Appendix B, clause 3
- NORGESTREL
- Schedule 4
- NORIBOGAINE
- Schedule 4
- NORLEVORPHANOL
- cross reference: CAS No. 1531-12-0, NORLEVORPHANOL HYDROBROMIDE (CAS No. 63732-85-4), NORLEVORPHANOL RACEMATE (CAS No. 39131-41-4)
- Schedule 9
- NORMAL HUMAN IMMUNOGLOBULIN
- Schedule 4
- NORMETHADONE
- Schedule 8 Appendix K, clause 1
- NORMETHANDRONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- NORMORPHINE
- cross reference: CAS No. 466-97-7, NORMORPHINE HYDROCHLORIDE (CAS No. 3372-02-9)
- Schedule 9
- NORPIPANONE
- cross reference: CAS No. 561-48-8, NORPIPANONE HYDROCHLORIDE (CAS No. 6033-41-6), NORPIPANONE HYDROBROMIDE (CAS No. 6033-42-7)
- Schedule 9
- NORTRIPTYLINE
- Schedule 4 Appendix K, clause 1
- NOSCAPINE
- Schedule 2
- NOVALURON
- Appendix B, clause 3
- NOVOBIOCIN
- Schedule 4
- NOXIPTYLINE
- Schedule 4
- NUCLEAR POLYHEDROSIS VIRUS OF Helicoverpa armigera occlusion bodies
- Appendix B, clause 3
- NUSINERSEN
- Schedule 4
- NUTMEG OIL
- Schedule 5
- NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION
- Appendix A, clause 1
- NYSTATIN
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1
- O
- OBETICHOLIC ACID
- Schedule 4
- OCLACITINIB
- Schedule 4
- OCRELIZUMAB
- Schedule 4
- OCRIPLASMIN
- Schedule 4
- OCTAMYLAMINE
- Schedule 4
- OCTATROPINE
- Schedule 4
- 1-OCTEN-3-OL
- Schedule 6
- OCTHILINONE
- Schedule 6
- OCTREOTIDE
- Schedule 4
- OCTYL ALCOHOLS
- Appendix B, clause 3
- N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE
- cross reference: OCTYLBICYCLOHEPTENEDICARBOXIMIDE
- Schedule 5
- OCTYL NITRITE
- Schedule 4 Appendix E, clause 3
- N-(N-OCTYL)-2-PYRROLIDONE cross reference: DESIGNATED SOLVENT, N-(N-DODECYL)-2-PYRROLIDONE, N-METHYL-2-PYRROLIDONE
- Schedule 6 Schedule 5 Appendix E, clause 3
- ODEVIXIBAT Schedule 4
- OESTRADIOL cross reference: ESTRADIOL
- OESTRIOL cross reference: ESTRIOL
- OESTROGENS cross reference: ESTROGENS
- OESTRONE cross reference: ESTRONE
- OFATUMUMAB
- Schedule 4
- OFLOXACIN
- Schedule 4
- OLANZAPINE
- Schedule 4 Appendix K, clause 1
- OLAPARIB
- Schedule 4
- OLAQUINDOX
- Schedule 6
- OLARATUMAB
- Schedule 4
- OLEANDOMYCIN
- Schedule 5 Schedule 4
- OLEANDRIN
- Schedule 4
- OLEIC ACID
- Appendix B, clause 3
- N-OLEYL-1,3-DIAMINOPROPANE
- Schedule 6
- OLIPUDASE ALFA
- Schedule 4
- OLMESARTAN
- Schedule 4
- OLODATEROL
- Schedule 4
- OLOPATADINE
- Schedule 4 Schedule 2
- OLSALAZINE
- Schedule 4
- OLUTASIDENIB
- Schedule 4
- OMBERACETAM cross reference: RACETAMS, NOOPEPT, N-PHENYLACETYL-L-PROLYLGLYCINE ETHYL ESTER
- Schedule 4
- OMBITASVIR
- Schedule 4
- OMALIZUMAB
- Schedule 4
- OMEGA-3-ACID ETHYL ESTERS
- Schedule 4
- OMEPRAZOLE
- Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1
- OMETHOATE
- Schedule 7 Schedule 6 Schedule 5
- ONASEMNOGENE ABEPARVOVEC
- Schedule 4
- ONDANSETRON
- Schedule 4
- OPICAPONE
- Schedule 4
- OPIPRAMOL
- Schedule 4
- OPIUM cross reference: NOSCAPINE, PAPAVERINE
- Schedule 8 Appendix K, clause 1
- ORANGE OIL (BITTER)
- Schedule 5 Appendix E, clause 3
- ORANGE OIL, SWEET
- Appendix B, clause 3
- ORBIFLOXACIN
- Schedule 4
- ORCIPRENALINE
- Schedule 4 Appendix F, clause 4
- ORELABRUTINIB
- Schedule 4
- ORGANOPHOSPHORUS COMPOUNDS cross reference: MALATHION
- Schedule 4
- ORLISTAT
- Schedule 4 Schedule 3
- ORNIDAZOLE
- Schedule 4
- ORNIPRESSIN
- Schedule 4
- ORPHENADRINE
- Schedule 4
- ORTHOPTERIN
- Schedule 4
- OSELTAMIVIR
- Schedule 4
- OSILODROSTAT
- Schedule 4
- OSIMERTINIB
- Schedule 4
- OUABAIN
- Schedule 4
- OVANDROTONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- OXABETRINIL
- Appendix B, clause 3
- OXABOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- OXACILLIN
- Schedule 4
- OXADIARGYL
- Schedule 5
- OXADIAZON
- Schedule 6
- OXADIXYL
- Schedule 5
- OXALATES
- Appendix F, clause 4
- OXALIC ACID
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- OXALIPLATIN
- Schedule 4
- OXAMYL
- Schedule 7
- OXANDROLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- OXANTEL EMBONATE
- Schedule 5
- OXAPROZIN
- Schedule 4
- OXAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- OXCARBAZEPINE
- Schedule 4
- OXATHIAPIPROLIN
- Appendix B, clause 3
- OXEDRINE cross reference: SYNEPHRINE
- Schedule 4
- OXETACAINE cross reference: OXETHAZAINE
- Schedule 4 Schedule 2
- OXFENDAZOLE
- Schedule 5
- OXIBENDAZOLE
- Schedule 5
- OXICONAZOLE
- Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1
- OXIRACETAM cross reference: RACETAMS
- Schedule 4
- OXITROPIUM
- Schedule 4
- OXOLAMINE
- Schedule 4
- OXOLINIC ACID
- Schedule 4
- OXPENTIFYLLINE cross reference: PENTOXIFYLLINE
- OXPRENOLOL
- Schedule 4
- OXYBUPROCAINE
- Schedule 4
- OXYBUTYNIN
- Schedule 4
- OXYCARBOXIN
- Schedule 5
- OXYCLOZANIDE
- Schedule 6
- OXYCODONE
- Schedule 8 Appendix K, clause 1
- OXYDEMETON METHYL
- Schedule 7
- OXYFLUORFEN
- Appendix B, clause 3
- OXYMESTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- OXYMETAZOLINE
- Schedule 2 Appendix F, clause 4
- OXYMETHOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- OXYMORPHONE
- Schedule 8
- OXYPHENBUTAZONE
- Schedule 4
- OXYPHENCYCLIMINE
- Schedule 4
- OXYPHENISATIN
- cross reference: CAS No. 125-13-3
- Schedule 10
- OXYPHENONIUM
- Schedule 4
- OXYQUINOLINE
- Schedule 2 Appendix F, clause 4
- OXYTETRACYCLINE
- Schedule 5 Schedule 4
- OXYTHIOQUINOX
- Schedule 5
- OXYTOCIN
- Schedule 4 Appendix G, clause 1
- OZANIMOD
- Schedule 4
- P
- PACLITAXEL
- Schedule 4
- PACLOBUTRAZOL
- Schedule 5
- PAECILOMYCES LILACINUS STRAIN 251
- Schedule 6
- PAINT
- Appendix F, clause 4
- PALBOCICLIB
- Schedule 4
- PALIFERMIN
- Schedule 4
- PALIPERIDONE
- Schedule 4 Appendix K, clause 1
- PALIVIZUMAB
- Schedule 4
- PALMAROSA OIL
- Appendix B, clause 3
- PALMITIC ACID
- Appendix B, clause 3
- PALMITOYLETHANOLAMIDE
- cross reference: PALMIDROL Schedule 6
- PALONOSETRON
- Schedule 4
- PALOPEGTERIPARATIDE
- Schedule 4
- PALOVAROTENE
- Schedule 4 Appendix F, clause 4 Appendix L, clause 2
- PAMAQUIN
- Schedule 4
- PAMIDRONIC ACID cross reference: PAMIDRONATE DISODIUM
- Schedule 4
- PANCREATIC ENZYMES cross reference: LIPASE
- Schedule 4
- PANCURONIUM
- Schedule 4
- PANITUMUMAB
- Schedule 4
- PANOBINOSTAT
- Schedule 4
- PANTOPRAZOLE
- Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1
- PAPAVERETUM
- Appendix K, clause 1
- PAPAVERINE cross reference: OPIUM
- Schedule 4 Schedule 2
- PAPER
- Appendix A, clause 1
- PARA-AMINOPROPIOPHENONE (PAPP) cross reference: 4-AMINOPROPIOPHENONE
- PARACETAMOL cross reference: ASPIRIN, IBUPROFEN, METOCLOPRAMIDE, SALICYLAMIDE, CAFFEINE
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4
- Appendix H, clause 1
- para-DICHLOROBENZENE cross reference: PDB
- Appendix F, clause 4
- PARA-FLUOROFENTANYL
- cross reference: CAS No. 90736-23-5
- Schedule 9
- PARAFORMALDEHYDE cross reference: FREE FORMALDEHYDE (CAS No. 30525-89-4)
- Schedule 10 Schedule 6 Schedule 2 Appendix E, clause 3
- PARALDEHYDE
- Schedule 4
- PARAMETHADIONE
- Schedule 4
- PARAMETHASONE
- Schedule 4
- PARAQUAT
- Schedule 7
- PARATHION
- Schedule 7
- PARATHION-METHYL
- Schedule 7 Schedule 6
- PARBENDAZOLE
- Schedule 6
- PARECOXIB
- Schedule 4
- PARICALCITOL
- Schedule 4
- PARITAPREVIR
- Schedule 4
- PAROMOMYCIN
- Schedule 4
- PAROXETINE
- Schedule 4
- PASIREOTIDE
- Schedule 4
- PATCHOULI OIL
- Appendix B, clause 3
- PATIROMER SORBITEX CALCIUM
- Schedule 4
- PATISIRAN
- Schedule 4
- PAZOPANIB
- Schedule 4
- PEBULATE
- Schedule 6
- PECAZINE
- Schedule 4
- PECTINASE derived from Aspergillus niger
- Appendix B, clause 3
- PEFLOXACIN
- Schedule 4
- PEGAPTANIB
- Schedule 4
- PEGASPARGASE
- Schedule 4
- PEGBOVIGRASTIM
- Appendix B, clause 3
- PEGCETACOPLAN
- Schedule 4
- PEGFILGRASTIM
- Schedule 4
- PEGINTERFERON
- Schedule 4
- PEGUNIGALSIDASE ALFA
- Schedule 4
- PEGVALIASE
- Schedule 4
- PEGVISOMANT
- Schedule 4
- PEMIGATINIB
- Schedule 4
- PERAMIVIR
- Schedule 4
- PHENOLS
- Appendix E, clause 3
- PEMBROLIZUMAB
- Schedule 4
- PEMETREXED
- Schedule 4
- PEMOLINE
- Schedule 4
- PEMPIDINE
- Schedule 4
- PENBUTOLOL
- Schedule 4
- PENCICLOVIR
- Schedule 4
- PENCONAZOLE
- Schedule 5
- PENCYCURON
- Appendix B, clause 3
- PENDIMETHALIN
- Schedule 5
- PENETHAMATE
- Schedule 4
- PENFLUFEN
- Schedule 5
- PENICILLAMINE
- Schedule 4
- PENNYROYAL OIL
- Schedule 6 Appendix E, clause 3
- PENTACHLOROPHENOL
- Schedule 7 Schedule 6 Appendix F, clause 4
- PENTADECANOIC ACID
- Appendix B, clause 3
- PENTAERYTHRITYL TETRANITRATE
- Schedule 4
- PENTAGASTRIN
- Schedule 4
- PENTAMETHONIUM
- Schedule 4
- PENTAMIDINE
- Schedule 4
- PENTAZOCINE
- Schedule 8 Appendix K, clause 1
- PENTHIENATE
- Schedule 4
- PENTHIOPYRAD
- Schedule 5
- PENTOBARBITONE cross reference: PENTOBARBITAL
- PENTOBARBITAL
- Schedule 8 Schedule 4 Appendix D, clause 9 Appendix K, clause 1
- PENTOLINIUM
- Schedule 4
- PENTOSAN POLYSULFATE SODIUM
- Schedule 4
- PENTOXIFYLLINE
- Schedule 4
- 1-PENTYL-3-(1-NAPHTHOYL)INDOLE cross reference: JWH-018 (CAS No. 209414-07-3)
- Schedule 9
- 1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE cross reference: JWH-122 (CAS No. 619294-47-2)
- Schedule 9
- PEPPERMINT OIL
- Appendix B, clause 3
- PERACETIC ACID
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- PERAMPANEL
- Schedule 4 Appendix D, clause 5 Appendix K, clause 1
- PERFLUIDONE
- Schedule 6
- PERGOLIDE
- Schedule 4
- PERHEXILINE
- Schedule 4
- PERICIAZINE
- Schedule 4 Appendix K, clause 1
- PERICYAZINE cross reference: PERICIAZINE
- PERINDOPRIL
- Schedule 4
- PERMANGANATES cross reference: POTASSIUM PERMANGANATE
- Schedule 6 Appendix F, clause 4
- PERMETHRIN
- Schedule 6 Schedule 5 Schedule 4
- PERPHENAZINE
- Schedule 4 Appendix K, clause 1
- PERTUSSIS ANTIGEN
- cross reference: TRIPLE ANTIGEN VACCINE
- Schedule 4
- PERTUZUMAB
- Schedule 4
- PETASITES spp.
- Schedule 10
- PETHIDINE
- Schedule 8 Appendix K, clause 1
- PETROL
- Schedule 5 Appendix E, clause 3
- PHEDRAZINE
- Schedule 2
- PHENACEMIDE
- Schedule 4
- PHENACETIN
- Schedule 4
- PHENADOXONE
- cross reference: CAS No. 467-84-5, PHENADOXONE HYDROCHLORIDE (CAS No. 545-91-5)
- Schedule 9
- PHENAGLYCODOL
- Schedule 4
- PHENAMPROMIDE
- cross reference: CAS No. 129-83-9
- Schedule 9
- PHENAZOCINE
- cross reference: CAS No. 127-35-5, PHENAZOCINE RACEMATE (CAS No. 58073-76-0), PHENOAZOCINE HYDROBROMIDE (CAS No. 1239-04-9)
- Schedule 9
- PHENAZONE
- Schedule 5 Schedule 4 Schedule 2
- PHENAZOPYRIDINE
- Schedule 4
- PHENCYCLIDINE cross reference: PCP (CAS No. 77-10-1), PHENCYCLIDINE HYDROCHLORIDE (CAS No. 956-90-1)
- Schedule 9
- PHENDIMETRAZINE
- Schedule 8
- PHENELZINE
- Schedule 4 Appendix K, clause 1
- N-PHENETHYL-4-PIPERIDONE
- cross reference: CAS No. 39742-60-4
- Schedule 9
- PHENETICILLIN
- Schedule 4
- PHENFORMIN
- Schedule 4
- PHENGLUTARIMIDE
- Schedule 4
- PHENIBUT cross reference: BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID (CAS No. 1078-21-3), PHENIBUT HYDROCHLORIDE (CAS No. 3060-41-1), PHENIBUT HYDROBROMIDE (CAS No. 10
- Schedule 9
- PHENINDIONE
- Schedule 4
- PHENIRAMINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- PHENISATIN
- Schedule 4
- PHENISOPHAM
- Schedule 5
- PHENMEDIPHAM
- Appendix B, clause 3
- PHENMETRAZINE
- Schedule 8
- PHENOBARBITAL
- Schedule 4 Appendix K, clause 1
- PHENOBARBITONE cross reference: PHENOBARBITAL
- PHENOL cross reference: CREOSOTE, PHENOLS, TAR, XYLENOLS
- Schedule 6 Schedule 5 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- PHENOLPHTHALEIN
- Schedule 4
- PHENOMORPHAN
- cross reference: CAS No. 468-07-5
- Schedule 9
- PHENOPERIDINE
- Schedule 8 Appendix K, clause 1
- PHENOTHIAZINE
- Schedule 6
- d-PHENOTHRIN
- Appendix B, clause 3
- PHENOXYBENZAMINE
- Schedule 4
- 2-PHENOXYETHANOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- PHENOXYMETHYL OXIRANE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- PHENOXYMETHYLPENICILLIN
- Schedule 4
- PHENPROMETHAMINE
- cross reference: CAS No. 93-88-9
- Schedule 10
- PHENSUXIMIDE
- Schedule 4
- PHENTERMINE
- Schedule 4 Appendix D, clause 5
- PHENTHIMENTONIUM
- Schedule 4
- PHENTOLAMINE
- Schedule 4
- PHENYLACETYLINDOLES
- Schedule 9
- PHENYLBUTAZONE
- Schedule 4
- PHENYLENEDIAMINES cross reference: ALKYLATED, ARYLATED, HALOGENATED and NITRO-PHENYLENEDIAMINES, DIETHYL-PARA-PHENYLENEDIAMINE, DIMETHYL-PARA-PHENYLENEDIAMINE
- Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- PHENYLEPHRINE cross reference: CODEINE, IBUPROFEN, PARACETAMOL
- Schedule 4 Schedule 2 Appendix F, clause 4
- 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE cross reference: PEPAP (CAS No. 64-52-8)
- Schedule 9
- PHENYLMERCURIC ACETATE cross reference: MERCURY
- Schedule 7 Appendix J, clause 1
- PHENYL METHYL KETONE cross reference: DESIGNATED SOLVENT
- Schedule 5 Appendix E, clause 3
- o-PHENYLPHENOL
- Schedule 5
- Appendix E, clause 3 Appendix F, clause 4
- 4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER cross reference: PETHIDINE INTERMEDIATE B
- Schedule 8
- PHENYL METHYL PYRAZOLONE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- PHENYLPIRACETAM cross reference: RACETAMS
- Schedule 4
- PHENYLPROPANOLAMINE
- Schedule 4
- PHENYLTOLOXAMINE
- Schedule 4 Appendix K, clause 1
- PHENYTOIN
- Schedule 4 Appendix F, clause 4
- PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract)
- Schedule 4
- PHOLCODINE
- Schedule 8 Schedule 4 Schedule 2 Appendix K, clause 1
- PHORATE
- Schedule 7
- PHOSALONE
- Schedule 6
- PHOSFOLAN
- Schedule 7
- PHOSMET
- Schedule 6
- PHOSPHIDES, METALLIC cross reference: ALUMINIUM PHOSPHIDE, MAGNESIUM PHOSPHIDE, ZINC PHOSPHIDE
- Schedule 7 Appendix J, clause 1
- PHOSPHINE
- Schedule 7 Appendix J, clause 1
- PHOSPHODIESTERASE TYPE 5 INHIBITORS
- Schedule 4
- PHOSPHONIC ACID cross reference: PHOSPHOROUS ACID
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- PHOSPHORIC ACID
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- PHOSPHORUS
- Appendix G, clause 1
- PHOSPHORUS, YELLOW
- Schedule 7
- Appendix E, clause 3
- Appendix F, clause 4
- PHOTOGRAPHIC PAPER or FILM
- Appendix A, clause 1
- PHOXIM
- Schedule 6
- o-PHTHALADEHYDE
- Appendix F, clause 4
- o-PHTHALALDEHYDE
- Appendix E, clause 3
- PHTHALALDEHYDE
- Schedule 6 Schedule 5
- PHTHALYLSULFATHIAZOLE
- Schedule 4
- PHYSOSTIGMINE
- Schedule 4
- PHYTASE
- Appendix B, clause 3
- PIBRENTASVIR
- Schedule 4
- PICARIDIN
- Schedule 5
- PICLORAM
- Appendix B, clause 3
- PICOLINAFEN
- Appendix B, clause 3
- PICRAMIC ACID (including its salts) cross reference: 2-AMINO-4,6-DINITROPHENOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- PICRIC ACID
- Appendix E, clause 3 Appendix F, clause 4
- PICROTOXIN
- Schedule 4
- PIGMENTS
- Appendix A, clause 1
- PILOCARPINE
- Schedule 4
- PIMECROLIMUS
- Schedule 4
- PIMELIC ACID
- Appendix B, clause 3
- PIMINODINE
- cross reference: CAS No. 13495-09-5, PIMINODINE DIHYDROCHLORIDE (CAS No. 113862-30-9). PIMINODINE ESILATE (CAS No. 7081-52-9)
- Schedule 9
- PIMOBENDAN
- Schedule 4
- PIMOZIDE
- Schedule 4 Appendix K, clause 1
- PINACIDIL
- Schedule 4
- PINAVERIUM BROMIDE
- Schedule 4
- PINDOLOL
- Schedule 4
- PINDONE
- Schedule 6
- PINE OILS
- Schedule 6 Schedule 5
- PINOXADEN
- Schedule 6 Schedule 5
- PIOGLITAZONE
- Schedule 4
- PIPECURONIUM
- Schedule 4
- PIPEMIDIC ACID
- Schedule 4
- PIPENZOLATE
- Schedule 4
- PIPER METHYSTICUM cross reference: KAVA, KAVALACTONES
- Schedule 4
- PIPERACILLIN
- Schedule 4
- PIPERAZINE
- Schedule 5 Schedule 2
- PIPERIDINE
- Schedule 4
- PIPERIDOLATE
- Schedule 4
- PIPERONYL BUTOXIDE
- Appendix B, clause 3
- PIPEROPHOS
- Schedule 6
- PIPOBROMAN
- Schedule 4
- PIPOTHIAZINE
- Schedule 4
- PIPRADROL
- Schedule 4
- PIRACETAM
- cross reference: RACETAMS
- Schedule 4
- PIRBUTEROL
- Schedule 4
- PIRENOXINE cross reference: CATALIN
- Schedule 4
- PIRENZEPINE
- Schedule 4
- PIRETANIDE
- Schedule 4
- PIRFENIDONE
- Schedule 4
- PIRIMICARB
- Schedule 6
- Schedule 5
- PIRIMIPHOS-ETHYL
- Schedule 6
- PIRIMIPHOS-METHYL
- Schedule 6
- PIRITRAMIDE
- Schedule 8
- PIROXICAM
- Schedule 4
- PIRPROFEN
- Schedule 4
- PIRTOBRUTINIB
- Schedule 4
- PITAVASTATIN
- Schedule 4
- PITUITARY HORMONES
- Schedule 4
- PIVAMPICILLIN
- Schedule 4
- PIZOTIFEN
- Schedule 4 Appendix K, clause 1
- PLASMID DNA (rE. coli DH5α pINGhT) cross reference: VACCINES – PLASMID DNA
- PLERIXAFOR
- Schedule 4
- PLICAMYCIN
- Schedule 4
- PLITIDEPSIN
- Schedule 4 Appendix L, clause 2
- PLOZASIRAN
- Schedule 4
- PNEUMOCOCCAL VACCINE
- Schedule 4
- PODOPHYLLOTOXIN cross reference: PODOPHYLLIN
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4
- Appendix H, clause 1
- PODOPHYLLUM EMODI cross reference: PODOPHYLLIN
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4
- Appendix H, clause 1
- PODOPHYLLUM PELTATUM cross reference: PODOPHYLLIN
- Schedule 4 Schedule 3
- Schedule 2 Appendix F, clause 4
- Appendix H, clause 1
- PODOPHYLLUM RESIN cross reference: PODOPHYLLIN
- Appendix G, clause 1
- POLIHEXANIDE
- cross reference: 1-(DIAMINOMETHYLIDENE)-2-HEXYLGUANIDINE, POLY (IMINOCARBONIMIDOYLIMINOCARBONIMIDOYL IMINO-1,6-HEXANEDIYL), POLYHEXAMETHYLENE BIGUANIDE (PHMB)
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- POLIOMYELITIS VACCINE
- Schedule 4
- POLIXETONIUM SALTS
- Schedule 6 Schedule 5
- POLOXALENE
- Appendix B, clause 3
- POLY (GNRF) OVALBUMIN
- Appendix B, clause 3
- POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE cross reference: POLYDADMAC
- Appendix B, clause 3
- POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS
- Schedule 5 Appendix E, clause 3
- POLYACRYLAMIDE
- Schedule 4
- POLYCAPROLACTONE
- Schedule 4
- POLYESTRADIOL
- Schedule 4
- POLYETHANOXY (15) TALLOW AMINE
- Schedule 5 Appendix E, clause 3
- POLYHEDROSIS VIRUS of Helico zea occlusion bodies
- Appendix B, clause 3
- POLYLACTIC ACID
- Schedule 4
- POLYMYXIN
- Schedule 4
- POLYOXIN D ZINC SALT
- Schedule 5
- POLYSORBATE 20
- Appendix B, clause 3
- POLYSULFATED GLYCOSAMINOGLYCANS
- Schedule 4
- POLYTHIAZIDE
- Schedule 4
- POMALIDOMIDE
- Schedule 4 Appendix D, clause 4 Appendix F, clause 4 Appendix L, clause 2
- PONATINIB
- Schedule 4
- PONESIMOD
- Schedule 4
- Appendix L, clause 2
- PORACTANT
- Schedule 4
- PORCELAIN
- Appendix A, clause 1
- PORCINE SOMATOTROPHIN
- Appendix B, clause 3
- POSACONAZOLE
- Schedule 4
- POTASSIUM AZELOYL DIGLYCINATE
- Schedule 6
- POTASSIUM BICARBONATE
- Appendix B, clause 3
- POTASSIUM BROMATE
- Schedule 6 Appendix E, clause 3
- POTASSIUM BROMIDE
- Schedule 4
- POTASSIUM CHLORATE
- Schedule 5 Schedule 2 Appendix E, clause 3
- POTASSIUM CHLORIDE
- Schedule 4
- POTASSIUM CYANATE
- Schedule 6 Appendix E, clause 3
- POTASSIUM HYDROXIDE
- cross reference: CAS No. 1310-58-3
- Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- POTASSIUM METABISULPHITE
- Schedule 5 Appendix F, clause 4
- POTASSIUM NITRITE
- Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- POTASSIUM PERCHLORATE
- Schedule 4
- POTASSIUM PEROXOMONOSULFATE TRIPLE SALT
- Schedule 6 Schedule 5
- POTASSIUM PERSULFATE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- POTASSIUM SORBATE
- Appendix B, clause 3
- POTASSIUM SULFIDE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- PRACTOLOL
- Schedule 4
- PRADOFLOXACIN
- Schedule 4
- PRALATREXATE
- Schedule 4
- PRALIDOXIME
- Schedule 4
- PRALLETHRIN
- Schedule 6 Schedule 5
- PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2)
- Schedule 4 Appendix D, clause 5
- PRALSETINIB
- Schedule 4
- PRAMIPEXOLE
- Schedule 4
- PRAMIRACETAM
- cross reference: RACETAMS
- Schedule 4
- PRAMOCAINE
- Schedule 4
- PRAMPINE
- Schedule 4
- PRASTERONE cross reference: DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- PRASUGREL
- Schedule 4
- PRAVASTATIN
- Schedule 4
- PRAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1
- PRAZIQUANTEL
- Schedule 4
- PRAZOSIN
- Schedule 4
- PREDNISOLONE
- Schedule 4
- PREDNISONE
- Schedule 4
- PREGABALIN
- Schedule 4 Appendix K, clause 1
- PREGNENOLONE
- Schedule 4
- PRENALTEROL
- Schedule 4
- PRENYLAMINE
- Schedule 4
- PRILOCAINE
- Schedule 4 Schedule 2
- PRIMAQUINE
- Schedule 4
- PRIMIDONE
- Schedule 4
- PRINTING INKS or INK ADDITIVES
- Appendix A, clause 1
- PROBENECID
- Schedule 4
- PROBUCOL
- Schedule 4
- PROCAINAMIDE
- Schedule 4
- PROCAINE
- Schedule 4
- PROCAINE BENZYLPENICILLIN
- Schedule 4
- PROCAINE PENICILLIN cross reference: PROCAINE BENZYLPENICILLIN
- PROCARBAZINE
- Schedule 4
- PROCHLORAZ
- Schedule 6
- PROCHLORPERAZINE
- Schedule 4 Schedule 3 Appendix K, clause 1
- PROCYCLIDINE
- Schedule 4 Schedule 2
- PROCYMIDONE
- Schedule 7
- PROFENOFOS
- Schedule 6
- PROFOXYDIM
- Schedule 5
- PROGESTERONE
- Schedule 5 Schedule 4 Appendix G, clause 1
- PROGESTOGENS
- Schedule 4
- PROGLUMIDE
- Schedule 4
- PROGUANIL
- Schedule 4
- PROHEPTAZINE
- cross reference: CAS No. 77-14-5
- Schedule 9
- PROHEXADIONE CALCIUM
- Schedule 5
- PROLINTANE
- Schedule 4
- PROMACYL
- Schedule 6
- PROMAZINE
- Schedule 4 Appendix K, clause 1
- PROMETHAZINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- PROMETRYN
- Schedule 5
- PROMOXOLANE
- Schedule 4
- PROPACHLOR
- Schedule 6
- PROPAFENONE
- Schedule 4
- PROPAMIDINE
- Schedule 4 Schedule 2
- PROPAMOCARB
- Schedule 5
- PROPANIDID
- Schedule 4
- PROPANIL
- Schedule 5
- PROPANTHELINE
- Schedule 4
- PROPAQUIZAFOP
- Schedule 5
- PROPARGITE
- Schedule 6
- PROPENTOFYLLINE
- Schedule 4
- PROPERIDINE
- cross reference: CAS No. 561-76-2
- Schedule 9
- PROPETAMPHOS
- Schedule 6
- PROPETANDROL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- PROPICONAZOLE
- Schedule 6 Schedule 5
- PROPINEB
- Schedule 6
- PROPIONIBACTERIUM ACNES
- Schedule 4
- PROPIONIC ACID
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- PROPIRAM
- Schedule 8
- PROPOFOL
- Schedule 4
- PROPOXUR
- Schedule 6 Schedule 5
- PROPRANOLOL
- Schedule 4 Appendix G, clause 1
- PROPYL ACETATES
- Appendix B, clause 3
- n-PROPYL ALCOHOL
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- n-PROPYL NITRITE
- cross reference: CAS No. 543-67-9
- Schedule 10
- PROPYLENE GLYCOL
- Appendix B, clause 3
- 2-PROPYLENE GLYCOL 1-MONOMETHYL
- Appendix B, clause 3
- PROPYLENE OXIDE
- Schedule 7 Appendix J, clause 1
- PROPYLHEXEDRINE
- Schedule 4
- PROPYLPHENIDINE
- cross reference: CAS No. 6266-42-8 Schedule 9
- PROPYLTHIOURACIL
- Schedule 4
- PROPYPHENAZONE
- Schedule 4
- PROPYZAMIDE
- Schedule 5
- PROQUAZONE
- Schedule 4
- PROQUINAZID
- Schedule 6
- PROSCILLARIDIN
- Schedule 4
- PROSTAGLANDINS
- Schedule 4
- PROSTIANOL
- Schedule 4
- PROSULFOCARB
- Schedule 6
- PROSULFURON
- Schedule 6
- PROTAMINE
- Schedule 4
- PROTHIOCONAZOLE
- Appendix B, clause 3
- PROTHIOCONAZOLE-DESCHLORO
- Schedule 5
- PROTHIOCONAZOLE-TRIAZOLIDINETHIONE
- Schedule 5
- PROTHIOFOS
- Schedule 6
- PROTHIONAMIDE
- Schedule 4
- PROTHIPENDYL
- Schedule 4
- PROTIRELIN
- Schedule 4
- PROTONITAZENE
- cross reference: CAS No. 95958-84-2
- Schedule 9
- PROTOVERATRINES
- Schedule 4
- PROTRIPTYLINE
- Appendix K, clause 1
- PROTRIPTYLINE
- Schedule 4
- PROXYMETACAINE
- Schedule 4
- PRUCALOPRIDE
- Schedule 4
- PSEUDOEPHEDRINE
- Schedule 4 Schedule 3
- PSEUDOMONAS FLUORESCENS
- Appendix B, clause 3
- PSILOCYBINE cross reference: PSILOCYBIN, CAS No. 520-52-5
- Schedule 9 Schedule 8 Appendix D, clause 5 Appendix D, clause 9
- PTERIDIUM spp.
- Schedule 10
- d-PULEGONE
- Schedule 6 Appendix E, clause 3
- PULMONARIA spp.
- Schedule 10
- PYDIFLUMETOFEN
- Appendix B, clause 3
- PYMETROZINE
- Schedule 5
- PYRACLOFOS
- Schedule 6
- PYRACLOSTROBIN
- Schedule 5
- PYRAFLUFEN-ETHYL
- Schedule 5
- PYRANTEL
- Schedule 2
- PYRASULFOTOLE
- Schedule 5
- PYRAZINAMIDE
- Schedule 4
- PYRAZOLAM
- cross reference: CAS No. 39243-02-2
- Schedule 9
- PYRAZOPHOS
- Schedule 6
- PYRETHRINS cross reference: CHRYSANTHEMIC ACID ESTERS, CINEROLONE, JASMOLONE, PYRETHRIC ACIDS, PYRETHROLONE
- Schedule 5 Schedule 2
- PYRIDABEN
- Schedule 6 Schedule 5
- PYRIDALYL
- Schedule 6
- PYRIDATE
- Schedule 6
- PYRIDINOLCARBAMATE
- Schedule 4
- PYRIDOSTIGMINE
- Schedule 4
- PYRIDOXAL
- Schedule 4
- PYRIDOXAMINE
- Schedule 4
- PYRIDOXINE
- Schedule 4
- PYRIFENOX
- Schedule 5
- PYRIMETHAMINE
- Schedule 4
- PYRIMETHANIL
- Appendix B, clause 3
- PYRINURON
- Schedule 7 Appendix J, clause 1
- PYRIOFENONE
- Schedule 6 Schedule 5
- PYRIPROLE
- Schedule 6
- PYRIPROXYFEN
- Appendix B, clause 3
- PYRITHIOBAC SODIUM
- Schedule 5
- PYRITHIONE COPPER
- Schedule 6
- PYRITHIONE ZINC
- Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3
- PYROVALERONE
- Schedule 4
- PYROXASULFONE
- Schedule 6
- PYROXSULAM
- Schedule 6
- PYRVINIUM cross reference: VIPRYNIUMA
- Schedule 4
- Q
- QUASSIA
- Appendix B, clause 3
- QUATERNARY AMMONIUM COMPOUNDS cross reference: BENZALKONIUM CHLORIDE, DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS
- Schedule 6 Schedule 5
- Appendix E, clause 3
- QUAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives)
- QUETIAPINE
- Schedule 4 Appendix K, clause 1
- QUINAGOLIDE
- Schedule 4
- QUINALBARBITONE cross reference: SECOBARBITAL
- QUINAPRIL
- Schedule 4
- QUINBOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- QUINCLORAC
- Schedule 5
- QUINETHAZONE
- Schedule 4
- QUINIDINE
- Schedule 4
- QUININE cross reference: QUININE (CAS No. 130-95-0), QUININE SULFATE (1:1) (CAS No. 549-56-4), QUININE SULFATE (2:1) (CAS No. 804-63-7), QUININE SULFATE (2:1) D
- Schedule 7 Schedule 6 Schedule 5 Schedule 4 Appendix F, clause 4
- QUINISOCAINE cross reference: DIMETHISOQUINE
- Schedule 4
- QUINOLINE cross reference: 2,3-BENZAPYRIDINE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- QUINOXYFEN
- Appendix B, clause 3
- QUINTOZENE cross reference: PENTACHLORONITROBENZENE
- Schedule 5
- QUINUPRISTIN
- Schedule 4
- QUIZALOFOP ETHYL cross reference: QUIZALOFOP ETHYL (D + ISOMER)
- Schedule 6
- QUIZALOFOP-p-ETHYL
- Schedule 6 Schedule 5
- QUIZALOFOP-p-TEFURYL
- Schedule 6
- R
- RABEPRAZOLE
- Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1
- RABIES VACCINE
- Schedule 4
- RACEMETHORPHAN
- cross reference: CAS No. 510-53-2
- Schedule 9
- RACEMORAMIDE
- Schedule 8
- RACEMORPHAN
- cross reference: CAS No. 297-90-5
- Schedule 9
- RACETAMS
- Schedule 4
- RACTOPAMINE
- Schedule 5 Schedule 4
- RADIOGRAPHIC CONTRAST MEDIA cross reference: RADIOPAQUES
- Appendix A, clause 1
- RADIOISOTOPES
- Appendix A, clause 1
- RALOXIFENE
- Schedule 4
- RALTEGRAVIR
- Schedule 4
- RALTITREXED
- Schedule 4
- RAMIPRIL
- Schedule 4
- RAMUCIRUMAB
- Schedule 4
- RANIBIZUMAB
- Schedule 4
- RANITIDINE
- Schedule 4 Schedule 2 Appendix F, clause 4
- RANOLAZINE
- Schedule 4
- RAPACURONIUM
- Schedule 4
- RASAGILINE
- Schedule 4
- RASBURICASE
- Schedule 4
- RAUWOLFIA SERPENTINA
- Schedule 4
- RAUWOLFIA VOMITORIA
- Schedule 4
- RAZOXANE
- Schedule 4
- REBOXETINE
- Schedule 4
- RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
- Schedule 4
- RED YEAST RICE
- Schedule 4
- REGDANVIMAB
- Schedule 4
- REGORAFENIB
- Schedule 4
- RELUGOLIX
- Schedule 4
- REMDESIVIR
- Schedule 4
- REMIBRUTINIB
- Schedule 4
- REMIFENTANIL
- Schedule 8
- REMOXIPRIDE
- Schedule 4
- REPAGLINIDE
- Schedule 4
- REPOTRECTINIB
- Schedule 4
- RESCALURE
- cross reference: (3S,6R)-(3S,6S)-6-isopropenyl-3-methyldec-9-en-1-yl acetate, insect sex pheromone
- Schedule 6
- RESERPINE
- Schedule 4
- RESLIZUMAB
- Schedule 4
- RESMETHRIN
- Schedule 6 Schedule 5
- RESORCINOL cross reference: 1,3-BENZENEDIOL
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- RETAPAMULIN
- Schedule 4
- RETEPLASE
- Schedule 4
- RETIFANLIMAB
- Schedule 4
- RETIGABINE
- Schedule 4 Appendix K, clause 1
- RHIZOBIUM RHIZOGENES
- Appendix B, clause 3
- RIBAVIRIN
- Schedule 4
- RIBOCICLIB
- Schedule 4
- RIDAFOROLIMUS
- Schedule 4
- RIFABUTIN
- Schedule 4
- RIFAMPICIN
- Schedule 4
- RIFAMYCIN
- Schedule 4
- RIFAPENTINE
- Schedule 4
- RIFAXIMIN
- Schedule 4
- RILPIVIRINE
- Schedule 4
- RILUZOLE
- Schedule 4
- RIMEGEPANT
- Schedule 4
- RIMEXOLONE
- Schedule 4
- RIMITEROL
- Schedule 4
- RIMONABANT
- Schedule 4
- RIMSULFURON
- Schedule 5
- RIOCIGUAT
- Schedule 4 Appendix D, clause 4 Appendix L, clause 2
- RIPRETINIB
- Schedule 4
- RISANKIZUMAB
- Schedule 4
- RISDIPLAM
- Schedule 4
- RISEDRONIC ACID
- Schedule 4
- RISPERIDONE
- Schedule 4 Appendix K, clause 1
- RITLECITINIB
- Schedule 4
- RITODRINE
- Schedule 4
- RITONAVIR
- Schedule 4
- RITUXIMAB
- Schedule 4
- RIVAROXABAN
- Schedule 4
- RIVASTIGMINE
- Schedule 4
- RIZATRIPTAN
- Schedule 4 Schedule 3 Appendix H, clause 1
- ROBENACOXIB
- Schedule 4
- ROBENIDINE
- Schedule 5
- ROFECOXIB
- Schedule 4
- ROFLUMILAST
- Schedule 4
- ROLICYCLIDINE cross reference: PCPY, PHP (CAS No. 2201-39-0)
- Schedule 9
- ROLITETRACYCLINE
- Schedule 4
- ROLZIRACETAM
- cross reference: RACETAMS
- Schedule 4
- ROMIDEPSIN
- Schedule 4
- ROMIFIDINE
- Schedule 4
- ROMIPLOSTIM
- Schedule 4
- ROMOSOZUMAB
- Schedule 4
- RONIDAZOLE
- Schedule 4
- ROPINIROLE
- Schedule 4
- ROPIVACAINE
- Schedule 4
- ROSEMARY OIL
- Appendix B, clause 3
- ROSIGLITAZONE
- Schedule 4
- ROSIN cross reference: COLOPHONY
- Schedule 5
- ROSOXACIN
- Schedule 4
- ROSUVASTATIN
- Schedule 4
- ROTENONE cross reference: CUBE
- Schedule 6
- ROTIGOTINE
- Schedule 4 Appendix K, clause 1
- ROXIBOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- ROXITHROMYCIN
- Schedule 4
- ROZANOLIXIZUMAB
- Schedule 4
- RUBELLA VACCINE
- Schedule 4
- RUBOXISTAURIN
- Schedule 4
- RUFINAMIDE
- Schedule 4 Appendix K, clause 1 Appendix L, clause 2
- RUPATADINE
- Schedule 4 Appendix K, clause 1
- RUXOLITINIB
- Schedule 4
- S
- SACITUZUMAB GOVITECAN
- Schedule 4
- SACUBITRIL
- Schedule 4
- SAFINAMIDE
- Schedule 4
- SAFLUFENACIL
- Schedule 7 Schedule 5
- SAFROLE cross reference: CAS No. 94-59-7, SASSAFRAS OIL
- Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- SAGE OIL cross reference: DALMATIAN, THUJONE
- Schedule 6 Appendix E, clause 3
- SAGE OIL (Spanish) cross reference: CAMPHOR
- Appendix B, clause 3
- SALBUTAMOL
- Schedule 4 Schedule 3 Appendix F, clause 4
- SALCATONIN cross reference: CALCITONIN SALMON
- SALICYLAMIDE cross reference: ASPIRIN, CAFFEINE, PARACETAMOL
- Schedule 4 Schedule 2 Appendix F, clause 4
- SALICYLANILIDE
- Schedule 5
- SALICYLIC ACID cross reference: CHOLINE SALICYLATE
- Schedule 3
- Appendix H, clause 1
- SALINOMYCIN
- Schedule 6 Schedule 4
- SALMETEROL
- Schedule 4
- SALVIA DIVINORUM
- Schedule 9
- SANDALWOOD OIL
- Appendix B, clause 3
- SANGUINARIA CANADENSIS (bloodroot)
- Schedule 10
- SANGUINARINE cross reference: CAS No. 2447-54-3, SANGUINARIA CANADENSIS (bloodroot)
- SANTONIN
- Schedule 3
- SAPROPTERIN
- Schedule 4
- SAQUINAVIR
- Schedule 4
- SARILUMAB
- Schedule 4
- SAROLANER
- Schedule 6 Schedule 5
- SARS-COV-2 (COVID-19) VACCINE
- Schedule 4
- SASSAFRAS OIL cross reference: SAFROLE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- SAXAGLIPTIN
- Schedule 4
- SCHOENOCAULON OFFICINALE cross reference: SABADILLA
- Schedule 4
- SCHRADAN
- Schedule 7
- SCOPOLIA CARNIOLICA
- Schedule 4
- SEAWEED
- Appendix B, clause 3
- SEBELIPASE ALFA
- Schedule 4
- SEBETRALSTAT
- Schedule 4
- SECBUTOBARBITAL
- Schedule 8 Appendix K, clause 1
- SECBUTOBARBITONE cross reference: SECBUTOBARBITAL
- SECOBARBITAL
- Schedule 8 Appendix K, clause 1
- SECUKINUMAB
- Schedule 4
- SEDAXANE
- Schedule 5
- SEEDS
- Appendix A, clause 1
- SELADELPAR
- Schedule 4
- SELAMECTIN
- Schedule 5
- SELECTIVE ANDROGEN RECEPTOR MODULATORS cross reference: SARM
- Schedule 4 Appendix D, clause 5
- SELEGILINE
- Schedule 4
- SELENIUM cross reference: BARIUM SELENATE, SELENIUM COMPOUNDS, SELENIUM ARSENIDE, SELENIUM SULFIDE
- Schedule 7 Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 Appendix G, clause 1
- SELETRACETAM
- Cross reference RACETAMS
- Schedule 4 Appendix K, clause 1
- SELEXIPAG
- Schedule 4
- SELINEXOR
- Schedule 4
- Appendix L, clause 2
- SELPERCATINIB
- Schedule 4
- SELUMETINIB
- Schedule 4
- Appendix L, clause 2
- SEMAGLUTIDE
- Schedule 4
- SEMDURAMICIN
- Schedule 7 Schedule 6
- SENECIO spp.
- Schedule 10
- SEPIAPTERIN
- Schedule 4
- SERELAXIN
- Schedule 4
- SERMORELIN
- Schedule 4
- SERTINDOLE
- Schedule 4
- SERTRALINE
- Schedule 4
- SETHOXYDIM
- Schedule 5
- SEVELAMER
- Schedule 4
- SEVOFLURANE
- Schedule 4
- SEX HORMONES
- Schedule 4
- SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1 cross reference: EPIDERMAL GROWTH FACTOR
- SIBUTRAMINE
- Schedule 4
- SIDURON
- Schedule 5
- SILANDRONE
- Schedule 4 Appendix D, clause 5 (Anabolic steroidal agent)
- SILDENAFIL
- Schedule 4
- SILICOFLUORIDES cross reference: BARIUM SILICOFLUORIDE, FLUORIDES, FLUOROSILICATES, HEXAFLUOROSILICATES MAGNESIUM FLUOSILICATE,
- Schedule 6 Schedule 5
- SILICONES
- Schedule 10 Schedule 4 Appendix F, clause 4
- SILODOSIN
- Schedule 4
- SILTUXIMAB
- Schedule 4
- SILVER
- Schedule 2
- SILVER NITRATE cross reference: SILVER SALTS
- Schedule 6 Appendix E, clause 3
- SILVER OXIDE
- Appendix B, clause 3
- SILVER SULFADIAZINE
- Schedule 4
- SIMAZINE
- Appendix B, clause 3
- SIMEPREVIR
- Schedule 4
- SIMVASTATIN
- Schedule 4
- SINBIOALLETHRIN
- Schedule 6 Schedule 5
- SINGLE-USE TUBES
- Appendix A, clause 1
- SIPONIMOD
- Schedule 4
- SIROLIMUS
- Schedule 4
- SISOMICIN
- Schedule 4
- SITAGLIPTIN
- Schedule 4
- SITAXENTAN
- Schedule 4 Appendix D, clause 6 Appendix F, clause 4 Appendix L, clause 2
- SLIMICIDES
- Appendix A, clause 1
- SODIUM ALUMINATE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- SODIUM BICARBONATE
- Appendix B, clause 3
- SODIUM BROMATE
- Schedule 6 Appendix E, clause 3
- SODIUM BROMIDE
- Schedule 5 Schedule 4
- SODIUM CELLULOSE PHOSPHATE
- Schedule 4
- SODIUM CHLORATE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- SODIUM CITRATE DIHYDRATE
- Schedule 4
- SODIUM CROMOGLYCATE
- Schedule 4 Schedule 2
- SODIUM DIACETATE
- Schedule 5 Appendix E, clause 3
- SODIUM DICHLOROISOCYANURATE
- Appendix E, clause 3
- SODIUM DODECYLBENZENE SULFONATE
- Schedule 5 Appendix E, clause 3, Part Appendix F, clause 4
- SODIUM FLUORIDE
- Appendix F, clause 4
- SODIUM GLYCEROPHOSPHATE HYDRATE
- Schedule 4
- SODIUM HYDROGEN SULFATE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- SODIUM HYDROSULFITE
- Schedule 5 Appendix F, clause 4
- SODIUM HYDROXIDE cross reference: CAS No. 1310-73-2, LYE WATER
- Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- SODIUM LAURETH-6 CARBOXYLATE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- SODIUM METABISULPHITE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- SODIUM MORRHUATE
- Schedule 4
- SODIUM NITRITE
- Schedule 7 Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- SODIUM NITROPRUSSIDE
- Schedule 4
- SODIUM OXYBATE
- Schedule 8 Appendix D, clause 1 Appendix K, clause 1
- SODIUM PERCARBONATE
- Schedule 6 Schedule 5
- Appendix E, clause 3
- SODIUM PERSULFATE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- SODIUM PHENYLBUTYRATE
- Schedule 4
- SODIUM PHOSPHATE
- Schedule 4 Schedule 3
- SODIUM PICOSULFATE
- Schedule 3
- SODIUM POLYSTYRENE SULPHONATE
- Schedule 5 Schedule 4
- SODIUM PROPIONATE
- Appendix B, clause 3
- SODIUM SALICYLATE
- Schedule 4
- SODIUM STANNATE
- Schedule 5, Appendix E, clause 3
- SODIUM SULFIDE
- Schedule 6
- Schedule 5
- Appendix E, clause 3
- Appendix F, clause 4
- SODIUM TETRADECYLSULFATE
- Schedule 4
- SODIUM THIOSULFATE ANHYDROUS
- Schedule 4
- SODIUM TRICHLOROACETATE
- Appendix E, clause 3
- SODIUM ZIRCONIUM CYCLOSILICATE.
- Schedule 4
- SODIUMHYDROSULFITE
- Appendix E, clause 3
- SOFOSBUVIR
- Schedule 4
- SOLASODINE
- Schedule 4
- SOLIFENACIN
- Schedule 4
- SOMAPACITAN
- Schedule 4
- Appendix D, clause 5
- SOMATOSTATIN
- Schedule 4
- SOMATOTROPIN EQUINE
- Schedule 4
- SOMATROGON
- Schedule 4
- Appendix D, clause 5
- SOMATROPIN cross reference: HUMAN GROWTH HORMONE
- Schedule 4 Appendix D, clause 5
- SONIDEGIB
- Schedule 4
- SONTOQUINE
- Schedule 4
- SORAFENIB
- Schedule 4
- SOTALOL
- Schedule 4
- SOTATERCEPT
- Schedule 4
- SOTORASIB
- Schedule 4
- SOTROVIMAB
- Schedule 4
- SPARFLOXACIN
- Schedule 4
- SPARTEINE
- Schedule 4
- SPECTINOMYCIN
- Schedule 4
- SPESOLIMAB
- Schedule 4
- SPIDOXAMAT
- Schedule 5
- SPINETORAM
- Schedule 5
- SPINOSAD
- Schedule 5
- SPIRAMYCIN
- Schedule 4
- SPIRAPRIL
- Schedule 4
- SPIROMESIFEN
- Schedule 5
- SPIRONOLACTONE
- Schedule 4
- SPIROPIDION
- Schedule 6
- SPIROTETRAMAT
- Schedule 6
- SPIROXAMINE
- Schedule 6
- SQUILL
- Schedule 2
- STANOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- STANOZOLOL
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- STAR ANISE OIL
- Schedule 5
- STAVUDINE
- Schedule 4
- STENABOLIC (SR9009) and other synthetic REV-ERB agonists cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667
- Schedule 4 Appendix D, clause 5
- STENBOLONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- STERIC ACID
- Appendix B, clause 3
- STEROID HORMONES
- Schedule 4
- STILBESTROL cross reference: STILBOESTROL, DIETHYLSTILBESTROL
- Schedule 4
- STIRIPENTOL
- Schedule 4 Appendix K, clause 1
- STREPTODORNASE
- Schedule 4
- STREPTOKINASE
- Schedule 4
- STREPTOMYCES LYDICUS WYEC 108
- Appendix B, clause 3
- STREPTOMYCIN
- Schedule 4
- STRONTIUM RANELATE
- Schedule 4
- STROPHANTHINS
- Schedule 4
- STROPHANTHUS spp.
- Schedule 4 Appendix G, clause 1
- STRYCHNINE cross reference: NUX VOMICA
- Schedule 7 Schedule 4 Appendix E, clause 3 Appendix G, clause 1 Appendix J, clause 1
- STRYCHNOS spp.
- Schedule 4
- STYRAMATE
- Schedule 4
- STYRENE cross reference: DESIGNATED SOLVENT
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- SUCCIMER
- Schedule 4
- SUCRALFATE
- Appendix B, clause 3
- SUCROFERRIC OXYHYDROXIDE
- Schedule 4
- SUFENTANIL
- Schedule 8
- SUGAMMADEX
- Schedule 4
- SULBACTAM
- Schedule 4
- SULCOFURON
- Schedule 7 Schedule 6 Appendix E, clause 3 Appendix J, clause 1
- SULCONAZOLE
- Schedule 4 Schedule 2
- SULESOMAB
- Appendix B, clause 3
- SULFACETAMIDE
- Schedule 5 Schedule 4 Schedule 3
- SULFADIAZINE
- Schedule 5 Schedule 4
- SULFADIMETHOXINE
- Schedule 4
- SULFADIMIDINE
- Schedule 5 Schedule 4
- SULFADOXINE
- Schedule 4
- SULFAFURAZOLE
- Schedule 4
- SULFAGUANIDINE
- Schedule 4
- SULFAMERAZINE
- Schedule 5 Schedule 4
- SULFAMETHIZOLE
- Schedule 4
- SULFAMETHOXAZOLE
- Schedule 4
- SULFAMETHOXYDIAZINE
- Schedule 4
- SULFAMETHOXYPYRIDAZINE
- Schedule 4
- SULFAMETROLE
- Schedule 4
- SULFAMIC ACID
- Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- SULFAMONOMETHOXINE
- Schedule 4
- SULFAMOXOLE
- Schedule 4
- SULFAPHENAZOLE
- Schedule 4
- SULFAPYRIDINE
- Schedule 4
- SULFAQUINOXALINE
- Schedule 4
- SULFASALAZINE
- Schedule 4
- SULFATHIAZOLE
- Schedule 5 Schedule 4
- SULFATROXAZOLE
- Schedule 4
- SULFENTRAZONE
- Schedule 7
- SULFINPYRAZONE
- Schedule 4
- SULFLURAMID
- Schedule 6
- SULFOMETURON-METHYL
- Schedule 5
- SULFOMYXIN
- Schedule 4
- SULFONAMIDE ANTIBIOTICS cross reference: SULFACETAMIDE, SULPHANILAMIDE
- Schedule 4
- SULFONMETHANE cross reference: ALKYL SULFONALS, SULFONAL
- Schedule 4
- SULFOSULFURON
- Appendix B, clause 3
- SULFOTEP
- Schedule 7
- SULFOXAFLOR
- Schedule 6 Schedule 5
- SULFURIC ACID
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- SULFURYL FLUORIDE
- Schedule 6
- SULINDAC
- Schedule 4
- SULPHATED POLYSACCHARIDES
- Appendix B, clause 3
- SULPROFOS
- Schedule 6
- SULTAMICILLIN
- Schedule 4
- SULTHIAME
- Schedule 4
- SUMATRIPTAN
- Schedule 4 Schedule 3 Appendix H, clause 1
- SUNIFIRAM
- cross reference: RACETAMS
- Schedule 4
- SUNITINIB
- Schedule 4
- SUPROFEN
- Schedule 4
- SUTILAINS
- Schedule 4
- SUVOREXANT
- Schedule 4 Appendix K, clause 1
- SUXAMETHONIUM
- Schedule 4
- SUXETHONIUM
- Schedule 4
- SYMPHYTUM spp. cross reference: COMFREY
- Schedule 10 Schedule 5 Appendix F, clause 4
- SYNTHETIC CANNABINOMIMETICS
- Schedule 9
- T
- 2,4,5-T
- Schedule 6
- TACRINE
- Schedule 4
- TACROLIMUS
- Schedule 4
- TADALAFIL
- Schedule 4
- TAFAMIDIS
- Schedule 4
- TAFASITAMAB
- Schedule 4
- TAFENOQUINE SUCCINATE
- Schedule 4
- TAFLUPROST
- Schedule 4
- TAGRAXOFUSP
- Schedule 4
- TALAZOPARIB
- Schedule 4
- TALIGLUCERASE ALFA
- Schedule 4
- TALIMOGENE LAHERPAREPVEC
- Schedule 4
- TALLOW ALKYLAMINE ACETATES
- Schedule 6
- N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE
- Schedule 6
- TAMOXIFEN
- Schedule 4
- TAMSULOSIN
- Schedule 4
- TANACETUM VULGARE cross reference: OIL OF TANSY, TANSY OIL
- Schedule 4
- TANNIC ACID
- Appendix B, clause 3
- TANNIC ACID/BENZYL ALCOHOL PRODUCT
- Appendix B, clause 3
- TAPENTADOL
- Schedule 8 Appendix K, clause 1
- TAPINAROF
- Schedule 4
- TAR ACIDS
- Schedule 6
- TASIPIMIDINE SULFATE
- Schedule 4
- TASONERMIN
- Schedule 4
- TAZAROTENE
- Schedule 4 Appendix F, clause 4
- TAZOBACTAM
- Schedule 4
- TB-500
- Schedule 4 Appendix D, clause 5
- 2,3,6-TBA
- Schedule 5
- T-CELL RECEPTOR ANTIBODY
- Schedule 4
- TCMTB cross reference: 2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE
- Schedule 6
- TDE cross reference: 1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE
- Schedule 6 Schedule 5
- TEBENTAFUSP
- Schedule 4
- TEBUCONAZOLE cross reference: TERBUCONAZOLE
- Schedule 5
- TEBUFENOZIDE
- Schedule 5
- TEBUFENPYRAD
- Schedule 6
- TEBUTHIURON
- Schedule 6
- TECLISTAMAB
- Schedule 4
- TEDUGLUTIDE
- Schedule 4
- TEFLUTHRIN
- Schedule 7 Schedule 5
- TEGAFUR
- Schedule 4
- TEGASEROD
- Schedule 4
- TEICOPLANIN
- Schedule 4
- TELAPREVIR
- Schedule 4
- TELBIVUDINE
- Schedule 4
- TELITHROMYCIN
- Schedule 4
- TELMISARTAN
- Schedule 4
- TELOTRISTAT ETHYL
- Schedule 4
- TEMAZEPAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives)
- Appendix K, clause 1
- TEMEPHOS
- Schedule 6 Schedule 5
- TEMOZOLOMIDE
- Schedule 4
- TEMSIROLIMUS
- Schedule 4
- TENECTEPLASE
- Schedule 4
- TENIPOSIDE
- Schedule 4
- TENOCYCLIDINE cross reference: TCP (CAS No. 21500-98-1)
- Schedule 9
- TENOFOVIR
- Schedule 4
- TENOXICAM
- Schedule 4
- TEPLIZUMAB Schedule 4 Appendix L, clause 2
- TEPOTINIB
- Schedule 4
- TEPOXALIN
- Schedule 4
- TEPP
- Schedule 8
- TEPRALOXYDIM
- Schedule 5
- TEPROTUMUMAB
- Schedule 4 Appendix F, clause 4 Appendix L, clause 2
- TERAZOSIN
- Schedule 4
- TERBACIL
- Appendix B, clause 3, Part 3
- TERBINAFINE
- Schedule 4 Schedule 2
- TERBUFOS
- Schedule 7
- TERBUTALINE
- Schedule 4 Schedule 3 Appendix F, clause 4
- TERBUTHYLAZINE
- Schedule 6
- TERBUTRYN
- Schedule 5
- TERFENADINE
- Schedule 4 Appendix F, clause 4
- TERIFLUNOMIDE
- Schedule 4 Appendix F, clause 4 Appendix L, clause 2
- TERIPARATIDE
- Schedule 4 Appendix D, clause 1
- TERLIPRESSIN
- Schedule 4
- TERMITE BARRIERS
- Appendix A, clause 1
- TERODILINE
- Schedule 4
- TEROPTERIN
- Schedule 4
- TERPENES, CHLORINATED cross reference: CHLORINATED TERPENES
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- TESTOLACTONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- TESTOSTERONE
- Schedule 6 Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) Appendix G, clause 1
- TETANUS ANTITOXIN
- Schedule 4
- TETANUS TOXOID
- cross reference: TRIPLE ANTIGEN VACCINE
- Schedule 4
- 1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE cross reference: HEXAMINE, HEXAMETHYLENETETRAMINE, METHENAMINE
- Schedule 5
- TETRABENAZINE
- Schedule 4
- TETRACAINE cross reference: AMETHOCAINE
- Schedule 4 Schedule 2
- TETRACHLOROETHANE
- Schedule 7 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1
- TETRACHLOROETHYLENE cross reference: DESIGNATED SOLVENT
- Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 Appendix F, clause 4
- TETRACHLORVINPHOS
- Schedule 5
- TETRACONAZOLE
- Schedule 6 Schedule 5
- TETRACOSACTIDE
- Schedule 4
- TETRACOSACTRIN cross reference: TETRACOSACTIDE
- TETRACYCLINE
- Schedule 5 Schedule 4
- TETRADIFON
- Schedule 6
- TETRAETHYLAMMONIUM
- Schedule 4
- TETRAHYDROCANNABINOLIC ACID cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS
- TETRAHYDROCANNABINOLS cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS
- Schedule 9 Schedule 8 Appendix D, clause 1 Appendix K, clause 1
- TETRAHYDROCANNABIDIVAROL cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS
- TETRAHYDROFURFURYL ALCOHOL
- Schedule 6
- TETRAHYDROZOLINE cross reference: TETRYZOLINE
- 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE cross reference: STABAXOL
- Schedule 7
- Schedule 6 Appendix J, clause 1
- TETRAMETHRIN
- Schedule 5
- TETRAMISOLE
- Schedule 6
- TETRANILIPROLE
- Schedule 5
- TETROXOPRIM
- Schedule 4
- TETRYZOLINE cross reference: TETRAHYDROZOLINE
- Schedule 2 Appendix F, clause 4
- TEZACAFTOR
- Schedule 4
- TEZEPELUMAB
- Schedule 4
- THALIDOMIDE
- Schedule 4 Appendix D, clause 2 Appendix F, clause 4 Appendix L, clause 2
- THALLIUM cross reference: THALLIUM SULFATE
- Schedule 7 Appendix J, clause 1
- THAUMATIN
- Appendix B, clause 3
- THEBACON
- Schedule 8
- THEBAINE
- Schedule 8
- THENYLDIAMINE
- Schedule 4 Appendix K, clause 1
- THEOPHYLLINE
- Schedule 4 Schedule 3
- THEVETIA PERUVIANA
- Schedule 4
- THEVETIN
- Schedule 4
- THIABENDAZOLE
- Schedule 5 Schedule 2
- THIACETARSAMIDE
- Schedule 4
- THIACLOPRID
- Schedule 6
- THIAFENTANIL
- Schedule 8
- THIAMBUTOSINE
- Schedule 4
- THIAMETHOXAM
- Schedule 6 Schedule 5
- THIAZAFLURON
- Schedule 6
- THIAZOPYR
- Schedule 5
- THIAZOSULFONE
- Schedule 4
- THIDIAZURON
- Appendix B, clause 3
- THIETHYLPERAZINE
- Schedule 4 Appendix K, clause 1
- THIFENSULFURON
- Schedule 5
- THIOACETAZONE
- Schedule 4
- THIOBENCARB
- Schedule 5
- THIOCARLIDE
- Schedule 4
- THIODICARB
- Schedule 6 Schedule 5
- THIOFANOX
- Schedule 7
- THIOFENTANYL
- cross reference: CAS No. 1165-22-6
- Schedule 9
- THIOGUANINE cross reference: TIOGUANINE
- THIOMESTERONE cross reference: TIOMESTERONE
- Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- THIOMETON
- Schedule 6
- THIOPENTAL
- Schedule 4
- THIOPENTONE cross reference: THIOPENTAL
- THIOPHANATE-METHYL
- Schedule 6 Schedule 5
- THIOPROPAZATE
- Schedule 4 Appendix K, clause 1
- THIOPROPERAZINE
- Schedule 4
- THIORIDAZINE
- Schedule 4 Appendix K, clause 1
- THIOSTREPTON
- Schedule 4
- THIOTEPA cross reference: TRIETHYLENE THIOPHOSPHORAMIDE
- Schedule 4
- THIOTHIXENE
- Schedule 4 Appendix K, clause 1
- THIOURACIL
- Schedule 4
- THIOUREA cross reference: ALKYL THIOUREAS
- Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- THIRAM
- Schedule 6
- THUJONE
- Schedule 6 Appendix E, clause 3
- THYME OIL
- Schedule 5 Appendix E, clause 3
- THYMOL
- Schedule 6
- THYMOSIN BETA 4 (THYMOSIN β4)
- Schedule 4 Appendix D, clause 5
- THYMOXAMINE
- Schedule 4
- THYROID
- Schedule 4
- THYROTROPHIN cross reference: TSH
- Schedule 4
- THYROXINE
- Schedule 4 Appendix G, clause 1
- TIAFENACIL
- Appendix B, clause 3
- TIAGABINE
- Schedule 4
- TIAMULIN
- Schedule 4
- TIANEPTINE
- Schedule 4 Appendix D, clause 5
- TIAPROFENIC ACID
- Schedule 4
- TIARAMIDE
- Schedule 4
- TIBOLONE
- Schedule 4
- TICAGRELOR
- Schedule 4
- TICARCILLIN
- Schedule 4
- TICLOPIDINE
- Schedule 4
- TIEMONIUM
- Schedule 4
- TIENILIC ACID
- Schedule 4
- TIGECYCLINE
- Schedule 4
- TIGILANOL TIGLATE
- Schedule 4
- TIGLOIDINE
- Schedule 4
- TIGOLANER
- Schedule 6 Schedule 5
- TILDIPIROSIN
- Schedule 4
- TILETAMINE
- Schedule 4
- TILIDINE
- Schedule 8
- TILMANOCEPT
- Schedule 4
- TILMICOSIN
- Schedule 4
- TILUDRONIC ACID cross reference: DISODIUM TILUDRONATE
- Schedule 4
- TIMBER cross reference: WALLBOARD
- Appendix A, clause 1
- TIMOLOL
- Schedule 4
- TIMOTHY-GRASS POLLEN EXTRACT cross reference: PHLEUM PRATENSE POLLEN EXTRACT
- Schedule 4
- TIN ORGANIC COMPOUNDS cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS, DIP
- Schedule 7
- TINIDAZOLE
- Schedule 4
- TINZAPARIN
- Schedule 4
- TIOCARBAZIL
- Schedule 5
- TIOCONAZOLE
- Schedule 4 Schedule 3 Schedule 2
- Appendix H, clause 1
- TIOGUANINE cross reference: THIOGUANINE
- Schedule 4
- TIOTROPIUM
- Schedule 4
- TIPEPIDINE
- Schedule 4
- TIPIRACIL
- Schedule 4
- TIPRANAVIR
- Schedule 4
- TIRBANIBULIN
- Schedule 4
- TIRILAZAD
- Schedule 4
- TIROFIBAN
- Schedule 4
- TIRZEPATIDE
- Schedule 4
- Appendix L, clause 2
- TISLELIZUMAB
- Schedule 4
- TIXAGEVIMAB
- Schedule 4
- TOBRAMYCIN
- Schedule 4
- TOCAINIDE
- Schedule 4
- TOCERANIB
- Schedule 4
- TOCILIZUMAB
- Schedule 4
- TOFACITINIB
- Schedule 4
- TOFERSEN
- Schedule 4
- TOLAZAMIDE
- Schedule 4
- TOLAZOLINE
- Schedule 4
- TOLBUTAMIDE
- Schedule 4
- TOLCAPONE
- Schedule 4
- TOLCLOFOS-METHYL
- Schedule 5
- TOLFENAMIC ACID
- Schedule 4
- o-TOLIDINE
- Schedule 7 Appendix E, clause 3 Appendix J, clause 1
- TOLMETIN
- Schedule 4
- TOLONIUM
- Schedule 4
- TOLPROPAMINE
- Schedule 4
- TOLRESTAT
- Schedule 4
- TOLTERODINE
- Schedule 4
- TOLTRAZURIL
- Schedule 5
- TOLUENE cross reference: XYLENE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- 2,4-TOLUENEDIAMINE
- cross reference: CAS No. 95-80-7
- Schedule 10
- TOLUENEDIAMINES
- Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- o-TOLUIDINE
- cross reference: CAS No. 95-53-4
- Schedule 10
- TOLVAPTAN
- Schedule 4
- TOLYLFLUANID
- Schedule 6
- TOPIRAMATE
- Schedule 4
- TOPOTECAN
- Schedule 4
- TOPRAMEZONE
- Schedule 5
- TORASEMIDE
- Schedule 4
- TOREMIFENE
- Schedule 4
- TOXOIDS
- Schedule 4
- TRABECTEDIN
- Schedule 4 Appendix K, clause 1
- TRALKOXYDIM
- Schedule 5
- TRAMADOL
- Schedule 4 Appendix K, clause 1
- TRAMAZOLINE
- Schedule 2 Appendix F, clause 4
- TRAMETINIB DIMETHYL SULFOXIDE
- Schedule 4
- TRANDOLAPRIL
- Schedule 4
- TRANEXAMIC ACID Schedule 4
- TRANSFLUTHRIN
- Schedule 6
- TRANYLCYPROMINE
- Schedule 4 Appendix K, clause 1
- TRASTUZUMAB
- Schedule 4
- TRASTUZUMAB DERUXTECAN
- Schedule 4
- Appendix L, clause 2
- TRASTUZUMAB EMTANSINE
- Schedule 4
- TRAVOPROST
- Schedule 4
- TRAZODONE
- Schedule 4
- TRENBOLONE cross reference: TRIENBOLONE, TRIENOLONE
- Schedule 5 Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
- TREOSULPHAN
- Schedule 4
- TREPROSTINIL
- Schedule 4
- TRESTOLONE
- Schedule 4 Appendix D, clause 5 (androgenic steroidal agents)
- TRETAMINE
- Schedule 4
- TRETINOIN
- Schedule 4 Appendix D, clause 4 Appendix F, clause 4 Appendix L, clause 2
- TRIACETYLOLEANDOMYCIN
- Schedule 4
- TRIADIMEFON
- Schedule 6 Schedule 5
- TRIADIMENOL
- Schedule 5
- TRI-ALLATE
- Schedule 5
- TRIAMCINOLONE
- Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4, Part 2
- Appendix H, clause 1
- TRIAMIPHOS
- Schedule 7
- TRIAMTERENE
- Schedule 4
- TRIASULFURON
- Appendix B, clause 3
- TRIAZBUTIL
- Schedule 7
- TRIAZIQUONE
- Schedule 4
- TRIAZOLAM
- Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives)
- TRIBENURON-METHYL
- Schedule 5
- TRIBUFOS cross reference: s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE
- Schedule 7
- TRICHLORFON cross reference: METRIFONATE
- Schedule 6
- TRICHLORMETHIAZIDE
- Schedule 4
- TRICHLOROACETIC ACID
- Schedule 6 Schedule 5 Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- TRICHLOROACETIC ACID ALKALI SALTS
- Schedule 5 Appendix E, clause 3
- 1,1,1-TRICHLOROETHANE cross reference: CAS No. 71-55-6, DESIGNATED SOLVENT
- Schedule 10 Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- TRICHLOROETHYLENE cross reference: TRICHLOROETHENE
- Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- TRICHLOROISOCYANURIC ACID cross reference: CHLORINATING COMPOUNDS
- Appendix E, clause 3
- TRICHLOROPHENOL
- Schedule 6 Appendix F, clause 4
- TRICHODERMA HARZIANUM
- Appendix B, clause 3
- TRICHODESMA AFRICANA
- Schedule 10
- TRICLABENDAZOLE
- Schedule 6
- TRICLOFOS
- Schedule 4
- TRICLOPYR
- Schedule 6
- TRICLOSAN
- Schedule 6
- TRICYCLAMOL
- Schedule 4
- TRIDEMORPH
- Schedule 6
- TRIDIHEXETHYL
- Schedule 4
- TRIDIPHANE
- Schedule 5
- TRIENTINE
- Schedule 4
- TRIETAZINE
- Schedule 5
- TRIETHANOLAMINE cross reference: TROLAMINE
- TRIETHYL PHOSPHATE
- Schedule 6 Appendix E, clause 3
- TRIETHYLENE GLYCOL
- Appendix B, clause 3
- TRIFAROTENE
- Schedule 4
- TRIFLOXYSTROBIN
- Schedule 5
- TRIFLOXYSULFURON
- Appendix B, clause 3
- TRIFLUDIMOXAZIN
- Schedule 5
- TRIFLUMIZOLE
- Schedule 5
- TRIFLUMURON
- Schedule 5
- TRIFLUOPERAZINE
- Schedule 4 Appendix K, clause 1
- TRIFLUOROMETHANESULFONIC ACID
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE cross reference: TFMPP (CAS No. 15532-75-9), TFMPP HYDROCHLORIDE (CAS No. 16015-69-3)
- Schedule 9
- TRIFLUPERIDOL
- Schedule 4
- TRIFLUPROMAZINE
- Schedule 4
- TRIFLURALIN
- Appendix B, clause 3
- TRIFLURIDINE
- Schedule 4
- TRIFORINE
- Appendix B, clause 3
- TRIHEXYPHENIDYL cross reference: BENZHEXOL
- Schedule 4
- TRIISOPROPANOLAMINE LAURYL ETHER SULFATE
- Schedule 5 Appendix E, clause 3 Appendix F, clause 4
- TRILOSTANE
- Schedule 4
- TRIMEPERIDINE
- cross reference: CAS No. 29606-10-8
- Schedule 9
- TRIMEPRAZINE cross reference: ALIMEMAZINE
- TRIMETAPHAN
- Schedule 4
- TRIMETHOPRIM
- Schedule 4
- 3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE cross reference: TMA (CAS No. 1082-88-8), TMA HYDROCHLORIDE (CAS No. 5688-80-2)
- Schedule 9
- 3,4,5-TRIMETHOXYPHENETHYLAMINE cross reference: MESCALINE, METHOXYPHENAMINE, METHOXY-PHENYLETHYLAMINE (CAS No. 54-04-6), MESCALINE HYDROCHLORIDE (CAS No. 832-92
- Schedule 9
- 1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE
- cross reference: CAS No. 17097-73-3
- Schedule 9
- TRIMIPRAMINE
- Schedule 4 Appendix K, clause 1
- TRIMUSTINE
- Schedule 4
- TRINEXAPAC-ETHYL
- Schedule 5
- TRINITROPHENOL
- Schedule 6 Schedule 4
- 3,6,9-TRIOXAUNDECANEDIOIC ACID
- Schedule 5 Appendix F, clause 4
- TRIOXYSALEN
- Schedule 4
- TRIPARANOL
- cross reference: CAS No. 78-41-1
- Schedule 10
- TRIPELENNAMINE
- Schedule 4
- TRIPLE ANTIGEN VACCINE
- cross reference: DIPHTHERIA TOXOID, PERTUSSIS ANTIGEN, TETANUS TOXOID
- TRIPROLIDINE
- Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1
- TRIPTORELIN
- Schedule 4
- TRISODIUM NITRILOTRIACETATE
- Schedule 6
- TRITICONAZOLE
- Schedule 5
- TROGLITAZONE
- Schedule 4
- TROLAMINE
- Schedule 5 Schedule 4 Appendix E, clause 3 Appendix F, clause 4
- TROMETAMOL
- Schedule 4
- TROPICAMIDE
- Schedule 4
- TROPISETRON
- Schedule 4
- TROVAFLOXACIN
- Schedule 4
- TROXIDONE
- Schedule 4
- TRYPTOPHAN
- Schedule 4
- TUAMINOHEPTANE
- Schedule 2
- TUCATINIB
- Schedule 4
- TUBERCULIN
- Schedule 4
- TUBOCURARINE
- Schedule 4
- TULATHROMYCIN
- Schedule 4
- TULOBUTEROL
- Schedule 4
- TURPENTINE OIL cross reference: OIL OF TURPENTINE
- Schedule 5 Appendix E, clause 3
- TUSSILAGO FARFARA cross reference: COLTSFOOT
- Schedule 10
- TYLOSIN
- Schedule 4
- TYMAZOLINE
- Schedule 4 Appendix F, clause 4
- TYPHOID VACCINE
- Schedule 4
- U
- ULIPRISTAL
- Schedule 4 Schedule 3 Appendix H, clause 1
- ULOCLADIUM OUDEMANSII
- Appendix B, clause 3
- UMECLIDINIUM
- Schedule 4
- UNIFIRAM
- cross reference: RACETAMS
- Schedule 4
- UNOPROSTONE
- Schedule 4
- UPADACITINIB
- Schedule 4
- URACIL
- Schedule 4
- URAPIDIL
- Schedule 4
- UREA
- Appendix B, clause 3
- URETHANE
- Schedule 4
- UROFOLLITROPIN cross reference: FOLLICLE-STIMULATING HORMONE, HUMAN
- Schedule 4 Appendix D, clause 1
- UROKINASE
- Schedule 4
- URSODEOXYCHOLIC ACID
- Schedule 4
- USTEKINUMAB
- Schedule 4
- V
- VACCINES
- Schedule 4
- VACCINES – PLASMID DNA cross reference: PLASMID DNA (rE. coli DH5α pINGhT)
- Schedule 4
- VACCINIA VIRUS VACCINE
- Schedule 4
- VADADUSTAT
- Schedule 4 Appendix D, clause 5
- VALACICLOVIR
- Schedule 4
- VALDECOXIB
- Schedule 4
- VALGANCICLOVIR
- Schedule 4
- VALNOCTAMIDE
- Schedule 4
- VALPROIC ACID
- Schedule 4
- VALSARTAN
- Schedule 4
- VAMIDOTHION
- Schedule 6
- VANCOMYCIN
- Schedule 4
- VANDETANIB
- Schedule 4
- VANZACAFTOR
- Schedule 4
- VARDENAFIL
- Schedule 4
- VARENICLINE
- Schedule 4
- VARICELLA VACCINE
- Schedule 4
- VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN (RECOMBINANT)
- cross reference: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
- VASOPRESSIN
- Schedule 4
- VATINOXAN HYDROCHLORIDE
- Schedule 4
- VECURONIUM
- Schedule 4
- VEDAPROFEN
- Schedule 4
- VEDOLIZUMAB
- Schedule 4
- VELAGLIFLOZIN
- Schedule 4
- VELAGLUCERASE ALFA
- Schedule 4
- VELMANASE ALFA
- Schedule 4
- VELPATASVIR
- Schedule 4
- VEMURAFENIB
- Schedule 4
- VENETOCLAX
- Schedule 4
- VENLAFAXINE
- Schedule 4
- VERAPAMIL
- Schedule 4
- VERATRUM
- Schedule 4
- VERDINEXOR
- Schedule 4
- VERICIGUAT
- Schedule 4
- VERNAKALANT
- Schedule 4
- VERNOLATE
- Schedule 5
- VERTEPORFIN
- Schedule 4
- VETIVER OIL
- Appendix B, clause 3
- VIDARABINE
- Schedule 4
- VIGABATRIN
- Schedule 4
- VILANTEROL
- Schedule 4
- VILDAGLIPTIN
- Schedule 4
- VILOXAZINE
- Schedule 4
- VINBLASTINE
- Schedule 4
- VINCAMINE
- Schedule 4
- VINCLOZOLIN
- Schedule 6 Appendix F, clause 4
- VINCRISTINE
- Schedule 4
- VINDESINE
- Schedule 4
- VINFLUNINE
- Schedule 4
- VINORELBINE
- Schedule 4
- VINYL ACETATE MONOMER
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- VINYL CHLORIDE
- Schedule 7 Appendix J, clause 1
- VINYL ETHER
- Schedule 4
- VIRGINIAMYCIN
- Schedule 5 Schedule 4
- VISMODEGIB
- Schedule 4
- VISNADINE
- Schedule 4
- VITAMIN A
- Schedule 4
- VITAMIN D cross reference: COLECALCIFEROL, ERGOCALCIFEROL
- Schedule 4 Schedule 3 Appendix H, clause 1
- VITAMIN K cross reference: PHYTOMENADIONE
- Appendix B, clause 3
- VITREOUS ENAMELS
- Appendix A, clause 1
- VORAPAXAR
- Schedule 4
- VORASIDENIB
- Schedule 4
- VORETIGENE NEPARVOVEC
- Schedule 4
- VORICONAZOLE
- Schedule 4
- VORINOSTAT
- Schedule 4
- VORTIOXETINE
- Schedule 4
- VOSORITIDE
- Schedule 4
- VOXILAPREVIR
- Schedule 4
- VUTRISIRAN
- Schedule 4
- W
- WALLBOARD cross reference: TIMBER
- Appendix A, clause 1
- WARFARIN
- Schedule 6 Schedule 5 Schedule 4
- WILD CHERRY BARK
- Schedule 10
- WRITING CORRECTION PENS
- Appendix A, clause 1
- X
- XAMOTEROL
- Schedule 4
- XANTHINOL NICOTINATE
- Schedule 4
- XANTHOPHYLL cross reference: LUTEIN
- Appendix B, clause 3
- XIMELAGATRAN
- Schedule 4
- XIPAMIDE
- Schedule 4
- XYLANASE derived from Aspergillus niger
- Appendix B, clause 3
- XYLAZINE
- Schedule 4
- XYLENE cross reference: TOLUENE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- XYLOMETAZOLINE
- Schedule 2 Appendix F, clause 4
- Y
- YLANG YLANG OIL
- Appendix B, clause 3
- YOHIMBINE cross reference: ASPIDOSPERMA QUEBRACHO
- Schedule 4
- Z
- (Z)-9-TRICOSENE cross reference: TRICOSENE
- Appendix B, clause 3
- ZAFIRLUKAST
- Schedule 4
- ZALCITABINE
- Schedule 4
- ZALEPLON
- Schedule 4
- ZANAMIVIR
- Schedule 4
- ZANUBRUTINIB
- Schedule 4
- ZERANOL
- Schedule 6 Schedule 4
- ZETA-CYPERMETHRIN
- Schedule 7 Schedule 6
- ZIDOVUDINE
- Schedule 4
- ZILPATEROL
- Schedule 4
- ZILUCOPLAN
- Schedule 4
- ZIMELDINE
- Schedule 4
- ZINC BORATE
- Schedule 6
- ZINC CHLORIDE
- Schedule 4
- Schedule 2
- Appendix E, clause 3
- ZINC COMPOUNDS
- Schedule 4
- ZINC LACTATE
- Schedule 6 Appendix F, clause 4
- ZINC NAPHTHENATE
- Appendix B, clause 3
- ZINC para-PHENOLSULFONATE
- Schedule 6
- ZINC SULFATE
- Schedule 6 Appendix E, clause 3 Appendix F, clause 4
- ZINEB cross reference: DITHIOCARBAMATES, MANCOZEB, PROPINEB, THIRAM
- Schedule 5
- ZIPRASIDONE
- Schedule 4 Appendix K, clause 1
- ZIRAM
- Schedule 7 Schedule 6
- ZOLAZEPAM
- Schedule 4
- ZOLBETUXIMAB
- Schedule 4
- ZOLEDRONIC ACID
- Schedule 4
- ZOLMITRIPTAN
- Schedule 4 Schedule 3 Appendix H, clause 1
- ZOLPIDEM
- Schedule 4 Appendix K, clause 1
- ZONISAMIDE
- Schedule 4 Appendix K, clause 1
- ZOPICLONE
- Schedule 4 Appendix K, clause 1
- ZOXAZOLAMINE
- Schedule 4
- ZUCLOPENTHIXOL
- Schedule 4
- [1] “Cultivation”, “production” and “manufacture” have the same meaning as in the Narcotic Drugs Act 1967
- Schedule 1 · Blank
- Schedule 2 · Pharmacy medicines
- Note: See section 16, subsection 54(1) and section 58.
- ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) for therapeutic use.
- ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
- ACONITUM spp. for therapeutic use in adults:
- (a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or
- (b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs conta
- ALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:
- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing alimemazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;
- except in preparations for the treatment of children under 2 years of age.
- ALOXIPRIN.
- AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.
- ANTAZOLINE in eye drops.
- ASPIRIN except when:
- (a) included in Schedule 4, 5 or 6; or
- (b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than w
- (i) enclosed in a primary pack that contains 12 or less individually wrapped powders or sachets of granules; and
- (ii) compliant with the requirements of the required advisory statements for medicine labels; or
- (c) in tablets or capsules containing aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:
- (i) either:
- (A) packed in blister or strip packing; or
- (B) in a container with a child-resistant closure; and
- (ii) either:
- (A) in a primary pack that contains not more than 25 tablets or capsules, each containing 325 mg or less of aspirin; or
- (B) in a primary pack that contains not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; or
- (C) in a primary pack that contains not more than 100 tablets or capsules, each containing 100 mg or less of aspirin, and that is labelled for the prevention of
- (iii) compliant with the requirements of the required advisory statements for medicine labels.
- ASTODRIMER SODIUM when used in a nasal spray.
- ATROPA BELLADONNA (belladonna):
- (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or
- (b) for oral use in adults and children 6 years of age and over:
- (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
- (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or
- ATROPINE (excluding atropine methonitrate) for oral use:
- (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or le
- AZELAIC ACID in dermal preparations for human therapeutic use.
- AZELASTINE:
- (a) in preparations for nasal use; or
- (b) in topical eye preparations containing 0.05% or less of azelastine.
- BECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of beclometasone per actuation when the maximum recommended daily dose is no greater than
- BENZOCAINE in preparations for topical use other than eye drops:
- (a) containing 10% or less of total local anaesthetic substances, except in dermal preparations containing 2% or less of total local anaesthetic substances; or
- (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of tota
- BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide except in preparations containing 5% or less of b
- BENZYDAMINE in preparations for topical use, except:
- (a) in preparations for dermal use; or
- (b) in divided topical oral preparations containing 3 mg or less of benzydamine; or
- (c) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.
- BEPHENIUM SALTS.
- BIFONAZOLE in preparations for dermal use except:
- (a) in preparations containing 1% or less of bifonazole for the treatment of the scalp; or
- (b) in preparations for the treatment of tinea pedis.
- BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 20 mg bilastine for the treatment of adults and children aged 12 years
- BISACODYL in divided preparations for:
- (a) oral use except in a primary pack containing 20 dosage units or less containing 5 mg or less of bisacodyl per dosage unit; or
- (b) rectal use except:
- (i) in a primary pack containing 12 dosage units or less of suppositories containing 10 mg or less of bisacodyl per dosage unit; or
- (ii) in a primary pack containing 25 dosage units or less of enemas containing 10 mg or less of bisacodyl per dosage unit.
- BRIMONIDINE in ophthalmic preparations for adult use containing not more than 0.025% of brimonidine.
- BROMHEXINE.
- BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;
- except in preparations for the treatment of children under 2 years of age.
- BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 m
- CARBETAPENTANE except in preparations containing 0.5% or less of carbetapentane.
- CARBOCISTEINE.
- CETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and
- (a) in a primary pack containing not more than 10 days’ supply; and
- (b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
- CHLOPHEDIANOL.
- CHLORBUTANOL for human use in topical preparations containing 5% or less of chlorbutanol except in preparations containing 0.5% or less of chlorbutanol.
- CHLOROFORM in preparations for therapeutic use except:
- (a) when included in Schedule 4; or
- (b) in preparations containing 0.5% or less of chloroform.
- CHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:
- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing chlorphenamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;
- except in preparations for the treatment of children under 2 years of age.
- CHOLINE SALICYLATE in preparations for oromucosal use.
- CICLOPIROX:
- (a) in preparations for dermal use containing 2% or less of ciclopirox except in preparations for the treatment of tinea pedis; or
- (b) in preparations for application to the nails containing 8% or less of ciclopirox.
- CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5% or less of total local anaesthetic substances.
- CINNAMEDRINE.
- CLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
- CREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10% or less of creosote derived from wood other tha
- DATURA spp. for oral use:
- (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or le
- except when separately specified in these Schedules.
- DATURA STRAMONIUM (stramonium) for oral use when:
- (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or le
- except for smoking or burning.
- DATURA TATULA (stramonium) for oral use:
- (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or le
- except for smoking or burning.
- DELPHINIUM STAPHISAGRIA except in preparations containing 0.2% or less of Delphinium staphisagria.
- DESLORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when:
- (a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and
- (b) labelled with a recommended daily dose not exceeding 5 mg of desloratadine.
- DEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:
- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing dexchlorphenamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper
- except in preparations for the treatment of children under 2 years of age.
- DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg
- DIBROMOPROPAMIDINE for ophthalmic use.
- DICLOFENAC when:
- (a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with
- (b) in preparations for dermal use containing 4% or less of diclofenac except in preparations for dermal use containing 2% or less of diclofenac or for the trea
- (c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.
- DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children und
- DIPHENHYDRAMINE in oral preparations:
- (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
- (b) when combined with one or more other therapeutically active substances when:
- (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;
- except in preparations for the treatment of children under 2 years of age.
- DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:
- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;
- except in preparations for the treatment of children under 2 years of age.
- DUBOISIA LEICHHARDTII for oral use:
- (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or le
- DUBOISIA MYOPOROIDES for oral use:
- (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or le
- ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.
- ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease,
- ETAFEDRINE.
- ETHER for therapeutic use except:
- (a) when included in Schedule 4; or
- (b) in preparations containing 10% or less of ether.
- ETOFENAMATE in preparations for external use.
- FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.
- FELBINAC in preparations for external use.
- FEXOFENADINE in preparations for oral use except in divided preparations:
- (a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
- (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
- (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or
- (b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
- (i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and
- (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or
- (c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:
- (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
- (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.
- FLUORIDES for human use:
- (a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or
- (b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:
- (i) for therapeutic use when compliant with the requirements of the required advisory statements for medicine labels except in preparations containing 220 mg/kg
- (ii) for non-therapeutic use when labelled with warnings to the following effect:
- (A) Do not swallow; and
- (B) Do not use [this product/insert name of product] in children 6 years of age or less;
- except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant
- (C) Do not swallow; and
- (D) Do not use [this product/insert name of product] in children 6 years of age or less;
- except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriat
- FLURBIPROFEN in preparations for topical oral use when:
- (a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit except when:
- (i) in a primary pack containing not more than 16 dosage units; and
- (ii) labelled only for the treatment of adults and children over 12 years; or
- (b) in undivided preparations containing either:
- (i) 0.25% or less of flurbiprofen per dose; or
- (ii) 10 mg or less of flurbiprofen per dose;
- except when:
- (iii) in a primary pack containing not more than 15 mL; and
- (iv) labelled only for the treatment of adults 18 years and over.
- FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommende
- FOLIC ACID for human therapeutic use except:
- (a) when included in Schedule 4; or
- (b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.
- FOLINIC ACID for human therapeutic use except:
- (a) when included in Schedule 4; or
- (b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.
- FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
- (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or
- (b) in other preparations containing 0.2% or less of free formaldehyde.
- GELSEMIUM SEMPERVIRENS.
- GLUTARAL for human therapeutic use.
- GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treat
- HEXACHLOROPHENE in preparations for human use containing 3% or less of hexachlorophene except:
- (a) in preparations for use on infants, as specified in Schedule 4; or
- (b) in preparations for cosmetic use, as specified in Schedule 6; or
- (c) in other preparations containing 0.75% or less of hexachlorophene.
- HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use:
- (a) for dermal use in preparations containing 0.5% or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therape
- (b) for dermal use in preparations containing 1% or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal subs
- (i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and
- (ii) not labelled for the treatment of children under 12 years of age; or
- (c) for rectal use in preparations containing 0.5% or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically acti
- (i) in undivided preparations in packs of 35 g or less; or
- (ii) in packs containing 12 or less suppositories.
- HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use cont
- (a) in hair preparations containing 0.3% or less of hydroquinone; or
- (b) in cosmetic nail preparations containing 0.02% or less of hydroquinone.
- HYOSCINE:
- (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
- (b) for oral use:
- (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloid
- (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or l
- HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per
- HYOSCYAMINE:
- (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or
- (b) for oral use:
- (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloid
- (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or l
- HYOSCYAMUS NIGER for oral use:
- (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
- (b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or le
- except in a pack containing 0.03 mg or less of total solanaceous alkaloids.
- IBUPROFEN in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen, when:
- (a) in liquid preparations that are sold in the manufacturer’s original pack containing 8 g or less of ibuprofen; or
- (b) in divided immediate release preparations:
- (i) each containing 400 mg or less of ibuprofen in a primary pack containing not more than 12 dosage units; and
- (ii) that are labelled not for the treatment of children under 12 years; or
- (c) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:
- (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and
- (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and
- (iii) in a primary pack containing not more than 25 dosage units; and
- (iv) compliant with the requirements of the required advisory statements for medicine labels; and
- (v) not labelled for the treatment of children 6 years or under; and
- (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.
- INDANAZOLINE.
- INDOMETACIN in preparations for external use containing 1% or less of indometacin.
- IODINE:
- (a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or
- (b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives or iodophors);
- except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate
- IPRATROPIUM in preparations for nasal use.
- IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in
- (a) when included in Schedule 4; or
- (b) when labelled with a recommended daily dose of 24 mg or less of iron:
- (i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or
- (ii) in divided preparations:
- (A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or
- (B) containing 5 mg or less of iron per dosage unit.
- ISOCONAZOLE for human use in dermal preparations.
- ISOPROPAMIDE in preparations for dermal use containing 2% or less of isopropamide.
- KETOCONAZOLE in preparations for dermal use except:
- (a) in preparations containing 1% or less of ketoconazole for the treatment of the scalp; or
- (b) in preparations for the treatment of tinea pedis.
- KETOTIFEN for ophthalmic use in preparations containing 0.025% or less of ketotifen.
- LANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux dise
- LEVOCABASTINE in topical eye or nasal preparations.
- LEVOCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of ag
- (a) in a primary pack containing not more than 5 days’ supply; and
- (b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
- LIDOCAINE in preparations for topical use other than eye drops:
- (a) containing 10% or less of total local anaesthetic substances, except:
- (i) in dermal preparations containing 2% or less of total local anaesthetic substances; or
- (ii) in aqueous sprays for oromucosal use containing 0.6% or less of total local anaesthetic substances; or
- (b) in divided preparations containing 200 mg or less of total local anaesthetic substances, except in lozenges containing 30 mg or less of total local anaesthe
- LINDANE in preparations for human external therapeutic use containing 2% or less of lindane.
- LITHIUM in preparations for dermal use containing 1% or less of lithium except:
- (a) when present as an excipient at 0.25% or less of lithium; or
- (b) in preparations containing 0.01% or less of lithium.
- LOBELIA INFLATA except for smoking or burning.
- LOBELINE except in preparations for smoking or burning.
- LODOXAMIDE in preparations for ophthalmic use.
- LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit
- LORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when:
- (a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and
- (b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
- MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.
- MEBENDAZOLE for human therapeutic use.
- MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for
- MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.
- MEPYRAMINE for dermal use.
- MERCUROCHROME in preparations for external use containing 2% or less of mercurochrome except when included in Schedule 6.
- MERCURY for external use in preparations containing 0.5% or less of mercury.
- METHOXAMINE in preparations for external use except in preparations containing 1% or less of methoxamine.
- METHOXYPHENAMINE.
- METHYLEPHEDRINE.
- MICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
- MINOXIDIL in preparations for dermal use containing 5% or less of minoxidil.
- MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 m
- NAPHAZOLINE.
- NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.
- NICLOSAMIDE for human therapeutic use.
- NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.
- NOSCAPINE.
- NYSTATIN in dermal preparations.
- OLOPATADINE in preparations for nasal use delivering 600 micrograms or less of olopatadine per dose when the maximum recommended daily dose is no greater than 4
- OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal refl
- OXETACAINE (oxethazaine) in preparations for internal use.
- OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.
- OXYMETAZOLINE.
- OXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, except in preparations for external use containing 1% or less of such substances.
- PAPAVERINE except when included in Schedule 4.
- PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal
- PARACETAMOL for therapeutic use:
- (a) in liquid preparations for oral use containing a maximum of 10 g of paracetamol per container; or
- (b) when combined with ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a
- (c) in tablets or capsules in blister or strip packaging enclosed in a primary pack containing not more than 50 tablets or capsules; or
- (d) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 25 wrapped powders or sachets of granules; or
- (e) in other preparations except:
- (i) when included in Schedule 3 or 4; or
- (ii) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other
- (A) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;
- (B) compliant with the requirements of the required advisory statements for medicine labels;
- (C) not labelled for the treatment of children 6 years of age or less; and
- (D) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin; or
- (iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine an
- (A) packed in blister or strip packaging;
- (B) in a primary pack containing not more than 16 tablets or capsules;
- (C) compliant with the requirements of the required advisory statements for medicine labels;
- (D) not labelled for the treatment of children 6 years of age or less; and
- (E) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin.
- PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
- (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or
- (b) in other preparations containing 0.2% or less of free formaldehyde.
- PHEDRAZINE.
- PHENAZONE for human external use.
- PHENIRAMINE:
- (a) in eye drops; or
- (b) when combined with one or more other therapeutically active substances in oral preparations when:
- (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;
- except in preparations for the treatment of children under 2 years of age.
- PHENOL, or any homologue boiling below 220°C, for human therapeutic use except:
- (a) when included in Schedule 4; or
- (b) in preparations for external use containing 1% or less of phenol and in preparations for external use containing 3% or less of cresols and xylenols and othe
- PHENYLEPHRINE except:
- (a) when included in Schedule 4; or
- (b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or
- (c) in topical eye or nasal preparations containing 1% or less of phenylephrine.
- PHOLCODINE:
- (a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or
- (b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and
- PIPERAZINE for human therapeutic use.
- PODOPHYLLOTOXIN in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.
- PODOPHYLLUM EMODI (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.
- PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.
- POTASSIUM CHLORATE for therapeutic use except in preparations containing 10% or less of potassium chlorate.
- PRILOCAINE in preparations for dermal use containing 10% or less of total local anaesthetic substances.
- PROCYCLIDINE in preparations containing 5% or less of procyclidine for dermal use.
- PROMETHAZINE in oral preparations:
- (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
- (b) when combined with one or more other therapeutically active substances when:
- (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;
- except in preparations for the treatment of children under 2 years of age.
- PROPAMIDINE for ophthalmic use.
- PYRANTEL for human therapeutic use.
- PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparatio
- PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with th
- RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal re
- RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days’ supply except:
- (a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14
- (b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7
- SALICYLAMIDE except when included in Schedule 4.
- SELENIUM in preparations for human therapeutic use except:
- (a) for topical use containing 3.5% or less of selenium sulfide;
- (b) when included in Schedule 4; or
- (c) for oral use with a recommended daily dose of 150 micrograms or less.
- SILVER for therapeutic use except:
- (a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the required advisory statements for medicine labe
- (b) in other preparations containing 1% or less of silver.
- SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.
- SODIUM NITRITE for therapeutic use (excluding when present as an excipient).
- SQUILL except in preparations containing 1% or less of squill.
- SULCONAZOLE in preparations for dermal use.
- TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.
- TETRACAINE in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances except in dermal preparations cont
- TETRACHLOROETHYLENE for human therapeutic use.
- TETRYZOLINE.
- THIABENDAZOLE for human therapeutic use.
- TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.
- TRAMAZOLINE.
- TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than
- TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:
- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper;
- except in preparations for the treatment of children under 2 years of age.
- TUAMINOHEPTANE.
- TYMAZOLINE.
- XYLOMETAZOLINE.
- ZINC CHLORIDE for human dermal use except in preparations containing 5% or less of zinc chloride.
- Schedule 3 · Pharmacist only medicines
- Note: See sections 16 and 31, subsections 54(2) and 57(1) and section 59.
- ADAPALENE in topical preparations containing 0.1% or less of adapalene for the treatment of acne vulgaris in adults and in children over 12 years of age.
- ADRENALINE in:
- (a) preparations containing 1% or less of adrenaline; or
- (b) intranasal preparations containing 2% or less of adrenaline;
- except in preparations that are not for injection containing 0.02% or less of adrenaline.
- ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30 g or
- ALIMEMAZINE:
- (a) in solid oral preparations except when included in Schedule 2; or
- (b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL;
- except in preparations for the treatment of children under 2 years of age.
- AMINOPHYLLINE in liquid oral preparations containing 2% or less of aminophylline.
- AMYL NITRITE when in preparations for human therapeutic use and packaged in containers with child-resistant closures.
- ASTODRIMER SODIUM except:
- (a) when included in Schedule 2; or
- (b) in a condom lubricant.
- AZATADINE in oral preparations.
- BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 10 mg of bilastine for the treatment of children 6-11 years of age exce
- BROMPHENIRAMINE in oral preparations except:
- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.
- BUCLIZINE in oral preparations.
- BUTOCONAZOLE in preparations for vaginal use.
- CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Register when:
- (a) the cannabidiol is either plant derived or, when synthetic, only contains the (-)-CBD enantiomer; and
- (b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and
- (c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the pre
- (d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and
- (e) packed in blister or strip packaging or in a container fitted with a child-resistant closure; and
- (f) in packs containing not more than 30 days’ supply; and
- (g) for persons aged 18 years and over.
- CELECOXIB in tablets or capsules each containing 200 mg or less of celecoxib, in a primary pack containing not more than 10 dosage units for the short-term trea
- CHLORAMPHENICOL for ophthalmic use only.
- CHLORBUTANOL in preparations for human use except:
- (a) when included in Schedule 2; or
- (b) in preparations containing 0.5% or less of chlorbutanol.
- CHLORPHENAMINE in oral preparations except:
- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.
- CICLOPIROX in preparations for dermal use and for application to the nails except:
- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of tinea pedis.
- CIMETIDINE in a primary pack containing not more than 14 days’ supply.
- CLEMASTINE in preparations for oral use.
- CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of clobetasone in pac
- CLOTRIMAZOLE in preparations for vaginal use.
- CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less.
- CYPROHEPTADINE in oral preparations.
- CYTISINE in divided oral and oromucosal preparations with a recommended daily dose of 9 mg or less of cytisine as an aid in withdrawal from tobacco smoking in a
- DEXCHLORPHENAMINE in oral preparations except:
- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.
- DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units except when
- DIHYDROCODEINE when indicated for cough suppression and compounded with one or more other therapeutically active substances:
- (a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
- (b) in undivided preparations containing 0.25% or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.
- DIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.
- DIMENHYDRINATE in oral preparations except when included in Schedule 2.
- DIMETHINDENE in oral preparations.
- DIPHENHYDRAMINE in oral preparations except:
- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.
- DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to a
- DITHRANOL for therapeutic use.
- DOXYLAMINE in oral preparations except:
- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.
- ECONAZOLE in preparations for vaginal use.
- ELETRIPTAN for oral use in tablets containing 40 mg or less per tablet and when in a pack containing not more than 2 dosage units for the acute relief of migrai
- ERYTHRITYL TETRANITRATE for therapeutic use.
- FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).
- FLAVOXATE.
- FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.
- FLUORIDES for human topical use:
- (a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure except when included in or expressly exc
- (b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion except:
- (i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the
- (ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with
- (A) Do not swallow; and
- (B) Do not use [this product/name of product] in children six years of age or less; or
- (iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.
- GLUCAGON.
- GLYCERYL TRINITRATE:
- (a) in preparations for oral use; or
- (b) in preparations for rectal use.
- HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1% or less of hydroco
- (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal subst
- (b) for dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or
- (c) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:
- (i) in undivided preparations, in packs of 35 g or less; or
- (ii) in packs containing 12 or less suppositories;
- except when included in Schedule 2.
- HYOSCINE BUTYLBROMIDE in undivided preparations for oral use with a recommended single dose not exceeding 20 mg of hyoscine butylbromide in a pack containing 10
- IBUPROFEN when:
- (a) either:
- (i) in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units; or
- (ii) in a modified release dosage form, each containing 600 mg of ibuprofen, in a primary pack containing not more than 32 dosage units; and
- (b) labelled:
- (i) with a recommended daily dose of 1200 mg or less of ibuprofen; and
- (ii) not for the treatment of children under 12 years;
- except when:
- (c) included in Schedule 2; or
- (d) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg
- (i) ibuprofen is the only therapeutically active constitutent, other than phenylephrine or when combined with an effervescent agent; and
- (ii) packed in a blister or strip packaging or in a container with a child-resistant closure; and
- (iii) in a primary pack containing not more than 25 dosage units; and
- (iv) compliant with the requirements of the required advisory statements for medicine labels; and
- (v) not labelled for the treatment of children 6 years or under; and
- (vi) when combined with phenylephrine—not labelled for the treatment of children under 12 years.
- INOSITOL NICOTINATE.
- ISOCONAZOLE in preparations for vaginal use.
- ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.
- KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.
- LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal
- LEVONORGESTREL for emergency post-coital contraception.
- MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.
- MAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose.
- MALATHION in preparations for human external use except in preparations containing 2% or less of malathion.
- MANNITYL HEXANITRATE for therapeutic use.
- MELATONIN in:
- (a) modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of primary insomnia characterised by poor quality
- (b) immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing n
- MEPYRAMINE in oral preparations.
- METHDILAZINE in oral preparations.
- METHENAMINE in preparations for therapeutic use.
- METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs c
- MICONAZOLE for human use in topical preparations:
- (a) for the treatment of oral candidiasis; or
- (b) for vaginal use.
- MOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.1% or less of mometasone in packs containing 15 g or less.
- NALOXONE when used for the treatment of opioid overdose.
- NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment
- NARATRIPTAN when in divided oral preparations containing 2.5 mg or less of naratriptan per dosage unit and when sold in a pack containing not more than 2 dosage
- NICOTINE in therapeutic vaping goods (within the meaning of the Therapeutic Goods Regulations 1990) in final dosage form for smoking cessation or the management
- (a) for supply to persons aged 18 years and over; and
- (b) the pharmacist requests and sights evidence of the patient’s identity and age; and
- (c) the pharmacist provides professional advice to the patient on alternative cessation supports and therapies, appropriate dose and frequency depending on age,
- (d) the pharmacist provides contact details about smoking cessation support services to the patient; and
- (e) the quantity of the goods does not exceed the quantity that is reasonably required for a patient’s therapeutic use for 1 month and that quantity is supplied
- (f) the concentration of nicotine in the goods does not exceed 20 mg/mL; and
- except:
- (g) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tob
- (h) in tobacco prepared and packed for smoking.
- NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except:
- (a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
- (b) nicotinamide.
- NICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.
- NYSTATIN in preparations for topical use except when included in Schedule 2.
- OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal refl
- ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.
- OXICONAZOLE in preparations for vaginal use.
- PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal
- PARACETAMOL:
- (a) when combined with ibuprofen in a primary pack containing 30 dosage units or less except when included in Schedule 2; or
- (b) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing not more than 100 tablets or capsules; o
- (c) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing more than 100 tablets or capsules intend
- (d) in non-modified release tablets or capsules containing not more than 500 mg paracetamol and in a primary pack containing not more than 100 tablets or capsul
- (e) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine pack and labelled “For dispe
- (f) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 50 wrapped powders or sachets of granules except
- (g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended on
- (h) in liquid preparations for oral use except when in Schedule 2.
- PHENIRAMINE in oral preparations except:
- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.
- PODOPHYLLOTOXIN in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when includ
- PODOPHYLLUM EMODI (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts excep
- PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts ex
- PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.
- PROMETHAZINE in oral preparations except:
- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of children under 2 years of age.
- PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:
- (a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or
- (b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).
- RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal re
- RIZATRIPTAN when in divided oral preparations containing 5 mg or less of rizatriptan per dosage unit and when sold in a pack containing not more than 2 dosage u
- SALBUTAMOL as the only therapeutically active substance:
- (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
- (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.
- SALICYLIC ACID in preparations for dermal use except in preparations containing 40% or less of salicylic acid.
- SANTONIN.
- SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
- SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.
- SULFACETAMIDE in preparations for ophthalmic use containing 10% or less of sulfacetamide.
- SUMATRIPTAN when in divided oral preparations containing 50 mg or less of sumatriptan per dosage unit and when sold in a pack containing not more than 2 dosage
- TERBUTALINE as the only therapeutically active substance:
- (a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or
- (b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.
- THEOPHYLLINE in liquid oral preparations containing 2% or less of theophylline.
- TIOCONAZOLE in preparations for vaginal use.
- TRIAMCINOLONE for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5 g or less.
- TRIPROLIDINE in oral preparations except:
- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.
- ULIPRISTAL for emergency post-coital contraception.
- VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in prepara
- ZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less of zolmitriptan per dosage unit and when sold in a pack containing not more than 2 dosa
- Schedule 4 · Prescription only medicines and prescription animal remedies
- Note 1: See sections 16, 28, 31 and 49, subsections 54(2) and 57(1) and section 60.
- Note 2: Substances marked # are listed in Appendix D.
- ABACAVIR.
- ABALOPARATIDE.
- ABATACEPT.
- ABIRATERONE ACETATE.
- ABCIXIMAB.
- ABEMACICLIB.
- ABROCITINIB.
- ACALABRUTINIB.
- ACAMPROSATE CALCIUM.
- ACARBOSE.
- ACEBUTOLOL.
- ACEPROMAZINE.
- ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.
- ACETARSOL.
- ACETAZOLAMIDE.
- ACETOHEXAMIDE.
- ACETYL ISOVALERYLTYLOSIN.
- ACETYLCARBROMAL.
- ACETYLCHOLINE.
- ACETYLCYSTEINE except:
- (a) when included in Schedule 2; or
- (b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
- ACETYLDIGITOXIN.
- ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.
- ACETYLSTROPHANTHIDIN.
- ACICLOVIR except in preparations containing 5% or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.
- ACIPIMOX.
- # ACITRETIN.
- ACLIDINIUM BROMIDE.
- ACOKANTHERA OUABAIO.
- ACOKANTHERA SCHIMPERI.
- ACONITUM spp. except:
- (a) when included in Schedule 2; or
- (b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or
- (c) in preparations for dermal use in adults containing 0.02% or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.
- ACRIVASTINE.
- ADALIMUMAB.
- ADAPALENE except when included in Schedule 3.
- ADEFOVIR.
- ADENOSINE for human therapeutic use in preparations for injection.
- ADIPHENINE.
- ADONIS VERNALIS.
- ADRAFINIL.
- ADRENALINE in:
- (a) topical preparations for the treatment of wounds in humans; or
- (b) all other preparations containing adrenaline except when included in or expressly excluded from Schedule 3.
- ADRENOCORTICAL HORMONES except when separately specified in these Schedules.
- AFAMELANOTIDE.
- AFATINIB DIMALEATE.
- AFLIBERCEPT.
- AGALSIDASE.
- AGLEPRISTONE.
- AGOMELATINE.
- ALANYLGLUTAMINE.
- ALATROFLOXACIN MESILATE.
- ALBENDAZOLE except:
- (a) when included in Schedule 5 or 6; or
- (b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.
- ALCLOFENAC.
- ALCLOMETASONE except when included in Schedule 3.
- ALCURONIUM.
- ALDESLEUKIN.
- ALDOSTERONE.
- ALECTINIB.
- # ALEFACEPT.
- ALEMTUZUMAB.
- ALENDRONIC ACID.
- ALFACALCIDOL.
- ALFUZOSIN.
- ALGLUCERASE.
- ALGLUCOSIDASE.
- ALIMEMAZINE except when included in Schedule 2 or 3.
- ALIROCUMAB.
- ALISKIREN.
- ALKYL NITRITES except when separately specified in these Schedules.
- ALLERGENS for therapeutic use.
- ALLOPURINOL.
- ALLYLESTRENOL.
- ALOGLIPTIN.
- ALOSETRON.
- ALPELISIB.
- ALPHA1-PROTEINASE INHIBITOR (HUMAN).
- ALPHADOLONE.
- ALFAXALONE.
- ALPRENOLOL.
- ALPROSTADIL.
- ALSEROXYLON.
- ALTEPLASE.
- ALTRENOGEST.
- ALTRETAMINE (hexamethylmelamine).
- AMANTADINE.
- AMBENONIUM CHLORIDE.
- # AMBRISENTAN.
- AMBUCETAMIDE.
- AMBUTONIUM BROMIDE.
- AMCINONIDE.
- AMIFAMPRIDINE.
- AMIFOSTINE.
- AMIKACIN.
- AMILORIDE.
- AMINOCAPROIC ACID.
- AMINOGLUTETHIMIDE.
- 5-AMINOLEVULINIC ACID.
- AMINOMETRADINE.
- AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.
- AMINOPHYLLINE except when included in Schedule 3.
- AMINOPTERIN.
- 4-AMINOPYRIDINE for therapeutic use.
- AMINOREX.
- AMINOSALICYLIC ACID.
- AMIODARONE.
- AMIPHENAZOLE.
- AMISOMETRADINE.
- AMISULPRIDE.
- AMITRIPTYLINE.
- AMLODIPINE.
- AMMI VISNAGA.
- AMMONIUM BROMIDE for therapeutic use.
- AMOBARBITAL when packed and labelled for injection.
- AMODIAQUINE.
- AMOROLFINE except:
- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of tinea pedis.
- AMOXAPINE.
- AMOXICILLIN.
- AMPHOMYCIN.
- AMPHOTERICIN B.
- AMPICILLIN.
- AMPRENAVIR.
- AMRINONE.
- AMSACRINE.
- AMYL NITRITE except when included in Schedule 3.
- AMYLOCAINE.
- # ANABOLIC STEROIDAL AGENTS.
- ANACAULASE-BCDB.
- ANAGRELIDE.
- ANAKINRA.
- ANASTROZOLE.
- ANCESTIM.
- ANCROD and its immunoglobulin antidote.
- ANDEXANET ALFA.
- ANECORTAVE.
- # ANDROGENIC STEROIDAL AGENTS.
- # ANDROISOXAZOLE.
- # ANDROSTANOLONE.
- # ANDROSTENEDIOL.
- # ANDROSTENEDIONE.
- ANGIOTENSIN AMIDE.
- ANIDULAFUNGIN.
- ANIMAL BLOOD PRODUCTS for veterinary use including:
- (a) whole blood;
- (b) blood components, including red cells, white cells, platelets, and plasma (including cryoprecipitate); and
- (c) the following plasma-derived therapeutic proteins, and their equivalent recombinant alternatives:
- (i) albumin;
- (ii) anticoagulation complex;
- (iii) C1 esterase inhibitors;
- (iv) clotting factors;
- (v) fibrinogen;
- (vi) protein C;
- (vii) prothrombin complex concentrate (PCC);
- (viii) thrombin;
- (ix) haemoglobin.
- ANIRACETAM.
- ANISTREPLASE.
- ANTAZOLINE except when included in Schedule 2.
- ANTIBIOTIC SUBSTANCES except:
- (a) when separately specified in these Schedules; or
- (b) nisin.
- ANTIGENS for human therapeutic use except when separately specified in this Schedule.
- ANTIHISTAMINES except:
- (a) when included in Schedule 2 or 3; or
- (b) when separately specified in this Schedule.
- ANTIMONY for therapeutic use except when separately specified in these Schedules.
- ANTISERA (immunosera) for human use by injection except when separately specified in these Schedules.
- # AOD-9604 (CAS No. 221231-10-3).
- APADAMTASE ALFA.
- APALUTAMIDE.
- APIXABAN.
- APOCYNUM spp.
- APOMORPHINE.
- APRACLONIDINE.
- APRAMYCIN.
- APREMILAST.
- APREPITANT.
- APROTININ.
- ARBUTIN (BETA) in oral preparations except herbal preparations containing 500 mg or less beta-arbutin per recommended daily dose.
- ARECOLINE.
- ARIPIPRAZOLE.
- ARMODAFINIL.
- ARSENIC for human therapeutic use except when separately specified in these Schedules.
- ARTEMETHER.
- ARTESUNATE.
- ARTICAINE.
- ASCIMINIB.
- ASENAPINE.
- ASFOTASE ALFA.
- ASPARAGINASE.
- ASPIRIN when:
- (a) combined with caffeine, paracetamol or salicylamide; or
- (b) combined with any derivative of the substances mentioned in paragraph (a); or
- (c) for injection.
- ASTEMIZOLE.
- ASUNAPREVIR.
- # ATAMESTANE.
- ATAZANAVIR.
- ATENOLOL.
- ATEZOLIZUMAB.
- ATINVICITINIB.
- ATIPAMEZOLE.
- ATOMOXETINE.
- ATORVASTATIN.
- ATOSIBAN.
- ATOVAQUONE.
- ATRACURIUM BESILATE.
- ATROPA BELLADONNA (belladonna) except when included in Schedule 2.
- ATROPINE except when included in Schedule 2.
- ATROPINE METHONITRATE.
- AURANOFIN.
- AUROTHIOMALATE SODIUM.
- AVACINCAPTAD PEGOL.
- AVACOPAN.
- AVATROMBOPAG.
- AVELUMAB.
- AVILAMYCIN except:
- (a) in animal feed premixes containing 15% or less of avilamycin activity; or
- (b) in animal feeds containing 50 mg/kg or less of avilamycin activity.
- AVIPTADIL.
- AXITINIB.
- AVOPARCIN.
- AZACITIDINE.
- AZACYCLONOL.
- AZAPERONE.
- AZAPROPAZONE.
- AZARIBINE.
- AZATADINE except when included in Schedule 3.
- AZATHIOPRINE.
- AZELAIC ACID for therapeutic use except when included in Schedule 2.
- AZELASTINE except when included in Schedule 2.
- AZITHROMYCIN.
- AZLOCILLIN.
- AZTREONAM.
- BACAMPICILLIN.
- BACITRACIN.
- BACLOFEN.
- BALOXAVIR MARBOXIL.
- BALSALAZIDE.
- BAMBERMYCIN (flavophospholipol) except:
- (a) when included in Schedule 6; or
- (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
- BAMBUTEROL.
- BAMETHAN.
- BAMIPINE.
- BARBITURATES except when separately specified in these Schedules.
- BARICITINIB.
- BASILIXIMAB.
- BAZEDOXIFENE.
- BECAPLERMIN.
- BECLAMIDE.
- BECLOMETASONE except when included in Schedule 2.
- BELANTAMAB MAFODOTIN.
- BELATACEPT.
- BELIMUMAB.
- BELUMOSUDIL.
- BELZUTIFAN.
- BEMEGRIDE.
- BEMPEDOIC ACID.
- BENACTYZINE.
- BENAZEPRIL.
- BENDAMUSTINE.
- BENDROFLUAZIDE.
- BENETHAMINE PENICILLIN.
- BENORYLATE.
- BENOXAPROFEN.
- BENPERIDOL.
- BENRALIZUMAB.
- BENSERAZIDE.
- BENZATHINE PENICILLIN.
- BENZILONIUM.
- BENZOCAINE except:
- (a) when included in Schedule 2; or
- (b) in dermal preparations containing 2% or less of total local anaesthetic substances; or
- (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
- # BENZODIAZEPINE derivatives except when separately specified in these Schedules.
- BENZOYL PEROXIDE in preparations for human therapeutic use except:
- (a) when included in Schedule 2; or
- (b) in preparations for external use containing 5% or less of benzoyl peroxide.
- BENZPHETAMINE.
- BENZTHIAZIDE.
- BENZATROPINE.
- BENZYDAMINE except:
- (a) when included in Schedule 2; or
- (b) in preparations for dermal use; or
- (c) in divided topical oral preparations containing 3 mg or less of benzydamine; or
- (d) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.
- BENZYLPENICILLIN.
- BEPRIDIL.
- BERACTANT.
- BESIFLOXACIN.
- BETAHISTINE.
- BETAMETHASONE.
- BETAXOLOL.
- BETHANECHOL CHLORIDE.
- BETHANIDINE.
- BEVACIZUMAB.
- BEVANTOLOL.
- # BEXAROTENE.
- BEZAFIBRATE.
- BEZLOTOXUMAB.
- BIBROCATHOL.
- BICALUTAMIDE.
- BICTEGRAVIR.
- BIFONAZOLE except:
- (a) when included in Schedule 2; or
- (b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or
- (c) in preparations for dermal use for the treatment of tinea pedis.
- BILASTINE except when included in Schedule 2 or 3.
- BIMATOPROST.
- BINIMETINIB.
- BIPERIDEN.
- BISMUTH COMPOUNDS for cosmetic use, except:
- (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5% or less; or
- (b) bismuth oxychloride.
- BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.
- BISOPROLOL.
- BIVALIRUDIN.
- BLEOMYCIN.
- BLINATUMOMAB.
- BOCEPREVIR.
- # BOLANDIOL.
- # BOLASTERONE.
- # BOLAZINE.
- # BOLDENONE (dehydrotestosterone).
- # BOLENOL.
- # BOLMANTALATE.
- BORON, including boric acid and borax, for human therapeutic use except:
- (a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose; or
- (b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or
- (c) when present as an excipient.
- BORTEZOMIB.
- # BOSENTAN.
- BOSUTINIB.
- BOTULINUM TOXINS for human use except when separately specified in these Schedules.
- # BPC-157.
- BRENTUXIMAB VEDOTIN.
- BRETYLIUM TOSILATE.
- BREXPIPRAZOLE.
- BRIGATINIB.
- BRIMONIDINE except when included in Schedule 2.
- BRINZOLAMIDE.
- BRIVARACETAM.
- # BROMAZEPAM.
- BROMIDES, inorganic, for therapeutic use except when separately specified in these Schedules.
- BROMOCRIPTINE.
- BROMOFORM for therapeutic use.
- BROMPHENIRAMINE except when included in Schedule 2 or 3.
- BROMVALETONE.
- BRUGMANSIA spp.
- BUCLIZINE except when included in Schedule 3.
- BUDESONIDE except when included in Schedule 2.
- BUFEXAMAC.
- BULEVIRTIDE.
- BUMETANIDE.
- BUPHENINE.
- BUPIVACAINE except when included in Schedule 5.
- BUPROPION.
- BUSERELIN.
- BUSPIRONE.
- BUSULPHAN.
- BUTACAINE.
- BUTAMBEN except in dermal preparations containing 2% or less of total local anaesthetic substances.
- BUTOCONAZOLE except when included in Schedule 3.
- BUTRACONAZOLE.
- BUTYLCHLORAL HYDRATE.
- BUTYL NITRITE.
- CABAZITAXEL.
- CABERGOLINE.
- CABOTEGRAVIR.
- CABOZANTINIB.
- CADMIUM COMPOUNDS for human therapeutic use.
- CAFFEINE for internal therapeutic use except:
- (a) in divided preparations when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or
- (b) in undivided preparations with a concentration of less than 5% of caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg
- CALCIFEDIOL for human internal therapeutic use except in preparations containing 10 micrograms or less of calcifediol per recommended daily dose.
- CALCIPOTRIOL.
- CALCITONIN.
- CALCITONIN SALMON.
- CALCITRIOL.
- CALCIUM CARBIMIDE for therapeutic use.
- CALCIUM HYDROXYLAPATITE in preparations for injection or implantation:
- (a) for tissue augmentation; or
- (b) for cosmetic use.
- CALCIUM POLYSTYRENE SULPHONATE.
- CALOTROPIS GIGANTEA.
- CALOTROPIS PROCERA.
- # CALUSTERONE.
- CAMPHORATED OIL for therapeutic use.
- CAMPHOTAMIDE.
- CANAGLIFLOZIN.
- CANAKINUMAB.
- CANDESARTAN CILEXETIL.
- CANDICIDIN.
- CANINE TICK ANTI-SERUM.
- CANNABIDIOL in preparations for therapeutic use or analytical and scientific research where:
- (a) cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and
- (b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the pre
- except when:
- (c) included in Schedule 3; or
- (d) in hemp seed oil at a concentration of 75 mg/kg or less.
- CANTHARIDIN.
- CAPECITABINE.
- CAPIVASERTIB.
- CAPMATINIB.
- CAPREOMYCIN.
- # CAPROMORELIN.
- CAPTODIAME.
- CAPTOPRIL.
- CAPURIDE.
- CARAMIPHEN.
- CARBACHOL.
- CARBAMAZEPINE.
- CARBARYL for human therapeutic use.
- CARBAZOCHROME.
- CARBENICILLIN.
- CARBENOXOLONE for internal use.
- CARBETOCIN.
- CARBIDOPA.
- CARBIMAZOLE.
- CARBOCROMEN.
- CARBOPLATIN.
- CARBOPROST.
- CARBROMAL.
- CARBUTAMIDE.
- CARBUTEROL.
- CARFILZOMIB.
- CARGLUMIC ACID (N-carbamoyl-L-glutamic acid).
- CARINDACILLIN.
- CARIPRAZINE.
- CARISOPRODOL.
- CARMUSTINE.
- CARNIDAZOLE.
- CARPROFEN.
- CARVEDILOL.
- CASIRIVIMAB.
- CASPOFUNGIN.
- CATHINE.
- CATUMAXOMAB.
- CEDAZURIDINE.
- CEFACETRILE.
- CEFACLOR.
- CEFADROXIL.
- CEFALEXIN.
- CEFALORIDINE.
- CEFALOTIN.
- CEFAMANDOLE.
- CEFAPIRIN.
- CEFAZOLIN.
- CEFEPIME.
- CEFETAMET.
- CEFIDEROCOL.
- CEFIXIME.
- CEFODIZIME.
- CEFONICID.
- CEFOPERAZONE.
- CEFOTAXIME.
- CEFOTETAN.
- CEFOTIAM.
- CEFOVECIN for veterinary use.
- CEFOXITIN.
- CEFPIROME.
- CEFPODOXIME.
- CEFQUINOME.
- CEFTAROLINE FOSAMIL.
- CEFSULODIN.
- CEFTAZIDIME.
- CEFTIBUTEN.
- CEFTIOFUR.
- CEFTRIAXONE.
- CEFUROXIME.
- CELECOXIB except when included in Schedule 3.
- CELIPROLOL.
- CENEGERMIN.
- CEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2% or less of emetine.
- CEPHAELIS IPECACUANHA except in preparations containing 0.2% or less of emetine.
- CEPHALONIUM.
- CEPHRADINE.
- CERITINIB.
- CERIVASTATIN.
- CERLIPONASE ALFA.
- CERTOLIZUMAB PEGOL.
- CERULETIDE.
- CETIRIZINE except
- (a) when included in Schedule 2; or
- (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:
- (i) in a primary pack containing not more than 10 days’ supply; and
- (ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
- CETRORELIX.
- CETUXIMAB.
- CHENODEOXYCHOLIC ACID.
- CHLORAL FORMAMIDE.
- CHLORAL HYDRATE except in preparations for topical use containing 2% or less of chloral hydrate.
- CHLORALOSE except when included in Schedule 6.
- CHLORAMBUCIL.
- CHLORAMPHENICOL except when included in Schedule 3.
- # CHLORANDROSTENOLONE.
- CHLORAZANIL.
- CHLORCYCLIZINE.
- # CHLORDIAZEPOXIDE.
- CHLORMERODRIN.
- CHLORMETHIAZOLE.
- CHLORMEZANONE.
- CHLOROFORM for use in anaesthesia.
- # 4-CHLOROMETHANDIENONE.
- 2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.
- CHLOROQUINE.
- CHLOROTHIAZIDE.
- CHLOROTRIANISENE.
- # CHLOROXYDIENONE.
- CHLORPHENAMINE except when included in Schedule 2 or 3.
- CHLORPHENTERMINE.
- CHLORPROMAZINE.
- CHLORPROPAMIDE.
- CHLORPROTHIXENE.
- CHLORQUINALDOL for human topical use.
- CHLORTALIDONE.
- CHLORTETRACYCLINE except when included in Schedule 5.
- CHLORZOXAZONE.
- CHOLERA VACCINE.
- CHOLIC ACID.
- CHYMOPAPAIN for human therapeutic use.
- CICLACILLIN.
- CICLESONIDE.
- CICLOPIROX except:
- (a) when included in Schedule 2 or 3; or
- (b) in preparations for the treatment of tinea pedis.
- CICLOSPORIN.
- CIDOFOVIR.
- CILASTATIN.
- CILAZAPRIL.
- CILGAVIMAB.
- CILOSTAZOL.
- CIMETIDINE except when included in Schedule 3.
- CIMICOXIB.
- CINACALCET.
- CINCHOCAINE except when included in Schedule 2.
- CINNARIZINE.
- CINOXACIN.
- CIPAGLUCOSIDASE ALFA.
- CIPROFLOXACIN.
- CISAPRIDE.
- CISATRACURIUM BESILATE.
- CISPLATIN.
- CITALOPRAM.
- # CJC-1295 (CAS No. 863288-34-0).
- CLADRIBINE.
- CLANOBUTIN.
- CLARITHROMYCIN.
- CLASCOTERONE.
- CLAVULANIC ACID.
- CLEMASTINE except when included in Schedule 3.
- CLEMIZOLE.
- CLENBUTEROL.
- CLEVIDIPINE.
- CLIDINIUM BROMIDE.
- CLINDAMYCIN.
- CLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use except when separately specified in this Schedule.
- CLOBAZAM.
- CLOBETASOL.
- CLOBETASONE (clobetasone-17-butyrate) except when included in Schedule 3.
- CLOCORTOLONE.
- CLODRONIC ACID (includes sodium clodronate).
- CLOFARABINE.
- CLOFAZIMINE.
- CLOFENAMIDE.
- CLOFIBRATE.
- # CLOMIFENE.
- CLOMIPRAMINE.
- CLOMOCYCLINE.
- # CLONAZEPAM.
- CLONIDINE.
- CLOPAMIDE.
- CLOPIDOGREL.
- CLOPROSTENOL.
- # CLORAZEPATE.
- CLOREXOLONE.
- CLORPRENALINE.
- # CLOSTEBOL (4-chlorotestosterone).
- CLOTRIMAZOLE except:
- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.
- CLOXACILLIN.
- # CLOZAPINE.
- COBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.
- COBICISTAT.
- COBIMETINIB.
- CODEINE when compounded with one or more other therapeutically active substances:
- (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
- (b) in undivided preparations containing 1% or less of codeine.
- CO-DERGOCRINE.
- COLCHICINE.
- COLCHICUM AUTUMNALE.
- COLESTIPOL.
- COLESTYRAMINE for human therapeutic use.
- COLFOSCERIL PALMITATE for human therapeutic use.
- COLISTIN.
- COLLAGEN in preparations for injection or implantation:
- (a) for tissue augmentation; or
- (b) for cosmetic use.
- COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.
- COLURACETAM.
- CONCIZUMAB.
- CONVALLARIA KEISKI.
- CONVALLARIA MAJALIS.
- COPPER COMPOUNDS for human use except:
- (a) when separately specified in these Schedules; or
- (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or
- (c) in other preparations containing 5% or less of copper compounds.
- # CORIFOLLITROPIN ALFA.
- CORONILLA spp.
- CORTICOSTERONE.
- CORTICOTROPHIN.
- CORTISONE.
- CO-TRIMOXAZOLE.
- COUMARIN for therapeutic use (excluding when present as an excipient).
- CRISABOROLE.
- CRIZOTINIB.
- CROFELEMER.
- CUPRIMYXIN.
- CURARE.
- CYCLANDELATE.
- CYCLIZINE except when included in Schedule 3.
- CYCLOBENZAPRINE.
- # CYCLOFENIL.
- CYCLOHEXIMIDE.
- CYCLOPENTHIAZIDE.
- CYCLOPENTOLATE.
- CYCLOPHOSPHAMIDE.
- CYCLOPROPANE for therapeutic use.
- CYCLOSERINE.
- CYCLOTHIAZIDE.
- CYCRIMINE.
- CYMARIN.
- CYPROHEPTADINE except when included in Schedule 3.
- CYPROTERONE.
- CYTARABINE.
- CYTISINE except when included in Schedule 3.
- DABRAFENIB MESILATE.
- DABIGATRAN.
- DACARBAZINE.
- DACLATASVIR.
- DACLIZUMAB.
- DACTINOMYCIN.
- DALFOPRISTIN.
- DALTEPARIN (includes dalteparin sodium).
- DANAPAROID (includes danaparoid sodium).
- # DANAZOL.
- DANICOPAN.
- DANTHRON for human use.
- DANTROLENE.
- DAPAGLIFLOZIN.
- DAPOXETINE.
- DAPSONE.
- DAPTOMYCIN.
- DARATUMUMAB.
- # DARBEPOETIN.
- DARIFENACIN.
- DAROLUTAMIDE.
- DARUNAVIR.
- DATOPOTAMAB DERUXTECAN.
- DATURA spp. except:
- (a) when included in Schedule 2; or
- (b) when separately specified in this Schedule.
- DASABUVIR.
- DASATINIB.
- DATURA STRAMONIUM (stramonium) except:
- (a) when included in Schedule 2; or
- (b) for smoking or burning.
- DATURA TATULA (stramonium) except:
- (a) when included in Schedule 2; or
- (b) for smoking or burning.
- DAUNORUBICIN.
- DEANOL for therapeutic use.
- DEBRISOQUINE.
- DECAMETHONIUM.
- DECITABINE.
- DEFERASIROX.
- DEFERIPRONE.
- DEFIBROTIDE.
- DEFLAZACORT.
- DEGARELIX.
- # DEHYDROCHLOROMETHYLTESTOSTERONE.
- DEHYDROCORTICOSTERONE.
- DELAVIRDINE MESILATE.
- DELGOCITINIB.
- DEMBREXINE except when included in Schedule 5.
- DEMECARIUM.
- DEMECLOCYCLINE.
- DENGUE VACCINE.
- DENOSUMAB.
- DEOXYCHOLIC ACID.
- DEOXYCORTONE.
- DEOXYRIBONUCLEASE except:
- (a) when separately specified in this Schedule; or
- (b) for external use.
- DEPEMOKIMAB.
- DERACOXIB.
- DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT.
- DESFERRIOXAMINE.
- DESFLURANE.
- DESIPRAMINE.
- DESIRUDIN.
- DESLANOSIDE.
- DESLORATADINE except:
- (a) when included in Schedule 2; or
- (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:
- (i) in a primary pack containing 10 dosage units or less; and
- (ii) labelled with a recommended daily dose not exceeding 5 mg of desloratadine.
- DESLORELIN.
- DESMOPRESSIN (D.D.A.V.P.).
- DESOGESTREL.
- DESONIDE.
- DESOXYMETHASONE.
- DESVENLAFAXINE.
- DETOMIDINE.
- DEUCRAVACITINIB.
- DEUTETRABENAZINE.
- DEUTIVACAFTOR.
- DEXAMETHASONE.
- DEXCHLORPHENAMINE except when included in Schedule 2 or 3.
- DEXFENFLURAMINE.
- DEXMEDETOMIDINE.
- DEXRAZOXANE.
- DEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.
- # DEXTROPROPOXYPHENE:
- (a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or
- (b) liquid preparations containing 2.5% or less of dextropropoxyphene.
- DEXTRORPHAN (excluding its stereoisomers).
- DIAMTHAZOLE.
- DIAVERIDINE.
- # DIAZEPAM.
- DIAZOXIDE.
- DIBENZEPIN.
- DIBOTERMIN.
- DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.
- DICHLORALPHENAZONE.
- DICHLOROPHEN for human therapeutic use.
- DICHLORPHENAMIDE.
- DICLOFENAC except:
- (a) when included in Schedule 2 or 3; or
- (b) in preparations for dermal use unless:
- (i) for the treatment of solar keratosis; or
- (ii) containing more than 4% of diclofenac.
- DICLOXACILLIN.
- DICYCLOMINE.
- DIDANOSINE.
- DIENESTROL.
- DIENOGEST.
- DIETHAZINE.
- DIETHYLCARBAMAZINE for human therapeutic use.
- DIETHYLPROPION.
- DIFELIKEFALIN.
- DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of d
- DIFLORASONE.
- DIFLOXACIN.
- DIFLUCORTOLONE.
- DIFLUNISAL.
- DIGITALIS LANATA.
- DIGITALIS PURPUREA.
- DIGITOXIN.
- DIGOXIN.
- DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).
- DIHYDRALAZINE.
- DIHYDROCODEINE when compounded with one or more other therapeutically active substances:
- (a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine;
- except when included in Schedule 3.
- DIHYDROERGOTOXINE.
- # DIHYDROLONE.
- DIHYDROSTREPTOMYCIN.
- DIHYDROTACHYSTEROL.
- DIIODOHYDROXYQUINOLINE (iodoquinol) except:
- (a) when included in Schedule 3; or
- (b) for human internal use.
- DIISOPROPYLAMINE DICHLOROACETATE.
- DILTIAZEM.
- DIMENHYDRINATE except when included in Schedule 2 or 3.
- DIMERCAPROL.
- # DIMETHANDROSTANOLONE.
- # DIMETHAZINE.
- DIMETHINDENE except when included in Schedule 3.
- DIMETHOTHIAZINE.
- DIMETHOXANATE.
- DIMETHYL FUMARATE.
- DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except:
- (a) when included in Schedule 6; or
- (b) in in vitro test kits; or
- (c) when used as a flavour component in compliance with the current Therapeutic Goods (Permissible Ingredients) determination for listed medicines.
- DIMETRIDAZOLE.
- DIMIRACETAM.
- 2,4-DINITROCHLOROBENZENE for therapeutic use.
- DINITROCRESOLS for therapeutic use except when separately specified in these Schedules.
- DINITRONAPHTHOLS for therapeutic use except when separately specified in these Schedules.
- DINITROPHENOLS for therapeutic use.
- DINITROTHYMOLS for therapeutic use except when separately specified in these Schedules.
- # DINOPROST.
- # DINOPROSTONE.
- DIPERODON.
- DIPHEMANIL except in preparations for dermal use.
- DIPHENHYDRAMINE except when included in Schedule 2 or 3.
- DIPHENIDOL.
- DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the d
- DIPHENYLPYRALINE.
- DIPHTHERIA TOXOID.
- DIPIVEFRIN.
- DIPYRIDAMOLE.
- DIRITHROMYCIN.
- DIRLOTAPIDE.
- DIROXIMEL FUMARATE.
- DISOPHENOL.
- DISOPYRAMIDE.
- DISTIGMINE.
- DISULFIRAM for therapeutic use.
- DISULPHAMIDE.
- DITHIAZANINE except when included in Schedule 6.
- DITIOCARB.
- DOBUTAMINE.
- DOCETAXEL.
- DOFETILIDE.
- DOLASETRON.
- DOLUTEGRAVIR.
- DOMPERIDONE.
- DONEPEZIL.
- DOPAMINE.
- DOPEXAMINE.
- DORAVIRINE.
- DORIPENEM.
- DORNASE.
- DORZOLAMIDE.
- DOSULEPIN.
- DOXANTRAZOLE.
- DOXAPRAM.
- DOXAZOSIN.
- DOXEPIN.
- DOXORUBICIN.
- DOXYCYCLINE.
- DOXYLAMINE except when included in Schedule 2 or 3.
- DRONEDARONE.
- DROPERIDOL.
- DROSPIRENONE.
- # DROSTANOLONE.
- DROTRECOGIN.
- DUBOISIA LEICHHARDTII except when included in Schedule 2.
- DUBOISIA MYOPOROIDES except when included in Schedule 2.
- DULAGLUTIDE.
- DULOXETINE.
- DUPILUMAB.
- DURVALUMAB.
- DUTASTERIDE.
- DYDROGESTERONE.
- ECONAZOLE except:
- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.
- ECOTHIOPATE (includes ecothiopate iodide).
- ECTYLUREA.
- ECULIZUMAB.
- EDARAVONE.
- EDETIC ACID for human therapeutic use except:
- (a) in preparations containing 0.25% or less of edetic acid; or
- (b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or
- (c) in contact lens preparations.
- EDOXUDINE.
- EDROPHONIUM.
- EFALIZUMAB.
- EFANESOCTOCOG ALFA.
- EFAVIRENZ.
- EFGARTIGIMOD ALFA.
- EFLORNITHINE.
- ELACESTRANT DIHYDROCHLORIDE.
- ELAFIBRANOR.
- ELBASVIR.
- ELETRIPTAN except when included in Schedule 3.
- ELEXACAFTOR.
- ELINZANETANT.
- ELOSULFASE ALFA.
- ELOTUZUMAB.
- ELRANATAMAB.
- ELTENAC.
- ELTROMBOPAG.
- ELUXADOLINE.
- ELVITEGRAVIR.
- EMEPRONIUM.
- EMETINE except in preparations containing 0.2% or less of emetine.
- EMPAGLIFLOZIN.
- EMTRICITABINE.
- ENALAPRIL.
- ENASIDENIB.
- ENCORAFENIB.
- # ENESTEBOL.
- ENFLICOXIB.
- ENFLURANE for therapeutic use.
- ENFORTUMAB VEDOTIN.
- ENFUVIRTIDE.
- # ENOBOSARM.
- ENOXACIN.
- ENOXAPARIN.
- ENOXIMONE.
- ENPROSTIL.
- ENROFLOXACIN.
- ENTACAPONE.
- ENTECAVIR.
- ENTRECTINIB.
- # ENZALUTAMIDE.
- EPHEDRA spp. except in preparations containing 0.001% or less of ephedrine.
- # EPHEDRINE.
- EPICILLIN.
- EPINASTINE.
- EPIRUBICIN.
- # EPITIOSTANOL.
- EPLERENONE.
- EPLONTERSEN.
- # EPOETINS.
- EPOPROSTENOL.
- EPROSARTAN.
- EPTIFIBATIDE.
- ERENUMAB.
- ERGOMETRINE.
- ERGOT.
- ERGOTAMINE.
- ERGOTOXINE.
- ERIBULIN MESILATE.
- ERLOTINIB.
- ERTAPENEM.
- ERTUGLIFLOZIN.
- ERYSIMUM spp.
- ERYTHROMYCIN.
- # ERYTHROPOIETIN.
- # ERYTHROPOIETINS except when separately specified in these Schedules.
- ESCITALOPRAM.
- ESLICARBAZEPINE ACETATE.
- ESMOLOL.
- ESOMEPRAZOLE except when included in Schedule 2.
- ESTETROL MONOHYDRATE.
- ESTRADIOL except when included in Schedule 5.
- ESTRIOL.
- ESTRAMUSTINE.
- ESTROGENS except when separately specified in these Schedules.
- ESTRONE.
- ESTROPIPATE (piperazine estrone sulfate).
- ETACRYNIC ACID.
- ETANERCEPT.
- ETHAMBUTOL.
- ETHAMIVAN.
- ETHCHLORVYNOL.
- ETHER for use in anaesthesia.
- ETHINAMATE.
- ETHINYLESTRADIOL.
- ETHIONAMIDE.
- # ETHISTERONE.
- ETHOGLUCID.
- ETHOHEPTAZINE.
- ETHOPROPAZINE.
- ETHOSUXIMIDE.
- ETHOTOIN.
- ETHOXZOLAMIDE.
- ETHYL CHLORIDE for human therapeutic use.
- # ETHYLDIENOLONE.
- ETHYLMORPHINE when compounded with one or more other therapeutically active substances:
- (a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine.
- # ETHYLESTRENOL.
- ETIDOCAINE.
- ETIDRONIC ACID (includes etidronate disodium):
- (a) for internal use; or
- (b) in topical preparations except in preparations containing 1% or less of etidronic acid.
- ETILEFRIN.
- ETIPROSTON.
- ETODOLAC.
- ETOFENAMATE except when included in Schedule 2.
- ETOMIDATE.
- ETONOGESTREL.
- ETOPOSIDE.
- ETORICOXIB.
- ETRANACOGENE DEZAPARVOVEC.
- ETRASIMOD.
- ETRAVIRINE.
- # ETRETINATE.
- ETYNODIOL.
- EVEROLIMUS.
- EXEMESTANE.
- EXENATIDE.
- EZETIMIBE.
- FAMCICLOVIR except when included in Schedule 3.
- FAMOTIDINE except when included in Schedule 2.
- FARICIMAB.
- FASORACETAM.
- FEBUXOSTAT.
- FEDRATINIB.
- FELBINAC except when included in Schedule 2.
- FELODIPINE.
- FELYPRESSIN.
- FENBENDAZOLE except when included in Schedule 5.
- FENBUFEN.
- FENCAMFAMIN.
- FENCLOFENAC.
- FENFLURAMINE.
- FENOFIBRATE.
- FENOLDOPAM.
- FENOPROFEN.
- FENOTEROL.
- FENPIPRAMIDE.
- FENPIPRANE.
- FENPROPOREX.
- FENPROSTALENE.
- FERRIC DERISOMALTOSE.
- FEXOFENADINE except:
- (a) when included in Schedule 2; or
- (b) in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
- (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
- (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or
- (c) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
- (i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and
- (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or
- (d) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:
- (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
- (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.
- FEZOLINETANT.
- FIBRINOLYSIN except for external use.
- # FIBROBLAST GROWTH FACTORS.
- FIDAXOMICIN.
- FILGOTINIB.
- FILGRASTIM.
- FINASTERIDE.
- FINERENONE.
- FINGOLIMOD.
- FIROCOXIB.
- FLECAINIDE.
- FLEROXACIN.
- FLOCTAFENINE.
- FLORFENICOL.
- FLUANISONE.
- FLUCLOROLONE.
- FLUCLOXACILLIN.
- FLUCONAZOLE except when included in Schedule 3.
- FLUCYTOSINE.
- FLUDARABINE.
- FLUDROCORTISONE.
- FLUFENAMIC ACID.
- FLUMAZENIL.
- FLUMETASONE.
- FLUMETHIAZIDE.
- FLUNISOLIDE.
- FLUNIXIN MEGLUMINE.
- FLUOCINOLONE.
- FLUOCINONIDE.
- FLUOCORTIN.
- FLUOCORTOLONE.
- FLUORESCEIN in preparations for injection.
- FLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3.
- FLUOROMETHOLONE.
- FLUOROURACIL.
- FLUOXETINE.
- # FLUOXYMESTERONE.
- FLUPENTIXOL.
- FLUPHENAZINE.
- FLUPROSTENOL.
- FLURALANER in injectable preparations for use in companion animals.
- FLURANDRENOLONE.
- # FLURAZEPAM.
- FLURBIPROFEN except when:
- (a) included in Schedule 2; or
- (b) in divided preparations for topical oral use that contain 10 mg or less of flurbiprofen per dosage unit and that are:
- (i) in a primary pack containing not more than 16 dosage units; and
- (ii) labelled only for the treatment of adults and children over 12 years; or
- (c) in undivided preparations for topical oral use containing either:
- (i) 0.25% or less of flurbiprofen per dose; or
- (ii) 10 mg or less of flurbiprofen per dose; and
- that are:
- (iii) in a primary pack containing not more than 15 Ml; and
- (iv) labelled only for the treatment of adults 18 years and over.
- FLUROXENE for human therapeutic use.
- FLUSPIRILENE.
- FLUTAMIDE.
- FLUTICASONE except when included in Schedule 2.
- FLUVASTATIN.
- FLUVOXAMINE.
- FOLIC ACID in preparations for human use for injection.
- FOLINIC ACID in preparations for human use for injection.
- FOLLICLE-STIMULATING HORMONE except when separately specified in this Schedule.
- # FOLLISTATIN.
- # FOLLITROPIN ALFA.
- # FOLLITROPIN BETA.
- # FOLLITROPIN DELTA.
- FOMEPIZOLE.
- FOMIVIRSEN.
- FONDAPARINUX.
- # FORMEBOLONE.
- FORMESTANE.
- FORMOTEROL
- FOSAMPRENAVIR.
- FOSAPREPITANT.
- FOSCARNET.
- FOSFESTROL (diethylstilbestrol diphosphate).
- FOSFOMYCIN.
- FOSINOPRIL.
- FOSNETUPITANT.
- FOSPHENYTOIN.
- FOSTEMSAVIR.
- FOTEMUSTINE.
- FRAMYCETIN.
- FRUQUINTINIB.
- FULVESTRANT.
- FURALTADONE.
- # FURAZABOL.
- FURAZOLIDONE.
- FUROSEMIDE (frusemide).
- FUSIDIC ACID.
- FUTIBATINIB.
- FUZAPLADIB SODIUM.
- GABAPENTIN.
- GADOQUATRANE.
- GALANTAMINE.
- GALANTHUS spp.
- GALCANEZUMAB.
- GALLAMINE.
- GALSULFASE.
- GANCICLOVIR.
- GANIRELIX.
- GARADACIMAB.
- GATIFLOXACIN.
- GRAZOPREVIR.
- GEFITINIB.
- GEMCITABINE.
- GEMEPROST.
- GEMFIBROZIL.
- GEMIFLOXACIN.
- GEMTUZUMAB OZOGAMICIN.
- GENTAMICIN.
- GEPOTIDACIN.
- GESTODENE.
- GESTONORONE.
- # GESTRINONE.
- GHRH INJECTABLE PLASMID.
- GILTERITINIB.
- GITALIN.
- GIVOSIRAN.
- GLATIRAMER ACETATE.
- GLECAPREVIR.
- GLIBENCLAMIDE.
- GLIBORNURIDE.
- GLICLAZIDE.
- GLIMEPIRIDE.
- GLIPIZIDE.
- GLIPTINS except when separately specified in these Schedules.
- GLISOXEPIDE.
- GLOFITAMAB.
- GLUTATHIONE for parenteral use.
- # GLUTETHIMIDE.
- GLYCERYL TRINITRATE except when included in Schedule 3.
- GLYCOPYRRONIUM.
- GLYMIDINE.
- GnRH VACCINE.
- GOLIMUMAB.
- GONADORELIN.
- GONADOTROPHIC HORMONES except when separately specified in this Schedule.
- GOSERELIN.
- GRAMICIDIN.
- GRANISETRON.
- GRAPIPRANT.
- GREPAFLOXACIN.
- GRISEOFULVIN.
- # GROWTH HORMONE RELEASING HORMONES* (GHRHs).
- # GROWTH HORMONE RELEASING PEPTIDES (GHRPs).
- # GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6).
- # GROWTH HORMONE SECRETAGOGUES* (GHSs).
- GUAIFENESIN for human therapeutic use except:
- (a) when included in Schedule 2; or
- (b) in oral liquid preparations containing 2% or less of guaifenesin; or
- (c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit.
- GUANABENZ.
- GUANACLINE.
- GUANETHIDINE.
- GUANFACINE.
- GUANIDINE for therapeutic use.
- GUSELKUMAB.
- HACHIMYCIN.
- HAEMATIN.
- HAEMOPHILUS INFLUENZAE VACCINE.
- HALCINONIDE.
- HALOFANTRINE.
- HALOFENATE.
- HALOFUGINONE in preparations containing 0.1% or less of halofuginone for the treatment of animals.
- HALOPERIDOL.
- HALOTHANE for therapeutic use.
- HEMEROCALLIS (Hemerocallis flava).
- HEPARINS for internal use except when separately specified in this Schedule.
- HEPATITIS A VACCINE.
- HEPATITIS B VACCINE.
- HETACILLIN.
- HEXACHLOROPHENE:
- (a) in preparations for use on infants; or
- (b) in other preparations except:
- (i) when included in Schedule 2 or 6; or
- (ii) in preparations containing 0.75% or less of hexachlorophene.
- HEXAMETHONIUM.
- # HEXARELIN.
- HEXETIDINE for human internal use.
- HEXOBENDINE.
- HEXOCYCLIUM.
- HEXOPRENALINE.
- HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE).
- HISTAMINE for therapeutic use except in preparations containing 0.5% or less of histamine.
- HMG-CoA REDUCTASE INHIBITORS (including "statins") except when separately specified in these Schedules.
- HOMATROPINE.
- HUMAN CHORIONIC GONADOTROPHIN except in pregnancy test kits.
- HUMAN PAPILLOMAVIRUS VACCINE.
- HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation.
- HYDRALAZINE.
- HYDRARGAPHEN.
- HYDROCHLOROTHIAZIDE.
- HYDROCORTISONE:
- (a) for human use except when included in Schedule 2 or 3; or
- (b) for the treatment of animals.
- HYDROCYANIC ACID for therapeutic use except in preparations containing 10 mg/kg or less of hydrocyanic acid.
- HYDROFLUMETHIAZIDE.
- HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use except:
- (a) when included in Schedule 2; or
- (b) in hair preparations containing 0.3% or less of hydroquinone; or
- (c) in cosmetic nail preparations containing 0.02% or less of hydroquinone.
- HYDROXYCARBAMIDE.
- HYDROXYCHLOROQUINE.
- HYDROXYEPHEDRINE.
- HYDROXYPHENAMATE.
- HYDROXYPROGESTERONE.
- # HYDROXYSTENOZOL.
- HYDROXYZINE.
- HYGROMYCIN.
- HYOSCINE except when included in Schedule 2.
- HYOSCYAMINE except when included in Schedule 2.
- HYOSCINE BUTYLBROMIDE except when included in Schedule 2 or Schedule 3.
- HYOSCYAMUS NIGER except:
- (a) when included in Schedule 2; or
- (b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.
- HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.
- HYPROMELLOSE in preparations for injection.
- IBAFLOXACIN for veterinary use.
- IBANDRONIC ACID.
- IBOGAINE.
- IBRITUMOMAB.
- IBRUTINIB.
- IBUFENAC.
- IBUPROFEN except when:
- (a) included in Schedule 2 or 3; or
- (b) in preparations for dermal use; or
- (c) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg
- (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and
- (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and
- (iii) in a primary pack containing not more than 25 dosage units; and
- (iv) compliant with the requirements of the required advisory statements for medicine labels; and
- (v) not labelled for the treatment of children 6 years and under; and
- (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.
- # IBUTAMOREN.
- IBUTEROL.
- IBUTILIDE.
- ICATIBANT.
- IDARUBICIN.
- IDARUCIZUMAB.
- IDEBENONE.
- IDOXURIDINE except in preparations containing 0.5% or less of idoxuridine for dermal use.
- IDURSULFASE.
- IFOSFAMIDE.
- ILOPROST.
- ILUNOCITINIB.
- IMATINIB.
- IMDEVIMAB.
- IMEPITOIN.
- IMIDAPRIL.
- IMIGLUCERASE.
- IMIPENEM.
- IMIPRAMINE.
- IMIQUIMOD.
- IMLIFIDASE.
- IMLUNESTRANT.
- IMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.
- INAVOLISIB.
- INCLISIRAN.
- INDACATEROL.
- INDAPAMIDE.
- INDINAVIR.
- INDOMETACIN except when included in Schedule 2.
- INDOPROFEN.
- INDORAMIN.
- INEBILIZUMAB.
- INFIGRATINIB.
- INFLIXIMAB.
- INFLUENZA AND CORYZA VACCINES:
- (a) for parenteral use; or
- (b) for nasal administration.
- INGENOL MEBUTATE.
- INOTUZUMAB OZOGAMICIN.
- INSULIN DEGLUDEC.
- INSULIN GLARGINE.
- # INSULIN-LIKE GROWTH FACTOR I.
- # INSULIN-LIKE GROWTH FACTORS except when separately specified in this Schedule.
- INSULINS.
- INTERFERONS.
- INTERLEUKINS except when separately specified in these Schedules.
- IODOTHIOURACIL.
- # IPAMORELIN.
- IPILIMUMAB.
- IPRATROPIUM except when included in Schedule 2.
- IPRIFLAVONE.
- IPRINDOLE.
- IPRONIAZID.
- IPTACOPAN.
- IRBESARTAN.
- IRINOTECAN.
- IRON COMPOUNDS in injectable preparations for human use.
- ISAVUCONAZOLE.
- ISOAMINILE.
- ISOAMYL NITRITE.
- ISOBUTYL NITRITE.
- ISOCARBOXAZID.
- ISOCONAZOLE except when included in Schedule 2, 3 or 6.
- ISOETARINE.
- ISOFLURANE for therapeutic use.
- ISOMETHEPTENE.
- ISONIAZID.
- ISOPRENALINE.
- ISOPRINOSINE.
- ISOPROPAMIDE except when included in Schedule 2.
- ISOSORBIDE DINITRATE except when included in Schedule 3.
- ISOSORBIDE MONONITRATE.
- # ISOTRETINOIN.
- ISOXICAM.
- ISOXSUPRINE.
- ISRADIPINE.
- ITRACONAZOLE.
- IVABRADINE.
- IVACAFTOR.
- IVERMECTIN:
- (a) for human use; or
- (b) for the treatment of mange in dogs.
- IVOSIDENIB.
- IXABEPILONE.
- IXAZOMIB.
- IXEKIZUMAB.
- JAPANESE ENCEPHALITIS VACCINE.
- KANAMYCIN.
- KETANSERIN except in topical veterinary preparations containing 0.5% or less of ketanserin.
- # KETAZOLAM.
- KETOCONAZOLE except:
- (a) when included in Schedule 2; or
- (b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or
- (c) in preparations for dermal use for the treatment of tinea pedis.
- KETOPROFEN except:
- (a) in preparations for dermal use; or
- (b) when included in Schedule 3.
- KETOROLAC (includes ketorolac trometamol).
- KETOTIFEN except when included in Schedule 2.
- KHELLIN.
- KITASAMYCIN except:
- (a) when included in Schedule 5; or
- (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.
- LABETALOL.
- LACIDIPINE.
- LACOSAMIDE.
- LAMIVUDINE.
- LAMOTRIGINE.
- LANADELUMAB.
- LANATOSIDES.
- LANDIOLOL.
- LANREOTIDE.
- LANSOPRAZOLE except when included in Schedule 2 or 3.
- LANTHANUM for therapeutic use.
- LAPATINIB.
- LARONIDASE.
- LAROPIPRANT.
- LAROTRECTINIB.
- LATAMOXEF.
- LATANOPROST.
- LAUDEXIUM.
- LAUROMACROGOLS in preparations for injection except:
- (a) when present as an excipient; or
- (b) when separately specified in these Schedules.
- LAZERTINIB.
- LEBRIKIZUMAB.
- LECANEMAB.
- LEDIPASVIR.
- LEFETAMINE.
- LEFLUNOMIDE.
- LEMBOREXANT.
- LENACAPAVIR.
- # LENALIDOMIDE.
- LENIOLISIB.
- LENOGRASTIM.
- LENVATINIB.
- LEPIRUDIN.
- LEPTAZOL.
- LERCANIDIPINE.
- LESINURAD.
- LETERMOVIR.
- LETROZOLE.
- LEUPRORELIN.
- LEVALLORPHAN.
- LEVAMISOLE:
- (a) for human therapeutic use; or
- (b) in preparations for the prevention or treatment of heartworm in dogs.
- LEVETIRACETAM.
- LEVOBUNOLOL.
- LEVOBUPIVACAINE.
- LEVOCABASTINE except when included in Schedule 2.
- LEVOCETIRIZINE except:
- (a) when included in Schedule 2; or
- (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
- (i) in a primary pack containing not more than 5 days’ supply; and
- (ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
- LEVODOPA.
- LEVOMEPROMAZINE.
- LEVOMILNACIPRAN.
- LEVONORGESTREL except when included in Schedule 3.
- LEVOSIMENDAN.
- LIDOCAINE except:
- (a) when included in Schedules 2 or 5; or
- (b) in dermal preparations containing 2% or less of total local anaesthetic substances per dosage unit; or
- (c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.
- LIDOFLAZINE.
- LIFITEGRAST.
- LINACLOTIDE.
- LINAGLIPTIN.
- LINCOMYCIN.
- LINDANE for human therapeutic use except when included in Schedule 2.
- LINEZOLID.
- LIOTHYRONINE.
- LIPEGFILGRASTIM.
- LIRAGLUTIDE.
- LISINOPRIL.
- LISURIDE.
- LITHIUM for therapeutic use except:
- (a) when included in Schedule 2; or
- (b) when present as an excipient in preparations for dermal use containing 0.25% or less of lithium; or
- (c) in preparations containing 0.01% or less of lithium.
- LIXISENATIDE.
- LODOXAMIDE except when included in Schedule 2.
- LOFEXIDINE.
- LOGIPARIN for internal use.
- LOMEFLOXACIN.
- LOMUSTINE.
- # LONAPEGSOMATROPIN.
- LONCASTUXIMAB TESIRINE.
- LOPERAMIDE except:
- (a) when included in Schedule 2; or
- (b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.
- LOPINAVIR.
- # LOPRAZOLAM.
- LORACARBEF.
- LORATADINE except:
- (a) when included in Schedule 2; or
- (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:
- (i) in a primary pack containing 10 dosage units or less; and
- (ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
- # LORAZEPAM.
- LORLATINIB.
- # LORMETAZEPAM.
- LOSARTAN.
- LOTEPREDNOL.
- LOXAPINE.
- LUMACAFTOR.
- LUMASIRAN.
- LUMEFANTRINE.
- LUMIRACOXIB.
- LURASIDONE.
- LURBINECTEDIN.
- LUSPATERCEPT.
- # LUTEINISING HORMONE except in ovulation test kits.
- LYMECYCLINE.
- # MACITENTAN for human use.
- MAFENIDE except when included in Schedule 6.
- MANDRAGORA OFFICINARUM.
- MANNOMUSTINE.
- MAPROTILINE.
- MARAVIROC.
- MARBOFLOXACIN.
- MARIBAVIR.
- MAROPITANT.
- MARSTACIMAB.
- MAVACAMTEN.
- MAVACOXIB.
- MAZINDOL.
- MEASLES VACCINE.
- MEBANAZINE.
- MEBEVERINE.
- MEBHYDROLIN.
- # MEBOLAZINE.
- MEBUTAMATE.
- MECAMYLAMINE.
- MECASERMIN.
- MECILLINAM.
- MECLOCYCLINE.
- MECLOFENAMATE.
- MECLOFENOXATE.
- MECLOZINE except when included in Schedule 2.
- # MEDAZEPAM.
- MEDETOMIDINE.
- MEDIGOXIN (methyldigoxin).
- MEDROXYPROGESTERONE.
- MEDRYSONE.
- MEFENAMIC ACID except when included in Schedule 2.
- MEFENOREX.
- MEFLOQUINE.
- MEFRUSIDE.
- MEGESTROL.
- MELAGATRAN.
- MELANOTAN II.
- MELATONIN for human use except when included in Schedule 3.
- MELENGESTROL except when included in Schedule 6.
- MELOXICAM except when included in Schedule 6.
- MELPHALAN.
- MEMANTINE.
- MENINGOCOCCAL VACCINE.
- MENINGOCOCCAL GROUP B VACCINE.
- MENOTROPHIN.
- MEPACRINE.
- MEPENZOLATE.
- MEPHENESIN.
- MEPHENTERMINE.
- MEPINDOLOL.
- # MEPITIOSTANE.
- MEPIVACAINE.
- MEPROBAMATE.
- MEPTAZINOL.
- MEPYRAMINE except when included in Schedule 2 or 3.
- MEQUITAZINE.
- MERCAPTAMINE for human therapeutic use.
- MERCAPTOMERIN.
- MERCAPTOPURINE.
- MERCUROCHROME except when included in Schedule 2 or 6.
- MERCURY for cosmetic or therapeutic use except:
- (a) when separately specified in these Schedules; or
- (b) in a sealed device which prevents access to the mercury.
- MEROPENEM.
- MERSALYL.
- # MESABOLONE.
- MESALAZINE.
- MESNA.
- # MESTANOLONE (androstalone).
- # MESTEROLONE.
- MESTRANOL.
- # METANDIENONE.
- METARAMINOL.
- # METENOLONE.
- METERGOLINE.
- METFORMIN.
- METHACHOLINE.
- METHACYCLINE.
- METHALLENESTRIL.
- # METHANDRIOL.
- METHANTHELINIUM.
- METHAZOLAMIDE.
- METHDILAZINE except when included in Schedule 3.
- # METHENOLONE.
- METHICILLIN.
- METHIMAZOLE.
- METHISAZONE.
- METHIXENE.
- METHOCARBAMOL.
- METHOHEXITONE.
- METHOIN.
- METHOTREXATE.
- METHOXAMINE except:
- (a) when included in Schedule 2; or
- (b) in preparations for external use containing 1% or less of methoxamine.
- METHOXSALEN.
- METHOXYFLURANE.
- METHSUXIMIDE.
- METHYCLOTHIAZIDE.
- METHYL AMINOLEVULINATE.
- #METHYLANDROSTANOLONE.
- # METHYLCLOSTEBOL.
- METHYLDOPA.
- METHYLENE BLUE in preparations for injection.
- METHYLERGOMETRINE.
- METHYLMERCURY for therapeutic use.
- METHYLNALTREXONE.
- METHYLPENTYNOL.
- METHYLPHENOBARBITAL.
- METHYLPHENYLPIRACETAM.
- METHYLPREDNISOLONE.
- METHYLROSANILINIUM CHLORIDE for human use except when used as a dermal marker.
- METHYL SALICYLATE in preparations for internal therapeutic use.
- # METHYLTESTOSTERONE.
- METHYLTHIOURACIL.
- # METHYLTRIENOLONE.
- METHYPRYLONE.
- METHYSERGIDE.
- METOCLOPRAMIDE except when included in Schedule 3.
- METOLAZONE.
- METOPROLOL.
- # METRIBOLONE.
- METRIFONATE (trichlorfon) for human therapeutic use.
- METRONIDAZOLE.
- METYRAPONE.
- MEXILETINE.
- MEZLOCILLIN.
- MIANSERIN.
- MIBEFRADIL.
- # MIBOLERONE.
- MICAFUNGIN.
- MICONAZOLE except:
- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.
- # MIDAZOLAM.
- MIDOSTAURIN.
- MIDODRINE.
- MIFEPRISTONE.
- MIGALASTAT.
- MIGLITOL.
- MIGLUSTAT.
- MILBEMYCIN OXIME except when included in Schedule 5.
- MILNACIPRAN.
- MILRINONE.
- MINOCYCLINE.
- MINOXIDIL except when included in Schedule 2.
- MIRABEGRON.
- MIRIKIZUMAB.
- MIRTAZAPINE.
- MIRVETUXIMAB SORAVTANSINE.
- MISOPROSTOL.
- MITOBRONITOL.
- MITOMYCIN.
- MITOTANE.
- MITOXANTRONE.
- MITRATAPIDE.
- MIVACURIUM CHLORIDE.
- MOBOCERTINIB.
- MOCLOBEMIDE.
- MODAFINIL.
- MOLGRAMOSTIM.
- # MOLIDUSTAT.
- MOLINDONE.
- MOLNUPIRAVIR.
- MOMELOTINIB.
- MOMETASONE except when included in Schedule 2 or Schedule 3.
- MONENSIN except:
- (a) when included in Schedule 5 or 6; or
- (b) in animal feeds containing 360 mg/kg or less of antibiotic substances.
- MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use except in cosmetic nail preparations containing 0.02% or less of monobenz
- MONOCLONAL ANTIBODIES for therapeutic use except:
- (a) in diagnostic test kits; or
- (b) when separately specified in these Schedules.
- MONOETHANOLAMINE in preparations for injection.
- MONTELUKAST.
- MOPERONE.
- MORAZONE.
- MORICIZINE.
- MOTRAZEPAM.
- MOTRETINIDE.
- MOXIDECTIN in preparations for injection containing 10% or less of moxidectin except when included in Schedule 5 or 6.
- MOXIFLOXACIN.
- MOXONIDINE.
- MUMPS VACCINE.
- MUPIROCIN.
- MURAGLITAZAR.
- MUROMONAB.
- MUSTINE (nitrogen mustard).
- MYCOPHENOLIC ACID (includes mycophenolate mofetil).
- NABUMETONE.
- NADOLOL.
- NADROPARIN.
- NAFARELIN.
- NAFTIDROFURYL.
- NALBUPHINE.
- NALIDIXIC ACID.
- NALMEFENE.
- NALORPHINE.
- NALOXEGOL.
- NALOXONE except when in Schedule 3.
- NALTREXONE.
- # NANDROLONE.
- NAPROXEN except when included in Schedule 2 or 3.
- NARASIN except:
- (a) when included in Schedule 6; or
- (b) in animal feeds containing 100 mg/kg or less of antibiotic substances.
- NARATRIPTAN except when included in Schedule 3.
- NATALIZUMAB.
- NATAMYCIN except for use as a food additive.
- NATEGLINIDE.
- NEBACUMAB.
- NEBIVOLOL.
- NEBRACETAM.
- NEDOCROMIL.
- NEFAZODONE.
- NEFIRACETAM.
- NEFOPAM.
- NELARABINE.
- NELFINAVIR (includes nelfinavir mesilate).
- NEOMYCIN.
- NEOSTIGMINE.
- NEPAFENAC.
- NERATINIB.
- NERIUM OLEANDER.
- NESIRITIDE.
- NETILMICIN.
- NETUPITANT.
- NEVIRAPINE.
- NIALAMIDE.
- NICARDIPINE.
- NICERGOLINE.
- NICOFURANOSE.
- NICORANDIL.
- # NICOTINE in preparations for human use except:
- (a) when included in Schedule 3; or
- (b) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tob
- (c) in tobacco prepared and packed for smoking.
- NICOTINIC ACID in preparations for:
- (a) human therapeutic use except:
- (i) when separately specified in these Schedules; or
- (ii) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
- (iii) nicotinamide; or
- (b) animal therapeutic use when packed and labelled for injection.
- NICOUMALONE.
- NIFEDIPINE.
- NIFENAZONE.
- NIKETHAMIDE.
- NILOTINIB.
- NILUTAMIDE.
- NIMESULIDE.
- NIMODIPINE.
- NIMORAZOLE.
- NINTEDANIB.
- NIRAPARIB.
- NIRIDAZOLE.
- NIRMATRELVIR.
- NIRSEVIMAB.
- NISOLDIPINE.
- NITISINONE.
- # NITRAZEPAM.
- NITRENDIPINE.
- NITRIC OXIDE for human therapeutic use.
- NITROFURANTOIN.
- NITROFURAZONE.
- NITROUS OXIDE for therapeutic use.
- NITROXOLINE.
- NIVOLUMAB.
- NIZATIDINE except when included in Schedule 2.
- NOMEGESTROL.
- NOMIFENSINE.
- NORADRENALINE.
- # 19-NORANDROSTENEDIOL.
- # 19-NORANDROSTENEDIONE.
- # NORANDROSTENOLONE.
- # NORBOLETHONE.
- # NORCLOSTEBOL.
- NORELGESTROMIN.
- # NORETHANDROLONE.
- NORETHISTERONE.
- NORFLOXACIN.
- NORGESTREL.
- NORIBOGAINE.
- NORMAL HUMAN IMMUNOGLOBULIN.
- # NORMETHANDRONE.
- NORTRIPTYLINE.
- NOVOBIOCIN.
- NOXIPTYLINE.
- NUSINERSEN.
- NYSTATIN except when included in Schedule 2 or 3.
- OBETICHOLIC ACID.
- OCLACITINIB.
- OCRELIZUMAB.
- OCRIPLASMIN.
- OCTAMYLAMINE.
- OCTATROPINE.
- OCTREOTIDE.
- OCTYL NITRITE.
- ODEVIXIBAT.
- OFATUMUMAB.
- OFLOXACIN.
- OLANZAPINE.
- OLAPARIB.
- OLARATUMAB.
- OLEANDOMYCIN except:
- (a) when included in Schedule 5; or
- (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
- OLEANDRIN.
- OLIPUDASE ALFA.
- OLMESARTAN.
- OLODATEROL.
- OLOPATADINE except when included in Schedule 2.
- OLSALAZINE.
- OLUTASIDENIB.
- OMALIZUMAB.
- OMBERACETAM.
- OMBITASVIR.
- OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post-myocardial infarction and/or hypertriglyceridae
- OMEPRAZOLE except when included in Schedule 2 or 3.
- ONASEMNOGENE ABEPARVOVEC.
- ONDANSETRON.
- OPICAPONE.
- OPIPRAMOL.
- ORBIFLOXACIN.
- ORCIPRENALINE.
- ORELABRUTINIB.ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:
- (a) when separately specified in these Schedules; or
- (b) in preparations containing 2% or less of malathion for external use.
- ORLISTAT except when included in Schedule 3.
- ORNIDAZOLE.
- ORNIPRESSIN.
- ORPHENADRINE.
- ORTHOPTERIN.
- OSELTAMIVIR.
- OSILODROSTAT.
- OSIMERTINIB.
- OUABAIN.
- # OVANDROTONE.
- # OXABOLONE.
- OXACILLIN.
- OXALIPLATIN.
- # OXANDROLONE.
- OXAPROZIN.
- # OXAZEPAM.
- OXCARBAZEPINE.
- OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.
- OXETACAINE (oxethazaine) except when included in Schedule 2.
- OXICONAZOLE except:
- (a) when included in Schedule 2 or 3; or
- (b) in preparations for the treatment of tinea pedis.
- OXIRACETAM.
- OXITROPIUM.
- OXOLAMINE.
- OXOLINIC ACID.
- OXPRENOLOL.
- OXYBUPROCAINE.
- OXYBUTYNIN.
- # OXYMESTERONE.
- # OXYMETHOLONE.
- OXYPHENBUTAZONE.
- OXYPHENCYCLIMINE.
- OXYPHENONIUM.
- OXYTETRACYCLINE except when included in Schedule 5.
- OXYTOCIN.
- OZANIMOD.
- PACLITAXEL.
- PALBOCICLIB.
- PALIFERMIN.
- PALIPERIDONE.
- PALIVIZUMAB.
- PALONOSETRON.
- PALOPEGTERIPARATIDE.
- PALOVAROTENE.
- PAMAQUIN.
- PAMIDRONIC ACID (includes pamidronate disodium).
- PANCREATIC ENZYMES except:
- (a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or
- (b) when separately specified in these Schedules.
- PANCURONIUM.
- PANITUMUMAB.
- PANOBINOSTAT.
- PANTOPRAZOLE except when included in Schedule 2 or 3.
- PAPAVERINE in preparations for injection.
- PARACETAMOL:
- (a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules; or
- (b) when combined with ibuprofen in a primary pack containing more than 30 dosage units; or
- (c) in modified release tablets or capsules containing more than 665 mg paracetamol; or
- (d) in non-modified release tablets or capsules containing more than 500 mg paracetamol; or
- (e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol; or
- (f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules except in Schedule 3; or
- (g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules except when
- (h) for injection; or
- (i) for the treatment of animals.
- PARALDEHYDE.
- PARAMETHADIONE.
- PARAMETHASONE.
- PARECOXIB.
- PARICALCITOL.
- PARITAPREVIR.
- PAROMOMYCIN.
- PAROXETINE.
- PASIREOTIDE.
- PATIROMER SORBITEX CALCIUM.
- PATISIRAN.
- PAZOPANIB.
- PECAZINE.
- PEFLOXACIN.
- PEGAPTANIB.
- PEGASPARGASE.
- PEGCETACOPLAN.
- PEGFILGRASTIM.
- PEGINTERFERON.
- PEGUNIGALSIDASE ALFA.
- PEGVALIASE.
- PEGVISOMANT.
- PEMBROLIZUMAB.
- PEMETREXED.
- PEMIGATINIB.
- PEMOLINE.
- PEMPIDINE.
- PENBUTOLOL.
- PENCICLOVIR except in preparations containing 1% or less of penciclovir for the treatment of herpes labialis in packs containing 10 g or less.
- PENETHAMATE.
- PENICILLAMINE.
- PENTAERYTHRITYL TETRANITRATE.
- PENTAGASTRIN.
- PENTAMETHONIUM.
- PENTAMIDINE (includes pentamidine isetionate).
- PENTHIENATE.
- # PENTOBARBITAL when packed and labelled for injection.
- PENTOLINIUM.
- PENTOSAN POLYSULFATE SODIUM.
- PENTOXIFYLLINE.
- PERAMIVIR.
- # PERAMPANEL.
- PERGOLIDE.
- PERHEXILINE.
- PERICIAZINE.
- PERINDOPRIL.
- PERMETHRIN for human therapeutic use except in preparations containing 5% or less of permethrin.
- PERPHENAZINE.
- PERTUSSIS ANTIGEN.
- PERTUZUMAB.
- PHENACEMIDE.
- PHENACETIN for therapeutic use (excluding when present as an excipient).
- PHENAGLYCODOL.
- PHENAZONE except when included in Schedule 2 or 5.
- PHENAZOPYRIDINE.
- PHENELZINE.
- PHENETICILLIN.
- PHENFORMIN.
- PHENGLUTARIMIDE.
- PHENINDIONE.
- PHENIRAMINE except when included in Schedule 2 or 3.
- PHENISATIN.
- PHENOBARBITAL.
- PHENOL in preparations for injection.
- PHENOLPHTHALEIN for human therapeutic use.
- PHENOXYBENZAMINE.
- PHENOXYMETHYLPENICILLIN.
- PHENSUXIMIDE.
- # PHENTERMINE.
- PHENTHIMENTONIUM.
- PHENTOLAMINE.
- PHENYLBUTAZONE.
- PHENYLEPHRINE:
- (a) in preparations for injection; or
- (b) in preparations for human ophthalmic use containing 5% or more of phenylephrine.
- PHENYLPIRACETAM.
- PHENYLPROPANOLAMINE.
- PHENYLTOLOXAMINE.
- PHENYTOIN.
- PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract).
- PHOLCODINE:
- (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of pholcodine;
- except when included in Schedule 2.
- PHOSPHODIESTERASE TYPE 5 INHIBITORS except:
- (a) when separately specified in these Schedules; or
- (b) when present as an unmodified, naturally occurring substance.
- PHTHALYLSULFATHIAZOLE.
- PHYSOSTIGMINE.
- PIBRENTASVIR.
- PICROTOXIN.
- PILOCARPINE except in preparations containing 0.025% or less of pilocarpine.
- PIMECROLIMUS.
- PIMOBENDAN.
- PIMOZIDE.
- PINACIDIL.
- PINAVERIUM BROMIDE.
- PINDOLOL.
- PIOGLITAZONE.
- PIPECURONIUM.
- PIPEMIDIC ACID.
- PIPENZOLATE.
- PIPER METHYSTICUM (kava) in preparations for human use except when included on the Register in preparations:
- (a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:
- (i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or
- (ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not exceed 3 g;
- and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the required advisory statements for medicine labels; or
- (b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome and/or root or containing aqueous dispersions or aq
- (c) in dermal preparations.
- PIPERACILLIN.
- PIPERIDINE.
- PIPERIDOLATE.
- PIPOBROMAN.
- PIPOTHIAZINE.
- PIPRADROL.
- PIRACETAM.
- PIRBUTEROL.
- PIRENOXINE (catalin).
- PIRENZEPINE.
- PIRETANIDE.
- PIRFENIDONE.
- PIROXICAM except in preparations for dermal use.
- PIRPROFEN.
- PIRTOBRUTINIB.
- PITAVASTATIN.
- PITUITARY HORMONES except when separately specified in these Schedules.
- PIVAMPICILLIN.
- PIZOTIFEN.
- PLICAMYCIN.
- PLITIDEPSIN.
- PLERIXAFOR.
- PLOZASIRAN.
- PNEUMOCOCCAL VACCINE.
- PODOPHYLLOTOXIN for human use:
- (a) internally; or
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations except when included in Schedule 2 or 3.
- PODOPHYLLUM EMODI (podophyllin) for human use:
- (a) internally; or
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations except when included in Schedule 2 or 3.
- PODOPHYLLUM PELTATUM (podophyllin) for human use:
- (a) internally; or
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations except when included in Schedule 2 or 3.
- POLIDEXIDE.
- POLIOMYELITIS VACCINE.
- POLYACRYLAMIDE in preparations for injection or implantation:
- (a) for tissue augmentation; or
- (b) for cosmetic use; or
- (c) for veterinary use.
- POLYCAPROLACTONE in preparations for injection or implantation:
- (a) for tissue augmentation; or
- (b) for cosmetic use.
- POLYESTRADIOL.
- POLYLACTIC ACID in preparations for injection or implantation:
- (a) for tissue augmentation; or
- (b) for cosmetic use.
- POLYMYXIN.
- POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when separately specified in these Schedules.
- POLYTHIAZIDE.
- # POMALIDOMIDE.
- PONATINIB.
- PONESIMOD.
- PORACTANT.
- POSACONAZOLE.
- POTASSIUM BROMIDE for therapeutic use.
- POTASSIUM CHLORIDE in oral preparations for human therapeutic use except:
- (a) when containing less than 550 mg of potassium chloride per dosage unit; or
- (b) in preparations for oral rehydration therapy; or
- (c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or
- (d) in preparations for enteral feeding.
- POTASSIUM PERCHLORATE for therapeutic use.
- PRACTOLOL.
- PRADOFLOXACIN.
- PRALATREXATE.
- PRALIDOXIME.
- PRAMIPEXOLE.
- PRAMIRACETAM.
- PRAMOCAINE.
- # PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2 (GHRP-2)).
- PRALSETINIB.
- PRAMPINE.
- # PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).
- PRASUGREL.
- PRAVASTATIN.
- # PRAZEPAM.
- PRAZIQUANTEL for human therapeutic use.
- PRAZOSIN.
- PREDNISOLONE.
- PREDNISONE.
- PREGABALIN.
- PREGNENOLONE.
- PRENALTEROL.
- PRENYLAMINE.
- PRILOCAINE except when included in Schedule 2.
- PRIMAQUINE.
- PRIMIDONE.
- PROBENECID.
- PROBUCOL.
- PROCAINAMIDE.
- PROCAINE.
- PROCAINE BENZYLPENICILLIN.
- PROCARBAZINE.
- PROCHLORPERAZINE except when included in Schedule 3.
- PROCYCLIDINE except when included in Schedule 2.
- PROGESTERONE except when included in Schedule 5.
- PROGESTOGENS except when separately specified in these Schedules.
- PROGLUMIDE.
- PROGUANIL.
- PROLINTANE.
- PROMAZINE.
- PROMETHAZINE except when included in Schedule 2 or 3.
- PROMOXOLANE.
- PROPAFENONE.
- PROPAMIDINE for therapeutic use except when included in Schedule 2.
- PROPANIDID.
- PROPANTHELINE.
- PROPENTOFYLLINE.
- # PROPETANDROL.
- PROPIONIBACTERIUM ACNES for therapeutic use.
- PROPOFOL.
- PROPRANOLOL.
- PROPYLHEXEDRINE.
- PROPYLTHIOURACIL.
- PROPYPHENAZONE.
- PROQUAZONE.
- PROSCILLARIDIN.
- PROSTAGLANDINS except when separately specified in this Schedule.
- PROSTIANOL.
- PROTAMINE.
- PROTHIONAMIDE.
- PROTHIPENDYL.
- PROTIRELIN.
- PROTOVERATRINES.
- PROTRIPTYLINE.
- PROXYMETACAINE.
- PRUCALOPRIDE.
- PSEUDOEPHEDRINE except when included in Schedule 3.
- PYRAZINAMIDE.
- PYRIDINOLCARBAMATE.
- PYRIDOSTIGMINE.
- PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use except:
- (a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with t
- (b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.
- PYRIMETHAMINE.
- PYROVALERONE.
- PYRVINIUM.
- # QUAZEPAM.
- QUETIAPINE.
- QUINAGOLIDE.
- QUINAPRIL.
- # QUINBOLONE.
- QUINETHAZONE.
- QUINIDINE.
- QUININE for human therapeutic use except when the maximum recommended daily dose is 50 mg or less of quinine.
- QUINISOCAINE (dimethisoquin).
- QUINUPRISTIN.
- RABEPRAZOLE except when included in Schedule 2 or 3.
- RABIES VACCINE.
- RACETAMS except when separately specified in these Schedules.
- RACTOPAMINE except when included in Schedule 5.
- RALOXIFENE.
- RALTEGRAVIR.
- RALTITREXED.
- RAMIPRIL.
- RAMUCIRUMAB.
- RANIBIZUMAB.
- RANITIDINE except:
- (a) when included in Schedule 2; or
- (b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not
- (c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 d
- RANOLAZINE.
- RAPACURONIUM.
- RASAGILINE.
- RASBURICASE.
- RAUWOLFIA SERPENTINA.
- RAUWOLFIA VOMITORIA.
- RAZOXANE.
- REBOXETINE.
- RED YEAST RICE for human therapeutic use.
- REGDANVIMAB.
- REGORAFENIB.
- RELUGOLIX.
- REMDESIVIR.
- REMIBRUTINIB.
- REMOXIPRIDE.
- REPAGLINIDE.
- REPOTRECTINIB.
- RESERPINE.
- RESLIZUMAB.
- RETAPAMULIN.
- RETEPLASE.
- RETIFANLIMAB.
- RETIGABINE.
- RIBAVIRIN.
- RIBOCICLIB.
- RIDAFOROLIMUS.
- RIFABUTIN.
- RIFAMPICIN.
- RIFAMYCIN.
- RIFAPENTINE.
- RIFAXIMIN.
- RILPIVIRINE.
- RILUZOLE.
- RIMEGEPANT.
- RIMEXOLONE.
- RIMITEROL.
- RIMONABANT.
- # RIOCIGUAT.
- RIPRETINIB.
- RISANKIZUMAB.
- RISDIPLAM.
- RISEDRONIC ACID.
- RISPERIDONE.
- RITLECITINIB.
- RITODRINE.
- RITONAVIR.
- RITUXIMAB.
- RIVAROXABAN.
- RIVASTIGMINE.
- RIZATRIPTAN except when included in Schedule 3.
- ROBENACOXIB.
- ROCURONIUM.
- ROFECOXIB.
- ROFLUMILAST.
- ROLITETRACYCLINE.
- ROLZIRACETAM.
- ROMIDEPSIN.
- ROMIFIDINE.
- ROMIPLOSTIM.
- ROMOSOZUMAB.
- RONIDAZOLE.
- ROPINIROLE.
- ROPIVACAINE.
- ROSIGLITAZONE.
- ROSOXACIN.
- ROSUVASTATIN.
- ROTIGOTINE.
- # ROXIBOLONE.
- ROXITHROMYCIN.
- ROZANOLIXIZUMAB.
- RUBELLA VACCINE.
- RUBOXISTAURIN.
- RUFINAMIDE.
- RUPATADINE.
- RUXOLITINIB.
- SACITUZUMAB GOVITECAN.
- SACUBITRIL.
- SAFINAMIDE.
- SALBUTAMOL except when included in Schedule 3.
- SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.
- SALINOMYCIN except:
- (a) when included in Schedule 6; or
- (b) in animal feeds containing 60 mg/kg or less of antibiotic substances.
- SALMETEROL.
- SAPROPTERIN.
- SAQUINAVIR.
- SARILUMAB.
- SARS-COV-2 (COVID-19) VACCINE.
- SAXAGLIPTIN.
- SCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.
- SCOPOLIA CARNIOLICA for therapeutic use.
- SEBELIPASE ALFA.
- SEBETRALSTAT.
- SECUKINUMAB.
- SELADELPAR.
- # SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).
- SELEGILINE.
- SELENIUM:
- (a) for human oral use with a recommended daily dose of more than 300 micrograms; or
- (b) for the treatment of animals except:
- (i) when included in Schedule 6 or 7; or
- (ii) in solid, slow release bolus preparations containing 300 mg or less of selenium per dosage unit; or
- (iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit; or
- (iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
- (v) in feeds containing 1 g/tonne or less of selenium.
- SELETRACETAM.
- SELEXIPAG.
- SELINEXOR.
- SELPERCATINIB.
- SELUMETINIB.
- SEMAGLUTIDE.
- SEPIAPTERIN.
- SERELAXIN.
- SERMORELIN.
- SERTINDOLE.
- SERTRALINE.
- SEVELAMER.
- SEVOFLURANE.
- SEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.
- SIBUTRAMINE.
- # SILANDRONE.
- SILDENAFIL.
- SILICONES for intra-ocular use.
- SILODOSIN.
- SILTUXIMAB.
- SILVER SULFADIAZINE.
- SIMEPREVIR.
- SIMVASTATIN.
- SIPONIMOD.
- SIROLIMUS.
- SISOMICIN (sisomycin).
- SITAGLIPTIN.
- # SITAXENTAN.
- SODIUM BROMIDE for therapeutic use.
- SODIUM CELLULOSE PHOSPHATE for human internal use.
- SODIUM CITRATE DIHYDRATE for therapeutic use in dialysis, diafiltration, or total plasma exchange.
- SODIUM CROMOGLYCATE except when included in Schedule 2.
- SODIUM GLYCEROPHOSPHATE HYDRATE.
- SODIUM MORRHUATE in preparations for injection.
- SODIUM NITROPRUSSIDE for human therapeutic use.
- SODIUM PHENYLBUTYRATE.
- SODIUM PHOSPHATE in preparations for oral laxative use.
- SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.
- SODIUM SALICYLATE in preparations for internal use for the treatment of animals.
- SODIUM TETRADECYLSULFATE in preparations for injection.
- SODIUM THIOSULFATE ANHYDROUS for human therapeutic use in preparations for injection.
- SODIUM ZIRCONIUM CYCLOSILICATE.
- SOFOSBUVIR.
- SOLASODINE.
- SOLIFENACIN.
- # SOMAPACITAN.
- SOMATOSTATIN.
- SOMATOTROPIN EQUINE.
- # SOMATROGON.
- # SOMATROPIN (human growth hormone).
- SONIDEGIB.
- SONTOQUINE.
- SORAFENIB.
- SOTALOL.
- SOTATERCEPT.
- SOTORASIB.
- SOTROVIMAB.
- SPARFLOXACIN.
- SPARTEINE.
- SPECTINOMYCIN.
- SPESOLIMAB.
- SPIRAMYCIN.
- SPIRAPRIL.
- SPIRONOLACTONE.
- # STANOLONE.
- # STANOZOLOL.
- STAVUDINE.
- # STENABOLIC (SR9009) and other synthetic REV-ERB agonists.
- # STENBOLONE.
- STEROID HORMONES except when separately specified in these Schedules.
- STILBESTROL (diethylstilbestrol).
- STIRIPENTOL.
- STREPTODORNASE.
- STREPTOKINASE.
- STREPTOMYCIN.
- STRONTIUM RANELATE.
- STROPHANTHINS.
- STROPHANTHUS spp.
- STRYCHNINE in preparations containing 1.5% or less of strychnine for the treatment of animals.
- STRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of strychnine.
- STYRAMATE.
- SUCCIMER.
- SUCROFERRIC OXYHYDROXIDE.
- SUGAMMADEX.
- SULBACTAM.
- SULCONAZOLE except when included in Schedule 2.
- SULFACETAMIDE except when included in Schedule 3 or 5.
- SULFADIAZINE except when included in Schedule 5.
- SULFADIMETHOXINE.
- SULFADIMIDINE except when included in Schedule 5.
- SULFADOXINE.
- SULFAFURAZOLE.
- SULFAGUANIDINE.
- SULFAMERAZINE except when included in Schedule 5.
- SULFAMETHIZOLE.
- SULFAMETHOXAZOLE.
- SULFAMETHOXYDIAZINE.
- SULFAMETHOXYPYRIDAZINE.
- SULFAMETROLE.
- SULFAMONOMETHOXINE.
- SULFAMOXOLE.
- SULFAPHENAZOLE.
- SULFAPYRIDINE.
- SULFAQUINOXALINE.
- SULFASALAZINE.
- SULFATHIAZOLE except when included in Schedule 5.
- SULFATROXAZOLE.
- SULFINPYRAZONE.
- SULFOMYXIN.
- SULFONAMIDE ANTIBIOTICS except when separately specified in these Schedules.
- SULFONMETHANE (sulfonal) and alkyl sulfonals.
- SULINDAC.
- SULTAMICILLIN.
- SULTHIAME.
- SUMATRIPTAN except when included in Schedule 3.
- SUNIFIRAM.
- SUNITINIB.
- SUPROFEN.
- SUTILAINS.
- SUXAMETHONIUM.
- SUXETHONIUM.
- SUVOREXANT.
- TACRINE.
- TACROLIMUS.
- TADALAFIL.
- TAFAMIDIS.
- TAFASITAMAB.
- TAFENOQUINE SUCCINATE.
- TAFLUPROST.
- TAGRAXOFUSP.
- TALAZOPARIB.
- TALIGLUCERASE ALFA.
- TALIMOGENE LAHERPAREPVEC.
- TAMOXIFEN.
- TAMSULOSIN.
- TANACETUM VULGARE except in preparations containing 0.8% or less of oil of tansy.
- TAPINAROF.
- TASIPIMIDINE SULFATE.
- TASONERMIN.
- TAZAROTENE.
- TAZOBACTAM.
- # TB-500.
- T-CELL RECEPTOR ANTIBODY.
- TEBENTAFUSP.
- TECLISTAMAB.
- TEDUGLUTIDE.
- TEGAFUR.
- TEGASEROD.
- TELAPREVIR.
- TELITHROMYCIN.
- TEICOPLANIN.
- TELBIVUDINE.
- TELMISARTAN.
- TELOTRISTAT ETHYL.
- # TEMAZEPAM.
- TEMOZOLOMIDE.
- TEMSIROLIMUS.
- TENECTEPLASE.
- TENIPOSIDE.
- TENOFOVIR.
- TENOXICAM.
- TEPLIZUMAB.
- TEPOTINIB.
- TEPOXALIN.
- TEPROTUMUMAB.
- TERAZOSIN.
- TERBINAFINE except:
- (a) when included in Schedule 2; or
- (b) in preparations for dermal use for the treatment of tinea pedis.
- TERBUTALINE except when included in Schedule 3.
- TERFENADINE.
- TERIFLUNOMIDE.
- # TERIPARATIDE.
- TERLIPRESSIN.
- TERODILINE.
- TEROPTERIN.
- # TESTOLACTONE.
- # TESTOSTERONE except when included in Schedule 6.
- TETANUS ANTITOXIN except when used for short-term protection or treatment of tetanus in animals.
- TETANUS TOXOID for human use.
- TETRABENAZINE.
- TETRACAINE except:
- (a) when included in Schedule 2; or
- (b) in dermal preparations containing 2% or less of total local anaesthetic substances.
- TETRACOSACTIDE.
- TETRACYCLINE except when included in Schedule 5.
- TETRAETHYLAMMONIUM.
- TETROXOPRIM.
- TEZACAFTOR.
- TEZEPELUMAB.
- # THALIDOMIDE.
- THENYLDIAMINE.
- THEOPHYLLINE except when included in Schedule 3.
- THEVETIA PERUVIANA.
- THEVETIN.
- THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.
- THIAMBUTOSINE.
- THIAZOSULFONE.
- THIETHYLPERAZINE.
- THIOACETAZONE.
- THIOCARLIDE.
- # THIOMESTERONE (tiomesterone).
- THIOPENTAL.
- THIOPROPAZATE.
- THIOPROPERAZINE.
- THIORIDAZINE.
- THIOSTREPTON.
- THIOTEPA.
- THIOTHIXENE.
- THIOURACIL.
- THIOUREA for therapeutic use except in preparations containing 0.1% or less of thiourea.
- # THYMOSIN BETA 4 (THYMOSIN β4).
- THYMOXAMINE (includes thymoxamine hydrochloride).
- THYROID except when separately specified in this Schedule.
- THYROTROPHIN.
- THYROXINE (includes thyroxine sodium).
- TIAGABINE.
- TIAMULIN.
- # TIANEPTINE.
- TIAPROFENIC ACID.
- TIARAMIDE.
- TIBOLONE.
- TICAGRELOR.
- TICARCILLIN.
- TICLOPIDINE.
- TIEMONIUM.
- TIENILIC ACID.
- TIGECYCLINE.
- TIGILANOL TIGLATE.
- TIGLOIDINE.
- TILDIPIROSIN.
- TILETAMINE.
- TILMANOCEPT.
- TILMICOSIN.
- TILUDRONIC ACID (includes disodium tiludronate).
- TIMOLOL.
- TINIDAZOLE.
- TINZAPARIN (includes tinzaparin sodium).
- TIOCONAZOLE except:
- (a) when included in Schedule 2 or 3; or
- (b) in preparations for dermal use for the treatment of tinea pedis.
- TIOGUANINE.
- TIOTROPIUM.
- TIPEPIDINE.
- TIPIRACIL.
- TIPRANAVIR.
- TIRBANIBULIN.
- TIRILAZAD.
- TIROFIBAN.
- TIRZEPATIDE.
- TISLELIZUMAB.
- TIXAGEVIMAB.
- TOBRAMYCIN.
- TOCAINIDE.
- TOCERANIB.
- TOCILIZUMAB.
- TOFACITINIB.
- TOFERSEN.
- TOLAZAMIDE.
- TOLAZOLINE.
- TOLBUTAMIDE.
- TOLCAPONE.
- TOLFENAMIC ACID.
- TOLMETIN.
- TOLONIUM.
- TOLPROPAMINE.
- TOLRESTAT.
- TOLTERODINE.
- TOLVAPTAN.
- TOPIRAMATE.
- TOPOTECAN.
- TORASEMIDE.
- TOREMIFENE.
- TOXOIDS for human parenteral use except when separately specified in these Schedules.
- TRABECTEDIN.
- TRAMADOL.
- TRANDOLAPRIL.
- TRAMETINIB DIMETHYL SULFOXIDE.
- TRANEXAMIC ACID except in preparations containing 3% or less of tranexamic acid for dermal cosmetic use.
- TRANYLCYPROMINE.
- TRASTUZUMAB.
- TRASTUZUMAB DERUXTECAN.
- TRASTUZUMAB EMTANSINE.
- TRAVOPROST.
- TRAZODONE.
- # TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5.
- TREOSULPHAN.
- TREPROSTINIL.
- # TRESTOLONE.
- TRETAMINE.
- # TRETINOIN except for:
- (a) hydroxypinacolone retinoate in preparations for dermal use containing 0.5% or less of hydroxypinacolone retinoate; or
- (b) ethyl lactyl retinoate in preparations for dermal use containing 0.1% or less of ethyl lactyl retinoate.
- TRIACETYLOLEANDOMYCIN.
- TRIAMCINOLONE except when included in Schedule 2 or 3.
- TRIAMTERENE.
- TRIAZIQUONE.
- # TRIAZOLAM.
- TRICHLORMETHIAZIDE.
- TRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than ano
- TRICHLOROETHYLENE for therapeutic use.
- TRICLOFOS.
- TRICYCLAMOL.
- TRIDIHEXETHYL.
- TRIENTINE.
- TRIFAROTENE.
- TRIFLUOPERAZINE.
- TRIFLUPERIDOL.
- TRIFLUPROMAZINE.
- TRIFLURIDINE.
- TRIHEXYPHENIDYL.
- TRILOSTANE.
- TRIMETAPHAN.
- TRIMETHOPRIM.
- TRIMIPRAMINE.
- TRIMUSTINE.
- TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.
- TRIOXYSALEN.
- TRIPELENNAMINE.
- TRIPROLIDINE except when included in Schedule 2 or 3.
- TRIPTORELIN.
- TROGLITAZONE.
- TROLAMINE when in preparations for tattoo removal.
- TROMETAMOL in preparations for injection except in preparations containing 3% or less of trometamol.
- TROPICAMIDE.
- TROPISETRON.
- TROVAFLOXACIN.
- TROXIDONE.
- TRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.
- TUBERCULIN.
- TUBOCURARINE.
- TUCATINIB.
- TULATHROMYCIN.
- TULOBUTEROL.
- TYLOSIN.
- TYPHOID VACCINE.
- ULIPRISTAL except when included in Schedule 3.
- UMECLIDINIUM.
- UNIFIRAM.
- UNOPROSTONE.
- UPADACITINIB.
- URACIL.
- URAPIDIL.
- URETHANE (excluding its derivatives) for therapeutic use.
- # UROFOLLITROPIN.
- UROKINASE.
- URSODEOXYCHOLIC ACID.
- USTEKINUMAB.
- VACCINES for human therapeutic use except when separately specified in this Schedule.
- VACCINES for veterinary live virus except:
- (a) poultry vaccines; or
- (b) pigeon pox vaccine; or
- (c) scabby mouth vaccine; or
- (d) bovine ephemeral fever vaccine; or
- (e) bovine herpesvirus-1 vaccine.
- VACCINES – PLASMID DNA for animal use except when separately specified in these Schedules.
- VACCINIA VIRUS VACCINE.
- # VADADUSTAT.
- VALACICLOVIR.
- VALDECOXIB.
- VALGANCICLOVIR.
- VALNOCTAMIDE.
- VALPROIC ACID.
- VALSARTAN.
- VANCOMYCIN.
- VANDETANIB.
- VANZACAFTOR.
- VARDENAFIL.
- VARENICLINE.
- VARICELLA VACCINE.
- RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN.
- VASOPRESSIN.
- VATINOXAN HYDROCHLORIDE.
- VECURONIUM.
- VEDAPROFEN.
- VEDOLIZUMAB.
- VELAGLIFLOZIN.
- VELAGLUCERASE ALFA.
- VELMANASE ALFA.
- VELPATASVIR.
- VEMURAFENIB.
- VENETOCLAX.
- VENLAFAXINE.
- VERAPAMIL.
- VERATRUM spp. except when separately specified in this Schedule.
- VERDINEXOR.
- VERICIGUAT.
- VERNAKALANT.
- VERTEPORFIN.
- VIDARABINE.
- VIGABATRIN.
- VILANTEROL.
- VILDAGLIPTIN.
- VILOXAZINE.
- VINBLASTINE.
- VINCAMINE.
- VINCRISTINE.
- VINDESINE.
- VINFLUNINE.
- VINORELBINE.
- VINYL ETHER for therapeutic use.
- VIRGINIAMYCIN except when included in Schedule 5.
- VISMODEGIB.
- VISNADINE.
- VITAMIN A for human therapeutic or cosmetic use except:
- (a) in preparations for topical use containing 1% or less of Vitamin A; or
- (b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or
- (c) in preparations for parenteral nutrition replacement.
- VITAMIN D for human internal therapeutic use except:
- (a) in preparations containing 25 micrograms or less of vitamin D per recommended daily dose; or
- (b) when included in Schedule 3.
- VORAPAXAR.
- VORASIDENIB.
- VORETIGENE NEPARVOVEC.
- VORICONAZOLE.
- VORINOSTAT.
- VORTIOXETINE.
- VOSORITIDE.
- VOXILAPREVIR.
- VUTRISIRAN.
- WARFARIN for therapeutic use.
- XAMOTEROL.
- XANTHINOL NICOTINATE.
- XIMELAGATRAN.
- XIPAMIDE.
- XYLAZINE.
- YOHIMBINE.
- ZAFIRLUKAST.
- ZALCITABINE.
- ZALEPLON.
- ZANAMIVIR.
- ZANUBRUTINIB.
- ZERANOL except when included in Schedule 6.
- ZIDOVUDINE.
- ZILPATEROL.
- ZILUCOPLAN.
- ZIMELDINE.
- ZINC COMPOUNDS for human internal use except:
- (a) in preparations with a recommended daily dose of 25 mg or less of zinc; or
- (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the required adviso
- ZIPRASIDONE.
- ZOLAZEPAM.
- ZOLBETUXIMAB.
- ZOLEDRONIC ACID.
- ZOLMITRIPTAN except when included in Schedule 3.
- ZOLPIDEM.
- ZONISAMIDE.
- ZOPICLONE.
- ZOXAZOLAMINE.
- ZUCLOPENTHIXOL.
- Schedule 5 · Caution
- Note: See paragraph (e) of the definition of designated solvent in section 6, paragraph 7(j), sections 16 and 25, subsection 26(2) and sections 42, 46, 47, 49,
- ABAMECTIN
- (a) in preparations, for internal use for the treatment of animals, containing 1% or less of abamectin; or
- (b) in gel formulations containing 0.05% or less of abamectin in applicators containing 50 mg or less of abamectin.
- ABSCISIC ACID.
- ACEQUINOCYL.
- ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30% of acetic acid (CH3COOH) except:
- (a) when included in Schedule 2 or 6; or
- (b) for therapeutic use.
- ACETONE except in preparations containing 25% or less of designated solvents.
- ACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5% or less of acriflavinium chloride.
- AFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit
- (a) for the treatment and prevention of flea infestations and control of ticks in dogs; or
- (b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with milbemycin oxi
- AKLOMIDE.
- ALBENDAZOLE for the treatment of animals, in preparations containing 12.5% or less of albendazole except in intraruminal implants each containing 3.85 g or less
- ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:
- (a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5; or
- (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5; or
- (c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (d) in liquid or semi-solid preparations, the pH of which is more than 11.5, unless:
- (i) in food additive preparations for domestic use; or
- (ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5;
- except when separately specified in these Schedules.
- ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50% or less of alkoxylated fatty alkylamine polymer except in preparations containing 20% or les
- ALLETHRIN in preparations containing 10% or less of allethrin except:
- (a) in insecticidal mats; or
- (b) in other preparations containing 1% or less of allethrin.
- ALLOXYDIM.
- ALPHA-CYPERMETHRIN:
- (a) in aqueous preparations containing 3% or less of alpha-cypermethrin; or
- (b) in other preparations containing 1.5% or less of alpha-cypermethrin.
- AMETRYN.
- AMINES for use as curing agents for epoxy resins except when separately specified in these Schedules.
- AMINOACRIDINE in preparations for veterinary use containing 2.5% or less of aminoacridine.
- 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID except in plant growth preparations containing 40% or less of 1-aminocyclopropane-1-carboxylic acid.
- AMINOCYCLOPYRACHLOR except in preparations containing 25% or less of aminocyclopyrachlor.
- AMINOPYRALID in preparations containing 22% or less of aminopyralid.
- AMISULBROM.
- AMITROLE.
- AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of ammonia except:
- (a) in preparations for human internal therapeutic use; or
- (b) in preparations for inhalation when absorbed in an inert solid material; or
- (c) in preparations containing 0.5% or less of free ammonia.
- AMMONIUM THIOCYANATE except in preparations containing 10% or less of ammonium thiocyanate.
- ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins except when separately specified in these Schedules.
- ANISE OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compli
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricte
- KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 50% or less of anise oil.
- ASPIRIN for the treatment of animals, that is in divided preparations, when:
- (a) packed in blister or strip packaging; or
- (b) in a container with a child-resistant closure.
- ATRAZINE.
- AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5% or less of total l
- AZELAIC ACID except when included in Schedule 2 or 4.
- AZOXYSTROBIN.
- BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens.
- BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.
- BASIL OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compli
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 5% or less of methyl chavicol.
- BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFu)/mL or less of Beauveria bassiana.
- BENALAXYL.
- BENDIOCARB in preparations containing 2% or less of bendiocarb.
- BENTAZONE.
- BENZALKONIUM CHLORIDE in preparations containing 10% or less of benzalkonium chloride except in preparations containing 5% or less of benzalkonium chloride.
- BENZOFENAP.
- BENZOIC ACID (excluding its salts and derivatives) in preparations for agricultural use except preparations containing 1% or less of benzoic acid.
- BENZOYL PEROXIDE except:
- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 5% or less of benzoyl peroxide.
- BERGAMOT OIL except:
- (a) when steam distilled or rectified; or
- (b) in preparations for internal use; or
- (c) in preparations containing 0.4% or less of bergamot oil; or
- (d) in soaps or bath or shower gels that are washed off the skin; or
- (e) in medicines for human therapeutic use when compliant with the requirements of the required advisory statements for medicine labels; or
- (f) in other preparations when packed in containers labelled with the statement:
- Application to the skin may increase sensitivity to sunlight.
- BETACYFLUTHRIN:
- (a) in aqueous preparations containing 2.5% or less of betacyfluthrin; or
- (b) in solid preparations containing 8% or less of betacyfluthrin in a plastic matrix.
- BICYCLOPYRONE in preparations containing 20% or less of bicyclopyrone.
- BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3% or less of total bifluorides.
- BIOALLETHRIN in preparations containing 10% or less of bioallethrin except in preparations containing 1% or less of bioallethrin.
- BIORESMETHRIN except in preparations containing 10% or less of bioresmethrin.
- BISPYRIBAC except in preparations containing 10% or less of bispyribac.
- BIXAFEN.
- BORIC ACID except:
- (a) when included in Schedule 4; or
- (b) in cosmetic hand cleaning preparations when labelled with a warning to the following effect:
- NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and
- if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:
- NOT TO BE USED ON PEELING OR IRRITATED SKIN; or
- (c) in cosmetic talc preparations containing 5% or less calculated as boric acid when labelled with a warning to the following effect:
- NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and
- if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:
- NOT TO BE USED ON PEELING OR IRRITATED SKIN; or
- (d) in cosmetic oral hygiene preparations containing 0.1% or less calculated as boric acid when labelled with a warning to the following effect:
- NOT TO BE SWALLOWED. NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; or
- (e) in other cosmetic preparations containing 3% or less calculated as boric acid when labelled with a warning to the following effect:
- NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and
- if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:
- NOT TO BE USED ON PEELING OR IRRITATED SKIN; or
- (f) in preparations, other than insect baits, containing 6% or less calculated as boric acid.
- BORON TRIFLUORIDE in preparations containing 0.1% or less of boron trifluoride (BF3).
- BROFLANILIDE in preparations containing 0.3% or less of broflanilide.
- BROMUCONAZOLE in preparations containing 20% or less of bromuconazole.
- BUPIVACAINE in aqueous gel preparations containing 0.5% or less of bupivacaine, for the dermal spray-on administration to the wounds of animals.
- BUPROFEZIN except in preparations containing 40% or less of buprofezin.
- BUTHIDAZOLE.
- BUTOXYCARBOXIM in solid preparations containing 10% or less of butoxycarboxim.
- BUTRALIN.
- BUTROXYDIM.
- n-BUTYL ALCOHOL in preparations containing 10% or less of n-butyl alcohol except:
- (a) in preparations containing 5% or less of n-butyl alcohol; or
- (b) in preparations for cosmetic or therapeutic use other than spray form.
- CAMELLIA SINENSIS EXTRACT (GREEN TEA EXTRACT) for oral use except:
- (a) in preparations for human therapeutic use when compliant with the required advisory statements for medicine labels, or
- (b) in preparations containing 300 mg or less of epigallocatechin-3-gallate per maximum recommended daily dose.
- CAMPHOR as a natural component in essential oils containing 10% or less of camphor except:
- (a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow
- (b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (c) in rosemary oil, sage oil (Spanish), or lavandin oils; or
- (d) in preparations containing 2.5% or less of camphor.
- CARBAMIDE PEROXIDE in preparations containing 18% or less of carbamide peroxide except in preparations containing 9% or less of carbamide peroxide.
- CARBARYL:
- (a) in preparations containing 10% or less of carbaryl except when included in Schedule 4; or
- (b) when impregnated into plastic resin material containing 20% or less of carbaryl.
- CASSIA OIL except:
- (a) in food additives; or
- (b) in preparations for dermal use as a rubefacient containing 5% or less of cassia oil; or
- (c) in other preparations containing 2% or less of cassia oil.
- CHLORFENAC.
- CHLORFENAPYR. in preparations containing 0.5% or less of chlorfenapyr.
- CHLORFENSON.
- CHLORHEXIDINE in preparations containing 3% or less of chlorhexidine except:
- (a) in preparations containing 1% or less of chlorhexidine; or
- (b) when in solid preparations.
- CHLORINATING COMPOUNDS containing 20% or less of available chlorine, except:
- (a) when separately specified in these Schedules; or
- (b) sodium hypochlorite preparations with a pH of less than 11.5; or
- (c) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:
- WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or
- (d) liquid preparations containing less than 2% of available chlorine; or
- (e) other preparations containing 4% or less of available chlorine.
- CHLORNIDINE.
- CHLOROCRESOL except in preparations containing 3% or less of chlorocresol.
- CHLORPROPHAM.
- CHLORPYRIFOS:
- (a) in aqueous preparations containing 20% or less of microencapsulated chlorpyrifos; or
- (b) in controlled release granular preparations containing 10% or less of chlorpyrifos; or
- (c) in other preparations containing 5% or less of chlorpyrifos;
- except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.
- CHLORSULFURON.
- CHLORTETRACYCLINE in preparations:
- (a) for topical application to animals for ocular use only; or
- (b) containing 40% or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
- CINMETHYLIN.
- CINNAMON BARK OIL except:
- (a) in food additives; or
- (b) in preparations containing 2% or less of cinnamon bark oil.
- CIS-JASMONE when prepared and packaged as an agricultural chemical except when present as a fragrance.
- CLETHODIM.
- CLIMBAZOLE in preparations containing 40% or less of climbazole except:
- (a) in leave-on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or
- (b) in other preparations (that are not leave-on cosmetic preparations) containing 2% or less of climbazole.
- CLOFENTEZINE.
- CLOPYRALID.
- CLOQUINTOCET.
- CLORSULON.
- CLOTHIANIDIN in preparations containing 20% or less of clothianidin except in gel preparations dispensed in sealed cartridges containing 1% or less of clothiani
- CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil except in preparations containing 25% or less of clove oil.
- COPPER ACETATE in preparations containing 20% or less of copper acetate except in preparations containing 5% or less of copper acetate.
- COPPER COMPOUNDS in animal feed additives containing 5% or less of copper except in preparations containing 1% or less of copper.
- COPPER HYDROXIDE in preparations containing 50% or less of copper hydroxide except in preparations containing 12.5% or less of copper hydroxide.
- COPPER OXIDES in preparations containing 25% or less of copper oxides except:
- (a) in preparations for internal use; or
- (b) in marine paints; or
- (c) in other preparations containing 5% or less of copper oxides.
- COPPER OXYCHLORIDE in preparations containing 50% or less of copper oxychloride except in preparations containing 12.5% or less of copper oxychloride.
- COPPER SULFATE in preparations containing 15% or less of copper sulfate except:
- (a) in preparations for internal use; or
- (b) in other preparations containing 5% or less of copper sulfate.
- COUMATETRALYL in rodenticides containing 0.05% or less of coumatetralyl.
- 4-CPA.
- CYANATRYN.
- CYANOACRYLATE ESTERS in contact adhesives except:
- (a) when labelled with the warning:
- KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such
- (b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:
- (i) labelled with the approved name or trade name of the poison, the quantity and the warning:
- Can cause eye injury. Instantly bonds skin; and
- enclosed in a primary pack labelled with the warning:
- KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such
- CYANTRANILIPROLE.
- CYANURIC ACID (excluding its salts and derivatives).
- CYAZOFAMID.
- CYCLOHEXANONE PEROXIDE.
- CYCLOPROTHRIN except in preparations containing 10% or less of cycloprothrin.
- CYCLOXYDIM.
- CYFLUFENAMID.
- CYFLUMETOFEN.
- CYFLUTHRIN:
- (a) in wettable powders containing 10% or less of cyfluthrin; or
- (b) in emulsifiable concentrates containing 2% or less of cyfluthrin; or
- (c) in emulsions containing 5% or less of cyfluthrin.
- CYHALOFOP-BUTYL.
- CYMIAZOLE.
- CYPERMETHRIN in preparations containing 10% or less of cypermethrin.
- CYPHENOTHRIN in preparations containing 10% or less of cyphenothrin.
- CYPROCONAZOLE except in preparations containing 10% or less of cyproconazole.
- CYPRODINIL.
- CYTHIOATE for the treatment of animals:
- (a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resis
- (b) in undivided preparations containing 5% or less of cythioate.
- 2,4-D in preparations containing 20% or less of 2,4-D.
- DAMINOZIDE.
- 2,4-DB.
- DECOQUINATE:
- DELTAMETHRIN:
- (a) when impregnated in plastic resin strip material containing 4% or less of deltamethrin; or
- (b) in aqueous preparations containing 5% or less of deltamethrin when no organic solvent other than a glycol is present; or
- (c) in wettable granular preparations containing 25% or less of deltamethrin when packed in child-resistant packaging each containing 3 g or less of the formula
- (d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or
- (e) in other preparations containing 0.5% or less of deltamethrin;
- except:
- (f) in factory prepared mosquito nets containing 1% or less deltamethrin; or
- (g) in preparations containing 0.1% or less of deltamethrin.
- DEMBREXINE in oral preparations for the treatment of animals.
- 2,4-DES.
- DIAFENTHIURON.
- N,N-DIALLYLDICHLOROACETAMIDE except in preparations containing 10% or less of N,N-diallyldichloroacetamide.
- DIAZINON in dust preparations containing 2% or less of diazinon.
- DICAMBA (including its salts and derivatives) in preparations containing 20% or less of dicamba.
- DICHLONE.
- p-DICHLOROBENZENE.
- DICHLOROISOCYANURIC ACID containing 40% or less of available chlorine, except in:
- (a) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:
- WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or
- (b) liquid preparations containing less than 2% of available chlorine; or
- (c) other preparations containing 4% or less of available chlorine.
- DICHLOROMETHANE (methylene chloride) except:
- (a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10% or less of dichloromethane; or
- (b) in other preparations in pressurised spray packs; or
- (c) in paints and tinters containing 5% or less of dichloromethane; or
- (d) in preparations for human therapeutic use.
- DICHLOROPHEN for the treatment of animals.
- DICHLORVOS:
- (a) when impregnated in plastic resin strip material containing 20% or less of dichlorvos; or
- (b) in sustained release resin pellets containing 20% or less of dichlorvos for the treatment of animals; or
- (c) in pressurised spray packs containing 10 g or less of dichlorvos.
- DICLOBUTRAZOL.
- DICLORAN.
- DICOFOL.
- DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of diethanolamine except in preparations containing 5% or less of di
- DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:
- (a) when included in Schedule 10; or
- (b) in paints and tinters; or
- (c) in other preparations containing 2.5% or less of diethylene glycol.
- DIETHYLENE GLYCOL MONOBUTYL ETHER except in preparations containing 10% or less of diethylene glycol monobutyl ether.
- DIETHYLTOLUAMIDE (DEET) except:
- (a) in medicines for human therapeutic use containing 20% or less of diethyltoluamide, when compliant with the requirements of the required advisory statements
- (b) in preparations for human use, other than medicines, containing 20% or less of diethyltoluamide, when labelled with the warning statement:
- WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you k
- (c) in preparations other than for human use containing 20% or less of diethyltoluamide.
- DIFENOCONAZOLE.
- DIFLUBENZURON.
- DIMETHICODIETHYLBENZALMALONATE except when included in preparations containing 10% or less of dimethicodiethylbenzalmalonate.
- DIMETHIRIMOL.
- DIMETHOMORPH except in preparations containing 10% or less of dimethomorph.
- DIMETHYLACETAMIDE in preparations containing 40% or less of dimethylacetamide in single dose flow-limited tubes of 5 mL or less for dermal application to compan
- DIMETHYLFORMAMIDE in preparations containing 10% or less of dimethylformamide except in silicone rubber mastic containing 2% or less of dimethylformamide.
- 1,4-DIMETHYLNAPHTHALENE for use as agricultural chemicals.
- 3,7-DIMETHYL-2,6-OCTADIENAL and its isomers in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7-dimethyl-2,6,-oc
- DIMPROPYRIDAZ in preparations containing 13% or less of dimpropyridaz.
- DINICONAZOLE.
- DINOTEFURAN except in preparations containing 1% or less of dinotefuran.
- DI-n-PROPYL ISOCINCHOMERONATE except in preparations containing 25% or less of di-n-propyl isocinchomeronate.
- DIPHENAMID.
- DIRECT RED 254 in preparations containing 30% or less of Direct Red 254 calculated as free acid.
- DITHIOPYR.
- N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50% or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50% or less of a mixture of any two
- DORAMECTIN for internal use for the treatment of animals, in preparations containing 2% or less of doramectin.
- EMAMECTIN in preparations containing 2% or less of emamectin.
- EMODEPSIDE in preparations:
- (a) containing 2.5% or less of emodepside for the external treatment of animals; or
- (b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.
- EPOXICONAZOLE.
- EPOXY RESINS, LIQUID.
- EPRINOMECTIN in preparations containing 0.5% or less of eprinomectin.
- EPYRIFENACIL.
- ESBIOTHRIN in preparations containing 10% or less of esbiothrin except in pressurised spray packs containing 1% or less of esbiothrin.
- ESFENVALERATE in preparations containing 0.1% or less of esfenvalerate.
- ESTRADIOL in implant preparations for growth promotion in animals.
- 1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND N-METHYLMETHANAMINE.
- ETHER in preparations containing more than 10% of ether for use in internal combustion engines.
- ETHOFUMESATE.
- ETHOXYQUIN except in preparations containing 10% or less of ethoxyquin.
- ETHOXYSULFURON.
- ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:
- (a) when included in Schedule 10; or
- (b) in paints or tinters; or
- (c) in other preparations containing 2.5% or less of ethylene glycol.
- ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations containing 1% or less of ethyl methacrylate as residual monomer in a poly
- ETRIDIAZOLE.
- EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in preparations containing 25% or less of eugenol.
- EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora), except in preparations containing 40% or less of extract of lemo
- FENARIMOL.
- FENBENDAZOLE for the treatment of animals.
- FENBUCONAZOLE.
- FENCHLORAZOLE-ETHYL.
- FENNEL OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compli
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 5% or less of methyl chavicol.
- FENOPROP.
- FENOXAPROP-ETHYL.
- FENOXAPROP-p-ETHYL.
- FENPYRAZAMINE except in preparations containing 40% or less of fenpyrazamine.
- FENSON.
- FENTHION:
- (a) in preparations containing 25% or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or
- (b) in preparations containing 10% or less of fenthion.
- FIPRONIL in preparations containing 10% or less of fipronil except in preparations containing 0.05% or less of fipronil.
- FLAMPROP-METHYL.
- FLAMPROP-M-METHYL.
- FLAZASULFURON.
- FLORASULAM.
- FLUAZAINDOLIZINE in preparations containing 50% or less fluazaindolizine.
- FLUAZURON.
- FLUBENDAZOLE for the treatment of animals.
- FLUBENDIAMIDE.
- FLUCHLORALIN.
- FLUDIOXONIL except in preparations containing 10% or less of fludioxonil.
- FLUMETHRIN:
- (a) when impregnated in plastic resin strip material containing 3% or less of flumethrin; or
- (b) in oil based preparations containing 1% or less of flumethrin.
- FLUMICLORAC PENTYL.
- FLUOPYRAM except in preparations containing 50% or less of fluopyram.
- FLUORIDES in preparations containing 3% or less of fluoride ion except:
- (a) in preparations for human use; or
- (b) in preparations containing 15 mg/kg or less of fluoride ion.
- FLURALANER except when included in Schedule 4.
- FLUVALINATE in aqueous preparations containing 25% or less of fluvalinate.
- FLUXAPYROXAD.
- FORAMSULFURON.
- FORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5% or less of formic acid.
- FOSPIRATE when impregnated in plastic resin strip material containing 20% or less of fospirate.
- FURALAXYL.
- FURATHIOCARB in microencapsulated suspensions containing 50% or less of furathiocarb.
- GAMMA-CYHALOTHRIN in aqueous preparations containing 15% or less of microencapsulated gamma-cyhalothrin.
- GLUFOSINATE-AMMONIUM.
- GLUTARAL in preparations containing 5% or less of glutaral except:
- (a) when included in Schedule 2; or
- (b) in preparations containing 0.5% or less of glutaral when labelled with the statements:
- (A) IRRITANT; and
- (B) Avoid contact with eyes.
- GLYPHOSATE.
- HALOSULFURON-METHYL.
- HEXACONAZOLE except in preparations containing 5% or less of hexaconazole.
- HEXAZINONE in preparations containing 25% or less of hexazinone.
- HOMOBRASSINOLIDE.
- HYDRAMETHYLNON in solid baits containing 2% or less of hydramethylnon in welded plastic labyrinths.
- HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (
- (a) toluene and xylene when included in Schedule 6; or
- (b) benzene and liquid aromatic hydrocarbons when included in Schedule 7; or
- (c) food grade and pharmaceutical grade white mineral oils; or
- (d) in solid or semi-solid preparations; or
- (e) in preparations containing 25% or less of designated solvents; or
- (f) in preparations packed in pressurised spray packs; or
- (g) in adhesives packed in containers each containing 50 g or less of adhesive; or
- (h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or
- (i) in other preparations when packed in containers with a capacity of 2 mL or less.
- HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HCl) except:
- (a) in preparations containing 0.5% or less of hydrochloric acid (HCl); or
- (b) for therapeutic use.
- HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1% or less of hydrogen fluo
- HYDROGEN PEROXIDE (excluding its salts and derivatives):
- (a) in hair dye preparations containing 12% or less of hydrogen peroxide except in hair dyes containing 6% or less of hydrogen peroxide; or
- (b) in other preparations containing 6% (20 volume) or less of hydrogen peroxide except in preparations containing 3% (10 volume) or less of hydrogen peroxide.
- HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1% or less of hydrosilicofluoric acid (H2SiF6).
- 2-HYDROXYETHYL METHACRYLATE except:
- (a) when included in dental restorative preparations for therapeutic use; or
- (b) in nail preparations when labelled “Avoid contact with skin”; or
- (c) in other preparations containing 0.1% or less of 2-hydroxyethyl methacrylate when labelled “Avoid contact with skin”.
- 2-HYDROXYPROPYL METHACRYLATE in nail preparations except when labelled “Avoid contact with skin”.
- IMAZALIL.
- IMAZAMOX except in preparations containing 25% or less of imazamox.
- IMAZAPIC except in preparations containing 25% or less of imazapic.
- IMAZAPYR except in preparations containing 25% or less of imazapyr.
- IMAZETHAPYR except in preparations containing 25% or less of imazethapyr.
- IMIDACLOPRID in preparations containing 20% or less of imidacloprid except in preparations containing 5% or less of imidacloprid.
- IMIPROTHRIN in preparations containing 50% or less of imiprothrin except in preparations containing 10% or less of imiprothrin.
- INDOXACARB (includes the R and S enantiomers) in preparations containing 1% or less of indoxacarb.
- 3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10% or less of 3-iodo-2-propynyl butyl carbamate except:
- (a) in aqueous preparations not for cosmetic use containing 10% or less 3-iodo-2-propynyl butyl carbamate; or
- (b) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3-iodo-2-propynyl butyl carbamate.
- IODOSULFURON-METHYL-SODIUM.
- IPCONAZOLE in preparations containing 2% or less of ipconazole.
- IRON COMPOUNDS:
- (a) for the treatment of animals (excluding up to 1% of iron oxides when present as an excipient):
- (i) in preparations for injection containing 20% or less of iron except in preparations containing 0.1% or less of iron; or
- (ii) in other preparations containing 4% or less of iron except:
- (A) in liquid or gel preparations containing 0.1% or less of iron; or
- (B) in animal feeds or feed premixes; or
- (b) for use as agricultural chemicals except in preparations containing 4% or less of iron.
- ISOEUGENOL in preparations not intended for skin contact containing 25% or less of isoeugenol except in preparations containing 10% or less of isoeugenol.
- ISOPHORONE.
- ISOXABEN.
- ISOXAFLUTOLE.
- IVERMECTIN for use in animals:
- (a) in preparations for the prophylaxis of heartworm in cats and dogs; or
- (b) in intraruminal implants containing 160 mg or less of ivermectin; or
- (c) in preparations containing 3.5% or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authori
- (d) in other preparations containing 2% or less of ivermectin.
- KITASAMYCIN in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.
- LAMBDA-CYHALOTHRIN:
- (a) in aqueous preparations containing 1% or less of lambda- cyhalothrin; or
- (b) in aqueous preparations containing 10% or less of microencapsulated lambda-cyhalothrin.
- LASIODIPLODIA PSEUDOTHEOBROMAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
- LEMON OIL except:
- (a) when steam distilled or rectified; or
- (b) in preparations for internal use; or
- (c) in preparations containing 0.05% or less of lemon oil; or
- (d) in soaps or bath or shower gels that are washed off the skin; or
- (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or
- (f) in other preparations when packed in containers labelled with the statement:
- Application to the skin may increase sensitivity to sunlight.
- LEMONGRASS OIL in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7-dimethyl-2,6-octadienal.
- LEVAMISOLE in preparations containing 15% or less of levamisole for the treatment of animals except:
- (a) when included in Schedule 4; or
- (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.
- LIDOCAINE:
- (a) in aqueous gel preparations containing 4.5% or less of lidocaine, for the dermal spray-on administration to the wounds of animals; or
- (b) in injectable preparations containing 2% or less of lidocaine when packaged in a container with a tamper resistant cartridge which can only be dispensed thr
- LIME OIL except:
- (a) when steam distilled or rectified; or
- (b) in preparations for internal use; or
- (c) in preparations containing 0.5% or less of lime oil; or
- (d) in soaps or bath or shower gels that are washed off the skin; or
- (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or
- (f) in other preparations when packed in containers labelled with the statement:
- Application to the skin may increase sensitivity to sunlight.
- LINDANE in preparations containing 10% or less of lindane except when included in Schedule 2 or 4.
- LOTILANER.
- LUFENURON except:
- (a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or
- (b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.
- MACROPHOMINA PHASEOLINA except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
- MADURAMICIN in animal feed premixes containing 1% or less of antibiotic substances.
- MAGNESIUM CHLORATE except in preparations containing 10% or less of magnesium chlorate.
- MALACHITE GREEN in preparations for veterinary use containing 10% or less of malachite green.
- MALATHION in preparations containing 10% or less of malathion except:
- (a) for human therapeutic use; or
- (b) in dust preparations containing 2% or less of malathion.
- MANCOZEB.
- MANDESTROBIN except in preparations containing 25% or less of mandestrobin.
- MANDIPROPAMID.
- MARJORAM OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compli
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricte
- KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 50% or less of marjoram oil.
- MCPA:
- (a) in preparations containing 25% or less of MCPA (acid); or
- (b) in preparations containing 50% or less of the salts and esters of MCPA.
- MEBENDAZOLE for the treatment of animals:
- (a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or
- (b) in undivided preparations containing 25% or less of mebendazole.
- MECLOFENAMIC ACID for the treatment of animals.
- MECOPROP in preparations containing 2% or less of mecoprop.
- MEFENPYR-DIETHYL.
- MEFENTRIFLUCONAZOLE except in preparations containing 7.5% or less of mefentrifluconazole.
- MEPIQUAT.
- MERCAPTAMINE in cosmetic preparations containing 6% or less of mercaptamine except in preparations containing 1% or less of mercaptamine.
- MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations containing 20% or less of mercaptoacetic acid or its salts (as mercap
- MESOTRIONE.
- METAFLUMIZONE.
- METALAXYL in preparations containing 35% or less of metalaxyl.
- METALDEHYDE in preparations containing 2% or less of metaldehyde.
- METARYLPICOXAMID.
- METAZACHLOR.
- METHABENZTHIAZURON.
- METHANOL (excluding its derivatives) in preparations containing 10 % or less of methanol except:
- (a) when included in Schedule 10; or
- (b) in preparations containing 2% or less of methanol; or
- (c) when methanol is present only as a denaturant of ethanol.
- METHENAMINE in cosmetic preparations, except in preparations containing 0.15% or less of methenamine.
- METHIOCARB in pelleted preparations containing 2% or less of methiocarb.
- METHIOZOLIN.
- METHOXYCHLOR.
- METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) except:
- (a) when included in preparations or admixtures; or
- (b) when packed in containers having a capacity of more than 5 L.
- METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners”.
- METHYLENE BLUE in preparations for veterinary use containing 50% or less of methylene blue.
- METHYL ETHYL KETONE except in preparations containing 25% or less of designated solvents.
- METHYL ETHYL KETONE PEROXIDE.
- METHYL ISOAMYL KETONE except in preparations containing 25% or less of designated solvents.
- METHYL ISOBUTYL KETONE except in preparations containing 25% or less of designated solvents.
- N-METHYL-2-PYRROLIDONE:
- (a) when packed in single use containers having a capacity of 2 mL or less; or
- (b) in preparations containing 50% or less of N-methyl-2-pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N-methyl-2-pyrrol
- METHYL SALICYLATE in preparations containing 25% or less of methyl salicylate except:
- (a) in preparations for therapeutic use; or
- (b) in preparations containing 5% or less of methyl salicylate.
- 2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.
- METIRAM.
- METOBROMURON except in preparations containing 50% or less of metobromuron.
- METOFLUTHRIN:
- (a) in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk; or
- (b) when impregnated into a polyethylene slow release matrix containing 250 mg or less of metofluthrin.
- METOLACHLOR.
- METRAFENONE in preparations containing 50% or less of metrafenone.
- MILBEMECTIN in preparations containing 1% or less of milbemectin.
- MILBEMYCIN OXIME
- (a) for the prophylaxis of heartworm in dogs and cats; or
- (b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with afoxolaner, in
- MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.
- MONEPANTEL.
- MONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of monoethanolamine except:
- (a) when included in Schedule 4; or
- (b) in preparations containing 5% or less of monoethanolamine.
- MORANTEL in preparations containing 25% or less of morantel except in preparations containing 10% or less of morantel.
- MOXIDECTIN:
- (a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5% or less of moxidectin; or
- (b) in preparations for external use for the treatment of cats and dogs, containing 25 mg or less of moxidectin packed in single dose tubes; or
- (c) for internal use for the treatment of animals:
- (i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or
- (ii) in other preparations containing 2% or less of moxidectin.
- MYCLOBUTANIL.
- NAA except in preparations containing 25% or less of NAA.
- NALED when impregnated in plastic resin strip material containing 20% or less of naled.
- NAPTALAM.
- NEOSCYTALIDIUM NOVAEHOLLANDIAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
- NETOBIMIN for the treatment of animals, in preparations containing 12.5% or less of netobimin.
- NICLOSAMIDE in tablet or paste preparations for use in companion animals.
- NICOTINIC ACID when packed and labelled for use as an agricultural chemical.
- NITRIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid (HNO3) except in preparations containing 0.5% or less of
- NITROSCANATE for the treatment of animals.
- NONANOIC ACID:
- (a) when used in a pesticide; or
- (b) in other preparations except in preparations containing 10% or less of nonanoic acid.
- NONOXINOL 9 in preparations containing 25% or less of nonoxinol 9 except:
- (a) when labelled with the statements:
- (i) IRRITANT; and
- (ii) Avoid contact with eyes; or
- (b) in preparations containing 12.5% or less of nonoxinol 9; or
- (c) in preparations for human use.
- NORBORMIDE.
- NUTMEG OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compli
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 50% or less of nutmeg oil.
- N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10% or less of N-octyl bicycloheptene dicarboximide.
- N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50% or less of:
- (a) N-(N-octyl)-2-pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone; or
- (b) N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25% or less of designated solvents.
- OLEANDOMYCIN in animal feed premixes for growth promotion.
- OMETHOATE in pressurised spray packs containing 0.2% or less of omethoate.
- ORANGE OIL (BITTER) except:
- (a) when steam distilled or rectified; or
- (b) in preparations for internal use; or
- (c) in preparations containing 1.4% or less of orange oil (bitter); or
- (d) in soaps or bath or shower gels that are washed off the skin; or
- (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or
- (f) in other preparations when packed in containers labelled with the statement:
- Application to the skin may increase sensitivity to sunlight.
- OXADIARGYL.
- OXADIXYL.
- OXANTEL EMBONATE for the treatment of animals.
- OXFENDAZOLE for the treatment of animals.
- OXIBENDAZOLE for the treatment of animals.
- OXYCARBOXIN.
- OXYTETRACYCLINE in preparations:
- (a) for topical application to animals for ocular use only; or
- (b) containing 40% or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
- OXYTHIOQUINOX.
- PACLOBUTRAZOL.
- PENCONAZOLE.
- PENDIMETHALIN.
- PENFLUFEN.
- PENTHIOPYRAD except in preparations containing 20% or less of penthiopyrad.
- PERACETIC ACID in concentrations of 10% or less of peracetic acid.
- PERMETHRIN (excluding preparations for human therapeutic use):
- (a) in preparations containing 25% or less of permethrin; or
- (b) in preparations for external use, for the treatment of dogs, containing 50% or less of permethrin when packed in single use containers having a capacity of
- except in preparations containing 2% or less of permethrin.
- PETROL except preparations containing 25% or less of petrol.
- PHENAZONE for the external treatment of animals.
- PHENISOPHAM.
- PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15% or less of such subst
- PHENYL METHYL KETONE except in preparations containing 25% or less of designated solvents.
- o-PHENYLPHENOL except in preparations containing 5% or less of o-phenylphenol.
- PHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10% or less of phosphonic acid (H3PO3).
- PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35% or less of phosphoric acid (H3PO4) except:
- (a) in preparations containing 15% or less of phosphoric acid (H3PO4); or
- (b) in solid or semi-solid preparations; or
- (c) in professional dental kits.
- o-PHTHALALDEHYDE in preparations containing 1% or less of o-phthalaldehyde.
- PICARIDIN except in preparations containing 20% or less of picaridin.
- PINE OILS in preparations containing 25% or less of pine oils when packed and labelled as a herbicide.
- PINOXADEN in preparations containing 10% or less of pinoxaden.
- PIPERAZINE for animal use.
- PIRIMICARB in preparations containing 0.5% or less of pirimicarb.
- POLIXETONIUM SALTS in preparations containing 60% or less of polixetonium salts except in preparations containing 1% or less of polixetonium salts.
- POLYETHANOXY (15) TALLOW AMINE.
- POLYOXIN D ZINC SALT.
- POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS.
- POTASSIUM CHLORATE except:
- (a) when included in Schedule 2; or
- (b) in preparations containing 10% or less of potassium chlorate.
- POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide being:
- (a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.
- POTASSIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of potassium metabisulphite.
- POTASSIUM NITRITE in preparations containing 1% or less of potassium nitrite except:
- (a) in preparations containing 0.5% or less of potassium nitrite;
- (b) when present as an excipient in preparations for therapeutic use; or
- (c) in aerosols.
- POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:
- (a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or
- (b) liquid or semi-solid preparations, the pH of which is less than 2.5.
- POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.
- PRALLETHRIN (cis:trans=20:80) in preparations containing 10% or less of prallethrin except in insecticidal mats containing 1% or less of prallethrin.
- PROFOXYDIM except in preparations containing 20% or less of profoxydim.
- PROGESTERONE:
- (a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or
- (b) in implant preparations for growth promotion in cattle.
- PROHEXADIONE CALCIUM.
- PROMETRYN.
- PROPAMOCARB.
- PROPANIL.
- PROPAQUIZAFOP.
- PROPICONAZOLE in preparations containing 20% or less of propiconazole.
- PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80% or less of propionic acid, except:
- (a) in preparations containing 30% or less of propionic acid; or
- (b) for therapeutic use.
- PROPOXUR:
- (a) when impregnated in plastic resin strip material containing 10% or less of propoxur; or
- (b) in dust preparations containing 3% or less of propoxur; or
- (c) in granular sugar-based fly baits containing 1% or less of propoxur, a dark colouring agent and a separate bittering agent; or
- (d) in pressurised spray packs containing 2% or less of propoxur; or
- (e) in printed paper sheets for pest control containing 0.5% or less of propoxur and in any case not more than 100 mg of propoxur per sheet.
- n-PROPYL ALCOHOL in preparations containing 10% or less of n-propyl alcohol except:
- (a) in preparations containing 5% or less of n-propyl alcohol; or
- (b) in preparations for cosmetic or therapeutic use other than in spray form.
- PROPYZAMIDE.
- PROTHIOCONAZOLE-DESCHLORO except in preparations containing 0.5% or less of prothioconazole-deschloro.
- PROTHIOCONAZOLE-TRIAZOLIDINETHIONE except in preparations containing 0.5% or less of prothioconazole-triazolidinethione.
- PYMETROZINE.
- PYRACLOSTROBIN.
- PYRAFLUFEN-ETHYL.
- PYRASULFOTOLE.
- PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:
- (a) in preparations for human therapeutic use; or
- (b) in preparations containing 10% or less of such substances.
- PYRIDABEN in preparations containing 25% or less of pyridaben.
- PYRIFENOX.
- PYRITHIOBAC SODIUM.
- PYRITHIONE ZINC in paints containing 0.5% or less of pyrithione zinc calculated on the non-volatile content of the paint except in paints containing 0.1% or les
- PYRIOFENONE in preparations containing 30% or less of pyriofenone.
- QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20% or less of quaternary ammonium compounds except:
- (a) when separately specified in these Schedules; or
- (b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C
- (c) in preparations containing 5% or less of such quaternary ammonium compounds.
- QUINCLORAC.
- QUININE in preparations for veterinary use containing 1% or less of quinine.
- QUINTOZENE.
- QUIZALOFOP-p-ETHYL in aqueous preparations containing 40% or less of quizalofop-p-ethyl.
- RACTOPAMINE in animal feed premixes containing 10% or less of ractopamine.
- RESMETHRIN in preparations containing 10% or less of resmethrin.
- RIMSULFURON.
- ROBENIDINE except in preparations containing 20% or less of robenidine.
- ROSIN when packaged for use as a soldering flux or in flux-cored solder.
- SAFLUFENACIL in water dispersible granules or a water-based suspension concentrate.
- SALICYLANILIDE.
- SAROLANER for veterinary use in divided preparations each containing 120 mg or less of sarolaner per dosage unit.
- SEDAXANE.
- SELAMECTIN except in preparations containing 12% or less of selamectin.
- SETHOXYDIM.
- SIDURON.
- SILICOFLUORIDES in preparations containing 3% or less of fluoride ion except:
- (a) barium silicofluoride when separately specified in this Schedule; or
- (b) in preparations containing 15 mg/kg or less of fluoride ion.
- SINBIOALLETHRIN in preparations containing 10% or less of sinbioallethrin except in preparations containing 1% or less of sinbioallethrin.
- SODIUM BROMIDE except when included in Schedule 4.
- SODIUM CHLORATE except in preparations containing 10% or less of sodium chlorate.
- SODIUM DIACETATE except in preparations containing 60% or less of sodium diacetate.
- SODIUM DODECYLBENZENE SULFONATE except in preparations containing 30% or less of sodium dodecylbenzene sulfonate.
- SODIUM HYDROGEN SULFATE except in preparations containing 10% or less of sodium hydrogen sulfate.
- SODIUM HYDROSULFITE when packed for domestic use except in preparations containing 10% or less of sodium hydrosulfite.
- SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide being:
- (a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.
- SODIUM LAURETH-6 CARBOXYLATE except in preparations containing 1% or less of sodium laureth-6 carboxylate.
- SODIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of sodium metabisulphite.
- SODIUM NITRITE in preparations containing 1% or less of sodium nitrite except:
- (a) in preparations containing 0.5% or less of sodium nitrite; or
- (b) when present as an excipient in preparations for therapeutic use; or
- (c) in aerosols.
- SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35% or less of sodium percarbonate except in preparations containing 15% or less of sodium p
- SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in preparations containing 10% or less of sodium polystyrene sulphonate.
- SODIUM STANNATE except in preparations for cosmetic use containing 1% or less of sodium stannate.
- SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.
- SPIDOXAMAT.
- SPINETORAM.
- SPINOSAD except in aqueous suspensions containing 25% or less of spinosad.
- SPIROMESIFEN for agricultural use.
- STAR ANISE OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compli
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricte
- KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 50% or less of star anise oil.
- STYRENE (excluding its derivatives).
- SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
- SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
- SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
- SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
- SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of sulfamic acid (H3NO3S).
- SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
- SULFOMETURON-METHYL.
- SULFOXAFLOR in preparations containing 25% or less of sulfoxaflor.
- SYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use.
- 2,3,6-TBA.
- TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10% or less of TDE.
- TEBUCONAZOLE.
- TEBUFENOZIDE.
- TEFLUTHRIN in preparations containing 2% or less of tefluthrin.
- TEMEPHOS:
- (a) in liquid preparations containing 10% or less of temephos; or
- (b) in powders containing 2% or less of temephos; or
- (c) in preparations containing 40% or less of temephos when packed in single use containers having a capacity of 2 mL or less.
- TEPRALOXYDIM.
- TERBUTRYN.
- TETRACHLOROETHYLENE in preparations containing 5% or less of tetrachloroethylene except:
- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of animals; or
- (c) when absorbed into an inert solid.
- TETRACHLORVINPHOS except in animal feeds containing 0.2% or less of tetrachlorvinphos.
- TETRACONAZOLE in preparations containing 20% or less of tetraconazole.
- TETRACYCLINE in preparations:
- (a) for topical application to animals for ocular use only; or
- (b) containing 40% or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
- TETRAMETHRIN [(R, cis): (R, trans) = 20:80] except in pressurised spray packs.
- TETRANILIPROLE except in preparations containing 20% or less tetraniliprole.
- THIABENDAZOLE:
- (a) for the treatment of animals; or
- (b) when packed and labelled for use as a fungicide except in preparations containing 50% or less of thiabendazole.
- THIAMETHOXAM in preparations containing 60% or less of thiamethoxam.
- THIAZOPYR.
- THIFENSULFURON.
- THIOBENCARB.
- THIODICARB in pelleted preparations containing 1.5% or less of thiodicarb.
- THIOPHANATE-METHYL in preparations containing 25% or less of thiophanate-methyl.
- THYME OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compli
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 50% or less of thyme oil.
- TIGOLANER in preparations containing 10% or less of tigolaner.
- TIOCARBAZIL.
- TOLCLOFOS-METHYL.
- TOLTRAZURIL.
- TOPRAMEZONE
- TRALKOXYDIM.
- TRENBOLONE in implant preparations for growth promotion in animals.
- TRIADIMEFON in wettable powders containing 25% or less of triadimefon.
- TRIADIMENOL.
- TRI-ALLATE.
- TRIBENURON-METHYL.
- TRICHLOROACETIC ACID, alkali salts of.
- 1,1,1-TRICHLOROETHANE except:
- (a) in preparations packed in pressurised spray packs; or
- (b) in preparations containing 25% or less of designated solvents; or
- (c) in preparations, other than writing correction fluids or thinners for writing correction fluids in containers having a capacity of 50 mL or less; or
- (d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:
- (i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and
- (ii) the expression:
- WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;
- written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.
- TRIDIPHANE.
- TRIETAZINE.
- TRIFLOXYSTROBIN.
- TRIFLUDIMOXAZIN except in preparations containing 12.5% or less.
- TRIFLUMIZOLE.
- TRIFLUMURON.
- TRIISOPROPANOLAMINE LAURYL ETHER SULFATE except in preparations containing 30% or less of triisopropanolamine lauryl ether sulfate when labelled with the statem
- (a) Avoid contact with eyes and skin; and
- (b) Wash hands after handling.
- TRINEXAPAC-ETHYL except:
- (a) when packed in a sealed water-soluble measure pack; or
- (b) in solid preparations containing 25% or less of trinexapac-ethyl in packs of 50 g or less.
- 3,6,9-TRIOXAUNDECANEDIOIC ACID except in preparations containing 5% or less of 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.
- TRITICONAZOLE.
- TROLAMINE (excluding its salts and derivatives) except:
- (a) when in Schedule 4; or
- (b) in preparations containing 5% or less of trolamine.
- TURPENTINE OIL except in preparations containing 25% or less of turpentine oil.
- VIRGINIAMYCIN in animal feed additives containing 1% or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.
- VERNOLATE.
- WARFARIN in rodent baits containing 0.1% or less of warfarin.
- ZINEB.
- Schedule 6 · Poisons
- Note: See section 16, subsection 46(2), section 49, subsection 54(3) and sections 55 and 61.
- ABAMECTIN:
- (a) in preparations for pesticidal use containing 4% or less of abamectin except when included in Schedule 5; or
- (b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.
- ACEPHATE.
- ACETAMIPRID except in preparations containing 1% or less of acetamiprid.
- ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) except when included in Schedule 2.
- ACETIC ANHYDRIDE excluding its derivatives.
- ACIFLUORFEN.
- ACINITRAZOLE except in preparations containing 20% or less of acinitrazole.
- ACLONIFEN.
- ALBENDAZOLE for the treatment of animals except:
- (a) when included in Schedule 5; or
- (b) in intraruminal implants each containing 3.85 g or less of albendazole.
- ALDRIN.
- ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:
- (a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
- (b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.
- ALKOXYLATED FATTY ALKYLAMINE POLYMER except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.
- ALLETHRIN except:
- (a) when included in Schedule 5; or
- (b) in insecticidal mats containing 20% or less of allethrin; or
- (c) in other preparations containing 1% or less of allethrin.
- ALLYL ESTERS (excluding derivatives) being:
- (a) ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9); or
- (b) ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5); or
- (c) ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8); or
- (d) ALLYL HEXANOATE (CAS No. 123-68-2); or
- (e) ALLYL ISOVALERATE (CAS No. 2835-39-4); or
- (f) ALLYL NONANOATE (CAS No. 7493-72-3); or
- (g) ALLYL OCTANOATE (CAS No. 4230-97-1); or
- (h) ALLYL PHENYLACETATE (CAS No. 1797-74-6); or
- (i) ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9); or
- (j) ALLYL PHENOXYACETATE (CAS No. 7493-74-5); or
- (k) ALLYL (CYCLOHEXYLOXY)ACETATE (CAS No. 68901-15-5);
- in preparations containing 0.1% or less of free allyl alcohol by weight of allyl ester except in preparations containing 5% or less of allyl esters with 0.1% or
- ALPHA-CYPERMETHRIN:
- (a) in aqueous preparations containing 30% or less of alpha-cypermethrin; or
- (b) in other preparations containing 10% or less of alpha-cypermethrin;
- except when included in Schedule 5.
- AMICARBAZONE.
- AMIDITHION.
- AMIDOPROPYL BETAINES except:
- (a) in cosmetic wash-off preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines when labelled with
- IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or
- (b) in cosmetic leave-on preparations containing 1.5% or less of amidopropyl betaines; or
- (c) in other preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines, when labelled with warnings to
- (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
- (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.
- 2-AMINO-6-CHLORO-4-NITROPHENOL in hair dye and eyebrow/eyelash colouring preparations, except:
- (a) in preparations containing 2% or less of 2-amino-6-chloro-4-nitrophenol when applied directly to the hair, or containing 2% or less of 2-amino-6-chloro-4-ni
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- (b) in eyelash and eyebrow tinting products containing 1.5% or less of 2-amino-6-chloro-4-nitrophenol after mixing for use when the immediate container and prim
- WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause in
- written in letters not less than 1.5mm in height.
- 4-AMINO-m-CRESOL in hair dyes and eyebrow/eyelash colouring preparations except:
- (a) in hair dye preparations containing 1.5% or less of 4-amino-m-cresol after mixing for use when the immediate container and primary pack are labelled with th
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5mm in height; or
- (b) in eyelash and eyebrow tinting products containing 1.5% or less of 4-amino-m-cresol after mixing for use when the immediate container and primary pack are l
- WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause in
- written in letters not less than 1.5mm in height.
- 2-AMINO-5-ETHYLPHENOL in hair dye preparations except in preparations containing 1% or less of 2-amino-5-ethylphenol when the immediate container and primary pa
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directi
- written in letters not less than 1.5 mm in height.
- 4-AMINO-2-HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products except:
- (a) in hair dye preparations containing 1.5% or less of 4-amino-2-hydroxytoluene after mixing for use when the immediate container and primary pack are labelled
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5mm in height; or
- (b) in eyelash and eyebrow tinting products containing 1.5% or less of 4-amino-2-hydroxytoluene after mixing for use when the immediate container and primary pa
- WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause in
- written in letters not less than 1.5mm in height.
- AMINOCARB in preparations containing 25% or less of aminocarb.
- AMINOETHOXYVINYLGLYCINE except in preparations containing 15% or less of aminoethoxyvinylglycine.
- 1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.
- 4-AMINO-3-NITROPHENOL except:
- (a) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4-amino-3-nitrophenol when the immediate container an
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (b) in oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4-amino-3-nitrophenol after mixing under oxidative condit
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height.
- 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL (including its salts) except:
- (a) in non-oxidative hair dye preparations containing 2.5% or less of 2,2'-[(4-amino-3-nitrophenyl)imino]bisethanol after mixing when the immediate container an
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (b) in oxidative hair dye preparations containing 1.25% or less of 2,2'-[(4-amino-3-nitrophenyl)imino]bisethanol after mixing under oxidative conditions when th
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height.
- m-AMINOPHENOL except when used in hair dye and eyebrow/eyelash preparations at a concentration of 1.2% or less of m-aminophenol after mixing for use when the im
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- p- AMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of p-aminophenol after mixing for use when t
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- AMINOPYRALID except when included in Schedule 5.
- AMITRAZ.
- AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except:
- (a) when included in Schedule 5; or
- (b) in preparations for human internal therapeutic use; or
- (c) in preparations for inhalation when absorbed in an inert solid material; or
- (d) in preparations containing 0.5% or less of ammonia.
- AMMONIUM COCOYL ISETHIONATE, except in cosmetic rinse-off preparations containing 30% or less of ammonium cocoyl isethionate and, if containing more than 5% of
- IF IN EYES WASH OUT IMMEDIATELY WITH WATER.
- AMMONIUM PERSULFATE in hair preparations.
- ANILINE (excluding its salts and derivatives) except in preparations containing 1% or less of aniline.
- ANTIMONY COMPOUNDS except:
- (a) when included in Schedule 4; or
- (b) antimony chloride in polishes; or
- (c) antimony titanate pigments in paint; or
- (d) in paints or tinters containing 5% or less of antimony calculated on the non-volatile content of the paint or tinter.
- ARBUTIN (ALPHA) except:
- (a) in preparations for application to the face containing 2% or less alpha-arbutin with hydroquinone levels of 10mg/kg or less; or
- (b) in preparations for application to the body containing 0.5% or less alpha-arbutin with hydroquinone levels of 10mg/kg or less.
- ARBUTIN (BETA) except:
- (a) when included in Schedule 4; or
- (b) oral herbal preparations containing 500 mg or less beta-arbutin per recommended daily dose; or
- (c) in preparations for application to the face containing 7% or less beta-arbutin with hydroquinone levels of 10mg/kg or less.
- ARBUTIN (DEOXY OR OTHER DERIVATIVES).
- ARSENIC:
- (a) in ant poisons containing 0.4% or less of arsenic; or
- (b) in animal feed premixes containing 4% or less of arsenic; or
- (c) in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4,
- except when separately specified in this Schedule.
- ASPIRIN for the treatment of animals except when included in Schedule 4 or 5.
- AZACONAZOLE except in preparations containing 1% or less of azaconazole.
- AZADIRACHTA INDICA (Neem) including its extracts and derivatives except:
- (a) when included in Schedule 5; or
- (b) in preparations for human internal use; or
- (c) debitterised neem seed oil; or
- (d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compli
- (e) in preparations for dermal use containing 1% or less of cold pressed neem seed oil.
- AZAMETHIPHOS.
- AZOBENZENE.
- BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.
- BARIUM SALTS except:
- (a) when included in Schedule 5; or
- (b) barium sulfate; or
- (c) in paints or tinters containing 5% or less of barium calculated on the non-volatile content of the paint or tinter.
- BASIC BLUE 26 (CAS No. 2580-56-5) except when used as a colourant in cosmetics not intended to be in contact with mucous membranes.
- BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) except:
- (a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or
- (b) in hair dye preparations containing 1% or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:
- (i) KEEP OUT OF REACH OF CHILDREN;
- (ii) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
- (iii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying direc
- written in letters not less than 1.5 mm in height.
- BASIC RED 76 (CAS No. 68391-30-0) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products containing 2% or less of Basic Red 76 and 0.001%
- BAY OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (e) in preparations containing 25% or less of bay oil.
- BEAUVERIA BASSIANA except when included in Schedule 5.
- BENDIOCARB:
- (a) in wettable powders containing 80% or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb; or
- (b) in wettable powders containing 20% or less of bendiocarb and not less than 0.002% of denatonium benzoate when packed in containers or primary packs containi
- (c) in insoluble granular preparations containing 5% or less of bendiocarb; or
- (d) when impregnated in plastic resin strip material containing 10% or less of bendiocarb;
- except when included in Schedule 5.
- BENQUINOX.
- BENSULIDE.
- BENZALKONIUM CHLORIDE except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 5% or less of benzalkonium chloride.
- 1,2-BENZENEDIOL.
- BENZOVINDIFLUPYR.
- 6-BENZYLADENINE except in preparations containing 10% or less of 6-benzyladenine.
- BERYLLIUM.
- BETACYFLUTHRIN in preparations containing 12.5% or less of betacyfluthrin except when included in Schedule 5.
- BETA-CYPERMETHRIN.
- BHC (excluding lindane).
- BICYCLOPYRONE except when included in Schedule 5.
- BIFENTHRIN in preparations containing 25% or less of bifenthrin except in preparations containing 0.5% or less of bifenthrin.
- BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3% or less of total bifluorides except when included in Schedule 5.
- BIOALLETHRIN except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 1% or less of bioallethrin.
- 1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE (including its salts) except when in hair dye preparations containing 1.2% or less of 1,3-bis(2,4-diaminophenoxy)propane afte
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER except in rinse-off cosmetic products containing 1% or less of bis-isobutyl PEG/PPG-20/35/amodimeticone copol
- IF IN EYES, WASH OUT IMMEDIATELY WITH WATER.
- N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE except in preparations containing 1% or less of N,N-bis(phenylmethylene)-bicyclo- (2.2.1)hepta
- (a) IRRITANT; and
- (b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and
- (c) Avoid contact with eyes; and
- (d) Avoid contact with skin; and
- (e) Wear protective gloves when mixing or using; and
- (f) Ensure adequate ventilation when using.
- N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE except in preparations containing 1% or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptan
- (a) IRRITANT; and
- (b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and
- (c) Avoid contact with eyes; and
- (d) Avoid contact with skin; and
- (e) Wear protective gloves when mixing or using; and
- (f) Ensure adequate ventilation when using.
- BITHIONOL for the treatment of animals.
- BORON TRIFLUORIDE in preparations containing 1% or less of boron trifluoride (BF3) except when included in Schedule 5.
- BPA GLYCIDYL DIACRYLATE in preparations for cosmetic use.
- BPA GLYCIDYL DIMETHACRYLATE in preparations for cosmetic use.
- BRODIFACOUM in preparations containing 0.25% or less of brodifacoum.
- BROFLANILIDE except when included in Schedule 5.
- BROMADIOLONE in preparations containing 0.25% or less of bromadiolone.
- BROMETHALIN in rodent baits containing 0.01% or less of bromethalin.
- BROMOFORM except when included in Schedule 4.
- BROMOPHOS.
- BROMOPHOS-ETHYL.
- BROMOXYNIL in preparations containing 1.5% or less of bromoxynil.
- BROMUCONAZOLE except when included in Schedule 5.
- BROTIANIDE.
- BUNAMIDINE.
- BUTACARB.
- BUTOXYCARBOXIM except when included in Schedule 5.
- 2-BUTOXYETHANOL and its acetates except:
- (a) in plant growth regulator preparations containing 20% or less of such substances; or
- (b) in other preparations containing 10% or less of such substances.
- 2-BUTOXY-2'-THIOCYANODIETHYL ETHER.
- n-BUTYL ALCOHOL except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 5% or less of n-butyl alcohol; or
- (c) in preparations for cosmetic or therapeutic use other than in spray form.
- BUTYRIC ACID in preparations for use as insect lures.
- CACODYLIC ACID:
- (a) in animal feed premixes containing 4% or less of arsenic; or
- (b) in herbicide or defoliant preparations containing 10% or less of cacodylic acid.
- CADMIUM COMPOUNDS except:
- (a) when included in Schedule 4; or
- (b) in paints or tinters containing 0.1% or less of cadmium calculated on the non-volatile content of the paint or tinter.
- CADUSAFOS in aqueous preparations containing 20% or less of microencapsulated cadusafos.
- CAFFEINE except:
- (a) when included in Schedule 4; or
- (b) in divided preparations for internal human therapeutic use when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine;
- (c) in undivided preparations for internal human therapeutic use with a concentration of less than 5% of total caffeine and when labelled with a maximum recomme
- (d) in preparations for external use; or
- (e) in other preparations with a concentration of less than 5% of caffeine.
- CAJUPUT OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (e) in preparations containing 25% or less of cajuput oil; or
- (f) in oils containing 25% or less of cajuput oil.
- CALCIFEROL in rodent baits containing 0.1% or less of calciferol.
- CAMBENDAZOLE.
- CAMPHOR except:
- (a) when included in Schedule 4 or 5; or
- (b) when enclosed in an inhaler device which prevents ingestion of its contents; or
- (c) in solid or semi-solid preparations containing 12.5% or less of camphor; or
- (d) in liquid preparations containing 2.5% or less of camphor; or
- (e) in essential oils when the camphor is present as a natural component of the oil:
- (i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chi
- (iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restr
- (A) KEEP OUT OF REACH OF CHILDREN; and
- (B) NOT TO BE TAKEN; or
- (iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restri
- (A) KEEP OUT OF REACH OF CHILDREN; and
- (B) NOT TO BE TAKEN; or
- (f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.
- CAPTAN.
- CARBARYL except when included in Schedule 4 or 5.
- CARBON DISULFIDE.
- CARBAMIDE PEROXIDE except:
- (a) when included in Schedule 5; or
- (b) in other preparations containing 9% or less of carbamide peroxide.
- CARBETAMIDE.
- CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use except in wash-off preparations containing 1% or less of castor o
- CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.
- CHLORDANE.
- CHLORFENAPYR in preparations containing 36% or less of chlorfenapyr except when included in Schedule 5.
- CHLORFENETHOL.
- CHLORHEXIDINE in preparations containing 7% or less of chlorhexidine except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 1% or less of chlorhexidine; or
- (c) when in solid preparations.
- CHLORINATING COMPOUNDS except:
- (a) when included in Schedule 5; or
- (b) when separately specified in these Schedules; or
- (c) sodium hypochlorite preparations with a pH of less than 11.5; or
- (d) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:
- WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or
- (e) in liquid preparations containing less than 2% of available chlorine; or
- (f) in other preparations containing 4% or less of available chlorine.
- CHLORMEQUAT.
- CHLOROACETAMIDE
- (a) in preparations for cosmetic use; or
- (b) in preparations for topical therapeutic use; or
- (c) in other preparations containing more than 0.3% of chloroacetamide.
- 2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL except:
- (a) in non-oxidative hair dye preparations containing 3% or less of 2-chloro-6-(ethylamino)-4-nitrophenol after mixing for use when the immediate container and
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (b) in oxidative hair dye preparations containing 1.5% or less of 2-chloro-6-(ethylamino)-4-nitrophenol after mixing for use when the immediate container and pr
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height.
- CHLOROFORM except:
- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 10% or less of chloroform.
- ALPHA-CHLOROHYDRIN.
- CHLOROPHACINONE.
- (E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) except in preparations containing 5% or less of (E)-(S)-1-(4-chl
- CHLOROPICRIN in preparations containing 5% or less of chloropicrin.
- CHLOROTHALONIL except in water-based paint containing 0.5% or less of chlorothalonil.
- 2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE.
- CHLORPYRIFOS except:
- (a) when included in Schedule 5; or
- (b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.
- CHLORPYRIFOS-METHYL.
- CHLORTHIAMID.
- CHROMATES (including dichromates) except in paints or tinters containing 5% or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, stron
- CHROMIUM TRICHLORIDE HEXAHYDRATE except in preparations containing 0.5% or less chromium.
- CHROMIUM TRIOXIDE (excluding its salts and derivatives).
- CHRYSOIDINE BASE except when in Schedule 10.
- CINEOLE except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (e) in preparations containing 25% or less of cineole; or
- (f) in oils containing 25% or less of cineole; or
- (g) in rosemary oil or camphor oil (white).
- CINNAMON LEAF OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (e) in preparations containing 25% or less of cinnamon leaf oil.
- CLIMBAZOLE except:
- (a) when included in Schedule 5; or
- (b) in leave-on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or
- (c) in other preparations (that are not leave-on cosmetic preparations) containing 2% or less of climbazole.
- CLODINAFOP-PROPARGYL.
- CLOMAZONE.
- CLOSANTEL.
- CLOTHIANIDIN except
- (a) when included in Schedule 5; or
- (b) when in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.
- CLOTRIMAZOLE for the external treatment of animals.
- CLOVE OIL except:
- (a) when included in Schedule 5; or
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN;
- (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (f) in preparations containing 25% or less of clove oil.
- N-COCO-1,3-DIAMINOPROPANE.
- COCOYL GLYCINATE in cosmetic preparations except:
- (a) in leave-on preparations containing 5% or less of cocoyl glycinate; or
- (b) in wash-off preparations containing 30% or less of cocoyl glycinate and, when containing more than 5% of cocoyl glycinate labelled with a warning to the fol
- IF IN EYES WASH OUT IMMEDIATELY WITH WATER.
- COPPER ACETATE except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 5% or less of copper acetate.
- COPPER COMPOUNDS except:
- (a) when separately specified in these Schedules; or
- (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or
- (c) pigments where the solubility of the copper compound(s) in water is 1 g per litre or less; or
- (d) in feed additives containing 1% or less of copper; or
- (e) in other preparations containing 5% or less of copper compounds.
- COPPER HYDROXIDE except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 12.5% or less of copper hydroxide.
- COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.
- COPPER OXIDES except:
- (a) when included in Schedule 5; or
- (b) in preparations for internal use; or
- (c) in marine paints; or
- (d) in other preparations containing 5% or less of copper oxides.
- COPPER OXYCHLORIDE except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 12.5% of less of copper oxychloride.
- COPPER SULFATE except:
- (a) when included in Schedule 5; or
- (b) in preparations for internal use; or
- (c) in other preparations containing 5% or less of copper sulfate.
- COUMAPHOS:
- (a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or
- (b) in other preparations containing 5% or less of coumaphos.
- COUMATETRALYL in rodenticides containing 1% or less of coumatetralyl except when included in Schedule 5.
- CREOSOTE derived from wood other than beechwood except:
- (a) when included in Schedule 2; or
- (b) in preparations for human therapeutic use containing 10% or less of creosote derived from wood other than beechwood; or
- (c) in other preparations containing 3% or less of phenols and homologues of phenol boiling below 220°C.
- CROTOXYPHOS.
- CRUFOMATE.
- CYANAMIDE.
- CYANAZINE.
- CYCLANILIDE.
- N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM.
- CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) when p
- (a) DO NOT USE WITHOUT PROTECTIVE GLOVES; and
- (b) KEEP OUT OF EYES.
- CYFLUTHRIN except:
- (a) when included in Schedule 5; or
- (b) in pressurised spray packs containing 1% or less of cyfluthrin.
- CYOMETRINIL.
- CYPERMETHRIN except when included in Schedule 5.
- CYPHENOTHRIN except when included in Schedule 5.
- CYTHIOATE except when included in Schedule 5.
- 2,4-D except when included in Schedule 5.
- DAZOMET.
- DELTAMETHRIN:
- (a) in aqueous preparations containing 25% or less of deltamethrin, when no organic solvent, other than 10% or less of a glycol, is present; or
- (b) in wettable granular preparations containing 25% or less of deltamethrin; or
- (c) in water-dispersible tablets each containing 500 mg or less of deltamethrin; or
- (d) in emulsifiable concentrates containing 11% or less of deltamethrin in a solvent containing 40% or less of acetophenone and 45% or less of liquid hydrocarbo
- (e) in other preparations containing 3% or less of deltamethrin;
- except:
- (f) when included in Schedule 5; or
- (g) in factory prepared mosquito nets containing 1% or less of deltamethrin; or
- (h) in preparations containing 0.1% or less of deltamethrin.
- DERQUANTEL.
- 1-DEOXY-1-(METHYLAMINO)-d-GLUCITOL N-COCO ACYL DERIVATIVES except:
- (a) in cosmetic rinse-off preparations containing 8% or less of 1-deoxy-1-(methylamino)-d-glucitol N-coco acyl derivatives when labelled with the following stat
- IF IN EYES WASH OUT IMMEDIATELY WITH WATER, or
- (b) in household cleaning preparations, other than those intended to be sprayed, containing 10% or less of 1-deoxy-1-(methylamino)-d-glucitol N-coco acyl deriva
- IF IN EYES WASH OUT IMMEDIATELY WITH WATER.
- 2,4-DIAMINOPHENOXYETHANOL except when used in hair dye and eyebrow/eyelash preparations at concentrations of 2% or less of 2,4-diaminophenoxyethanol after mixin
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- DIAZINON except when included in Schedule 5.
- DICAMBA (including its salts and derivatives) except when included in Schedule 5.
- DICHLOBENIL.
- DICHLOFENTHION.
- DICHLOFLUANID.
- o-DICHLOROBENZENE.
- DICHLOROETHYL ETHER.
- DICHLOROISOCYANURIC ACID except:
- (a) when included in Schedule 5; or
- (b) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:
- WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or
- (c) in liquid preparations containing less than 2% of available chlorine; or
- (d) in other preparations containing 4% or less of available chlorine.
- 4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.
- DICHLOROPHEN except:
- (a) when included in Schedule 4 or 5; or
- (b) in fabrics other than when:
- (i) for human therapeutic use; or
- (ii) as part of a registered pesticidal product.
- 1,2-DICHLOROPROPANE.
- 2,4-DICHLORPROP (including the R and S enantiomers).
- DICHLORVOS in preparations containing 50% or less of dichlorvos except when included in Schedule 5.
- DICLOFOP-METHYL.
- DICYCLANIL except in preparations containing 6.5% or less of dicyclanil.
- DIDECYLDIMETHYLAMMONIUM SALTS except in preparations containing 1% or less of didecyldimethylammonium salts labelled with the statement:
- Avoid contact with eyes.
- DIELDRIN.
- DIETHANOLAMINE (excluding its salts and derivatives) except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 5% or less of diethanolamine.
- DIETHYLENE GLYCOL (excluding its salts and derivatives) except:
- (a) when included in Schedule 5 or 10; or
- (b) in paints or paint tinters; or
- (c) in other preparations containing 2.5% or less of diethylene glycol.
- DIETHYLENE GLYCOL MONOMETHYL ETHER.
- DIFENACOUM in preparations containing 0.25% or less of difenacoum.
- DIFENZOQUAT.
- DIFETHIALONE in rodent baits containing 0.0025% or less of difethialone.
- 5,6-DIHYDROXYINDOLINE.
- DIMETHENAMID-P.
- DIMETHIPIN.
- DIMETHOATE.
- 2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 0.25% or less of 2,6-dimethoxy-3,5-p
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- DIMETHYLACETAMIDE except when included in Schedule 5.
- N,N-DIMETHYLDECANAMIDE.
- DIMETHYLFORMAMIDE except:
- (a) when included in Schedule 5; or
- (b) in silicone rubber mastic containing 2% or less of dimethylformamide.
- 4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL except:
- (a) in leave-on cosmetic preparations containing 0.1% or less of 4,4-dimethyl-1-cyclohexene-1-propanal; or
- (b) in rinse-off cosmetic preparations containing 0.5% or less of 4,4-dimethyl-1-cyclohexene-1-propanal; or
- (c) in other preparations containing 1% or less of 4,4-dimethyl-1-cyclohexene-1-propanal.
- DIMETHYL DISULFIDE for agricultural use as a soil fumigant.
- 3,7-DIMETHYL-2,6-OCTADIEN-1-OL and its isomers except in products containing 5% or less 3,7-dimethyl-2,6-octadien-1-ol and its isomers.
- N,N-DIMETHYLOCTANAMIDE.
- DIMETHYL SULFOXIDE (excluding dimethyl sulfone):
- (a) when not for therapeutic use; or
- (b) in cosmetic preparations; or
- (c) for the treatment of animals:
- (i) when combined with no other therapeutic substance(s); or
- (ii) in liquid preparations containing copper salicylate and 1% or less of methyl salicylate as the only other therapeutic substances; or
- (iii) in clay poultices containing 2% or less of dimethyl sulfoxide; or
- (d) in other preparations except when containing 10% or less of dimethyl sulfoxide.
- DIMPROPYRIDAZ except when included in Schedule 5.
- DINITROCRESOLS and their homologues in preparations containing 5% or less of such compounds except:
- (a) when included in Schedule 4; or
- (b) when separately specified in this Schedule.
- DINITROPHENOLS and their homologues in preparations containing 5% or less of such compounds except:
- (a) when included in Schedule 4; or
- (b) when separately specified in this Schedule.
- DIOXACARB.
- DIOXANE except:
- (a) in preparations for cosmetic or human internal therapeutic use containing 0.001% or less of dioxane; or
- (b) in other preparations containing 0.01% or less of dioxane.
- DIPHACINONE.
- DIQUAT in preparations containing 20% or less of diquat.
- DIRECT RED 254 except when included in Schedule 5.
- DISPERSE YELLOW 3 except when in Schedule 10.
- DISULFIRAM except when included in Schedule 4.
- DISULFOTON in granular preparations containing 5% or less of disulfoton.
- DITHIANON.
- DITHIAZANINE in preparations containing 2% or less of dithiazanine for the treatment of animals.
- DIUREDOSAN.
- (Z,E)-7,9,11-DODECATRIENYL FORMATE for agricultural use as an insect pheromone, except when enclosed in a device which, in normal use, prevents access to its co
- N-(N-DODECYL)-2-PYRROLIDONE except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 25% or less of designated solvents.
- DODINE.
- DORAMECTIN for external use for the treatment of animals, in preparations containing 2% or less of doramectin.
- DSMA in herbicide or defoliant preparations containing 10% or less of DSMA.
- ECONAZOLE for the external treatment of animals.
- EMAMECTIN in preparations containing 5% or less of emamectin except when included in Schedule 5.
- EMODEPSIDE for the treatment of animals except when included in Schedule 5.
- ENDOSULFAN in aqueous preparations containing 33% or less of microencapsulated endosulfan.
- ENDOTHAL in preparations containing 20% or less of endothal.
- EPRINOMECTIN for internal use in preparations containing 5% or less of eprinomectin except when included in Schedule 5.
- EPTC.
- ESBIOTHRIN except:
- (a) when included in Schedule 5; or
- (b) in pressurised spray packs containing 1% or less of esbiothrin.
- ESFENVALERATE except when included in Schedule 5.
- ETHEPHON (excluding its salts and derivatives).
- ETHER except:
- (a) when included in Schedule 2, 4 or 5; or
- (b) in preparations containing 10% or less of ether.
- ETHIOFENCARB.
- ETHOATE-METHYL.
- ETHOPROPHOS in granular formulations containing 10% or less of ethoprophos and 2% of linseed oil.
- ETHYL BROMIDE.
- ETHYLENE CHLOROHYDRIN.
- ETHYLENE DICHLORIDE.
- ETHYLENE GLYCOL (excluding its salts and derivatives) except:
- (a) when included in Schedule 5 or 10; or
- (b) in paints or paint tinters; or
- (c) in other preparations containing 2.5% or less of ethylene glycol.
- ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except:
- (a) when separately specified in these Schedules; or
- (b) in preparations containing 10% or less of such substances.
- ETHYL FORMATE when packed and labelled for use as a fumigant.
- ETHYLHEXANEDIOL except in preparations containing 5% or less of ethylhexanediol.
- 2-ETHYLHEXANOIC ACID and its alkyl esters except in preparations containing 5% or less calculated as 2-ethylhexanoic acid.
- ETRIMFOS.
- EUCALYPTUS OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (e) in preparations containing 25% or less of eucalyptus oil.
- EUGENOL except:
- (a) when included in Schedule 5; or
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (f) in preparations containing 25% or less of eugenol.
- FAMOXADONE.
- FAMPHUR in preparations containing 20% or less of famphur.
- FEBANTEL except:
- (a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or
- (b) in undivided preparations containing 10% or less of febantel.
- FENAMIPHOS in granular preparations containing 5% or less of fenamiphos.
- FENAZAFLOR.
- FENBUTATIN OXIDE.
- FENCHLORPHOS.
- FENITROTHION.
- FENMEZODITIAZ.
- FENOXACRIM in preparations for the treatment of carpets during manufacture.
- FENPROPIDIN.
- FENPYROXIMATE.
- FENTHION in preparations containing 60% or less of fenthion except when included in Schedule 5.
- FENVALERATE.
- FIPRONIL except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 0.05% or less of fipronil.
- FLOCOUMAFEN in preparations containing 0.005% or less of flocoumafen.
- FLONICAMID.
- FLUAZAINDOLIZINE except when included in Schedule 5.
- FLUAZIFOP-BUTYL.
- FLUAZIFOP-p-BUTYL.
- FLUAZINAM.
- FLUCOFURON in preparations for the treatment of carpets during manufacture.
- FLUENSULFONE.
- FLUMETHRIN except when included in Schedule 5.
- FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.
- FLUORIDES except:
- (a) when included in Schedule 5; or
- (b) in preparations for human use; or
- (c) in preparations containing 15 mg/kg or less of fluoride ion.
- FLUPROPANATE.
- FLUPYRADIFURONE.
- FLUQUINCONAZOLE.
- FLUSILAZOL.
- FLUTRIAFOL except in fertilisers containing 0.5% or less of flutriafol.
- FLUVALINATE except when included in Schedule 5.
- FOLPET.
- FOMESAFEN SODIUM.
- FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde except:
- (a) for human therapeutic use; or
- (b) in oral hygiene preparations; or
- (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or
- (d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:
- PROTECT CUTICLES WITH GREASE OR OIL;
- (e) in all other cosmetic preparations; or
- (f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:
- CONTAINS FORMALDEHYDE.
- FORMOTHION.
- FOSPIRATE except when included in Schedule 5.
- FUMAGILLIN.
- FURFURAL except in preparations containing 0.1% or less of furfural.
- GLUTARAL except:
- (a) when included in Schedule 2 or 5; or
- (b) in preparations containing 0.5% or less of glutaral when labelled with the statements:
- IRRITANT; and
- Avoid contact with eyes.
- GLYCERYL THIOGLYCOLLATE in hair waving preparations except when labelled with directions for use that include the statement:
- Wear protective gloves when using. Keep out of eyes.
- GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical except:
- (a) in cosmetic preparations for salon use only, when labelled in accordance with requirements under applicable jurisdictional Work Health and Safety laws, as a
- (b) in preparations containing 5% or less of glycolic acid; or
- (c) in preparations containing 20% or less of glycolic acid with a pH of 3.5 or greater.
- GLYOXYLIC ACID (including its salts and esters) in cosmetic products.
- GUANIDINE except:
- (a) when included in Schedule 4; or
- (b) in preparations containing 1% or less of guanidine.
- GUAZATINE.
- HALOXON.
- HALOXYFOP.
- HC VIOLET 1 except:
- (a) in non-oxidative hair dye preparations containing 0.28% or less of HC Violet 1 after mixing when the immediate container and primary pack are labelled with
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (b) in oxidative hair dye preparations containing 0.25% or less of HC Violet 1 after mixing under oxidative conditions when the immediate container and primary
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height.
- HEPTACHLOR.
- HEXACHLOROPHENE:
- (a) in preparations for the treatment of animals; or
- (b) for cosmetic use.
- HEXAZINONE except when included in Schedule 5.
- HEXYLOXYETHANOL except in preparations containing 10% or less of hexyloxyethanol.
- HYDRAMETHYLNON except when included in Schedule 5.
- HYDRAZINE.
- HYDROCHLORIC ACID (excluding its salts and derivatives) except:
- (a) when included in Schedule 5; or
- (b) in preparations for therapeutic use; or
- (c) in preparations containing 0.5% or less of hydrochloric acid (HCl).
- HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1% or less of hydrogen fluori
- HYDROGEN PEROXIDE (excluding its salts and derivatives) except:
- (a) when included in Schedule 5; or
- (b) in hair dye preparations containing 6% (20 volume) or less of hydrogen peroxide; or
- (c) in other preparations containing 3% (10 volume) or less of hydrogen peroxide.
- HYDROQUINONE except:
- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 10% or less of hydroquinone.
- HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1% or less of hydrosilicofluoric acid (H2SiF6) except when included in
- HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE (including its salts) except in oxidative hair dye preparations containing 1.5% or less of hydroxyethyl-3,4-methylenediox
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- IMIDACLOPRID except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 5% or less of imidacloprid.
- IMIDOCARB.
- IMINOCTADINE TRIALBESILATE.
- IMIPROTHRIN except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 10% or less of imiprothrin.
- INDAZIFLAM.
- INDOXACARB (includes the R and S enantiomers) except when included in Schedule 5.
- INPYRFLUXAM.
- IODINE (excluding its salts, derivatives and iodophors) except:
- (a) when included in Schedule 2; or
- (b) in solid or semi-solid preparations containing 2.5% or less of available iodine.
- IODOPHORS except in preparations containing 1.5% or less of available iodine.
- 3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) except:
- (a) when included in Schedule 5; or
- (b) in aqueous preparations not for cosmetic use containing 10% or less of 3-iodo-2-propynyl butyl carbamate (Iodocarb); or
- (c) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3-iodo-2-propynyl butyl carbamate.
- IOXYNIL.
- IPCONAZOLE except when included in Schedule 5.
- IRON COMPOUNDS (excluding up to 1% of iron oxides when present as an excipient) for the treatment of animals except:
- (a) when included in Schedule 5; or
- (b) in liquid or gel preparations containing 0.1% or less of iron; or
- (c) in animal feeds or feed premixes.
- ISOCONAZOLE for the external treatment of animals.
- ISOCYANATES, free organic, boiling below 300° C, except in:
- (a) viscous polyurethane adhesives; or
- (b) viscous polyurethane sealants;
- containing not more than 0.7% of free organic isocyanates boiling below 300°C.
- ISOCYCLOSERAM.
- ISOEUGENOL except:
- (a) when included in Schedule 5; or
- (b) in preparations not intended for skin contact containing 10% or less of isoeugenol; or
- (c) in preparations intended for skin contact containing 0.02% or less of isoeugenol.
- ISOPYRAZAM.
- ISOTIANIL.
- LAMBDA-CYHALOTHRIN:
- (a) in aqueous preparations containing 25% or less of microencapsulated lambda-cyhalothrin; or
- (b) in emulsifiable granule formulations containing 25% or less lambda-cyhalothrin; or
- (c) in other preparations containing 1.6% or less of lambda-cyhalothrin;
- except when included in Schedule 5.
- LASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances.
- LAURETH CARBOXYLIC ACIDS (excluding their salts and derivatives) except:
- (a) in leave-on preparations containing 1.5% or less of laureth carboxylic acids; or
- (b) in wash-off preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with
- IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or
- (c) in other preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with war
- (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
- (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.
- LAURYL ISOQUINOLINIUM BROMIDE.
- LAURYL SULFATE SALTS (excluding their derivatives) except:
- (a) in wash-off preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with a warning to the f
- IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or
- (b) in leave-on preparations containing 1.5% or less of lauryl sulfates; or
- (c) in toothpaste and oral hygiene preparations containing 5% or less of lauryl sulfates; or
- (d) in other preparations for animal use containing 2% or less of lauryl sulfates; or
- (e) in other preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with warnings to the follo
- (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
- (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.
- LEAD COMPOUNDS except:
- (a) when included in, or expressly excluded from, Schedule 10; or
- (b) in preparations for cosmetic use containing 10 mg/kg or less of lead; or
- (c) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 25 mg/kg or less of lead; or
- (d) in ceramic glazes when labelled with the warning statement:
- CAUTION – Harmful if swallowed. Do not use on surfaces which contact food or drink;
- written in letters not less than 1.5 mm in height.
- LEPTOSPERMUM SCOPARIUM OIL (manuka oil) except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (e) in preparations containing 25% or less of Leptospermum scoparium oil.
- LEVAMISOLE for the treatment of animals except:
- (a) when included in Schedule 4 or 5; or
- (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.
- LINDANE except when included in Schedule 2, 4 or 5.
- MAFENIDE when packed and labelled for the treatment of ornamental fish only.
- MALATHION except:
- (a) when included in Schedule 5; or
- (b) for human therapeutic use; or
- (c) in dust preparations containing 2% or less of malathion.
- MCPA except when included in Schedule 5.
- MCPB.
- MEBENDAZOLE for the treatment of animals except when included in Schedule 5.
- MECOPROP except when included in Schedule 5.
- MECOPROP-P.
- MEFLUIDIDE.
- MELALEUCA OIL (tea tree oil) except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compli
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a chil
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (e) in preparations containing 25% or less of melaleuca oil.
- MELENGESTROL ACETATE when used as an animal feed additive.
- MELOXICAM in:
- (a) oral transmucosal preparations containing 1% or less of meloxicam for pre-surgical treatment and pain management in livestock during routine husbandry proce
- (b) injectable vaccines containing bacterial antigens and 1% or less of meloxicam for single use in lambs undergoing husbandry procedures at marking.
- MENAZON.
- MERCAPTAMINE for cosmetic use except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 1% or less of mercaptamine.
- MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid).
- 2-MERCAPTOETHANOL in preparations for use as insect lures.
- MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.
- MERCUROCHROME for the treatment of animals, in preparations for topical use.
- METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.
- METALAXYL except when included in Schedule 5.
- METALDEHYDE except when included in Schedule 5.
- METHACRIFOS in preparations containing 60% or less of methacrifos.
- METHAM.
- METAMITRON.
- METHANOL (excluding its derivatives) except:
- (a) when included in Schedule 5; or
- (b) when included in Schedule 10; or
- (c) in preparations containing 2% or less of methanol.
- METHIOCARB in preparations containing 20% or less of methiocarb except when included in Schedule 5.
- METHOMYL in fly-baits containing 1% or less of methomyl and not less than 0.002% of denatonium benzoate as a bittering agent.
- 6-METHOXY-N2-METHYL-2,3-PYRIDINEDIAMINE except when used in oxidative or non- oxidative hair dyes at a concentration of 1% or less when the immediate container
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- 2-METHOXY-5-NITROPHENOL.
- METHYLCHLOROISOTHIAZOLINONE except:
- (a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.0015% or less of methylchloroisothiazolinone
- (b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylchloroisothiazolinone and methylisothiazolin
- METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10% or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-res
- METHYLDIBROMO GLUTARONITRILE except when in Schedule 10.
- METHYLENE BISTHIOCYANATE except in preparations containing 1% or less of methylene bisthiocyanate.
- METHYLEUGENOL except in preparations containing 1% or less of methyleugenol.
- METHYL ETHYL KETONE OXIME except:
- (a) in viscous silicone adhesives or viscous silicone sealants containing 2.5% or less of methyl ethyl ketone oxime; or
- (b) in other preparations containing 1% or less of methyl ethyl ketone oxime.
- p-METHYLAMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of p-methylaminophenol after mixing for
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- METHYL ISOTHIOCYANATE.
- METHYL METHACRYLATE (excluding its derivatives) except:
- (a) for cosmetic use; or
- (b) in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.
- METHYL NEODECANAMIDE except in liquid preparations containing 2% or less of methyl neodecanamide.
- METHYLISOTHIAZOLINONE except:
- (a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.0015% or less of methylisothiazolinone; or
- (b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylisothiazolinone
- METHYLNORBORNYLPYRIDINE.
- N-METHYL-2-PYRROLIDONE except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 25% or less of designated solvents.
- 2-METHYLRESORCINOL except:
- (a) in non-oxidative hair dye preparations containing 1.8% or less of 2-methylresorcinol when the immediate container and primary pack are labelled with the fol
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;
- written in letters not less than 1.5 mm in height; or
- (b) in oxidative hair dye preparations containing 1.8% or less of 2-methylresorcinol after mixing under oxidative conditions when the immediate container and pr
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;
- written in letter not less than 1.5 mm in height.
- METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548-62-9) and the following TRIARYLMETHANE DYES:
- (a) Acid Violet 49 (CAS No. 1694-09-3);
- (b) Ethyl Violet (CAS No. 2390-59-2);
- (c) Basic Blue 7 (CAS No. 2390-60-5);
- (d) Methylium, 4-(dimethylamino)phenylbis4-(ethylamino)-3-methylphenyl-, acetate (CAS No. 72102-55-7);
- except when included in Schedule 4 or Schedule 10.
- METHYL SALICYLATE except:
- (a) when included in Schedule 5; or
- (b) in preparations for therapeutic use; or
- (c) in preparations containing 5% or less of methyl salicylate.
- METOFLUTHRIN except when included in Schedule 5.
- METOSULAM.
- METRAFENONE except when included in Schedule 5.
- METRIBUZIN.
- MICONAZOLE for the external treatment of animals.
- MILBEMECTIN except when included in Schedule 5.
- MOMFLUOROTHRIN except in preparations containing 0.2% or less of momfluorothrin.
- MONENSIN:
- (a) in animal feed premixes containing 12.5% or less of antibiotic substances; or
- (b) in stockfeed supplements, blocks or licks containing 0.75% or less of antibiotic substances.
- MONOETHANOLAMINE (excluding its salts and derivatives) except:
- (a) when included in Schedule 4 or 5; or
- (b) in preparations containing 5% or less of monoethanolamine.
- MORANTEL except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 10% or less of morantel.
- MOXIDECTIN:
- (a) in preparations for external use containing 2.5% or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or
- (b) in preparations for external use containing 2% or less of moxidectin for the treatment of animals; or
- (c) in preparations for internal use containing 10% or less of moxidectin for the treatment of sheep or cattle;
- except when included in Schedule 5.
- MSMA in herbicide or defoliant preparations containing 10% or less of MSMA.
- NALED except when included in Schedule 5.
- NAPHTHALENE (excluding its derivatives) except in liquid hydrocarbons.
- 1,5-NAPHTHALENEDIOL except:
- (a) in non-oxidative hair dye preparations containing 1% or less of 1,5-naphthalenediol when the immediate container and primary pack are labelled with the foll
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (b) in oxidative hair dye preparations containing 1% or less of 1,5-naphthalenediol after mixing under oxidative conditions when the immediate container and pri
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height.
- 2,7-NAPHTHALENEDIOL except:
- (a) in non-oxidative hair dye preparations containing 1% or less of 2,7-naphthalenediol when the immediate container and primary pack are labelled with the foll
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (b) in oxidative hair dye preparations containing 1% or less of 2,7-naphthalenediol after mixing under oxidative conditions when the immediate container and pri
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height.
- 1-NAPHTHOL except in hair dye preparations containing 1% or less of 1-naphthol after mixing under oxidative conditions when the immediate container and primary
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height.
- NAPHTHALOPHOS in preparations containing 80% or less of naphthalophos.
- NARASIN in animal feed premixes containing 12% or less of narasin.
- NETOBIMIN for the treatment of animals except when included in Schedule 5.
- NICKEL SULFATE.
- NICLOSAMIDE except when included in Schedule 2 or Schedule 5.
- NIMIDANE in preparations containing 25% or less of nimidane.
- NITENPYRAM except in divided preparations containing 100 mg or less of nitenpyram.
- NITRIC ACID (excluding its salts and derivatives) except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 0.5% or less of nitric acid (HNO3).
- NITROBENZENE except:
- (a) in solid or semi-solid polishes; or
- (b) in soaps containing 1% or less of nitrobenzene; or
- (c) in other preparations containing 0.1% or less of nitrobenzene.
- 3-NITRO-p-HYDROXYETHYLAMINOPHENOL except
- (a) in non-oxidative hair dye preparations containing 1.85% or less of 3-nitro-p-hydroxyethylaminophenol after mixing when the immediate container and primary p
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (b) in oxidative hair dye preparations containing 3% or less of 3-nitro-p-hydroxyethylaminophenol after mixing under oxidative conditions when the immediate con
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height.
- NITROPHENOLS, ortho, meta and para, except when separately specified in these Schedules.
- NITROPRUSSIDES in preparations containing 2.5% or less of nitroprussides except when included in Schedule 4.
- NITROUS OXIDE except when included in Schedule 4.
- NITROXYNIL.
- NONOXINOL 9 except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 25% or less of nonoxinol 9 when labelled with the statements:
- (i) IRRITANT; and
- (ii) Avoid contact with eyes; or
- (c) in preparations containing 12.5% or less of nonoxinol 9; or
- (d) in preparations for human use.
- 1-OCTEN-3-OL except in preparations containing 5% or less of 1-octen-3-ol.
- OCTHILINONE except in paints, jointing compounds and sealants containing 1% or less of octhilinone calculated on the non-volatile content.
- N-(N-OCTYL)-2-PYRROLIDONE except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 25% or less of designated solvents.
- OLAQUINDOX except in preparations containing 10% or less of olaquindox.
- N-OLEYL-1,3-DIAMINOPROPANE.
- OMETHOATE in preparations containing 30% or less of omethoate except when included in Schedule 5.
- OXADIAZON.
- OXALIC ACID except
- (a) in dental care preparations, including mouthwashes, containing 3% or less of soluble salts of oxalic acid; or
- (b) its insoluble salts.
- OXYCLOZANIDE.
- PAECILOMYCES LILACINUS STRAIN 251.
- PALMITOYLETHANOLAMIDE (excluding derivatives) except:
- (a) in preparations for therapeutic use; or
- (b) in preparations for dermal cosmetic use containing 1% or less of palmitoylethanolamide.
- PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde except:
- (a) for human therapeutic use; or
- (b) in oral hygiene preparations; or
- (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or
- (d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:
- PROTECT CUTICLES WITH GREASE OR OIL; or
- (e) in all other cosmetic preparations; or
- (f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:
- CONTAINS FORMALDEHYDE.
- PARATHION-METHYL in aqueous preparations containing 45% or less of microencapsulated parathion-methyl.
- PARBENDAZOLE.
- PEBULATE.
- PENNYROYAL OIL except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a chil
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (c) in preparations containing 4% or less of d-pulegone.
- PENTACHLOROPHENOL in preparations containing 1.5% or less of pentachlorophenol.
- PERACETIC ACID except when included in Schedule 5.
- PERFLUIDONE.
- PERMANGANATES except potassium permanganate in aqueous solutions containing 1% or less of potassium permanganate.
- PERMETHRIN except:
- (a) when included in Schedule 4 or 5; or
- (b) in preparations for human therapeutic use containing 5% or less of permethrin; or
- (c) in preparations containing 2% or less of permethrin.
- 2-PHENOXYETHANOL except:
- (a) in cosmetic preparations containing 1% or less of 2-phenoxyethanol; or
- (b) in other preparations containing 15% or less of 2-phenoxyethanol.
- PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, except:
- (a) when separately specified in these Schedules; or
- (b) in preparations containing 1% or less of phenols, and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.
- PHENOTHIAZINE (excluding its derivatives) except in preparations containing 10% or less of phenothiazine.
- PHENOXYMETHYL OXIRANE.
- PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives not elsewhere specified in these Schedules:
- (a) in preparations packed and labelled for photographic purposes; or
- (b) in preparations packed and labelled for testing water except tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenedia
- (c) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying direct
- written in letters not less than 1.5 mm in height; or
- (d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:
- WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause inju
- written in letters not less than 1.5 mm in height.
- PHENYL METHYL PYRAZOLONE except when used in hair dye and eyebrow/eyelash preparations at a concentration of 0.25% or less after mixing for use when the immedia
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dire
- written in letters not less than 1.5 mm in height.
- PHOSALONE.
- PHOSMET.
- PHOSPHORIC ACID (excluding its salts and derivatives) except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 15% or less of phosphoric acid (H3PO4); or
- (c) in solid or semi-solid preparations; or
- (d) in professional dental kits.
- PHOXIM.
- o-PHTHALALDEHYDE except when included in Schedule 5.
- PICRAMIC ACID including its salts (excluding other derivatives) except when used in hair dye products at a concentration of 0.6% or less of picramic acid after
- (a) KEEP OUT OF REACH OF CHILDREN; and
- (b) WARNING ‒ This product contains ingredients which may cause skin allergy to certain individuals. A preliminary test according to the accompanying directions
- written in letters not less than 1.5 mm in height.
- PINDONE.
- PINE OILs when packed and labelled as a herbicide except when included in Schedule 5.
- PINOXADEN except when included in Schedule 5.
- PIPEROPHOS.
- PIRIMICARB except when included in Schedule 5.
- PIRIMIPHOS-ETHYL.
- PIRIMIPHOS-METHYL.
- POLIHEXANIDE except:
- (a) in cosmetic preparations containing 0.3% or less of polihexanide; or
- (b) when packed and labelled for therapeutic use; or
- (c) in other preparations containing 5% or less of polihexanide.
- POLIXETONIUM SALTS except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 1% or less of polixetonium salts.
- POTASSIUM AZELOYL DIGLYCINATE except in preparations for cosmetic use containing 1% or less of potassium azeloyl diglycinate.
- POTASSIUM BROMATE except in preparations containing 0.5% or less of potassium bromate.
- POTASSIUM CYANATE.
- POTASSIUM HYDROXIDE (excluding its salts and derivatives) except:
- (a) when included in Schedule 5 or Schedule 10; or
- (b) in preparations containing 5% or less of potassium hydroxide being:
- (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
- (ii) liquid or semi-solid preparations, the pH of which is 11.5 or less.
- POTASSIUM NITRITE in preparations containing 40% or less of potassium nitrite except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 0.5% or less of potassium nitrite; or
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2% or less of potassium nitrite.
- POTASSIUM PEROXOMONOSULFATE TRIPLE SALT except:
- (a) when included in Schedule 5; or
- (b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or
- (c) in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:
- (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more; or
- (ii) liquid or semi-solid preparations, the pH of which is 2.5 or more.
- POTASSIUM PERSULFATE in hair preparations.
- PRALLETHRIN (cis:trans=20:80) except:
- (a) when included in Schedule 5; or
- (b) in insecticidal mats containing 1% or less of prallethrin.
- PROCHLORAZ.
- PROFENOFOS.
- PROMACYL.
- PROPACHLOR.
- PROPARGITE.
- PROPETAMPHOS.
- PROPICONAZOLE except when included in Schedule 5.
- PROPINEB.
- PROPIONIC ACID (excluding its salts and derivatives) except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 30% or less of propionic acid; or
- (c) for therapeutic use.
- PROPOXUR except when included in Schedule 5.
- n-PROPYL ALCOHOL except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 5% or less of n-propyl alcohol; or
- (c) in preparations for cosmetic or therapeutic use other than in spray form.
- PROQUINAZID.
- PROSULFOCARB.
- PROSULFURON.
- PROTHIOFOS.
- d-PULEGONE except in preparations containing 4% or less of d-pulegone.
- PYRACLOFOS.
- PYRAZOPHOS.
- PYRIDABEN except when included in Schedule 5.
- PYRIDALYL.
- PYRIDATE.
- PYRIPROLE.
- PYRITHIONE COPPER.
- PYRITHIONE ZINC except:
- (a) when included in Schedule 2 or 5; or
- (b) for human use in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required a
- (c) in semi-solid hair preparations for animal use; or
- (d) in shampoos for animal use containing 2% or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with wat
- (e) when immobilised in solid preparations containing 0.5% or less of pyrithione zinc; or
- (f) in paints, jointing materials or sealants containing 0.1% or less of pyrithione zinc calculated on the non-volatile content.
- PYRIOFENONE except when included in Schedule 5.
- PYROXASULFONE.
- PYROXSULAM.
- QUATERNARY AMMONIUM COMPOUNDS except:
- (a) when separately specified in these Schedules; or
- (b) when included in Schedule 5; or
- (c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C
- (d) in preparations containing 5% or less of such quaternary ammonium compounds.
- QUININE in cosmetic preparations except:
- (a) in rinse-off hair preparations containing 0.5% or less of quinine calculated as free base; or
- (b) in leave-on hair preparations containing 0.2% or less of quinine calculated as free base.
- QUINOLINE and its salts (excluding other derivatives).
- QUIZALOFOP ETHYL.
- QUIZALOFOP-p-ETHYL except when included in Schedule 5.
- QUIZALOFOP-p-TEFURYL.
- RESCALURE for agricultural use except when enclosed in a vapour releasing device which in normal use prevents access to its contents.
- RESMETHRIN except when included in Schedule 5.
- RESORCINOL except:
- (a) in preparations for human therapeutic use; or
- (b) in oxidative hair dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled wi
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (c) in oxidative eyelash and eyebrow dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying dir
- written in letters not less than 1.5 mm in height; or
- (d) in hair lotions/shampoo products containing 0.5% or less of resorcinol when the immediate container and primary pack are labelled with the following stateme
- WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals;
- written in letters not less than 1.5 mm in height.
- ROTENONE except in solid or semi-solid preparations containing 2% or less of rotenone.
- SAFROLE except:
- (a) for internal use; or
- (b) in other preparations containing 1% or less of safrole.
- SAGE OIL (Dalmatian) except:
- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a chil
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricte
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) NOT TO BE TAKEN; or
- (c) in preparations containing 4% or less of thujone.
- SALINOMYCIN in animal feed premixes containing 12% or less of antibiotic substances.
- SAROLANER except when included in Schedule 5.
- SASSAFRAS OIL except:
- (a) for internal use; or
- (b) in other preparations containing 1% or less of safrole.
- SELENIUM:
- (a) in preparations containing 2.5% or less of selenium when packed and labelled:
- (i) for the blueing of gun barrels; or
- (ii) for photographic purposes; or
- (iii) for the colouring of lead or lead alloys; or
- b) in coated granules containing 1% or less of selenium for application to pasture except in fertilisers containing 200 g/tonne or less of selenium; or
- (c) for the treatment of animals:
- (i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5% or less of selenium; or
- (ii) in animal feed premixes containing 2% or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium; or
- (iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or
- (iv) as barium selenate in preparations for injection containing 5% or less of selenium.
- SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5% or less of antibiotic substances.
- SILICOFLUORIDES except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 15 mg/kg or less of fluoride ion.
- SILVER NITRATE except:
- (a) when included in or expressly excluded from Schedule 2; or
- (b) in preparations containing 1% or less of silver.
- SINBIOALLETHRIN except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 1% or less of sinbioallethrin.
- SODIUM ALUMINATE (excluding its salts and derivatives) except:
- (a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
- (b) in liquid preparations, the pH of which is 11.5 or less.
- SODIUM BROMATE except in preparations containing 0.5% or less of sodium bromate.
- SODIUM HYDROXIDE (excluding its salts and derivatives) except:
- (a) when included in Schedule 5 or Schedule 10; or
- (b) in preparations containing 5% or less of sodium hydroxide being:
- (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
- (ii) liquid or semi-solid preparations, the pH of which is 11.5 or less.
- SODIUM NITRITE:
- (a) in preparations containing 15% or less of sodium nitrite except:
- (i) when included in Schedule 2 or 5; or
- (ii) in preparations containing 0.5% or less of sodium nitrite; or
- (iii) when present as an excipient in preparations for therapeutic use; or
- (iv) in aerosols containing 2% or less of sodium nitrite; or
- (b) for use in closed-loop water treatment systems (products).
- SODIUM PERCARBONATE (CAS No. 15630-89-4) except:
- (a) when included in Schedule 5; or
- (b) in preparations containing 15% or less of sodium percarbonate.
- SODIUM PERSULFATE:
- (a) in hair preparations; or
- (b) in products for the treatment of water for swimming pools and spas.
- SODIUM SULFIDE in preparations for use as insect lures.
- SPIROPIDION.
- SPIROTETRAMAT.
- SPIROXAMINE.
- SULCOFURON in preparations for the treatment of carpets during manufacture.
- SULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5.
- SULFLURAMID.
- SULFOXAFLOR except when included in Schedule 5.
- SULFURIC ACID (excluding its salts and derivatives) except:
- (a) in fire extinguishers; or
- (b) in preparations containing 0.5% or less of sulfuric acid (H2SO4).
- SULFURYL FLUORIDE.
- SULPROFOS.
- 2,4,5-T.
- N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.
- TAR ACIDS distilling within the range 230-290°C inclusive.
- TCMTB (2-[thiocyanomethylthio]benzothiazole).
- TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) except when included in Schedule 5.
- TEBUFENPYRAD.
- TEBUTHIURON.
- TEMEPHOS except when in Schedule 5.
- TERBUTHYLAZINE except in preparations containing 5% or less of terbuthylazine.
- TERPENES, CHLORINATED.
- TESTOSTERONE in implant preparations for use in animals.
- TETRACHLOROETHYLENE except:
- (a) when included in Schedule 2 or 5; or
- (b) in preparations containing 6% or less of tetrachloroethylene when absorbed into an inert solid; or
- (c) in preparations for the treatment of animals.
- TETRACONAZOLE except when included in Schedule 5.
- TETRADIFON.
- TETRAHYDROFURFURYL ALCOHOL (excluding its derivatives).
- 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2% or less of 2,2',6,6'-tetraisopropyl-diphenyl-carbodiimide.
- TETRAMISOLE in preparations for the treatment of animals.
- THIACLOPRID.
- THIAMETHOXAM except when included in Schedule 5.
- THIAZAFLURON.
- THIODICARB except when included in Schedule 5.
- THIOMETON.
- THIOPHANATE-METHYL except when included in Schedule 5.
- THIOUREA AND ALKYL THIOUREAS except:
- (a) when separately specified in these Schedules; or
- (b) for therapeutic use.
- THIRAM except in paint containing 0.5% or less of thiram.
- THUJONE except in preparations containing 4% or less of thujone.
- THYMOL when packed and labelled for use as a pesticide.
- TIGOLANER except when in Schedule 5.
- TOLUENE (excluding its derivatives) except in preparations containing 50% or less of toluene or toluene and xylene.
- TOLUENEDIAMINES not elsewhere specified in these Schedules:
- (a) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:
- (i) KEEP OUT OF REACH OF CHILDREN; and
- (ii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying direct
- written in letters not less than 1.5 mm in height; or
- (b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:
- WARNING – This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause inju
- written in letters not less than 1.5 mm in height; or
- (c) in nail polish preparations containing 2,5-toluenediamine except when labelled “avoid contact with skin”.
- TOLYLFLUANID.
- TRANSFLUTHRIN except:
- (a) in preparations containing 1% or less of transfluthrin; or
- (b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.
- TRIADIMEFON except:
- (a) when included in Schedule 5; or
- (b) in fertilisers containing 5 g/kg or less of triadimefon.
- TRICHLORFON except metrifonate included in Schedule 4.
- TRICHLOROACETIC ACID except:
- (a) when included in Schedule 4 or 5; or
- (b) in human dermal preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.
- TRICHLOROETHYLENE except when included in Schedule 4.
- TRICHLOROPHENOL.
- TRICLABENDAZOLE except in preparations containing 20% or less of triclabendazole.
- TRICLOPYR.
- TRICLOSAN in cosmetic preparations for human use containing more than 0.3% of triclosan.
- TRIDEMORPH.
- TRIETHYL PHOSPHATE.
- TRIFLUOROMETHANESULFONIC ACID.
- TRINITROPHENOL (excluding its derivatives) except:
- (a) in preparations for human therapeutic use; or
- (b) in preparations containing 5% or less of trinitrophenol.
- TRISODIUM NITRILOTRIACETATE except in preparations containing 20% or less of trisodium nitrilotriacetate.
- VAMIDOTHION.
- VINYL ACETATE MONOMER (excluding its derivatives) except:
- (a) in preparations for therapeutic use; or
- (b) in cosmetic preparations containing 0.01% or less of vinyl acetate as residual monomer in a polymer; or
- (c) in other preparations containing 1% or less of vinyl acetate.
- WARFARIN except when included in Schedule 4 or 5.
- XYLENE (excluding its derivatives) except in preparations containing 50% or less of xylene or xylene and toluene.
- ZERANOL in ear implants for use as a growth promotant in steer cattle.
- ZETA-CYPERMETHRIN in preparations containing 10% or less of zeta-cypermethrin.
- ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.
- ZINC CHLORIDE except:
- (a) when included in Schedule 2; or
- (b) in preparations containing 5% or less of zinc chloride.
- ZINC para-PHENOLSULFONATE except in preparations containing 5% or less of zinc para-phenolsulfonate.
- ZINC LACTATE in toothpaste except in toothpaste preparations containing 2.5% or less of zinc lactate and labelled with the statement:
- Not recommended for children under twelve years of age.
- ZINC SULFATE except:
- (a) when included in or expressly excluded from Schedule 4; or
- (b) in other preparations containing 5% or less of zinc sulfate.
- ZIRAM in granular preparations.
- Schedule 7 · Dangerous poisons
- Note: See section 16, subsection 54(4) and sections 55, 56, 62 and 65.
- ABAMECTIN except when included in Schedule 5 or 6.
- ACIBENZOLAR-S-METHYL.
- ACRIFLAVINIUM CHLORIDE for veterinary use except when in Schedule 5.
- ACROLEIN.
- ACRYLONITRILE.
- ALACHLOR.
- ALDICARB.
- ALDOXYCARB.
- ALLYL ALCOHOL except:
- (a) in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl ester; or
- (b) when separately specified in these Schedules.
- ALPHA-CYPERMETHRIN except when included in Schedule 5 or 6.
- AMINOACRIDINE for veterinary use except when included in Schedule 5.
- AMINOCARB except when included in Schedule 6.
- 2-AMINO-5-METHYLPHENOL except when included in Schedule 10.
- 4-AMINOPROPIOPHENONE.
- 4-AMINOPYRIDINE except when included in Schedule 4.
- AMITON.
- ARPRINOCID.
- ARSENIC except:
- (a) when separately specified in this Schedule; or
- (b) when included in Schedule 4 or 6; or
- (c) as selenium arsenide in photocopier drums; or
- (d) as 10,10'-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic; or
- (e) as 10,10'-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other tha
- (i) in contact with foodstuffs, animal feeds or potable water; or
- (ii) of clothing and footwear in contact with the skin; or
- (iii) used as infant wear; or
- (iv) intended for use as packaging materials; or
- (f) in animal feeds containing 75 g/tonne or less of arsenic; or
- (g) in paints containing 0.1% or less of arsenic calculated on the non-volatile content of the paint.
- AZAFENIDIN.
- AZINPHOS-ETHYL.
- AZINPHOS-METHYL.
- AZOCYCLOTIN.
- AZO DYES that are derivatives by diazotisation of any of the following substances:
- (a) p-aminoazobenzene (CAS No. 60-09-3);
- (b) o-aminoazotoluene (CAS No. 97-56-3);
- (c) o-anisidine (CAS No. 90-04-0);
- (d) p-chloroaniline (CAS No. 106-47-8);
- (e) 4-chloro-o-toluidine (CAS No. 95-69-2);
- (f) 2,4-diaminoanisole (CAS No. 615-05-4);
- (g) 6-methoxy-m-toluidine (p-cresidine) (CAS No. 120-71-8);
- (h) 4,4-methylenedianiline (CAS No. 101-77-9);
- (i) 2-naphthylamine (CAS No. 91-59-8);
- (j) 5-nitro-o-toluidine (CAS No. 99-55-8);
- (k) 2,4-toluenediamine (CAS No. 95-80-7);
- (l) o-toluidine (CAS No. 95-53-4);
- (m) 2,4,5-trimethylaniline (CAS No. 137-17-7);
- except for BASIC RED 76 (CAS No. 68391-30-0) when included in Schedule 6.
- BENDIOCARB except when included in Schedule 5 or 6.
- BENOMYL except in paints containing 0.5% or less of benomyl.
- BENZENE (excluding its derivatives) except:
- (a) preparations containing 15 mL/L or less of benzene; or
- (b) petrol containing 50 mL/L or less of benzene.
- BENZIDINE-BASED AZO DYES being:
- (a) 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[N-(4-chlorophenyl)-3-oxobutanamide] (CAS No. 94249-03-3); or
- (b) Acid Red 85 (Acid Fast Red A): 1,3-Naphthalenedisulfonic acid, 7-hydroxy-8-[[4'-[[4-[[(4-methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-, di
- (c) C.I Acid Black 29: (CAS No. 12217-14-0); or
- (d) C.I. Direct Orange 1: (CAS No. 54579-28-1); or
- (e) Direct Black 38: 2,7-Naphthalenedisulfonic acid, 4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)-, disodium salt (C
- (f) Direct Blue 2: 2,7-Naphthalenedisulfonic acid, 5-amino-3-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-4-hydroxy-, trisodium
- (g) Direct Blue 6: 2,7-Naphthalenedisulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[5-amino-4-hydroxy-, tetrasodium salt (CAS No. 2602-46-2); or
- (h) Direct Brown 2: 5-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxy- benzoic acid disodium salt (CAS No. 2429-82-5); o
- (i) Direct Brown 95: Cuprate(2-), [5-[[4'-[[2,6-dihydroxy-3-[(2-hydroxy-5-sulfophenyl)azo]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxybenzoato(4-)]-, disodium
- (j) Direct Green 1: 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-6-(phenylazo)-, disodium salt (CAS
- (k) Direct Green 6: 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-3-[(4-nitrophenyl)azo]-, disodium s
- (l) Direct Red 28 (Congo Red): 1-Naphthalenesulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[4-amino-, disodium salt (CAS No. 573-58-0); or
- (m) Direct Red 37: 1,3-Naphthalenedisulfonic acid, 8-[[4'-[(4-ethoxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-7-hydroxy-, disodium salt (CAS No. 3530-19-6).
- BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES.
- BETACYFLUTHRIN except when included in Schedule 5 or 6.
- BIFENTHRIN except:
- (a) when included in Schedule 6; or
- (b) in preparations containing 0.5% or less of bifenthrin.
- BIFLUORIDES (including ammonium, potassium and sodium salts) except when included in Schedule 5 or 6.
- BORON TRIFLUORIDE except when included in Schedule 5 or 6.
- BRODIFACOUM except when included in Schedule 6.
- BROMADIOLONE except when included in Schedule 6.
- BROMETHALIN except when included in Schedule 6.
- BROMINE (excluding its salts and derivatives).
- BROMOXYNIL except when included in Schedule 6.
- BRUCINE except in alcohol containing 0.02% or less of brucine as a denaturant.
- CACODYLIC ACID except:
- (a) when included in Schedule 6; or
- (b) in animal feeds containing 75 g/tonne or less of arsenic.
- CADUSAFOS except when included in Schedule 6.
- CALCIFEROL for use as a rodenticide except when included in Schedule 6.
- CAPTAFOL.
- CARBADOX.
- CARBENDAZIM except in paints, jointing compounds and sealants containing 0.35% or less of carbendazim.
- CARBOFURAN.
- CARBON TETRACHLORIDE except in chlorinated rubber based paint containing 1% or less of carbon tetrachloride.
- CARBONYL SULFIDE when packed and labelled for use as a fumigant.
- CARBOPHENOTHION.
- CARBOSULFAN.
- CHLORDECONE.
- CHLORDIMEFORM.
- CHLORFENAPYR except when included in Schedule 5 or 6.
- CHLORFENVINPHOS.
- CHLORINE (excluding its salts and derivatives).
- CHLORHEXIDINE except:
- (a) when included in Schedule 5 or 6; or
- (b) in preparations containing 1% or less of chlorhexidine; or
- (c) in solid preparations.
- CHLOROMETHIURON.
- 5-CHLORO-3-METHYL-4-NITROPYRAZOLE.
- 4-CHLORO-o-TOLUIDINE.
- CHLOROPICRIN except when included in Schedule 6.
- CHLORTHAL-DIMETHYL.
- CHLORTHIOPHOS.
- COLECALCIFEROL for use as a rodenticide.
- COUMAPHOS except when included in Schedule 6.
- COUMATETRALYL except when included in Schedule 5 or 6.
- CREOSOTE derived from coal.
- CREOSOTE derived from beechwood.
- CYANIDES, metallic except:
- (a) ferricyanides; or
- (b) ferrocyanides; or
- (c) when separately specified in these Schedules.
- CYANOGEN.
- CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) except
- CYHALOTHRIn (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.
- CYHEXATIN.
- DELTAMETHRIN except:
- (a) when included in Schedule 5 or 6; or
- (b) in factory prepared mosquito nets containing 1% or less of deltamethrin; or
- (c) in preparations containing 0.1% or less of deltamethrin.
- DEMETON.
- DEMETON-O-METHYL.
- DEMETON-S-METHYL.
- DIALIFOS.
- 4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).
- 1,2-DIBROMO-3-CHLOROPROPANE.
- 1,3-DICHLOROPROPENE except in biocidal preparations containing 0.3% or less of 1,3-dichloropropene.
- DICHLORVOS except when included in Schedule 5 or 6.
- DICROTOPHOS.
- DIFENACOUM except when included in Schedule 6.
- DIFETHIALONE except when included in Schedule 6.
- DIMEFOX.
- 4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).
- DIMETHYL SULFATE.
- DIMETILAN.
- DINITROCRESOLS except when included in Schedule 4 or 6.
- DINITROPHENOLS except when included in Schedule 4, 6 or 10.
- DINOCAP.
- DINOSEB.
- DIQUAT except when included in Schedule 6.
- DISULFOTON except when included in Schedule 6.
- DORAMECTIN except when included in Schedule 5 or 6.
- DSMA except when included in Schedule 6.
- EMAMECTIN except when included in Schedule 5 or 6.
- ENDOSULFAN except when included in Schedule 6.
- ENDOTHAL except when included in Schedule 6.
- ENDRIN.
- EPICHLOROHYDRIN.
- EPIDERMAL GROWTH FACTOR except in preparations for human therapeutic use.
- EPRINOMECTIN except when included in Schedule 5 or 6.
- ETACONAZOLE.
- ETHALFLURALIN.
- ETHION.
- ETHOPROPHOS except when included in Schedule 6.
- 2-ETHOXYETHANOL and its acetates except in preparations containing 0.5% or less of 2-ethoxyethanol.
- ETHYLENE DIBROMIDE.
- ETHYLENE OXIDE.
- FAMPHUR except when included in Schedule 6.
- FENAMIPHOS except when included in Schedule 6.
- FENOXACRIM except:
- (a) when included in Schedule 6; or
- (b) in treated carpets.
- FENSULFOTHION.
- FENTHION except when included in Schedule 5 or 6.
- FENTHION-ETHYL.
- FLOCOUMAFEN except when included in Schedule 6.
- FLUCOFURON except:
- (a) when included in Schedule 6; or
- (b) in treated carpets.
- FLUCYTHRINATE.
- FLUMIOXAZIN except when included in Schedule 6.
- FLUOROACETAMIDE.
- FLUOROACETIC ACID.
- FORMETANATE.
- FOSTHIAZATE.
- FURATHIOCARB except when included in Schedule 5.
- GAMMA-CYHALOTHRIN except when included in Schedule 5.
- HALOFUGINONE except when included in Schedule 4.
- HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.
- HCB.
- HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C except:
- (a) when in solid polymers; or
- (b) when containing 1% or less of total polycyclic aromatic compounds as measured by IP 346; or
- (c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.
- HYDROCYANIC ACID except:
- (a) when included in Schedule 4; or
- (b) its salts and derivatives other than cyanides separately specified in this Schedule; or
- (c) in preparations containing 10 mg/kg or less of hydrocyanic acid.
- HYDROFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.
- HYDROGEN SULFIDE.
- HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.
- IODOMETHANE.
- ISOCARBOPHOS.
- ISOFENPHOS.
- ISOPROTURON.
- IVERMECTIN except when included in Schedule 4 or 5.
- LAMBDA-CYHALOTHRIN except when included in Schedule 5 or 6.
- LEPTOPHOS.
- LITHIUM PERFLUOROOCTANE SULFONATE except in sealed bait stations containing 1% or less of lithium perfluorooctane sulfonate.
- MADURAMICIN except:
- (a) when included in Schedule 5; or
- (b) in animal feeds containing 5 mg/kg or less of antibiotic substances.
- MALACHITE GREEN for veterinary use except when included in Schedule 5.
- MAZIDOX.
- MECARBAM.
- 2-METHOXYETHANOL and its acetates except in preparations containing 0.5% or less of 2-methoxyethanol.
- MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.
- MERCURY except:
- (a) when separately specified in this Schedule; or
- (b) when included in Schedule 2, 4 or 6; or
- (c) in preparations containing 0.01% or less of mercury in organic form as a preservative; or
- (d) mercury (metallic) in scientific instruments; or
- (e) dental amalgams; or
- (f) in a sealed device, for therapeutic use, which prevents access to the mercury.
- METHACRIFOS except when included in Schedule 6.
- METHAMIDOPHOS.
- METHAPYRILENE.
- METHAZOLE.
- METHIDATHION.
- METHIOCARB except when included in Schedule 5 or 6.
- METHOMYL except when included in Schedule 6.
- METHOXYETHYLMERCURIC ACETATE.
- METHOXYETHYLMERCURIC CHLORIDE.
- METHYL BROMIDE.
- METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL except:
- (a) when included in Schedule 6; or
- (b) when used in laboratory analysis; or
- (c) when packed for industrial use in containers with a nominal capacity of 100 L or more.
- 4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA).
- METHYLENE BLUE for veterinary use except when included in Schedules 4 or 5.
- MEVINPHOS.
- MIPAFOX.
- MIREX.
- MOLINATE.
- MONOCROTOPHOS.
- MOXIDECTIN except when included in Schedule 4, 5 or 6.
- MSMA except when included in Schedule 6.
- NAPHTHALOPHOS except when included in Schedule 6.
- NICOTINE except:
- (a) when included in Schedule 3 or 4; or
- (b) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tob
- (c) in tobacco prepared and packed for smoking.
- NIMIDANE except when included in Schedule 6.
- NITROFEN.
- NITROPRUSSIDES except when included in Schedule 4 or 6.
- 2-NITROTOLUENE.
- OMETHOATE except when included in Schedule 5 or 6.
- OXAMYL.
- OXYDEMETON METHYL.
- PARAQUAT.
- PARATHION.
- PARATHION-METHYL except when included in Schedule 6.
- PENTACHLOROPHENOL except when included in Schedule 6.
- PHENYLMERCURIC ACETATE except in preparations containing 0.01% or less of mercury as a preservative.
- PHORATE.
- PHOSFOLAN.
- PHOSPHIDES, METALLIC.
- PHOSPHINE.
- PHOSPHORUS, YELLOW (excluding its salts and derivatives).
- POTASSIUM NITRITE except:
- (a) when included in Schedule 5 or 6; or
- (b) in preparations containing 0.5% or less of potassium nitrite; or
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2% or less of potassium nitrite.
- PROCYMIDONE.
- PROPYLENE OXIDE.
- PYRINURON.
- QUININE for veterinary use except when included in Schedule 5.
- SAFLUFENACIL except when included in Schedule 5.
- SCHRADAN.
- SELENIUM except:
- (a) when included in Schedule 6; or
- (b) as selenium arsenide in photocopier drums; or
- (c) in preparations for therapeutic use other than:
- (i) drench concentrates containing 2.5% or less of selenium; or
- (ii) pour-on preparations containing 0.5% or less of selenium; or
- (d) in paints or tinters containing 0.1% or less of selenium calculated on the non-volatile content of the paint or tinter; or
- (e) in fertilisers containing 200 g/tonne or less of selenium.
- SEMDURAMICIN except:
- (a) when included in Schedule 6; or
- (b) in animal feeds containing 25 mg/kg or less of antibiotic substances.
- SODIUM NITRITE except:
- (a) when included in Schedule 2, 5 or 6; or
- (b) in preparations containing 0.5% or less of sodium nitrite; or
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2% or less of sodium nitrite.
- STRYCHNINE except when included in Schedule 4.
- SULCOFURON except:
- (a) when included in Schedule 6; or
- (b) in treated carpets.
- SULFENTRAZONE.
- SULFOTEP.
- TEFLUTHRIN except when included in Schedule 5.
- TEPP.
- TERBUFOS.
- TETRACHLOROETHANE.
- 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE except when included in Schedule 6.
- THALLIUM.
- THIOFANOX.
- TIN ORGANIC COMPOUNDS, being dialkyl, trialkyl and triphenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl except:
- (a) when separately specified in this Schedule; or
- (b) in plastics; or
- (c) in semi-solid sealants, adhesives or elastomers containing 1% or less of the dialkyl, trialkyl or triphenyl tin component; or
- (d) in paint containing 1% or less of such compounds calculated as tin in the non-volatile content of the paint.
- o-TOLIDINE except in solid-state diagnostic therapeutic reagents.
- TRIAMIPHOS.
- TRIAZBUTIL.
- TRIBUFOS (S,S,S-tributylphosphorotrithioate).
- VINCLOZOLIN.
- VINYL CHLORIDE.
- ZETA-CYPERMETHRIN except when included in Schedule 6.
- ZIRAM except when included in Schedule 6.
- Schedule 8 · Controlled drugs
- Note 1: See paragraph 7(b), sections 16, 17, 28, 31, 50 and subsection 57(1).
- Note 2: Substances marked # are listed in Appendix D.
- ACETYLDIHYDROCODEINE.
- ACETYLMETHADOL.
- ACETYLMORPHINES.
- ALFENTANIL.
- ALPHACETYLMETHADOL.
- ALPHAPRODINE.
- # ALPRAZOLAM.
- AMFETAMINE.
- AMOBARBITAL except when included in Schedule 4.
- ANILERIDINE.
- BENZYLMORPHINE.
- BEZITRAMIDE.
- BUPRENORPHINE.
- BUTOBARBITAL.
- BUTORPHANOL.
- # CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:
- (a) cultivated or produced, or in products manufactured[1], in accordance with the Narcotic Drugs Act 1967; and/or
- (b) for use in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
- (c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or
- (d) in therapeutic goods supplied in accordance with the Act;
- except:
- (e) when it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
- (f) when separately specified in the NABIXIMOLS entry in this Schedule; or
- (g) when captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or
- (h) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.
- CARFENTANYL.
- COCAINE.
- CODEINE except when included in Schedule 4.
- CODEINE-N-OXIDE.
- CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).
- 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).
- CYCLOBARBITAL.
- DEXAMFETAMINE.
- DEXTROMORAMIDE.
- # DEXTROPROPOXYPHENE except when included in Schedule 4.
- DIFENOXIN except when included in Schedule 4.
- DIHYDROCODEINE except when included in Schedule 3 or 4.
- DIHYDROMORPHINE.
- # N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human therapeutic use for the treatment of post-traumatic stress disorder.
- DIPHENOXYLATE except when included in Schedule 3 or 4.
- DIPIPANONE.
- # DRONABINOL (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.
- DROTEBANOL.
- ESKETAMINE.
- ETHYLAMFETAMINE.
- ETHYLMORPHINE except when included in Schedule 4.
- FENTANYL.
- # FLUNITRAZEPAM.
- HYDROCODONE.
- HYDROMORPHINOL.
- HYDROMORPHONE.
- KETAMINE.
- LEVAMFETAMINE.
- LEVOMETHAMFETAMINE.
- LEVOMORAMIDE.
- LEVORPHANOL (excluding its stereoisomers).
- LISDEXAMFETAMINE.
- METHADONE.
- METAMFETAMINE.
- METHYLDIHYDROMORPHINE.
- METHYLPHENIDATE.
- 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).
- MORPHINE.
- MORPHINE METHOBROMIDE.
- MORPHINE-N-OXIDE.
- NABILONE.
- # NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cann
- NORCODEINE.
- NORMETHADONE.
- OPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.
- OXYCODONE.
- OXYMORPHONE.
- PENTAZOCINE.
- # PENTOBARBITAL except when included in Schedule 4.
- PETHIDINE.
- PHENDIMETRAZINE.
- PHENMETRAZINE.
- PHENOPERIDINE.
- 4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).
- PHOLCODINE except when included in Schedule 2 or 4.
- PIRITRAMIDE.
- PROPIRAM.
- # PSILOCYBINE in preparations for human therapeutic use for the treatment of treatment-resistant depression.
- RACEMORAMIDE.
- REMIFENTANIL.
- SECBUTOBARBITAL.
- SECOBARBITAL.
- # SODIUM OXYBATE for human therapeutic use.
- SUFENTANIL.
- TAPENTADOL.
- # TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:
- (a) included in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or
- (b) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or
- (c) in therapeutic goods supplied in accordance with the Act;
- except when:
- (d) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or
- (e) separately specified in the NABIXIMOLS entry in this Schedule; or
- (f) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or
- (g) in hemp seed oil at a concentration of 10 mg/kg or less.
- THEBACON.
- THEBAINE.
- THIAFENTANIL.
- TILIDINE.
- Schedule 9 · Prohibited substances
- Note 1: See paragraph 7(b) and subsection 57(2).
- Note 2: Trivial or unofficial names are marked *.
- ACETORPHINE.
- ACETYL-ALPHA-METHYLFENTANYL.
- ALKOXYAMFETAMINES and substituted alkoxyamfetamines except when separately specified in these Schedules.
- ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when separately specified in these Schedules.
- ALKYLTHIOAMFETAMINES and substituted alkylthioamfetamines except when separately specified in these Schedules.
- ALLYLPRODINE.
- ALPHAMEPRODINE.
- ALPHA-METHYLFENTANYL.
- ALPHA-METHYLTHIOFENTANYL.
- ALPHAMETHADOL.
- ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP).
- 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).
- 5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans except when separately specified in these Schedules.
- BENZETHIDINE.
- BENZOYLINDOLES except when separately specified in these Schedules.
- BENZYLPIPERAZINE *(BZP).
- BETACETYLMETHADOL.
- BETA-HYDROXYFENTANYL.
- BETA-HYDROXY-3-METHYLFENTANYL.
- BETAMEPRODINE.
- BETAMETHADOL.
- BETAPRODINE.
- 1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE *(Bromo-Dragonfly).
- 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).
- BUFOTENINE.
- BUTONITAZENE.
- CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), except:
- (a) when separately specified in these Schedules; or
- (b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols and hemp fibre products manufactured from such fibre; or
- (c) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.
- CATHINONES except when separately specified in these Schedules.
- CLONAZOLAM.
- CLONITAZENE.
- COCA LEAF.
- CODOXIME.
- 4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE.
- CYCLOHEXYLPHENOLS except:
- (a) when separately specified in these Schedules; or
- (b) in preparations containing 0.5% or less of cyclohexylphenols.
- DESCHLOROETIZOLAM.
- DESOMORPHINE.
- N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES except when separately specified in these Schedules.
- N,N-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES except when separately specified in these Schedules.
- DIAMPROMIDE.
- DIBENZOPYRANS except when separately specified in these Schedules.
- 3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBENZAMIDE (U-47700).
- 3,4-DICHLORO-N-{[1- (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH-7921).
- DICLAZEPAM.
- DIETHYLTHIAMBUTENE.
- N,N-DIETHYLTRYPTAMINE *(DET).
- 2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-B]INDOL-1-ONE (SGT-151).
- DIMENOXADOL.
- DIMEPHEPTANOL.
- 2,5-DIMETHOXYAMFETAMINE *(DMA).
- 2,5-DIMETHOXY-4-BROMOAMFETAMINE *(DOB).
- 2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE *(DOET).
- 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).
- 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).
- 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).
- 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).
- 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(DMHP).
- N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) except when included in Schedule 8.
- N,N-DIMETHYLAMFETAMINE (Dimetamfetamine).
- DIMETHYLTHIAMBUTENE.
- N,N-DIMETHYLTRYPTAMINE *(DMT).
- DIOXAPHETYL BUTYRATE.
- DIPHENIDINE.
- ECGONINE.
- EPHENIDINE.
- N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL MDA).
- ETHYLMETHYLTHIAMBUTENE.
- ETICYCLIDINE *(PCE).
- ETODESNITAZENE.
- ETONITAZENE.
- ETONITAZEPIPNE.
- ETONITAZEPYNE.
- ETORPHINE.
- ETOXERIDINE.
- FENETYLLINE.
- 4-FLUORO-N-METHYLAMFETAMINE.
- FLUBROMAZEPAM.
- FLUBROMAZOLAM.
- FLUNITAZENE.
- 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE *(AM-694).
- FURETHIDINE.
- HARMALA ALKALOIDS except in herbs, or preparations, for therapeutic use:
- (a) containing 0.1% or less of harmala alkaloids; or
- (b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.
- HEROIN.
- 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL).
- 4-HYDROXYBUTANOIC ACID and its salts except for sodium oxybate when in Schedule 8. *(GAMMA HYDROXYBUTYRATE (GHB)).
- 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL *(Cannabicyclohexanol or CP 47,497 C8 homologue).
- 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL *(CP 47,497).
- HYDROXYPETHIDINE.
- IBOTENIC ACID.
- ISOMETHADONE.
- ISOPHENIDINE.
- ISOTONITAZENE.
- KETOBEMIDONE.
- LEVOMETHORPHAN (excluding its stereoisomers).
- LEVOPHENACYLMORPHAN.
- LYSERGIC ACID.
- LYSERGIDE.
- MECLONAZEPAM.
- MECLOQUALONE.
- METAZOCINE.
- METHAQUALONE.
- METHCATHINONE.
- METHOXPHENIDINE.
- 5-METHOXY- α –METHYLTRYPTAMINE *(5-MeO-AMT).
- 5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE *(MMDA).
- 4-METHOXY- α –METHYLPHENYLETHYLAMINE *(PMA).
- 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE *(JWH-250).
- METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE *(SALVINORIN A).
- 4-METHYLAMINOREX.
- METHYLDESORPHINE.
- 3,4-METHYLENEDIOXYAMFETAMINE *(MDA).
- 3,4-METHYLENEDIOXYPYROVALERONE *(MDPV).
- 3-METHYLFENTANYL.
- 4-METHYLMETHCATHINONE *(MEPHEDRONE).
- N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(N-HYDROXY MDA).
- N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB).
- 2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).
- 6-METHYLNICOTINE.
- METHYLONE *(MDMC).
- 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).
- 4-METHYLTHIOAMFETAMINE.
- 3-METHYLTHIOFENTANYL.
- METODESNITAZENE.
- METONITAZENE.
- METOPON.
- MITRAGYNA SPECIOSA.
- MITRAGYNINE.
- MORPHERIDINE.
- (1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE *(JWH-200).
- MUSCIMOL.
- MYROPHINE.
- NAPHTHOYLINDOLES except when separately specified in these Schedules.
- NAPHTHYLMETHYLINDOLES except when separately specified in these Schedules.
- NAPHTHOYLPYRROLES except when separately specified in these Schedules.
- NAPHTHYLMETHYLINDENES except when separately specified in these Schedules.
- NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE *(JWH-073).
- NICOCODINE.
- NICODICODINE.
- NICOMORPHINE.
- NIFOXIPAM.
- NORACYMETHADOL.
- NORLEVORPHANOL.
- NORMORPHINE.
- NORPIPANONE.
- PARA-FLUOROFENTANYL.
- 1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. *(JWH-122).
- 1-PENTYL-3-(1-NAPHTHOYL)INDOLE *(JWH-018).
- PHENADOXONE.
- PHENAMPROMIDE.
- PHENAZOCINE.
- PHENCYCLIDINE *(PCP).
- PHENIBUT.
- N-PHENETHYL-4-PIPERIDONE.
- PHENOMORPHAN.
- PHENYLACETYLINDOLES except when separately specified in these Schedules.
- 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).
- PIMINODINE.
- PROHEPTAZINE.
- PROPERIDINE.
- PROPYLPHENIDINE.
- PROTONITAZENE.
- PSILOCYBINE except when included in Schedule 8.
- PYRAZOLAM.
- RACEMETHORPHAN.
- RACEMORPHAN.
- ROLICYCLIDINE *(PHP or PCPY).
- SALVIA DIVINORUM.
- SYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules.
- TENOCYCLIDINE *(TCP).
- TETRAHYDROCANNABINOLS and their alkyl homologues, except:
- (a) when included in Schedule 4 or Schedule 8; or
- (b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or
- (c) in hemp seed oil at a concentration of 10 mg/kg or less.
- THIOFENTANYL.
- 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).
- TRIMEPERIDINE.
- 3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE *(TMA).
- 3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine except:
- (a) methoxyphenamine; or
- (b) when separately specified in this Schedule.
- 1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.
- Schedule 10 · Substances of such danger to health as to warrant prohibition of supply and use
- Note 1: See subsection 57(2) and section 63.
- Note 2: Schedule 10 contains substances previously included in Appendix C.
- ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.
- ACORUS CALAMUS (calamus) for human therapeutic use.
- ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:
- (a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5; or
- (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
- (c) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.
- ALKYLAMINES WITH STIMULANT PROPERTIES except when separately specified in these schedules.
- 2-AMINO-5-METHYLPHENOL in preparations for cosmetic use.
- AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.
- AMYGDALIN for therapeutic use except in preparations containing 10 mg/kg or less of amygdalin.
- ANCHUSA OFFICINALIS for therapeutic use.
- o-ANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations
- APRONAL for therapeutic use.
- ARISTOLOCHIA spp. for therapeutic use.
- ARISTOLOCHIC ACID(S) for human therapeutic use.
- ASARUM spp. containing aristolochic acid(s) for human therapeutic use.
- AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except “debitterised neem seed oil”.
- BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.
- 1,2-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).
- 1,3-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).
- BITHIONOL for human therapeutic use.
- BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.
- BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.
- BUCLOSAMIDE for therapeutic use.
- BUNIODYL SODIUM for therapeutic use.
- 1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.
- BUTYL BENZYL PHTHALATE for cosmetic use.
- CACALIA spp. for therapeutic use.
- CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18% of carbamide peroxide except in preparations m
- CARDARINE.
- CHRYSOIDINE BASE in preparations for use in hair dyes.
- CINCHOPHEN and its derivatives for therapeutic use.
- CLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use except or when being used solely for experimental purposes in humans and whe
- (a) is in accordance with:
- (i) an approval granted under paragraph 19(1)(b) of the Act, including any conditions specified in the notice of approval; and
- (ii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(1A) of the Act; and
- (iii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(4A) of the Act; or
- (b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic Goods Regulations 1990.
- COAL TAR for cosmetic use other than in therapeutic goods.
- CONIUM MACULATUM (coniine) for therapeutic use.
- COTARNINE for therapeutic use.
- CROTALARIA spp. for therapeutic use.
- CROTON TIGLIUM for therapeutic use.
- CYNOGLOSSUM spp. for therapeutic use.
- DIBUTYL PHTHALATE for cosmetic use.
- DICOPHANE (DDT) for therapeutic use.
- DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of diethylene glycol.
- DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.
- DIETHYLHEXYL PHTHALATE for cosmetic use.
- DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of diethylph
- 5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2% of 5,6-dihydroxyindoline.
- DIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use.
- DIISOBUTYL PHTHALATE for cosmetic use.
- 1,3-DIMETHYLAMYLAMINE (DMAA).
- 1,3-DIMETHYLBUTYLAMINE (DMBA) except when separately specified in these schedules.
- 1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette).
- 1,5-DIMETHYLHEXYLAMINE (DMHA) except when separately specified in these schedules.
- DI(METHYLOXYETHYL) PHTHALATE for cosmetic use.
- 1,4-DIMETHYLPENTYLAMINE (DMPA).
- DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of dimethyl
- 2,4-DINITROPHENOL for human use.
- DISPERSE YELLOW 3 for use in hair dyes.
- DULCIN for therapeutic use.
- ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of ethylene glycol.
- EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.
- FARFUGIUM JAPONICUM for therapeutic use.
- FORMALDEHYDE (excluding its derivatives):
- (a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or
- (b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or
- (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or
- (d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when la
- CONTAINS FORMALDEHYDE.
- GAMMA BUTYROLACTONE (excluding its derivatives) in non-polymerised form in preparations for domestic and cosmetic use.
- HELIOTROPIUM spp. for therapeutic use.
- HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6% (20 volume) of hydrogen peroxide except in prepa
- ISOPROPYL NITRITE.
- JUNIPERUS SABINE [savin(e)] for therapeutic use.
- KAMBO.
- LEAD COMPOUNDS:
- (a) in anti-fouling paints except in preparations containing 0.06% or less of lead calculated on the non-volatile content of the paint; or
- (b) in paints (other than anti-fouling paints), tinters, inks or ink additives except in preparations containing 0.009% or less of lead calculated on the non-vo
- (c) for human therapeutic use except in preparations containing 10 mg/kg or less of lead.
- LIGULARIA DENTATA for therapeutic use.
- MELIA AZEDARACH including its extracts and derivatives.
- METHANOL in hand sanitiser preparations containing more than 5% methanol.
- METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.
- METHYL METHACRYLATE for cosmetic use except in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.
- METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet) and the following TRIARYLMETHANE DYES – for use in hair dyes:
- (a) Acid Violet 49; or
- (b) Ethyl Violet; or
- (c) Basic Blue 7; or
- (d) Basic Blue 26 (CI 44045).
- NAPHTHALENE (excluding derivatives) in preparations in block, ball, disc, pellet or flake form for domestic use except when enclosed in a device which, in norma
- OXYPHENISATIN for therapeutic use.
- PARAFORMALDEHYDE (excluding its derivatives):
- (a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or
- (b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or
- (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or
- (d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when la
- CONTAINS FORMALDEHYDE.
- PETASITES spp. for therapeutic use.
- PHENPROMETHAMINE.
- PHENYLENEDIAMINES, including alkylated, arylated, halogenated and nitro derivatives, in preparations for skin colouration, tattooing and dyeing of eyelashes or
- POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11
- n-PROPYL NITRITE.
- PTERIDIUM spp. for therapeutic use.
- PULMONARIA spp. for therapeutic use.
- SAFROLE for internal therapeutic use except in preparations containing 0.1% or less of safrole.
- SANGUINARIA CANADENSIS (bloodroot) in preparations for human use except in preparations containing 0.01% or less of SANGUINARINE.
- SENECIO spp. for therapeutic use.
- SILICONES for injection or implantation except when included in Schedule 4.
- SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.
- SYMPHYTUM spp. (Comfrey) in preparations for human or animal use except when in Schedule 5.
- 2,4-TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.
- TOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of eyelashes or eyebrows except when included in Schedule 6.
- o-TOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations
- 1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.
- TRICHODESMA AFRICANA for therapeutic use.
- TRIPARANOL for therapeutic use.
- TUSSILAGO FARFARA for therapeutic use.
- WILD CHERRY BARK for therapeutic use except in preparations containing:
- (a) 10 mg/kg or less of amygdalin; and
- (b) 10 mg/kg or less of hydrocyanic acid.
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.